Datasets:
ChatDOC
/
OCRFlux-pubtabnet-cross

Dataset card Data Studio Files Community
1
image_name
stringlengths
68
68
type
stringclasses
2 values
gt_table
stringlengths
116
12.6k
table_fragment_1
stringlengths
43
8.42k
table_fragment_2
stringlengths
39
8.21k
962df8b38618268f08b5a03901e1f9f09099fc484367305bbd87990eb56a11cd.png
complex
<table><tr><td colspan="5">Categorical variables</td></tr><tr><td> </td><td>Consented to participate n = 43 (37%)</td><td>Declined to participate n = 73 (63%)</td><td>All (n = 116)</td><td>P-value &#967;<sup>2 </sup>test</td></tr><tr><td>First degree relative with diabetes mellitus</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>No</td><td>22 (35%)</td><td>41 (65%)</td><td>63</td><td>0.601</td></tr><tr><td>Yes</td><td>21 (40%)</td><td>32 (60%)</td><td>53</td><td> </td></tr><tr><td>Smoker</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Past</td><td>17 (41%)</td><td>25 (59%)</td><td>42</td><td>0.790</td></tr><tr><td>Current</td><td>7 (39%)</td><td>11 (61%)</td><td>18</td><td> </td></tr><tr><td>Never</td><td>19 (34%)</td><td>37 (66%)</td><td>56</td><td> </td></tr><tr><td>Meets daily exercise requirements</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>No</td><td>5 (31%)</td><td>11 (69%)</td><td>16</td><td>0.604</td></tr><tr><td>Yes</td><td>38 (38%)</td><td>62 (62%)</td><td>100</td><td> </td></tr><tr><td>Meets daily fruit and vegetable requirements</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>No</td><td>0</td><td>3(100%)</td><td>3</td><td>0.178</td></tr><tr><td>Yes</td><td>43 (38%)</td><td>70 (62%)</td><td>113</td><td> </td></tr><tr><td><i>Insulin use during pregnancy</i></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><i>No</i></td><td><i>33 (46%)</i></td><td><i>38 (54%)</i></td><td><i>71</i></td><td><i>0.008 95% CI (7.5, 41)</i></td></tr><tr><td><i>Yes</i></td><td><i>10 (22%)</i></td><td><i>35 (77%)</i></td><td><i>45</i></td><td> </td></tr><tr><td>IFG at follow-up</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>No</td><td>34 (36%)</td><td>61 (64%)</td><td>95</td><td>0.544</td></tr><tr><td>Yes</td><td>12 (57%)</td><td>9 (43%)</td><td>21</td><td> </td></tr><tr><td>IGT at follow-up</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>No</td><td>41 (38%)</td><td>68 (62%)</td><td>109</td><td>0.631</td></tr><tr><td>Yes</td><td>2 (29%)</td><td>5 (71%)</td><td>7</td><td> </td></tr></table>
<table><tr><td colspan="5">Categorical variables</td></tr><tr><td></td><td>Consented to participate n = 43 (37%)</td><td>Declined to participate n = 73 (63%)</td><td>All (n = 116)</td><td>P-value χ2 test</td></tr><tr><td>First degree relative with diabetes mellitus</td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>22 (35%)</td><td>41 (65%)</td><td>63</td><td>0.601</td></tr><tr><td>Yes</td><td>21 (40%)</td><td>32 (60%)</td><td>53</td><td></td></tr><tr><td>Smoker</td><td></td><td></td><td></td><td></td></tr><tr><td>Past</td><td>17 (41%)</td><td>25 (59%)</td><td>42</td><td>0.790</td></tr><tr><td>Current</td><td>7 (39%)</td><td>11 (61%)</td><td>18</td><td></td></tr><tr><td>Never</td><td>19 (34%)</td><td>37 (66%)</td><td>56</td><td></td></tr><tr><td>Meets daily exercise requirements</td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>5 (31%)</td><td>11 (69%)</td><td>16</td><td>0.604</td></tr><tr><td>Yes</td><td>38 (38%)</td><td>62 (62%)</td><td>100</td><td></td></tr><tr><td>Meets daily fruit and vegetable requirements</td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>0</td><td>3(100%)</td><td>3</td><td>0.178</td></tr><tr><td>Yes</td><td>43 (38%)</td><td>70 (62%)</td><td>113</td><td></td></tr><tr><td>Insulin use during pregnancy</td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>33 (46%)</td><td>38 (54%)</td><td>71</td><td>0.008 95% CI (7.5, 41)</td></tr><tr><td>Yes</td><td>10 (22%)</td><td>35 (77%)</td><td>45</td><td></td></tr><tr><td>IFG at follow-up</td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>34 (36%)</td><td>61 (64%)</td><td>95</td><td>0.544</td></tr></table>
<table><tr><td>Yes</td><td>12 (57%)</td><td>9 (43%)</td><td>21</td><td></td></tr><tr><td>IGT at follow-up</td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>41 (38%)</td><td>68 (62%)</td><td>109</td><td>0.631</td></tr><tr><td>Yes</td><td>2 (29%)</td><td>5 (71%)</td><td>7</td><td></td></tr></table>
48d5fe6988bd7143390a05f83e068d6501b6abe74d9ed3c26be3b0151a5edb37.png
simple
<table><tr><td>Variable</td><td>Manipur n = 41</td><td>Nagaland n = 33</td><td>Total n = 74</td></tr><tr><td>Average age (range)</td><td>33 yrs (23&#8211;46)</td><td>32 yrs (20&#8211;52)</td><td>32.5 yrs (20&#8211;52)</td></tr><tr><td>Average length of widowhood (range)</td><td>4.5 yrs (3 mth-12.8 yrs)</td><td>4.2 yrs (1 mth-11 yrs)</td><td>4.3 yrs (1 mth-12.8 yrs)</td></tr><tr><td>Average no. children (range)</td><td>2.2 (1&#8211;4)</td><td>2.7 (0&#8211;7)</td><td>2.4 (0&#8211;7)</td></tr><tr><td>Ethnicity &#8211; n (%)</td><td></td><td></td><td></td></tr><tr><td> Naga</td><td>2 (5)</td><td>26 (79)</td><td>28 (38)</td></tr><tr><td> Meitei</td><td>26 (63)</td><td>0</td><td>26 (35)</td></tr><tr><td> Other</td><td>11 (27)</td><td>7 (21)</td><td>18(24)</td></tr><tr><td> Missing</td><td>2 (5)</td><td>0</td><td>2 (3)</td></tr><tr><td>Religion &#8211; n (%)</td><td></td><td></td><td></td></tr><tr><td> Christian</td><td>14 (34)</td><td>30 (91)</td><td>44 (59)</td></tr><tr><td> Hindu</td><td>25 (61)</td><td>2 (6)</td><td>27 (37)</td></tr><tr><td> Muslim</td><td>0</td><td>1 (3)</td><td>1 (1)</td></tr><tr><td> Missing</td><td>2 (5)</td><td>0</td><td>2 (3)</td></tr><tr><td>Employment &#8211; n (%)</td><td></td><td></td><td></td></tr><tr><td> Employed</td><td>2 (5)</td><td>10 (30)</td><td>12 (16)</td></tr><tr><td> Unemployed</td><td>37 (90)</td><td>23 (70)</td><td>60 (81)</td></tr><tr><td> Missing</td><td>2 (5)</td><td>0</td><td>2 (3)</td></tr><tr><td>Education &#8211; n (%)</td><td></td><td></td><td></td></tr><tr><td> None</td><td>-</td><td>7 (21)</td><td>7 (9)</td></tr><tr><td> Primary</td><td>5 (12)</td><td>1 (3)</td><td>6 (8)</td></tr><tr><td> Secondary</td><td>15 (37)</td><td>24 (73)</td><td>39 (53)</td></tr><tr><td> Tertiary</td><td>21 (51)</td><td>1 (3)</td><td>22 (30)</td></tr></table>
<table><tr><td>Variable</td><td>Manipur n = 41</td><td>Nagaland n = 33</td><td>Total n = 74</td></tr><tr><td>Average age (range)</td><td>33 yrs (23–46)</td><td>32 yrs (20–52)</td><td>32.5 yrs (20–52)</td></tr><tr><td>Average length of widowhood (range)</td><td>4.5 yrs (3 mth-12.8 yrs)</td><td>4.2 yrs (1 mth-11 yrs)</td><td>4.3 yrs (1 mth-12.8 yrs)</td></tr><tr><td>Average no. children (range)</td><td>2.2 (1–4)</td><td>2.7 (0–7)</td><td>2.4 (0–7)</td></tr><tr><td>Ethnicity – n (%)</td><td></td><td></td><td></td></tr><tr><td>Naga</td><td>2 (5)</td><td>26 (79)</td><td>28 (38)</td></tr><tr><td>Meitei</td><td>26 (63)</td><td>0</td><td>26 (35)</td></tr><tr><td>Other</td><td>11 (27)</td><td>7 (21)</td><td>18(24)</td></tr><tr><td>Missing</td><td>2 (5)</td><td>0</td><td>2 (3)</td></tr><tr><td>Religion – n (%)</td><td></td><td></td><td></td></tr><tr><td>Christian</td><td>14 (34)</td><td>30 (91)</td><td>44 (59)</td></tr><tr><td>Hindu</td><td>25 (61)</td><td>2 (6)</td><td>27 (37)</td></tr><tr><td>Muslim</td><td>0</td><td>1 (3)</td><td>1 (1)</td></tr><tr><td>Missing</td><td>2 (5)</td><td>0</td><td>2 (3)</td></tr><tr><td>Employment – n (%)</td><td></td><td></td><td></td></tr><tr><td>Employed</td><td>2 (5)</td><td>10 (30)</td><td>12 (16)</td></tr><tr><td>Unemployed</td><td>37 (90)</td><td>23 (70)</td><td>60 (81)</td></tr><tr><td>Missing</td><td>2 (5)</td><td>0</td><td>2 (3)</td></tr><tr><td>Education – n (%)</td><td></td><td></td><td></td></tr><tr><td>None</td><td>-</td><td>7 (21)</td><td>7 (9)</td></tr><tr><td>Primary</td><td>5 (12)</td><td>1 (3)</td><td>6 (8)</td></tr><tr><td>Secon</td><td>15 (37</td><td>24 (7</td><td>39 (</td></tr></table>
<table><tr><td>Variable</td><td>Manipur n = 41</td><td>Nagaland n = 33</td><td>Total n = 74</td></tr><tr><td>dary</td><td>)</td><td>3)</td><td>53)</td></tr><tr><td>Tertiary</td><td>21 (51)</td><td>1 (3)</td><td>22 (30)</td></tr></table>
15a2049b54b4aa951484b51cf70867d3b19a47a5dc2246a6ebd7f6e14fdaad91.png
complex
<table><tr><td rowspan="2">Taxonomy Level</td><td rowspan="2">Method</td><td colspan="2">V1V2 Region</td></tr><tr><td>CST = 0.8</td><td>CST = 0.5</td></tr><tr><td rowspan="5">Species</td><td>BLCA</td><td>0.570</td><td>0.716</td></tr><tr><td>Kraken</td><td>0.589</td><td>0.589</td></tr><tr><td>MEGAN</td><td>0.544</td><td>0.544</td></tr><tr><td>RDP</td><td>0.490</td><td>0.613</td></tr><tr><td>SPINGO</td><td>0.486</td><td>0.562</td></tr><tr><td rowspan="5">Genus</td><td>BLCA</td><td>0.729</td><td>0.79</td></tr><tr><td>Kraken</td><td>0.694</td><td>0.694</td></tr><tr><td>MEGAN</td><td>0.745</td><td>0.745</td></tr><tr><td>RDP</td><td>0.643</td><td>0.708</td></tr><tr><td>SPINGO</td><td>0.605</td><td>0.650</td></tr><tr><td rowspan="5">Family</td><td>BLCA</td><td>0.814</td><td>0.832</td></tr><tr><td>Kraken</td><td>0.777</td><td>0.777</td></tr><tr><td>MEGAN</td><td>0.869</td><td>0.869</td></tr><tr><td>RDP</td><td>0.775</td><td>0.805</td></tr><tr><td>SPINGO</td><td>NA</td><td>NA</td></tr></table>
<table><tr><td>Taxonomy Level</td><td>Method</td><td colspan="2">V1V2 Region</td></tr></table>
<table><tr><td>Taxonomy Level</td><td>Method</td><td>CST = 0.8</td><td>CST = 0.5</td></tr><tr><td rowspan="5">Species</td><td>BLCA</td><td>0.570</td><td>0.716</td></tr><tr><td>Kraken</td><td>0.589</td><td>0.589</td></tr><tr><td>MEGAN</td><td>0.544</td><td>0.544</td></tr><tr><td>RDP</td><td>0.490</td><td>0.613</td></tr><tr><td>SPINGO</td><td>0.486</td><td>0.562</td></tr><tr><td rowspan="5">Genus</td><td>BLCA</td><td>0.729</td><td>0.79</td></tr><tr><td>Kraken</td><td>0.694</td><td>0.694</td></tr><tr><td>MEGAN</td><td>0.745</td><td>0.745</td></tr><tr><td>RDP</td><td>0.643</td><td>0.708</td></tr><tr><td>SPINGO</td><td>0.605</td><td>0.650</td></tr><tr><td rowspan="5">Family</td><td>BLCA</td><td>0.814</td><td>0.832</td></tr><tr><td>Kraken</td><td>0.777</td><td>0.777</td></tr><tr><td>MEGAN</td><td>0.869</td><td>0.869</td></tr><tr><td>RDP</td><td>0.775</td><td>0.805</td></tr><tr><td>SPINGO</td><td>NA</td><td>NA</td></tr></table>
f7289d2bc840953ac0a348b9faaf57d4754e6d64def2126f38b4ff2f1b161d0f.png
complex
<table><tr><td></td><td>Baseline</td><td>One month after treatment</td><td>Three month after treatment</td></tr><tr><td colspan="4">PLI</td></tr><tr><td> Adults</td><td>0.195 &#177; 0.311<sup>a</sup></td><td>0.610 &#177; 0.512<sup>*</sup></td><td>0.780 &#177; 0.531<sup>*</sup></td></tr><tr><td> Adolescents</td><td>0.491 &#177; 0.367</td><td>0.637 &#177; 0.444<sup>*</sup></td><td>0.899 &#177; 0.490<sup>*</sup></td></tr><tr><td> Total</td><td>0.345 &#177; 0.292</td><td>0.680 &#177; 0.463<sup>*</sup></td><td>0.876 &#177; 0.462<sup>*</sup></td></tr><tr><td colspan="4">SBI</td></tr><tr><td> Adults</td><td>0.253 &#177; 0.412</td><td>1.123 &#177; 0.503<sup>*</sup></td><td>1.119 &#177; 0.148<sup>*</sup></td></tr><tr><td> Adolescents</td><td>0.278 &#177; 0.457</td><td>0.993 &#177; 0.492<sup>*</sup></td><td>1.002 &#177; 0.481<sup>*</sup></td></tr><tr><td> Total</td><td>0.283 &#177; 0.505</td><td>0.976 &#177; 0.0.484<sup>*</sup></td><td>0.984 &#177; 0.0.496<sup>*,#</sup></td></tr><tr><td colspan="4">PD</td></tr><tr><td> Adults</td><td>0.056 &#177; 0.122<sup>a</sup></td><td>1.188 &#177; 0.164<sup>*</sup></td><td>1.047 &#177; 0.148<sup>*</sup></td></tr><tr><td> Adolescents</td><td>1.015 &#177; 0.101</td><td>1.190 &#177; 0.172<sup>*</sup></td><td>1.021 &#177; 0.104<sup>*</sup></td></tr><tr><td> Total</td><td>1.020 &#177; 0.103</td><td>1.178 &#177; 0.180</td><td>1.100 &#177; 0.0.142<sup>*,#</sup></td></tr></table>
<table><tr><td></td><td>Baseline</td><td>One month after treatment</td><td>Three month after treatment</td></tr></table>
<table><tr><td colspan="4">PLI</td></tr><tr><td>Adults</td><td>0.195 ± 0.311a</td><td>0.610 ± 0.512*</td><td>0.780 ± 0.531*</td></tr><tr><td>Adolescents</td><td>0.491 ± 0.367</td><td>0.637 ± 0.444*</td><td>0.899 ± 0.490*</td></tr><tr><td>Total</td><td>0.345 ± 0.292</td><td>0.680 ± 0.463*</td><td>0.876 ± 0.462*</td></tr><tr><td colspan="4">SBI</td></tr><tr><td>Adults</td><td>0.253 ± 0.412</td><td>1.123 ± 0.503*</td><td>1.119 ± 0.148*</td></tr><tr><td>Adolescents</td><td>0.278 ± 0.457</td><td>0.993 ± 0.492*</td><td>1.002 ± 0.481*</td></tr><tr><td>Total</td><td>0.283 ± 0.505</td><td>0.976 ± 0.0.484*</td><td>0.984 ± 0.0.496*,#</td></tr><tr><td colspan="4">PD</td></tr><tr><td>Adults</td><td>0.056 ± 0.122a</td><td>1.188 ± 0.164*</td><td>1.047 ± 0.148*</td></tr><tr><td>Adolescents</td><td>1.015 ± 0.101</td><td>1.190 ± 0.172*</td><td>1.021 ± 0.104*</td></tr><tr><td>Total</td><td>1.020 ± 0.103</td><td>1.178 ± 0.180</td><td>1.100 ± 0.0.142*,#</td></tr></table>
d07d8bfbed200c43979cc09f245f22c3cf255911d9f46e9c27d01c2cc9948695.png
complex
<table><tr><td>Stages</td><td>Classification</td><td colspan="2">Macroscopic appearance</td><td>Oocyte size (&#956;m)</td><td colspan="2">GSI range</td></tr><tr><td></td><td></td><td>Testes</td><td>Ovary</td><td></td><td>F</td><td>M</td></tr><tr><td>I</td><td>Immature</td><td>Small, flat, translucent to whitish, poorly developed, with reduced fringes.</td><td>Small, transparent to translucent and not very voluminous. Oocyte not visible with naked eye.</td><td>209.61-592.78 (447.30 &#177; 99.42)<sup>a</sup></td><td>&lt;10.9</td><td>&lt;2.0</td></tr><tr><td>II</td><td>Develop</td><td>Whitish with voluminous fringes.</td><td>Large orange-pale, oocytes may be visible through the ovary tunic.</td><td>528.37-867.10 (711.24 &#177; 63.21)<sup>b</sup></td><td>11.0-18.9</td><td>2.5-5.5</td></tr><tr><td>III</td><td>Mature</td><td>Very large, firm, white in colour.</td><td>Very large occupying part of the abdominal cavity. Yellow oocyte turgescency.</td><td>604.15-894.33 (780.59 &#177; 50.71)<sup>c</sup></td><td>19.0-23.9</td><td>5.6-8.0</td></tr><tr><td>IV</td><td>Ripe</td><td>Full developed, turgid fringes, milky-whitish in colour. Milt run out of the fish.</td><td>Occupying the entire abdominal cavity. Ovulated oocytes can be fully expelled from the oviduct with gentle pressure.</td><td>725.27-991.81 (844.09 &#177; 57.59)<sup>d</sup></td><td>&gt;24.0</td><td>&gt; 8.0</td></tr><tr><td>V</td><td>Spent</td><td>Bloody and flaccid fringes.</td><td>Flaccid, red-brown or bloody in colour. Few remaining large oocytes observed, and smaller size oocytes may be seen.</td><td>227.64-770.82 (447.38 &#177; 139.02)<sup>a</sup></td><td>2.5-10.9</td><td>1.5-3.0</td></tr></table>
<table><tr><td>Stages</td><td>Classification</td><td colspan="2">Macroscopic appearance</td><td>Oocyte size (μm)</td><td colspan="2">GSI range</td></tr></table>
<table><tr><td></td><td></td><td>Testes</td><td>Ovary</td><td></td><td>F</td><td>M</td></tr><tr><td>I</td><td>Immature</td><td>Small, flat, translucent to whitish, poorly developed, with reduced fringes.</td><td>Small, transparent to translucent and not very voluminous. Oocyte not visible with naked eye.</td><td>209.61-592.78 (447.30 ± 99.42)a</td><td><10.9</td><td><2.0</td></tr><tr><td>II</td><td>Develop</td><td>Whitish with voluminous fringes.</td><td>Large orange-pale, oocytes may be visible through the ovary tunic.</td><td>528.37-867.10 (711.24 ± 63.21)b</td><td>11.0-18.9</td><td>2.5-5.5</td></tr><tr><td>III</td><td>Mature</td><td>Very large, firm, white in colour.</td><td>Very large occupying part of the abdominal cavity. Yellow oocyte turgescency.</td><td>604.15-894.33 (780.59 ± 50.71)c</td><td>19.0-23.9</td><td>5.6-8.0</td></tr><tr><td>IV</td><td>Ripe</td><td>Full developed, turgid fringes, milky-whitish in colour. Milt run out of the fish.</td><td>Occupying the entire abdominal cavity. Ovulated oocytes can be fully expelled from the oviduct with gentle pressure.</td><td>725.27-991.81 (844.09 ± 57.59)d</td><td>>24.0</td><td>> 8.0</td></tr><tr><td>V</td><td>Spent</td><td>Bloody and flaccid fringes.</td><td>Flaccid, red-brown or bloody in colour. Few remaining large oocytes observed, and smaller size oocytes may be seen.</td><td>227.64-770.82 (447.38 ± 139.02)a</td><td>2.5-10.9</td><td>1.5-3.0</td></tr></table>
58eb09085c930ba86e0311c6ff1d16d4908483ebfa1880770775fcb7e5b863ed.png
simple
<table><tr><td>Biotype</td><td>Human</td><td>Mouse</td></tr><tr><td>LincRNA</td><td>13245</td><td>6473</td></tr><tr><td>Antisense</td><td>10980</td><td>3612</td></tr><tr><td>TEC</td><td>1072</td><td>2759</td></tr><tr><td>Sense_intronic</td><td>984</td><td>294</td></tr><tr><td>Retained_intron</td><td>517</td><td>294</td></tr><tr><td>Processed_transcript</td><td>368</td><td>980</td></tr><tr><td>Sense_overlapping</td><td>310</td><td>50</td></tr><tr><td>3prime_overlapping_ncRNA</td><td>34</td><td>3</td></tr><tr><td>Pseudogene</td><td>20</td><td>24</td></tr><tr><td>Bidirectional_promoter_lncRNA</td><td>11</td><td>118</td></tr><tr><td>Non_coding</td><td>3</td><td>0</td></tr><tr><td>Macro_lncRNA</td><td>1</td><td>2</td></tr><tr><td>Total</td><td>27545</td><td>14609</td></tr></table>
<table><tr><td>Biotype</td><td>Human</td><td>Mouse</td></tr><tr><td>LincRNA</td><td>13245</td><td>6473</td></tr><tr><td>Antisense</td><td>10980</td><td>3612</td></tr><tr><td>TEC</td><td>1072</td><td>2759</td></tr><tr><td>Sense_intronic</td><td>984</td><td>294</td></tr><tr><td>Retained_intron</td><td>517</td><td>294</td></tr><tr><td>Processed_transcript</td><td>368</td><td>980</td></tr><tr><td>Sense_overlapping</td><td>310</td><td>50</td></tr><tr><td>3prime_overlapping_ncRNA</td><td>34</td><td>3</td></tr><tr><td>Pseudogene</td><td>20</td><td>24</td></tr><tr><td>Bidirectional_promoter_lncRNA</td><td>11</td><td>118</td></tr><tr><td>Non_coding</td><td>3</td><td>0</td></tr><tr><td>Macro_lncRNA</td><td>1</td><td>2</td></tr></table>
<table><tr><td>Total</td><td>27545</td><td>14609</td></tr></table>
45c38c69f2e42835df37fa39bbe1aad2835c5105f557991cff3e240d600e5e0a.png
complex
<table><tr><td></td><td colspan="3">FAF (%)</td><td colspan="3">NIA(%)</td></tr><tr><td></td><td>hypoFAF</td><td>mixedFAF</td><td>hyperFAF</td><td>hypoNIA</td><td>mixedNIA</td><td>hyperNIA</td></tr><tr><td>Detached area (<i>N</i> = 10)</td><td>10</td><td>20</td><td>70</td><td>30</td><td>20</td><td>50</td></tr><tr><td>Leakage spot (<i>N</i> = 13)</td><td>23.1</td><td>&#215;</td><td>76.9</td><td>92.3</td><td>&#215;</td><td>7.7</td></tr><tr><td>Window defect area (<i>N</i> = 8)</td><td>12.5</td><td>12.5</td><td>75</td><td>62.5</td><td>32.5</td><td>0</td></tr><tr><td>Overall image (<i>N</i> = 17)</td><td>17.6</td><td>11.8</td><td>70.6</td><td>58.8</td><td>17.6</td><td>23.5</td></tr><tr><td>PED (<i>N</i> = 22)</td><td></td><td></td><td></td><td>63.6</td><td>&#215;</td><td>36.4</td></tr></table>
<table><tr><td></td><td colspan="3">FAF (%)</td><td colspan="3">NIA(%)</td></tr><tr><td></td><td>hypoFAF</td><td>mixedFAF</td><td>hyperFAF</td><td>hypoNIA</td><td>mixedNIA</td><td>hyperNIA</td></tr><tr><td>Detached area (N = 10)</td><td>10</td><td>20</td><td>70</td><td>30</td><td>20</td><td>50</td></tr><tr><td>Leakage sp</td><td>23</td><td>×</td><td>76</td><td>92.3</td><td></td><td></td></tr></table>
<table><tr><td></td><td colspan="3">FAF (%)</td><td colspan="3">NIA(%)</td></tr><tr><td></td><td>hypoFAF</td><td>mixedFAF</td><td>hyperFAF</td><td>hypoNIA</td><td>mixedNIA</td><td>hyperNIA</td></tr><tr><td>ot (N = 13)</td><td>.1</td><td></td><td>.9</td><td></td><td>×</td><td>7.7</td></tr><tr><td>Window defect area (N = 8)</td><td>12.5</td><td>12.5</td><td>75</td><td>62.5</td><td>32.5</td><td>0</td></tr><tr><td>Overall image (N = 17)</td><td>17.6</td><td>11.8</td><td>70.6</td><td>58.8</td><td>17.6</td><td>23.5</td></tr><tr><td>PED (N = 22)</td><td></td><td></td><td></td><td>63.6</td><td>×</td><td>36.4</td></tr></table>
2bd2aeb796e5dd68e21c7c9178d491a6c2990c62df595361fe05d1e589ea04b1.png
simple
<table><tr><td></td><td>VAS Measure<sup>a</sup></td><td>M</td><td>SD</td><td>95% Confidence Interval</td><td>Response Range</td></tr><tr><td>Mechanism</td><td>Acceptance, equality, and non-judgment</td><td>80.1</td><td>20.7</td><td>[76.83, 83.34]</td><td>0&#8211;100</td></tr><tr><td></td><td>Dignity and self-worth</td><td>77.3</td><td>21.5</td><td>[73.88, 80.65]</td><td>1&#8211;100</td></tr><tr><td></td><td>Reduced experience of stigma</td><td>83</td><td>20.1</td><td>[79.78, 86.15]</td><td>10&#8211;100</td></tr><tr><td></td><td>Independence and self-efficacy</td><td>81</td><td>19.8</td><td>[77.79, 84.04]</td><td>8&#8211;100</td></tr><tr><td></td><td>Relationship to others and reduced isolation</td><td>74</td><td>23.8</td><td>[70.02, 77.63]</td><td>0&#8211;100</td></tr><tr><td></td><td>Sense of connection and belonging</td><td>79</td><td>21.9</td><td>[75.20, 82.24]</td><td>0&#8211;100</td></tr><tr><td>Outcome</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Feeling better and at peace</td><td>74</td><td>23</td><td>[70.31, 77.55]</td><td>0&#8211;100</td></tr><tr><td></td><td>Personhood</td><td>83</td><td>18.9</td><td>[80.00, 85.93]</td><td>0&#8211;100</td></tr><tr><td></td><td>Skills Acquired</td><td>75</td><td>23.6</td><td>[71.53, 79.05]</td><td>0&#8211;100</td></tr></table>
<table><tr><td></td><td>VAS Measurea</td><td>M</td><td>SD</td><td>95% Confidence Interval</td></tr><tr><td>Mechanism</td><td>Acceptance, equality, and non-judgment</td><td>80.1</td><td>20.7</td><td>[76.83, 83.34]</td></tr><tr><td></td><td>Dignity and self-worth</td><td>77.3</td><td>21.5</td><td>[73.88, 80.65]</td></tr><tr><td></td><td>Reduced experience of stigma</td><td>83</td><td>20.1</td><td>[79.78, 86.15]</td></tr><tr><td></td><td>Independence and self-efficacy</td><td>81</td><td>19.8</td><td>[77.79, 84.04]</td></tr><tr><td></td><td>Relationship to others and reduced isolation</td><td>74</td><td>23.8</td><td>[70.02, 77.63]</td></tr><tr><td></td><td>Sense of connection and belonging</td><td>79</td><td>21.9</td><td>[75.20, 82.24]</td></tr><tr><td>Outcome</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Feeling better and at peace</td><td>74</td><td>23</td><td>[70.31, 77.55]</td></tr><tr><td></td><td>Personhood</td><td>83</td><td>18.9</td><td>[80.00, 85.93]</td></tr><tr><td></td><td>Skills Acquired</td><td>75</td><td>23.6</td><td>[71.53, 79.05]</td></tr></table>
<table><tr><td>Response Range</td></tr><tr><td>0–100</td></tr><tr><td>1–100</td></tr><tr><td>10–100</td></tr><tr><td>8–100</td></tr><tr><td>0–100</td></tr><tr><td>0–100</td></tr><tr><td></td></tr><tr><td>0–100</td></tr><tr><td>0–100</td></tr><tr><td>0–100</td></tr></table>
b95c21e4ac4a22e3c7498338b2fb1ca2e64f1969b969e2e5356e6bdb64d10465.png
complex
<table><tr><td>Type of strategies</td><td>Strategies Medicines</td><td>NCMS (China)</td><td>National Health Insurance (Ghana)</td><td>Jamkesmas (Indonesia)</td><td>Seguro Popular (Mexico)</td></tr><tr><td rowspan="3"><i>Selection</i></td><td><i>Formulary</i></td><td><i>&#10003;</i></td><td><i>&#10003;</i></td><td><i>&#10003;</i></td><td><i>&#10003;</i></td></tr><tr><td>Cost sharing for medicines included in the formulary</td><td>&#10003;</td><td>&#10007;</td><td>&#10007;</td><td>&#10007;</td></tr><tr><td>Generic substitution</td><td>&#10007;</td><td>&#10003;</td><td>&#10007;</td><td>&#10007;</td></tr><tr><td rowspan="3"><i>Procurement</i></td><td>Medicines prices negotiation or rebates</td><td>&#10003;</td><td>&#10007;<sup>c</sup></td><td>&#10003;</td><td>(&#10003;)</td></tr><tr><td><i>Bulk procurement</i></td><td><i>&#10003;</i></td><td><i>&#10003;</i><sup><underline>a</underline></sup></td><td><i>&#10003;</i></td><td><i>&#10003;</i></td></tr><tr><td>Generic reference pricing</td><td>&#10007;</td><td>&#10003;</td><td>&#10007;<sup>a</sup></td><td>&#10003;</td></tr><tr><td rowspan="4"><i>Contracting</i></td><td>Fee for service for prescribers</td><td>&#10003;</td><td></td><td></td><td></td></tr><tr><td>Fixed salary for prescribers<sup>a</sup></td><td></td><td>&#10003;</td><td>&#10003;<sup>a</sup></td><td>&#10003;</td></tr><tr><td>Fixed reimbursement rates for medicines</td><td>&#10003;</td><td>&#10003;</td><td>&#10007;</td><td>&#10007;</td></tr><tr><td>Preferred provider network (accreditation)</td><td>&#10007;</td><td>&#10003;</td><td>&#10003;</td><td>&#10003;</td></tr><tr><td rowspan="4"><i>Utilization</i></td><td><i>Standard treatment guidelines</i></td><td>(<i>&#10003;</i>)</td><td><i>&#10003;</i></td><td><i>&#10003;</i></td><td><i>&#10003;</i></td></tr><tr><td>Payment for performance</td><td>(&#10003;)</td><td>&#10007;</td><td>&#10007;</td><td>&#10007;</td></tr><tr><td><i>Separation of prescribing and dispensing</i></td><td><i>&#10003;</i></td><td><i>&#10003;</i></td><td><i>&#10003;</i></td><td><i>&#10003;</i></td></tr><tr><td>Disease management programs</td><td>&#10003;</td><td>No info</td><td>&#10003;</td><td>&#10003;</td></tr><tr><td rowspan="3"><i>Monitoring and evaluation</i></td><td>User satisfaction monitoring</td><td>&#10007;</td><td>&#10007;</td><td>&#10007;</td><td>&#10003;</td></tr><tr><td>Medicines purchasing monitoring</td><td>&#10003;<sup>b</sup></td><td></td><td>&#10003;</td><td>&#10003;</td></tr><tr><td>Prescription monitoring</td><td>&#10007;</td><td>&#10007;</td><td>&#10007;</td><td>&#10007;</td></tr></table>
<table><tr><td>Type of strategies</td><td>Strategies Medicines</td><td>NCMS (China)</td><td>National Health Insurance (Ghana)</td><td>Jamkesmas (Indonesia)</td><td>Seguro Popular (Mexico)</td></tr><tr><td rowspan="3">Selection</td><td>Formulary</td><td>✓</td><td>✓</td><td>✓</td><td>✓</td></tr><tr><td>Cost sharing for medicines included in the formulary</td><td>✓</td><td>✗</td><td>✗</td><td>✗</td></tr><tr><td>Generic substitution</td><td>✗</td><td>✓</td><td>✗</td><td>✗</td></tr><tr><td rowspan="3">Procurement</td><td>Medicines prices negotiation or rebates</td><td>✓</td><td>✗c</td><td>✓</td><td>(✓)</td></tr><tr><td>Bulk procurement</td><td>✓</td><td>✓a</td><td>✓</td><td>✓</td></tr><tr><td>Generic reference pricing</td><td>✗</td><td>✓</td><td>✗a</td><td>✓</td></tr><tr><td rowspan="4">Contracting</td><td>Fee for service for prescribers</td><td>✓</td><td></td><td></td><td></td></tr><tr><td>Fixed salary for prescribersa</td><td></td><td>✓</td><td>✓a</td><td>✓</td></tr><tr><td>Fixed reimbursement rates for medicines</td><td>✓</td><td>✓</td><td>✗</td><td>✗</td></tr><tr><td>Preferred provider network (accreditation)</td><td>✗</td><td>✓</td><td>✓</td><td>✓</td></tr><tr><td>Utilization</td><td>Standard treatment guidelines</td><td>(✓)</td><td>✓</td><td>✓</td><td>✓</td></tr></table>
<table><tr><td rowspan="3">Utilization</td><td>Payment for performance</td><td>(✓)</td><td>✗</td><td>✗</td><td>✗</td></tr><tr><td>Separation of prescribing and dispensing</td><td>✓</td><td>✓</td><td>✓</td><td>✓</td></tr><tr><td>Disease management programs</td><td>✓</td><td>No info</td><td>✓</td><td>✓</td></tr><tr><td rowspan="3">Monitoring and evaluation</td><td>User satisfaction monitoring</td><td>✗</td><td>✗</td><td>✗</td><td>✓</td></tr><tr><td>Medicines purchasing monitoring</td><td>✓b</td><td></td><td>✓</td><td>✓</td></tr><tr><td>Prescription monitoring</td><td>✗</td><td>✗</td><td>✗</td><td>✗</td></tr></table>
61ffad6e7621d36b69c401f1af2d0989d88689b3e5de7f543d823634efc48705.png
simple
<table><tr><td>Type of epilepsy</td><td>No. of patients Males/females</td><td>Age ranges</td><td>Recording length ranges (mins)</td><td>No. of electrodes</td></tr><tr><td>General epilepsy</td><td>7/1</td><td>30&#8211;45</td><td>20&#8211;30</td><td>22</td></tr></table>
<table><tr><td>Type of epilepsy</td><td>No. of patients Males/females</td></tr><tr><td>General epilepsy</td><td>7/1</td></tr></table>
<table><tr><td>Age ranges</td><td>Recording length ranges (mins)</td><td>No. of electrodes</td></tr><tr><td>30–45</td><td>20–30</td><td>22</td></tr></table>
dc509dc42d477f9e7f0438b2882823d72fd1f6f34b76bb8fbe783bca7ab2f938.png
complex
<table><tr><td> </td><td colspan="2">Uncompressed</td><td colspan="2">192 k MP-3</td><td colspan="2">96 k MP-3</td></tr><tr><td> </td><td>Method I</td><td>Method II</td><td>Method I</td><td>Method II</td><td>Method I</td><td>Method II</td></tr><tr><td>IDR</td><td>99.1%</td><td>99.7%</td><td>98.9%</td><td>99.7%</td><td>99.0%</td><td>99.7%</td></tr><tr><td>FAR</td><td>1.5%</td><td>0.2%</td><td>1.9%</td><td>0.2%</td><td>1.6%</td><td>0.2%</td></tr><tr><td>FRR</td><td>0.3%</td><td>0.4%</td><td>0.2%</td><td>0.4%</td><td>0.3%</td><td>0.6%</td></tr><tr><td>ACC</td><td>98.7%</td><td>99.5%</td><td>98.5%</td><td>99.5%</td><td>98.6%</td><td>99.4%</td></tr></table>
<table><tr><td></td><td>Uncompressed</td></tr><tr><td></td><td>Method I</td></tr><tr><td>IDR</td><td>99.1%</td></tr><tr><td>FAR</td><td>1.5%</td></tr><tr><td>FRR</td><td>0.3%</td></tr><tr><td>ACC</td><td>98.7%</td></tr></table>
<table><tr><td>Uncompressed</td><td colspan="2">192 k MP-3</td><td colspan="2">96 k MP-3</td></tr><tr><td>Method II</td><td>Method I</td><td>Method II</td><td>Method I</td><td>Method II</td></tr><tr><td>99.7%</td><td>98.9%</td><td>99.7%</td><td>99.0%</td><td>99.7%</td></tr><tr><td>0.2%</td><td>1.9%</td><td>0.2%</td><td>1.6%</td><td>0.2%</td></tr><tr><td>0.4%</td><td>0.2%</td><td>0.4%</td><td>0.3%</td><td>0.6%</td></tr><tr><td>99.5%</td><td>98.5%</td><td>99.5%</td><td>98.6%</td><td>99.4%</td></tr></table>
fa37ca3da559fa68b41f7c7704485efc6394a4d6aa1025f4071e488ae5b3ffa0.png
complex
<table><tr><td>Independent predictor</td><td>Subgroup comparisons</td><td>Parameter estimate</td><td>95% CI</td><td>p Value</td></tr><tr><td rowspan="4">Patient expectation of change</td><td>Completely recover</td><td>0</td><td></td><td></td></tr><tr><td>Much improve</td><td>5.21</td><td>1.80 to 8.61</td><td>0.003</td></tr><tr><td>Slightly improve</td><td>12.43</td><td>8.20 to 16.67</td><td>&lt;0.001</td></tr><tr><td>No change/worse</td><td>&#8722;0.94</td><td>&#8722;8.53 to 6.66</td><td>0.809</td></tr><tr><td>Pain self-efficacy</td><td></td><td>&#8722;0.36</td><td>&#8722;0.50 to &#8722;0.22</td><td>&lt;0.001</td></tr><tr><td rowspan="3">Number of additional health problems</td><td>None</td><td>0</td><td></td><td></td></tr><tr><td>One</td><td>3.52</td><td>0.30 to 6.75</td><td>0.032</td></tr><tr><td>Two or more</td><td>6.62</td><td>1.48 to 9.75</td><td>0.008</td></tr><tr><td rowspan="3">Anxiety or depression</td><td>None</td><td>0</td><td></td><td></td></tr><tr><td>Moderate</td><td>2.19</td><td>&#8722;0.99 to 5.37</td><td>0.177</td></tr><tr><td>Extreme</td><td>12.02</td><td>1.49 to 22.56</td><td>0.025</td></tr><tr><td rowspan="2">Frequency of pain medication</td><td>None/occasional</td><td>0</td><td></td><td></td></tr><tr><td>Most/every day/night</td><td>3.85</td><td>0.61 to 7.09</td><td>0.020</td></tr><tr><td rowspan="4">Most strenuous exercise</td><td>None</td><td>0</td><td></td><td></td></tr><tr><td>Mild</td><td>&#8722;5.53</td><td>&#8722;10.32 to &#8722;0.74</td><td>0.024</td></tr><tr><td>Moderate</td><td>&#8722;8.98</td><td>&#8722;13.86 to &#8722;4.11</td><td>&lt;0.001</td></tr><tr><td>Strenuous</td><td>&#8722;6.82</td><td>&#8722;12.17 to &#8722;1.47</td><td>0.013</td></tr><tr><td colspan="2">Difference between passive and active abduction</td><td>0.07</td><td>0.004 to 0.142</td><td>0.038</td></tr><tr><td rowspan="2">Change during scapular facilitation</td><td>Yes</td><td>0</td><td></td><td></td></tr><tr><td>No</td><td>4.93</td><td>2.13 to 7.74</td><td>0.001</td></tr><tr><td>Severity of pain at rest</td><td></td><td>1.89</td><td>1.26 to 2.51</td><td>&lt;0.001</td></tr><tr><td colspan="2">Duration of shoulder symptoms (weeks)</td><td>0.02</td><td>0.01 to 0.03</td><td>0.002</td></tr><tr><td rowspan="2">Paraesthesia in the arm</td><td>No</td><td>0</td><td></td><td></td></tr><tr><td>Yes</td><td>&#8722;10.08</td><td>&#8722;18.73 to &#8722;1.43</td><td>0.022</td></tr><tr><td rowspan="3">Current employment status</td><td>Employed</td><td>0</td><td></td><td></td></tr><tr><td>Retired</td><td>2.96</td><td>0.10 to 6.02</td><td>0.058</td></tr><tr><td>Unemployed</td><td>14.30</td><td>7.72 to 20.87</td><td>&lt;0.001</td></tr></table>
<table><tr><td>Independent predictor</td><td>Subgroup comparisons</td></tr><tr><td rowspan="4">Patient expectation of change</td><td>Completely recover</td></tr><tr><td>Much improve</td></tr><tr><td>Slightly improve</td></tr><tr><td>No change/worse</td></tr><tr><td>Pain self-efficacy</td><td></td></tr><tr><td rowspan="3">Number of additional health problems</td><td>None</td></tr><tr><td>One</td></tr><tr><td>Two or more</td></tr><tr><td rowspan="3">Anxiety or depression</td><td>None</td></tr><tr><td>Moderate</td></tr><tr><td>Extreme</td></tr><tr><td rowspan="2">Frequency of pain medication</td><td>None/occasional</td></tr><tr><td>Most/every day/night</td></tr><tr><td rowspan="4">Most strenuous exercise</td><td>None</td></tr><tr><td>Mild</td></tr><tr><td>Moderate</td></tr><tr><td>Strenuous</td></tr><tr><td colspan="2">Difference between passive and active abduction</td></tr><tr><td rowspan="2">Change during scapular facilitation</td><td>Yes</td></tr><tr><td>No</td></tr><tr><td>Severity of pain at rest</td><td></td></tr><tr><td colspan="2">Duration of shoulder symptoms (weeks)</td></tr><tr><td rowspan="2">Paraesthesia in the arm</td><td>No</td></tr><tr><td>Yes</td></tr><tr><td rowspan="3">Current employment status</td><td>Employed</td></tr><tr><td>Retired</td></tr><tr><td>Unemployed</td></tr></table>
<table><tr><td>Parameter estimate</td><td>95% CI</td><td>p Value</td></tr><tr><td>0</td><td></td><td></td></tr><tr><td>5.21</td><td>1.80 to 8.61</td><td>0.003</td></tr><tr><td>12.43</td><td>8.20 to 16.67</td><td><0.001</td></tr><tr><td>−0.94</td><td>−8.53 to 6.66</td><td>0.809</td></tr><tr><td>−0.36</td><td>−0.50 to −0.22</td><td><0.001</td></tr><tr><td>0</td><td></td><td></td></tr><tr><td>3.52</td><td>0.30 to 6.75</td><td>0.032</td></tr><tr><td>6.62</td><td>1.48 to 9.75</td><td>0.008</td></tr><tr><td>0</td><td></td><td></td></tr><tr><td>2.19</td><td>−0.99 to 5.37</td><td>0.177</td></tr><tr><td>12.02</td><td>1.49 to 22.56</td><td>0.025</td></tr><tr><td>0</td><td></td><td></td></tr><tr><td>3.85</td><td>0.61 to 7.09</td><td>0.020</td></tr><tr><td>0</td><td></td><td></td></tr><tr><td>−5.53</td><td>−10.32 to −0.74</td><td>0.024</td></tr><tr><td>−8.98</td><td>−13.86 to −4.11</td><td><0.001</td></tr><tr><td>−6.82</td><td>−12.17 to −1.47</td><td>0.013</td></tr><tr><td>0.07</td><td>0.004 to 0.142</td><td>0.038</td></tr><tr><td>0</td><td></td><td></td></tr><tr><td>4.93</td><td>2.13 to 7.74</td><td>0.001</td></tr><tr><td>1.89</td><td>1.26 to 2.51</td><td><0.001</td></tr><tr><td>0.02</td><td>0.01 to 0.03</td><td>0.002</td></tr><tr><td>0</td><td></td><td></td></tr><tr><td>−10.08</td><td>−18.73 to −1.43</td><td>0.022</td></tr><tr><td>0</td><td></td><td></td></tr><tr><td>2.96</td><td>0.10 to 6.02</td><td>0.058</td></tr><tr><td>14.30</td><td>7.72 to 20.87</td><td><0.001</td></tr></table>
fcf48921bff3d04a14b718a07a7dfea48963b34d26cf4c9acb95c2c58db94417.png
complex
<table><tr><td></td><td colspan="2">Aripiprazole</td><td>SE</td><td colspan="2">SoC</td><td>SE</td></tr><tr><td>Total</td><td>N = 164</td><td>16.21</td><td>1.12</td><td>N = 162</td><td>10.01</td><td>1.13</td></tr><tr><td>Interpersonal relationships</td><td>N = 164</td><td>6.34</td><td>0.48</td><td>N = 162</td><td>4.23</td><td>0.48</td></tr><tr><td>Instrumental role</td><td>N = 162</td><td>3.14</td><td>0.31</td><td>N = 161</td><td>1.75</td><td>0.31</td></tr><tr><td>Intrapsychic foundation</td><td>N = 164</td><td>5.54</td><td>0.42</td><td>N = 162</td><td>3.33</td><td>0.42</td></tr><tr><td>Common activities</td><td>N = 164</td><td>1.11</td><td>0.12</td><td>N = 162</td><td>0.73</td><td>0.12</td></tr><tr><td>Residual symptoms</td><td>N = 164</td><td>6.65</td><td>0.5</td><td>N = 162</td><td>4.05</td><td>0.5</td></tr></table>
<table><tr><td></td><td colspan="2">Aripiprazole</td><td>SE</td><td colspan="2">SoC</td><td>SE</td></tr><tr><td>Total</td><td>N = 164</td><td>16.21</td><td>1.12</td><td>N = 162</td><td>10.01</td><td>1.13</td></tr><tr><td>Interpersonal relationships</td><td>N = 164</td><td>6.34</td><td>0.48</td><td>N = 162</td><td>4.23</td><td>0.48</td></tr><tr><td>Instrumental role</td><td>N = 162</td><td>3.14</td><td>0.31</td><td>N = 161</td><td>1.75</td><td>0.31</td></tr></table>
<table><tr><td>Intrapsychic foundation</td><td>N = 164</td><td>5.54</td><td>0.42</td><td>N = 162</td><td>3.33</td><td>0.42</td></tr><tr><td>Common activities</td><td>N = 164</td><td>1.11</td><td>0.12</td><td>N = 162</td><td>0.73</td><td>0.12</td></tr><tr><td>Residual symptoms</td><td>N = 164</td><td>6.65</td><td>0.5</td><td>N = 162</td><td>4.05</td><td>0.5</td></tr></table>
7c6911a0e85dea442538ed2c58a7b4c2497e8b55bfa0bc5746bd16e48a64e154.png
simple
<table><tr><td>Platoons</td><td>Bangolo</td><td>Danane&#769;</td><td>Kahin</td><td>Logouale&#769;</td><td>Guezon</td><td>BleniMe&#769;houin</td><td>Dieouzon</td><td>Zoukougbeu</td><td>Blotile</td><td>Duekoue</td></tr><tr><td>1</td><td></td><td></td><td>15</td><td></td><td>3</td><td></td><td></td><td></td><td></td><td>0.5</td></tr><tr><td>2</td><td></td><td></td><td></td><td>14</td><td></td><td></td><td>2</td><td>2</td><td>2</td><td></td></tr><tr><td>3</td><td>4</td><td>4</td><td></td><td></td><td>10</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>4</td><td>10</td><td></td><td></td><td></td><td>4</td><td>4</td><td></td><td></td><td></td><td></td></tr><tr><td>5</td><td>15</td><td></td><td></td><td></td><td>3</td><td></td><td></td><td></td><td></td><td></td></tr></table>
<table><tr><td>Platoons</td><td>Bangolo</td><td>Danané</td><td>Kahin</td><td>Logoualé</td><td>Guezon</td><td>BleniMéhouin</td><td>Dieouzon</td><td>Zoukougbeu</td><td>Blotile</td><td>Duekoue</td></tr><tr><td>1</td><td></td><td></td><td>15</td><td></td><td>3</td><td></td><td></td><td></td><td></td><td>0.5</td></tr><tr><td>2</td><td></td><td></td><td></td><td>14</td><td></td><td></td><td>2</td><td>2</td><td>2</td><td></td></tr><tr><td>3</td><td>4</td><td>4</td><td></td><td></td><td>10</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>4</td><td>10</td><td></td><td></td><td></td><td>4</td><td>4</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>1</td><td></td><td></td><td></td><td>3</td><td></td><td></td><td></td><td></td><td></td></tr></table>
<table><tr><td>Platoons</td><td>Bangolo</td><td>Danané</td><td>Kahin</td><td>Logoualé</td><td>Guezon</td><td>BleniMéhouin</td><td>Dieouzon</td><td>Zoukougbeu</td><td>Blotile</td><td>Duekoue</td></tr><tr><td>5</td><td>5</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
8d7e4a6374fcfcbd8cae7b9578085431d3d4a8e6632482353faefcf67b2ab395.png
complex
<table><tr><td>Characteristics</td><td>Male (<i>n</i> = 26) (mean &#177; SD)a</td><td>Female (<i>n</i> = 24) (mean &#177; SD)a</td></tr><tr><td colspan="3">Continuous variable</td></tr><tr><td> Age (years)</td><td>28.2 &#177; 3.18</td><td>30.4 &#177; 3.67</td></tr><tr><td> Prepregnant body mass index (kg/m<sup>2</sup>)</td><td>22.0 &#177; 3.43</td><td>22.8 &#177; 4.24</td></tr><tr><td> Gestational age (weeks)</td><td>39.0 &#177; 1.50</td><td>38.7 &#177; 1.49</td></tr><tr><td> Baby birth weight (g)</td><td>3,251 &#177; 382</td><td>2,958 &#177; 393</td></tr><tr><td> Baby birth length (cm)</td><td>51.6 &#177; 2.59</td><td>50.9 &#177; 2.63</td></tr><tr><td> Baby head circumference (cm)</td><td>33.9 &#177; 1.23</td><td>33.0 &#177; 1.46</td></tr><tr><td> Placental weight (g)</td><td>629 &#177; 141</td><td>579 &#177; 184</td></tr><tr><td> Fat content of placenta (%)</td><td>0.74 &#177; 0.12</td><td>0.77 &#177; 0.084</td></tr><tr><td colspan="3">Categorical variable</td></tr><tr><td> Cigarette smoking, <i>n</i> (%)</td><td>1 (3.85)</td><td>2 (8.33)</td></tr><tr><td> Passive smoking, <i>n</i> (%)</td><td>13 (50.0)</td><td>11 (45.8)</td></tr><tr><td> Alcohol drinking, <i>n</i> (%)</td><td>0 (0.0)</td><td>0 (0.0)</td></tr><tr><td> Potential dioxin-exposed occupation, <i>n</i> (%)</td><td>0 (0.0)</td><td>0 (0.0)</td></tr></table>
<table><tr><td>Characteristics</td><td>Male (n = 26) (mean ± SD)a</td><td>Female (n = 24) (mean ± SD)a</td></tr><tr><td colspan="3">Continuous variable</td></tr><tr><td>Age (years)</td><td>28.2 ± 3.18</td><td>30.4 ± 3.67</td></tr><tr><td>Prepregnant body mass index (kg/m2)</td><td>22.0 ± 3.43</td><td>22.8 ± 4.24</td></tr></table>
<table><tr><td>Characteristics</td><td>Male (n = 26) (mean ± SD)a</td><td>Female (n = 24) (mean ± SD)a</td></tr><tr><td>Gestational age (weeks)</td><td>39.0 ± 1.50</td><td>38.7 ± 1.49</td></tr><tr><td>Baby birth weight (g)</td><td>3,251 ± 382</td><td>2,958 ± 393</td></tr><tr><td>Baby birth length (cm)</td><td>51.6 ± 2.59</td><td>50.9 ± 2.63</td></tr><tr><td>Baby head circumference (cm)</td><td>33.9 ± 1.23</td><td>33.0 ± 1.46</td></tr><tr><td>Placental weight (g)</td><td>629 ± 141</td><td>579 ± 184</td></tr><tr><td>Fat content of placenta (%)</td><td>0.74 ± 0.12</td><td>0.77 ± 0.084</td></tr><tr><td colspan="3">Categorical variable</td></tr><tr><td>Cigarette smoking, n (%)</td><td>1 (3.85)</td><td>2 (8.33)</td></tr><tr><td>Passive smoking, n (%)</td><td>13 (50.0)</td><td>11 (45.8)</td></tr><tr><td>Alcohol drinking, n (%)</td><td>0 (0.0)</td><td>0 (0.0)</td></tr><tr><td>Potential dioxin-exposed occupation, n (%)</td><td>0 (0.0)</td><td>0 (0.0)</td></tr></table>
da0d86f884b5af50770f90b3d5e1a71dca38609c1e9d46e8dc8d4695c4a1fd60.png
simple
<table><tr><td>Gene</td><td>Position <i>TGFBR1 TGFBR2 </i>gene</td><td>HGVS names</td><td>Protein position</td><td>Number of patients</td><td>rsSNP number</td></tr><tr><td><i>TGFBR1</i></td><td>Exon 1</td><td>c.68_76delCGGCGGCG</td><td>p.Ala23Ala</td><td>4</td><td>rs11466445</td></tr><tr><td> </td><td>IVS 7 + 24</td><td>c.1255 + 24 G &gt; A</td><td> </td><td>2</td><td>rs334354</td></tr><tr><td><i>TGFBR2</i></td><td>IVS 3 + 7</td><td>c.338 + 7 A &gt; G</td><td> </td><td>2</td><td>rs1155705</td></tr><tr><td> </td><td>IVS 5-4</td><td>c.455-4 T &gt; A</td><td> </td><td>3</td><td>rs11466512</td></tr><tr><td> </td><td>Exon 4</td><td>c.458delA</td><td>p.Lys153</td><td>8</td><td>rs79375991</td></tr></table>
<table><tr><td>Gene</td><td>Position TGFBR1 TGFBR2 gene</td><td>HGVS names</td><td>Protein position</td><td>Number of patients</td><td>rsSNP number</td></tr><tr><td>TGFBR1</td><td>Ex</td><td>c</td><td>p.Ala23</td><td></td><td>r</td></tr></table>
<table><tr><td></td><td>on 1</td><td>.68_76delCGGCGGCG</td><td>Ala</td><td>4</td><td>s11466445</td></tr><tr><td></td><td>IVS 7 + 24</td><td>c.1255 + 24 G > A</td><td></td><td>2</td><td>rs334354</td></tr><tr><td>TGFBR2</td><td>IVS 3 + 7</td><td>c.338 + 7 A > G</td><td></td><td>2</td><td>rs1155705</td></tr><tr><td></td><td>IVS 5-4</td><td>c.455-4 T > A</td><td></td><td>3</td><td>rs11466512</td></tr><tr><td></td><td>Exon 4</td><td>c.458delA</td><td>p.Lys153</td><td>8</td><td>rs79375991</td></tr></table>
141672c67a1a8e1785f29e050c54791d39d7514465207a9ae09222e862539b51.png
simple
<table><tr><td>Subject</td><td>Question</td></tr><tr><td>Directions</td><td>How would you make the directions more clear/easy to understand?</td></tr><tr><td></td><td>What does "in the past month" mean to you?</td></tr><tr><td></td><td>When you see "the past month", what days did you include?</td></tr><tr><td>Items</td><td>In your own words, what do you think this question is asking?</td></tr><tr><td></td><td>What does this question mean to you? What did you think of when answering this question?</td></tr><tr><td></td><td>Was this question easy to understand? Are there any specific words that are difficult to understand?</td></tr><tr><td></td><td>How would you change the words to make it more clear?</td></tr><tr><td></td><td>Was this item hard to answer? If yes, why?</td></tr><tr><td></td><td>How did you choose your answer?</td></tr><tr><td>Domains</td><td>In your own words, what do you think this group of questions is asking about?</td></tr><tr><td></td><td>How do you think these items are related?</td></tr><tr><td></td><td>Are there any questions that do not belong in this group?</td></tr><tr><td>ResponseChoices</td><td>What do you think about the response choices?</td></tr><tr><td></td><td>How would you make the response choices clearer or easier to understand?</td></tr><tr><td>OverallAssessment</td><td>Are there things that we forgot to ask about that you think are important?</td></tr><tr><td></td><td>Overall thoughts/opinions of the questionnaire?</td></tr><tr><td></td><td>Anything you would change in the questionnaire as a whole?</td></tr></table>
<table><tr><td>Subject</td><td>Question</td></tr><tr><td>Directions</td><td>How would you make the directions more clear/easy to understand?</td></tr></table>
<table><tr><td>Subject</td><td>Question</td></tr><tr><td></td><td>What does "in the past month" mean to you?</td></tr><tr><td></td><td>When you see "the past month", what days did you include?</td></tr><tr><td>Items</td><td>In your own words, what do you think this question is asking?</td></tr><tr><td></td><td>What does this question mean to you? What did you think of when answering this question?</td></tr><tr><td></td><td>Was this question easy to understand? Are there any specific words that are difficult to understand?</td></tr><tr><td></td><td>How would you change the words to make it more clear?</td></tr><tr><td></td><td>Was this item hard to answer? If yes, why?</td></tr><tr><td></td><td>How did you choose your answer?</td></tr><tr><td>Domains</td><td>In your own words, what do you think this group of questions is asking about?</td></tr><tr><td></td><td>How do you think these items are related?</td></tr><tr><td></td><td>Are there any questions that do not belong in this group?</td></tr><tr><td>ResponseChoices</td><td>What do you think about the response choices?</td></tr><tr><td></td><td>How would you make the response choices clearer or easier to understand?</td></tr><tr><td>OverallAssessment</td><td>Are there things that we forgot to ask about that you think are important?</td></tr><tr><td></td><td>Overall thoughts/opinions of the questionnaire?</td></tr><tr><td></td><td>Anything you would change in the questionnaire as a whole?</td></tr></table>
2d89c52307c71abd5bb1bfda6fc30e398283205645ad1c3e4ad843f211beeba2.png
simple
<table><tr><td>Parameter</td><td>NL</td><td>HC</td><td>MS</td><td>Units</td></tr><tr><td>count</td><td>211 &#177; 10</td><td>216 &#177; 13</td><td>217 &#177; 11</td><td>x10<sup>3</sup>/&#956;l</td></tr><tr><td>&#223;TG</td><td>51.7 &#177; 2.2</td><td>55.6 &#177; 2.3</td><td>52.3 &#177; 2.8</td><td>pg/ml</td></tr><tr><td>PF4</td><td>16.6 &#177; 2.4</td><td>18.9 &#177; 2.7</td><td>18.6 &#177; 2.5</td><td>pg/ml</td></tr><tr><td>TXB<sub>2</sub></td><td>7.4 &#177; 1.3</td><td>12.8 &#177; 2.3*</td><td>10.7 &#177; 1.9*</td><td>pg/ml</td></tr><tr><td>PS PGI<sub>2</sub></td><td>0.96 &#177; 0.09</td><td>1.82 &#177; 0.51*</td><td>1.65 &#177; 0.22*</td><td>ng/ml</td></tr><tr><td>SI</td><td>2.9 &#177; 0.4</td><td>4.1 &#177; 0.6*</td><td>6.8 &#177; 2.2*</td><td>%</td></tr><tr><td>WU</td><td>0.95 &#177; 0.02</td><td>0.86 &#177; 0.04*</td><td>0.78 &#177; 0.06*</td><td>%</td></tr><tr><td>retention</td><td>88.4 &#177; 3.2</td><td>87.1 &#177; 3.7</td><td>89.0 &#177; 3.8</td><td>%</td></tr><tr><td>migration</td><td>386 &#177; 21</td><td>397 &#177; 26</td><td>391 &#177; 22</td><td>mm<sup>2</sup></td></tr></table>
<table><tr><td>Parameter</td><td>NL</td><td>HC</td></tr><tr><td>count</td><td>211 ± 10</td><td>216 ± 13</td></tr><tr><td>ßTG</td><td>51.7 ± 2.2</td><td>55.6 ± 2.3</td></tr><tr><td>PF4</td><td>16.6 ± 2.4</td><td>18.9 ± 2.7</td></tr><tr><td>TXB2</td><td>7.4 ± 1.3</td><td>12.8 ± 2.3*</td></tr><tr><td>PS PGI2</td><td>0.96 ± 0.09</td><td>1.82 ± 0.51*</td></tr><tr><td>SI</td><td>2.9 ± 0.4</td><td>4.1 ± 0.6*</td></tr><tr><td>WU</td><td>0.95 ± 0.02</td><td>0.86 ± 0.04*</td></tr><tr><td>retention</td><td>88.4 ± 3.2</td><td>87.1 ± 3.7</td></tr><tr><td>migration</td><td>386 ± 21</td><td>397 ± 26</td></tr></table>
<table><tr><td>MS</td><td>Units</td></tr><tr><td>217 ± 11</td><td>x103/μl</td></tr><tr><td>52.3 ± 2.8</td><td>pg/ml</td></tr><tr><td>18.6 ± 2.5</td><td>pg/ml</td></tr><tr><td>10.7 ± 1.9*</td><td>pg/ml</td></tr><tr><td>1.65 ± 0.22*</td><td>ng/ml</td></tr><tr><td>6.8 ± 2.2*</td><td>%</td></tr><tr><td>0.78 ± 0.06*</td><td>%</td></tr><tr><td>89.0 ± 3.8</td><td>%</td></tr><tr><td>391 ± 22</td><td>mm2</td></tr></table>
f4b8330dd98c0b9589fb6262a8214db46a92898735edf5b73933f12dd3a0bc62.png
complex
<table><tr><td colspan="2">Parameters</td><td>PC1</td><td>PC2</td><td>R<sup>2</sup></td><td><i>p</i>-Value</td></tr><tr><td colspan="2">Tide (m)</td><td>&#8722;0.8349</td><td>0.5504</td><td>0.01</td><td>0.894</td></tr><tr><td colspan="2">Sediment Temperature (&#176;C)</td><td>&#8722;0.4182</td><td>0.9084</td><td>0.01</td><td>0.931</td></tr><tr><td colspan="2">Salinity (ppt)</td><td>&#8722;0.3844</td><td>&#8722;0.9232</td><td>0.01</td><td>0.782</td></tr><tr><td colspan="2">pH</td><td>0.5676</td><td>0.8233</td><td>0.02</td><td>0.461</td></tr><tr><td colspan="2">Ammonia</td><td>&#8722;0.4668</td><td>&#8722;0.8844</td><td>0.01</td><td>0.698</td></tr><tr><td colspan="2">Nitrate</td><td>&#8722;1.0000</td><td>&#8722;0.0023</td><td>0.02</td><td>0.449</td></tr><tr><td colspan="2">Nitrite</td><td>0.8412</td><td>&#8722;0.5408</td><td>0.02</td><td>0.326</td></tr><tr><td colspan="2">Sulfide</td><td>0.9900</td><td>0.1414</td><td>0.02</td><td>0.352</td></tr><tr><td rowspan="5">Group</td><td>1</td><td>&#8722;0.1079</td><td>&#8722;0.1349</td><td rowspan="5">0.41</td><td rowspan="5">0.001</td></tr><tr><td>2</td><td>0.4435</td><td>0.1412</td></tr><tr><td>3</td><td>0.0883</td><td>0.6255</td></tr><tr><td>4</td><td>0.4232</td><td>0.4104</td></tr><tr><td>5</td><td>&#8722;0.0277</td><td>0.3129</td></tr><tr><td rowspan="5">Vegetation Zone</td><td>JS</td><td>0.0159</td><td>&#8722;0.1705</td><td rowspan="5">0.07</td><td rowspan="5">0.131</td></tr><tr><td>SAL</td><td>&#8722;0.0235</td><td>&#8722;0.0705</td></tr><tr><td>SS</td><td>&#8722;0.0573</td><td>&#8722;0.0658</td></tr><tr><td>S</td><td>0.0731</td><td>0.1548</td></tr><tr><td>T</td><td>0.0402</td><td>0.0563</td></tr></table>
<table><tr><td colspan="2">Parameters</td><td>PC1</td><td>PC2</td><td>R2</td><td>p-Value</td></tr><tr><td colspan="2">Tide (m)</td><td>−0.8349</td><td>0.5504</td><td>0.01</td><td>0.894</td></tr><tr><td colspan="2">Sediment Temperature (°C)</td><td>−0.4182</td><td>0.9084</td><td>0.01</td><td>0.931</td></tr><tr><td colspan="2">Salinity (ppt)</td><td>−0.3844</td><td>−0.9232</td><td>0.01</td><td>0.782</td></tr><tr><td colspan="2">pH</td><td>0.5676</td><td>0.8233</td><td>0.02</td><td>0.461</td></tr><tr><td colspan="2">Ammonia</td><td>−0.4668</td><td>−0.8844</td><td>0.01</td><td>0.698</td></tr><tr><td colspan="2">Nitrate</td><td>−1.0000</td><td>−0.0023</td><td>0.02</td><td>0.449</td></tr><tr><td colspan="2">Nitrite</td><td>0.8412</td><td>−0.5408</td><td>0.02</td><td>0.326</td></tr></table>
<table><tr><td colspan="2">Sulfide</td><td>0.9900</td><td>0.1414</td><td>0.02</td><td>0.352</td></tr><tr><td rowspan="5">Group</td><td>1</td><td>−0.1079</td><td>−0.1349</td><td rowspan="5">0.41</td><td rowspan="5">0.001</td></tr><tr><td>2</td><td>0.4435</td><td>0.1412</td></tr><tr><td>3</td><td>0.0883</td><td>0.6255</td></tr><tr><td>4</td><td>0.4232</td><td>0.4104</td></tr><tr><td>5</td><td>−0.0277</td><td>0.3129</td></tr><tr><td rowspan="5">Vegetation Zone</td><td>JS</td><td>0.0159</td><td>−0.1705</td><td rowspan="5">0.07</td><td rowspan="5">0.131</td></tr><tr><td>SAL</td><td>−0.0235</td><td>−0.0705</td></tr><tr><td>SS</td><td>−0.0573</td><td>−0.0658</td></tr><tr><td>S</td><td>0.0731</td><td>0.1548</td></tr><tr><td>T</td><td>0.0402</td><td>0.0563</td></tr></table>
6e6aff56806f49e827d54d3cf6c8b0aa5b808c9604c52e50c82406926b7b4fad.png
simple
<table><tr><td>References</td><td>Period of sample collection</td><td>Year of publication</td><td>Study area</td><td>Age of participants</td></tr><tr><td>Chandenier et al. [20]</td><td>1993</td><td>1995</td><td>Brazzaville, Niari, Kouilou, Pool</td><td>6&#8211;10 years</td></tr><tr><td>Durand et al. [21]</td><td>1998</td><td>2003</td><td>Pointe-Noire</td><td>No limit</td></tr><tr><td>Nsimba et al. [22]</td><td>1999&#8211;2002</td><td>2004</td><td>Brazzaville, Pointe-Noire</td><td>0.5&#8211;&lt;5 years</td></tr><tr><td>Nsimba et al. [23]</td><td>1999&#8211;2002</td><td>2005</td><td>Brazzaville, Pointe-Noire</td><td>0.5&#8211;&lt;5 years</td></tr><tr><td>Mayengue et al. [24]</td><td>2003</td><td>2005</td><td>Brazzaville</td><td>&#8804;5 years</td></tr><tr><td>Ndounga et al. [25]</td><td>2003&#8211;2004</td><td>2007</td><td>Brazzaville</td><td>&lt;5 years</td></tr><tr><td>Ndounga et al. [13]</td><td>2003&#8211;2006</td><td>2008</td><td>Brazzaville</td><td>No limit</td></tr><tr><td>Van den Broek et al. [26]</td><td>2004</td><td>2006</td><td>Kindamba</td><td>0.5&#8211;&lt;5 years</td></tr><tr><td>Mayengue et al. [27]</td><td>2005</td><td>2011</td><td>Brazzaville</td><td>No limit</td></tr><tr><td>Ndounga et al. [28]</td><td>2005</td><td>2013</td><td>Brazzaville</td><td>No limit</td></tr><tr><td>Pradine et al. [29]</td><td>2005&#8211;2006</td><td>2006</td><td>Pointe-Noire</td><td>1.4&#8211;17 years</td></tr><tr><td>Tsumori et al. [11]</td><td>2005&#8211;2006</td><td>2011</td><td>Brazzaville, Gamboma, Pointe-Noire</td><td>No limit</td></tr><tr><td>Oguike et al. [19]</td><td>2005&#8211;2006</td><td>2011</td><td>Brazzaville, Gamboma, Pointe-Noire</td><td>No limit</td></tr><tr><td>Moyen et al. [14]</td><td>2006</td><td>2010</td><td>Brazzaville</td><td>&#8804;15 years</td></tr><tr><td>Ndounga et al. [30]</td><td>2006</td><td>2012</td><td>Brazzaville</td><td>0.5&#8211;10 years</td></tr><tr><td>Murai et al. [31]</td><td>2006</td><td>2015</td><td>Brazzaville, Gamboma, Pointe-Noire</td><td>No limit</td></tr><tr><td>Mita et al. [32]</td><td>2006</td><td>2016</td><td>Brazzaville, Gamboma, Pointe-Noire</td><td>No limit</td></tr><tr><td>Culleton et al. [12]</td><td>2007</td><td>2009</td><td>Pointe-Noire</td><td>No limit</td></tr><tr><td>Koekemoer et al. [33]</td><td>2009</td><td>2011</td><td>Boutoto</td><td>Not applicable</td></tr><tr><td>Koukouikila-Koussounda et al. [15]</td><td>2010</td><td>2012</td><td>Brazzaville</td><td>&lt;10 years</td></tr><tr><td>Ibara-Okabande et al. [34]</td><td>2010&#8211;2011</td><td>2012</td><td>Brazzaville</td><td>&lt;10 years</td></tr><tr><td>Ndounga et al. [35]</td><td>2010&#8211;2011</td><td>2015</td><td>Brazzaville</td><td>&lt;10 years</td></tr><tr><td>Ossou-Nguiet et al. [18]</td><td>2011</td><td>2013</td><td>Brazzaville</td><td>0.4&#8211;14 years</td></tr><tr><td>Mbongo et al. [17]</td><td>2011&#8211;2013</td><td>2015</td><td>Brazzaville</td><td>15&#8211;39 years</td></tr><tr><td>Ntoumi et al. [9]</td><td>2011&#8211;2012</td><td>2013</td><td>Brazzaville, Pointe-Noire</td><td>&#8804;15 years</td></tr><tr><td>Koukouikila-Koussounda et al. [36]</td><td>2012&#8211;2013</td><td>2015</td><td>Brazzaville</td><td>12&#8211;44 years</td></tr><tr><td> Ntoumi et al. [16]</td><td>2012&#8211;2013</td><td>2016</td><td>Brazzaville</td><td>12&#8211;44 years</td></tr><tr><td>Singana et al. [10]</td><td>2012&#8211;2013</td><td>2016</td><td>Owando</td><td>&lt;12 years</td></tr></table>
<table><tr><td>References</td><td>Period of sample collection</td><td>Year of publication</td><td>Study area</td><td>Age of participants</td></tr><tr><td>Chandenier et al. [20]</td><td>1993</td><td>1995</td><td>Brazzaville, Niari, Kouilou, Pool</td><td>6–10 years</td></tr><tr><td>Durand et al. [21]</td><td>1998</td><td>2003</td><td>Pointe-Noire</td><td>No limit</td></tr><tr><td>Nsimba et al. [22]</td><td>1999–2002</td><td>2004</td><td>Brazzaville, Pointe-Noire</td><td>0.5–<5 years</td></tr><tr><td>Nsimba et al. [23]</td><td>1999–2002</td><td>2005</td><td>Brazzaville, Pointe-Noire</td><td>0.5–<5 years</td></tr><tr><td>Mayengue et al. [24]</td><td>2003</td><td>2005</td><td>Brazzaville</td><td>≤5 years</td></tr><tr><td>Ndounga et al. [25]</td><td>2003–2004</td><td>2007</td><td>Brazzaville</td><td><5 years</td></tr><tr><td>Ndounga et al. [13]</td><td>2003–2006</td><td>2008</td><td>Brazzaville</td><td>No limit</td></tr><tr><td>Van den Broek et al. [26]</td><td>2004</td><td>2006</td><td>Kindamba</td><td>0.5–<5 years</td></tr><tr><td>Mayengue et al. [27]</td><td>2005</td><td>2011</td><td>Brazzaville</td><td>No limit</td></tr><tr><td>Ndounga et al. [28]</td><td>2005</td><td>2013</td><td>Brazzaville</td><td>No limit</td></tr><tr><td>Pradine et al. [29]</td><td>2005–2006</td><td>2006</td><td>Pointe-Noire</td><td>1.4–17 years</td></tr><tr><td>Tsumori et al. [11]</td><td>2005–2006</td><td>2011</td><td>Brazzaville, Gamboma, Pointe-Noire</td><td>No limit</td></tr><tr><td>Oguike et al. [19]</td><td>2005–2006</td><td>2011</td><td>Brazzaville, Gamboma, Pointe-Noire</td><td>No limit</td></tr></table>
<table><tr><td>Moyen et al. [14]</td><td>2006</td><td>2010</td><td>Brazzaville</td><td>≤15 years</td></tr><tr><td>Ndounga et al. [30]</td><td>2006</td><td>2012</td><td>Brazzaville</td><td>0.5–10 years</td></tr><tr><td>Murai et al. [31]</td><td>2006</td><td>2015</td><td>Brazzaville, Gamboma, Pointe-Noire</td><td>No limit</td></tr><tr><td>Mita et al. [32]</td><td>2006</td><td>2016</td><td>Brazzaville, Gamboma, Pointe-Noire</td><td>No limit</td></tr><tr><td>Culleton et al. [12]</td><td>2007</td><td>2009</td><td>Pointe-Noire</td><td>No limit</td></tr><tr><td>Koekemoer et al. [33]</td><td>2009</td><td>2011</td><td>Boutoto</td><td>Not applicable</td></tr><tr><td>Koukouikila-Koussounda et al. [15]</td><td>2010</td><td>2012</td><td>Brazzaville</td><td><10 years</td></tr><tr><td>Ibara-Okabande et al. [34]</td><td>2010–2011</td><td>2012</td><td>Brazzaville</td><td><10 years</td></tr><tr><td>Ndounga et al. [35]</td><td>2010–2011</td><td>2015</td><td>Brazzaville</td><td><10 years</td></tr><tr><td>Ossou-Nguiet et al. [18]</td><td>2011</td><td>2013</td><td>Brazzaville</td><td>0.4–14 years</td></tr><tr><td>Mbongo et al. [17]</td><td>2011–2013</td><td>2015</td><td>Brazzaville</td><td>15–39 years</td></tr><tr><td>Ntoumi et al. [9]</td><td>2011–2012</td><td>2013</td><td>Brazzaville, Pointe-Noire</td><td>≤15 years</td></tr><tr><td>Koukouikila-Koussounda et al. [36]</td><td>2012–2013</td><td>2015</td><td>Brazzaville</td><td>12–44 years</td></tr><tr><td>Ntoumi et al. [16]</td><td>2012–2013</td><td>2016</td><td>Brazzaville</td><td>12–44 years</td></tr><tr><td>Singana et al. [10]</td><td>2012–2013</td><td>2016</td><td>Owando</td><td><12 years</td></tr></table>
9cbb49d65706be553b7263daaf1a3701b8d65d59204de7f6b4c7c6fd8a476065.png
complex
<table><tr><td rowspan="2">Category</td><td colspan="2">Repbase TEs</td><td colspan="2">TE proteins</td><td colspan="2"><i>de novo</i></td><td colspan="2">Combined TEs</td></tr><tr><td>Length (bp)</td><td>% of genome</td><td>Length (bp)</td><td>% of genome</td><td>Length (bp)</td><td>% of genome</td><td>Length (bp)</td><td>% of genome</td></tr><tr><td>DNA</td><td>25,035,683</td><td>1.43</td><td>6,450,126</td><td>0.37</td><td>56,943,252</td><td>3.26</td><td>70,663,766</td><td>4.04</td></tr><tr><td>LINE</td><td>124,676,466</td><td>7.13</td><td>132,747,210</td><td>7.60</td><td>191,015,014</td><td>10.93</td><td>213,508,152</td><td>12.22</td></tr><tr><td>SINE</td><td>20,281,741</td><td>1.16</td><td>-</td><td>0.00</td><td>54,941,907</td><td>3.14</td><td>57,180,364</td><td>3.27</td></tr><tr><td>LTR</td><td>7,613,766</td><td>0.44</td><td>17,931,338</td><td>1.03</td><td>16,104,019</td><td>0.92</td><td>28,021,391</td><td>1.60</td></tr><tr><td>Other</td><td>24,327</td><td>0.00</td><td>-</td><td>0.00</td><td>-</td><td>0.00</td><td>24,327</td><td>0.00</td></tr><tr><td>Unknown</td><td>761,119</td><td>0.04</td><td>-</td><td>0.00</td><td>283,563,847</td><td>16.23</td><td>284,276,315</td><td>16.27</td></tr><tr><td>Total</td><td>174,011,206</td><td>9.96</td><td>157,050,977</td><td>8.99</td><td>627,828,869</td><td>35.93</td><td>657,625,603</td><td>37.63</td></tr></table>
<table><tr><td rowspan="2">Category</td><td colspan="2">Repbase TEs</td><td colspan="2">TE proteins</td><td colspan="2">de novo</td><td colspan="2">Combined TEs</td></tr><tr><td>Length (bp)</td><td>% of genome</td><td>Length (bp)</td><td>% of genome</td><td>Length (bp)</td><td>% of genome</td><td>Length (bp)</td><td>% of genome</td></tr><tr><td>DNA</td><td>25,035,683</td><td>1.43</td><td>6,450,126</td><td>0.37</td><td>56,943,252</td><td>3.26</td><td>70,663,766</td><td>4.04</td></tr><tr><td>LINE</td><td>124,676,466</td><td>7.13</td><td>132,747,210</td><td>7.60</td><td>191,015,014</td><td>10.93</td><td>213,508,152</td><td>12.22</td></tr><tr><td>SINE</td><td>20,281,741</td><td>1.16</td><td>-</td><td>0.00</td><td>54,941,907</td><td>3.14</td><td>57,180,364</td><td>3.27</td></tr><tr><td>LTR</td><td>7,613,766</td><td>0.44</td><td>17,931,338</td><td>1.03</td><td>16,104,019</td><td>0.92</td><td>28,021,391</td><td>1.60</td></tr></table>
<table><tr><td>Other</td><td>24,327</td><td>0.00</td><td>-</td><td>0.00</td><td>-</td><td>0.00</td><td>24,327</td><td>0.00</td></tr><tr><td>Unknown</td><td>761,119</td><td>0.04</td><td>-</td><td>0.00</td><td>283,563,847</td><td>16.23</td><td>284,276,315</td><td>16.27</td></tr><tr><td>Total</td><td>174,011,206</td><td>9.96</td><td>157,050,977</td><td>8.99</td><td>627,828,869</td><td>35.93</td><td>657,625,603</td><td>37.63</td></tr></table>
309970d7b5749dfb1ec5853da66d5f48497ec2a0dccde5cc3f0ea975b01c0d37.png
simple
<table><tr><td><i>n</i> = 1450</td><td>Cluster 1<i>n</i> = 385</td><td>Cluster 2<i>n</i> = 431</td><td>Cluster 3<i>n</i> = 243</td><td>Cluster 4<i>n</i> = 391</td></tr><tr><td>Severity<sup>&#8743;</sup></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>(i) Moderate</td><td>23.8</td><td>25.3</td><td>31.2</td><td>49.4</td></tr><tr><td>(ii) Severe</td><td>16.8</td><td>9.1</td><td>8.2</td><td>23.1</td></tr><tr><td>Asthma<sup>&#8743;</sup></td><td>11.2</td><td>32.1</td><td>28.3</td><td>5.8</td></tr><tr><td>Pollen allergy<sup>&#8743;</sup></td><td>78.5</td><td>36.3</td><td>11.3</td><td>87.4</td></tr><tr><td>House dust mite allergy<sup>&#8743;</sup></td><td>18.8</td><td>33.5</td><td>32.1</td><td>51.5</td></tr><tr><td>Total IgE<sup><i>&#8727;</i></sup></td><td>138 (129)</td><td>89 (87)</td><td>116 (98)</td><td>221 (167)</td></tr><tr><td>FeNO<sup><i>&#8727;&#8727;</i></sup></td><td>35 (22)</td><td>69 (54)</td><td>54 (34)</td><td>36 (15)</td></tr></table>
<table><tr><td>n = 1450</td><td>Cluster 1n = 385</td><td>Cluster 2n = 431</td><td>Cluster 3n = 243</td><td>Cluster 4n = 391</td></tr><tr><td>Severity∧</td><td></td><td></td><td></td><td></td></tr><tr><td>(i) Moderate</td><td>23.8</td><td>25.3</td><td>31.2</td><td>49.4</td></tr><tr><td>(ii) Severe</td><td>16.8</td><td>9.1</td><td>8.2</td><td>23.1</td></tr></table>
<table><tr><td>Asthma∧</td><td>11.2</td><td>32.1</td><td>28.3</td><td>5.8</td></tr><tr><td>Pollen allergy∧</td><td>78.5</td><td>36.3</td><td>11.3</td><td>87.4</td></tr><tr><td>House dust mite allergy∧</td><td>18.8</td><td>33.5</td><td>32.1</td><td>51.5</td></tr><tr><td>Total IgE∗</td><td>138 (129)</td><td>89 (87)</td><td>116 (98)</td><td>221 (167)</td></tr><tr><td>FeNO∗∗</td><td>35 (22)</td><td>69 (54)</td><td>54 (34)</td><td>36 (15)</td></tr></table>
deb3d75db3ca918756c4602648e93d1c7f8cdb77490cdf7ae6c1703d131ca1ac.png
complex
<table><tr><td rowspan="2"></td><td colspan="2">SAR</td><td colspan="2">SEM</td></tr><tr><td>Coef.</td><td>z-Value</td><td>Coef.</td><td>z-Value</td></tr><tr><td>Household car ownership</td><td>0.35&#8270;&#8270;&#8270;</td><td>5.58</td><td>0.22&#8270;&#8270;&#8270;</td><td>3.42</td></tr><tr><td>Prop. of people going to work by public transport</td><td>0.39&#8270;</td><td>2.56</td><td>0.42&#8270;&#8270;</td><td>2.92</td></tr><tr><td>Prop. of people who are economically active</td><td>0.78&#8270;</td><td>2.57</td><td>1.07&#8270;&#8270;&#8270;</td><td>3.85</td></tr><tr><td>Prop. of white</td><td>0.22</td><td>1.93</td><td>0.22&#8270;</td><td>2.06</td></tr><tr><td>Median age</td><td>0.01&#8270;&#8270;&#8270;</td><td>3.91</td><td>0.02&#8270;&#8270;&#8270;</td><td>7.00</td></tr><tr><td>Prop. of households classified as deprived</td><td>&#8722; 0.01</td><td>&#8722; 0.06</td><td>&#8722; 0.19</td><td>&#8722; 0.98</td></tr><tr><td>Fuel poverty</td><td>&#8722; 0.004</td><td>&#8722; 0.84</td><td>&#8722; 0.002</td><td>&#8722; 0.45</td></tr><tr><td>Regions</td><td></td><td></td><td></td><td></td></tr><tr><td> London</td><td colspan="4">Reference case</td></tr><tr><td> East Midlands</td><td>0.29&#8270;&#8270;&#8270;</td><td>4.93</td><td>0.02</td><td>0.32</td></tr><tr><td> East of England</td><td>0.11&#8270;</td><td>2.10</td><td>0.02</td><td>0.44</td></tr><tr><td> North East</td><td>0.11</td><td>1.65</td><td>0.03</td><td>0.51</td></tr><tr><td> North West</td><td>0.09</td><td>1.70</td><td>&#8722; 0.09</td><td>&#8722; 1.41</td></tr><tr><td> South East</td><td>0.10&#8270;</td><td>2.01</td><td>0.04</td><td>0.73</td></tr><tr><td> South West</td><td>0.13&#8270;</td><td>2.20</td><td>0.06</td><td>1.00</td></tr><tr><td> West Midlands</td><td>0.13&#8270;</td><td>2.21</td><td>&#8722; 0.10</td><td>&#8722; 1.53</td></tr><tr><td> Yorkshire and the Humber</td><td>0.20&#8270;&#8270;&#8270;</td><td>3.40</td><td>0.03</td><td>0.55</td></tr><tr><td>Constant</td><td>&#8722; 0.39</td><td>&#8722; 1.00</td><td>&#8722; 0.83&#8270;</td><td>&#8722; 2.33</td></tr><tr><td><i>&#955;</i></td><td>&#8722; 55.35&#8270;&#8270;&#8270;</td><td>&#8722; 3.64</td><td></td><td></td></tr><tr><td><i>&#961;</i></td><td></td><td></td><td>550.47&#8270;&#8270;&#8270;</td><td>30.75</td></tr><tr><td>Statistics</td><td></td><td></td><td></td><td></td></tr><tr><td> N</td><td>320</td><td></td><td>320</td><td></td></tr><tr><td> Log-likelihood</td><td>247.75</td><td></td><td>278.91</td><td></td></tr><tr><td> AIC</td><td>&#8722; 459.49</td><td></td><td>&#8722; 521.81</td><td></td></tr></table>
<table><tr><td rowspan="2"></td><td colspan="2">SAR</td><td colspan="2">SEM</td></tr><tr><td>Coef.</td><td>z-Value</td><td>Coef.</td><td>z-Value</td></tr><tr><td>Household car ownership</td><td>0.35⁎⁎⁎</td><td>5.58</td><td>0.22⁎⁎⁎</td><td>3.42</td></tr><tr><td>Prop. of people going to work by public transport</td><td>0.39⁎</td><td>2.56</td><td>0.42⁎⁎</td><td>2.92</td></tr><tr><td>Prop. of people who are economically active</td><td>0.78⁎</td><td>2.57</td><td>1.07⁎⁎⁎</td><td>3.85</td></tr><tr><td>Prop. of white</td><td>0.22</td><td>1.93</td><td>0.22⁎</td><td>2.06</td></tr><tr><td>Median age</td><td>0.01⁎⁎⁎</td><td>3.91</td><td>0.02⁎⁎⁎</td><td>7.00</td></tr><tr><td>Prop. of households classified as deprived</td><td>− 0.01</td><td>− 0.06</td><td>− 0.19</td><td>− 0.98</td></tr><tr><td>Fuel poverty</td><td>− 0.004</td><td>− 0.84</td><td>− 0.002</td><td>− 0.45</td></tr><tr><td>Regions</td><td></td><td></td><td></td><td></td></tr><tr><td>London</td><td colspan="4">Reference case</td></tr><tr><td>East Midlands</td><td>0.29⁎⁎⁎</td><td>4.93</td><td>0.02</td><td>0.32</td></tr><tr><td>East of England</td><td>0.11⁎</td><td>2.10</td><td>0.02</td><td>0.44</td></tr><tr><td>North East</td><td>0.11</td><td>1.65</td><td>0.03</td><td>0.51</td></tr><tr><td>North West</td><td>0.09</td><td>1.70</td><td>− 0.09</td><td>− 1.41</td></tr><tr><td>South East</td><td>0.10⁎</td><td>2.01</td><td>0.04</td><td>0.73</td></tr><tr><td>South West</td><td>0.13⁎</td><td>2.20</td><td>0.06</td><td>1.00</td></tr><tr><td>West Midlands</td><td>0.13⁎</td><td>2.21</td><td>− 0.10</td><td>− 1.53</td></tr></table>
<table><tr><td rowspan="2"></td><td colspan="2">SAR</td><td colspan="2">SEM</td></tr><tr><td>Coef.</td><td>z-Value</td><td>Coef.</td><td>z-Value</td></tr><tr><td>Yorkshire and the Humber</td><td>0.20⁎⁎⁎</td><td>3.40</td><td>0.03</td><td>0.55</td></tr><tr><td>Constant</td><td>− 0.39</td><td>− 1.00</td><td>− 0.83⁎</td><td>− 2.33</td></tr><tr><td>λ</td><td>− 55.35⁎⁎⁎</td><td>− 3.64</td><td></td><td></td></tr><tr><td>ρ</td><td></td><td></td><td>550.47⁎⁎⁎</td><td>30.75</td></tr><tr><td>Statistics</td><td></td><td></td><td></td><td></td></tr><tr><td>N</td><td>320</td><td></td><td>320</td><td></td></tr><tr><td>Log-likelihood</td><td>247.75</td><td></td><td>278.91</td><td></td></tr><tr><td>AIC</td><td>− 459.49</td><td></td><td>− 521.81</td><td></td></tr></table>
bbf54ba10ce67ea7be00528556a32c527c1238ba604f655635a487936487fe43.png
simple
<table><tr><td>S. No.</td><td>Allergen</td><td>Mouse MHC class I</td><td>Mouse MHC class II</td><td>Human MHC class I</td><td>Human MHC class II</td></tr><tr><td>1</td><td><i>Asp f1</i></td><td>148&#8211;156 (VIYTYPNKV)</td><td> </td><td>147&#8211;155 (RVIYTYPNK)</td><td> </td></tr><tr><td> </td><td> </td><td> </td><td>9&#8211;23 (LLAATAVSVLAAPSP)</td><td>9&#8211;17 (LLAATAVSV)</td><td>1&#8211;15 (MVAIKNLFLLAATAV)</td></tr><tr><td>2</td><td><i>Asp f2</i></td><td> </td><td>5&#8211;19 (LRLAVLLPLAAPLVA)</td><td>9&#8211;17 (VLLPLAAPL)</td><td>4&#8211;18 (LLRLAVLLPLAAPLV)</td></tr><tr><td>3</td><td><i>Asp f5</i></td><td> </td><td>318&#8211;332 (LSFKYPYSVSSSPPS)</td><td>316&#8211;324 (SSLSFKYPY)</td><td>308&#8211;322 (LNNYRPSSSSLSFKY)</td></tr><tr><td> </td><td> </td><td> </td><td>319&#8211;333 (SFKYPYSVSSSPPSS)</td><td>314&#8211;322 (SSSSLSFKY)</td><td>305&#8211;319 (PSYLNNYRPSSSSLS)</td></tr><tr><td>4</td><td><i>Asp f17</i></td><td> </td><td>93&#8211;108 (DKFVAANAGGTVYED)</td><td>98&#8211;106 (AANAGGTVY)</td><td> </td></tr><tr><td>5</td><td><i>Asp f34</i></td><td> </td><td>75&#8211;89 (IQDGSLYLYAASATP)</td><td>74&#8211;82 (YIQDGSLYL)</td><td> </td></tr></table>
<table><tr><td>S. No.</td><td>Allergen</td><td>Mouse MHC class I</td></tr><tr><td>1</td><td>Asp f1</td><td>148–156 (VIYTYPNKV)</td></tr><tr><td></td><td></td><td></td></tr><tr><td>2</td><td>Asp f2</td><td></td></tr><tr><td>3</td><td>Asp f5</td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td>4</td><td>Asp f17</td><td></td></tr><tr><td>5</td><td>Asp f34</td><td></td></tr></table>
<table><tr><td>Mouse MHC class II</td><td>Human MHC class I</td><td>Human MHC class II</td></tr><tr><td></td><td>147–155 (RVIYTYPNK)</td><td></td></tr><tr><td>9–23 (LLAATAVSVLAAPSP)</td><td>9–17 (LLAATAVSV)</td><td>1–15 (MVAIKNLFLLAATAV)</td></tr><tr><td>5–19 (LRLAVLLPLAAPLVA)</td><td>9–17 (VLLPLAAPL)</td><td>4–18 (LLRLAVLLPLAAPLV)</td></tr><tr><td>318–332 (LSFKYPYSVSSSPPS)</td><td>316–324 (SSLSFKYPY)</td><td>308–322 (LNNYRPSSSSLSFKY)</td></tr><tr><td>319–333 (SFKYPYSVSSSPPSS)</td><td>314–322 (SSSSLSFKY)</td><td>305–319 (PSYLNNYRPSSSSLS)</td></tr><tr><td>93–108 (DKFVAANAGGTVYED)</td><td>98–106 (AANAGGTVY)</td><td></td></tr><tr><td>75–89 (IQDGSLYLYAASATP)</td><td>74–82 (YIQDGSLYL)</td><td></td></tr></table>
1a5ca9ef3d23d5d5062f9b38a689b5fe9537115239d0e7ebacae212182259878.png
simple
<table><tr><td>Patient sizes</td><td>Typical nasal trumpet sizes (Fr)</td></tr><tr><td>Large man</td><td>34, 30</td></tr><tr><td>Medium man</td><td>32, 28</td></tr><tr><td>Small man</td><td>30, 28</td></tr><tr><td>Large woman</td><td>32, 28</td></tr><tr><td>Medium woman</td><td>30, 28</td></tr><tr><td>Small woman</td><td>28, 26</td></tr></table>
<table><tr><td>Patient sizes</td><td>Typical nasal trumpet sizes (Fr)</td></tr></table>
<table><tr><td>Large man</td><td>34, 30</td></tr><tr><td>Medium man</td><td>32, 28</td></tr><tr><td>Small man</td><td>30, 28</td></tr><tr><td>Large woman</td><td>32, 28</td></tr><tr><td>Medium woman</td><td>30, 28</td></tr><tr><td>Small woman</td><td>28, 26</td></tr></table>
b2190455bef530091861ff19b70a46c4e839a248df9dea957ac711cbfeb3bb2f.png
complex
<table><tr><td></td><td colspan="2">LN-ER/PR+Her2- status</td><td colspan="2">LN+ER/PR-Her2+ status</td></tr><tr><td></td><td>Relapse</td><td>No relapse</td><td>Relapse</td><td>No relapse</td></tr><tr><td>Number of patients</td><td>12</td><td>81</td><td>39</td><td>51</td></tr><tr><td>Age in year</td><td>53.25&#177;14.27</td><td>51.07&#177;10.06</td><td>47.77&#177;9.10</td><td>46.41&#177;8.35</td></tr><tr><td>Time to relapse (months)</td><td>23.83&#177;8.29</td><td>-</td><td>17.59&#177;10.38</td><td>-</td></tr><tr><td>Pre-/post-menopausal</td><td>5/7</td><td>45/36</td><td>17/22</td><td>28/23</td></tr><tr><td>Tumor size (mm)</td><td>1.90&#177;0.67</td><td>2.34&#177;1.16</td><td>3.92&#177;1.82</td><td>3.2&#177;1.47</td></tr><tr><td>Family carcinoma history +/-</td><td>6/6</td><td>21/60</td><td>25/14</td><td>15/36</td></tr><tr><td>Stage I/IIa/IIb/III</td><td>8/2/2/0</td><td>46/29/6/0</td><td>6/14/9/10</td><td>17/23/7/4</td></tr><tr><td>Her2+/++/+++</td><td>-</td><td>-</td><td>14/20/5</td><td>23/19/9</td></tr><tr><td>ER content &#8804;30%/31%-60%/&gt;60%</td><td>3/4/5</td><td>12/34/35</td><td>-</td><td>-</td></tr><tr><td>PR content &#8804;30%/31%-60%/&gt;60%</td><td>4/0/8</td><td>8/30/43</td><td>-</td><td>-</td></tr><tr><td>PCNA content - / &#8804;30%/31%-60%/&gt;60%</td><td>1/1/2/8</td><td>7/7/27/40</td><td>0/3/23/13</td><td>6/7/23/15</td></tr><tr><td>P53 content - / &#8804;30%/31%-60%/&gt;60%</td><td>8/3/1/0</td><td>59/12/2/1</td><td>15/0/7/17</td><td>25/1/12/13</td></tr><tr><td>Lymph node &lt;4/4-9/&gt;9</td><td>-</td><td>-</td><td>16/13/10</td><td>34/12/5</td></tr><tr><td>Radiation/no radiation</td><td>12/0</td><td>81/0</td><td>39/0</td><td>51/0</td></tr><tr><td>Adjuvant therapy: hormonal (tamoxifen)</td><td>12/0</td><td>81/0</td><td>0/39</td><td>0/51</td></tr></table>
<table><tr><td></td><td colspan="2">LN-ER/PR+Her2- status</td><td colspan="2">LN+ER/PR-Her2+ status</td></tr><tr><td></td><td>Relapse</td><td>No relapse</td><td>Relapse</td><td>No relapse</td></tr><tr><td>Number of patients</td><td>12</td><td>81</td><td>39</td><td>51</td></tr></table>
<table><tr><td></td><td colspan="2">LN-ER/PR+Her2- status</td><td colspan="2">LN+ER/PR-Her2+ status</td></tr><tr><td></td><td>Relapse</td><td>No relapse</td><td>Relapse</td><td>No relapse</td></tr><tr><td>Age in year</td><td>53.25±14.27</td><td>51.07±10.06</td><td>47.77±9.10</td><td>46.41±8.35</td></tr><tr><td>Time to relapse (months)</td><td>23.83±8.29</td><td>-</td><td>17.59±10.38</td><td>-</td></tr><tr><td>Pre-/post-menopausal</td><td>5/7</td><td>45/36</td><td>17/22</td><td>28/23</td></tr><tr><td>Tumor size (mm)</td><td>1.90±0.67</td><td>2.34±1.16</td><td>3.92±1.82</td><td>3.2±1.47</td></tr><tr><td>Family carcinoma history +/-</td><td>6/6</td><td>21/60</td><td>25/14</td><td>15/36</td></tr><tr><td>Stage I/IIa/IIb/III</td><td>8/2/2/0</td><td>46/29/6/0</td><td>6/14/9/10</td><td>17/23/7/4</td></tr><tr><td>Her2+/++/+++</td><td>-</td><td>-</td><td>14/20/5</td><td>23/19/9</td></tr><tr><td>ER content ≤30%/31%-60%/>60%</td><td>3/4/5</td><td>12/34/35</td><td>-</td><td>-</td></tr><tr><td>PR content ≤30%/31%-60%/>60%</td><td>4/0/8</td><td>8/30/43</td><td>-</td><td>-</td></tr><tr><td>PCNA content - / ≤30%/31%-60%/>60%</td><td>1/1/2/8</td><td>7/7/27/40</td><td>0/3/23/13</td><td>6/7/23/15</td></tr><tr><td>P53 content - / ≤30%/31%-60%/>60%</td><td>8/3/1/0</td><td>59/12/2/1</td><td>15/0/7/17</td><td>25/1/12/13</td></tr><tr><td>Lymph node <4/4-9/>9</td><td>-</td><td>-</td><td>16/13/10</td><td>34/12/5</td></tr><tr><td>Radiation/no radiation</td><td>12/0</td><td>81/0</td><td>39/0</td><td>51/0</td></tr><tr><td>Adjuvant therapy: hormonal (tamoxifen)</td><td>12/0</td><td>81/0</td><td>0/39</td><td>0/51</td></tr></table>
7470de674ad24c741b9e04b8d3a51e346615159d607bfe99e2f2d5ce9a6bd95c.png
simple
<table><tr><td>Group</td><td>Water storage (24 hours)</td><td>Thermocycling (10,000 cycles)</td></tr><tr><td>NC</td><td>20.18 (2.01)<sup>c</sup></td><td>20.68 (4.60)<sup>b</sup></td></tr><tr><td>SBU</td><td>27.33 (2.81)<sup>b</sup></td><td>22.49 (4.11)<sup>b<i>&#8727;</i></sup></td></tr><tr><td>PC</td><td>30.50 (3.40)<sup>a</sup></td><td>28.77 (3.52)<sup>a</sup></td></tr></table>
<table><tr><td>Group</td></tr><tr><td>NC</td></tr><tr><td>SBU</td></tr><tr><td>PC</td></tr></table>
<table><tr><td>Water storage (24 hours)</td><td>Thermocycling (10,000 cycles)</td></tr><tr><td>20.18 (2.01)c</td><td>20.68 (4.60)b</td></tr><tr><td>27.33 (2.81)b</td><td>22.49 (4.11)b∗</td></tr><tr><td>30.50 (3.40)a</td><td>28.77 (3.52)a</td></tr></table>
5340c0cf513238af6b10d21866e785251395208684896dc08566b1b46ed3cb90.png
complex
<table><tr><td colspan="2">True Phylo</td><td colspan="3">QuartetS</td><td colspan="3">QuartetA</td><td colspan="3">QuartetM</td><td colspan="3">Quartet-Net</td><td colspan="3">Neighbor-Net</td><td colspan="3">Neighbor-Joining</td></tr><tr><td>Split</td><td>Wei</td><td>Split</td><td>Wei</td><td>BV</td><td>Split</td><td>Wei</td><td>BV</td><td>Split</td><td>Wei</td><td>BV</td><td>Split</td><td>Wei</td><td>BV</td><td>Split</td><td>Wei</td><td>BV</td><td>Split</td><td>Wei</td><td>BV</td></tr><tr><td>ab</td><td>1</td><td>ab</td><td>1.08</td><td>100</td><td>ab</td><td>1.09</td><td>100</td><td>ab</td><td>1.12</td><td>100</td><td>ab</td><td>1.08</td><td>100</td><td>ab</td><td>0.76</td><td>80</td><td>ab</td><td>0.41</td><td>56</td></tr><tr><td>abc</td><td>4</td><td>abc</td><td>4</td><td>100</td><td>abc</td><td>4</td><td>100</td><td>abc</td><td>4</td><td>100</td><td>abc</td><td>4</td><td>100</td><td>abc</td><td>4</td><td>100</td><td>abc</td><td>4</td><td>100</td></tr><tr><td>abd</td><td>1</td><td>abd</td><td>1.03</td><td>100</td><td>abd</td><td>1.03</td><td>100</td><td>abd</td><td>1.03</td><td>100</td><td>abd</td><td>1.02</td><td>100</td><td>abd</td><td>1.32</td><td>50</td><td> </td><td> </td><td> </td></tr><tr><td>abcd</td><td>4</td><td>abcd</td><td>3.99</td><td>100</td><td>abcd</td><td>3.99</td><td>100</td><td>abcd</td><td>3.99</td><td>100</td><td>abcd</td><td>3.99</td><td>100</td><td>abcd</td><td>4.17</td><td>100</td><td>abcd</td><td>3.97</td><td>100</td></tr><tr><td>abce</td><td>1</td><td>abce</td><td>1.01</td><td>100</td><td>abce</td><td>1.02</td><td>100</td><td>abce</td><td>1.01</td><td>100</td><td>abce</td><td>1.01</td><td>100</td><td>abce</td><td>0.86</td><td>46</td><td> </td><td> </td><td> </td></tr><tr><td>abcg</td><td>1</td><td>abcg</td><td>1.03</td><td>100</td><td>abcg</td><td>1.03</td><td>100</td><td>abcg</td><td>1.03</td><td>100</td><td>abcg</td><td>1.02</td><td>100</td><td>abcg</td><td>0.89</td><td>54</td><td> </td><td> </td><td> </td></tr><tr><td>aefg</td><td>1</td><td>aefg</td><td>1.02</td><td>100</td><td>aefg</td><td>1.03</td><td>100</td><td>aefg</td><td>1.02</td><td>100</td><td>aefg</td><td>1.02</td><td>100</td><td>aefg</td><td>1.39</td><td>50</td><td> </td><td> </td><td> </td></tr><tr><td>abcde</td><td>1</td><td>abcde</td><td>1.08</td><td>100</td><td>abcde</td><td>1.09</td><td>100</td><td>abcde</td><td>1.12</td><td>100</td><td>abcde</td><td>1.07</td><td>100</td><td>abcde</td><td>0.76</td><td>67</td><td>abcde</td><td>0.39</td><td>46</td></tr><tr><td>abcdg</td><td>1</td><td>abcdg</td><td>1.07</td><td>100</td><td>abcdg</td><td>1.08</td><td>100</td><td>abcdg</td><td>1.11</td><td>100</td><td>abcdg</td><td>1.07</td><td>100</td><td>abcdg</td><td>0.71</td><td>68</td><td>abcdg</td><td>0.39</td><td>54</td></tr><tr><td>abceg</td><td>2</td><td>abceg</td><td>2.07</td><td>100</td><td>abceg</td><td>2.09</td><td>100</td><td>abceg</td><td>2.12</td><td>100</td><td>abceg</td><td>2.07</td><td>100</td><td>abceg</td><td>2.36</td><td>47</td><td> </td><td> </td><td> </td></tr><tr><td>acefg</td><td>2</td><td>acefg</td><td>2.06</td><td>100</td><td>acefg</td><td>2.07</td><td>100</td><td>acefg</td><td>2.11</td><td>100</td><td>acefg</td><td>2.06</td><td>100</td><td>acefg</td><td>2.23</td><td>8</td><td> </td><td> </td><td> </td></tr><tr><td>adefg</td><td>1</td><td>adefg</td><td>1.08</td><td>100</td><td>adefg</td><td>1.09</td><td>100</td><td>adefg</td><td>1.12</td><td>100</td><td>adefg</td><td>1.07</td><td>100</td><td>adefg</td><td>0.76</td><td>73</td><td>adefg</td><td>0.43</td><td>44</td></tr><tr><td>a</td><td>10</td><td>a</td><td>10.31</td><td>100</td><td>a</td><td>10.15</td><td>100</td><td>a</td><td>10.17</td><td>100</td><td>a</td><td>10.43</td><td>100</td><td>a</td><td>10.07</td><td>100</td><td>a</td><td>9.42</td><td>100</td></tr><tr><td>b</td><td>6</td><td>b</td><td>6.25</td><td>100</td><td>b</td><td>6.11</td><td>100</td><td>b</td><td>6.07</td><td>100</td><td>b</td><td>6.33</td><td>100</td><td>b</td><td>7.62</td><td>100</td><td>b</td><td>7.15</td><td>100</td></tr><tr><td>c</td><td>10</td><td>c</td><td>10.26</td><td>100</td><td>c</td><td>10.11</td><td>100</td><td>c</td><td>10.12</td><td>100</td><td>c</td><td>10.38</td><td>100</td><td>c</td><td>10.05</td><td>100</td><td>c</td><td>9.40</td><td>100</td></tr><tr><td>d</td><td>4</td><td>d</td><td>4.21</td><td>100</td><td>d</td><td>4.06</td><td>100</td><td>d</td><td>4.08</td><td>100</td><td>d</td><td>4.26</td><td>100</td><td>d</td><td>6.02</td><td>100</td><td>d</td><td>6.82</td><td>100</td></tr><tr><td>e</td><td>10</td><td>e</td><td>10.28</td><td>100</td><td>e</td><td>10.14</td><td>100</td><td>e</td><td>10.16</td><td>100</td><td>e</td><td>10.41</td><td>100</td><td>e</td><td>10.12</td><td>100</td><td>e</td><td>9.43</td><td>100</td></tr><tr><td>f</td><td>6</td><td>f</td><td>6.25</td><td>100</td><td>f</td><td>6.11</td><td>100</td><td>f</td><td>6.06</td><td>100</td><td>f</td><td>6.34</td><td>100</td><td>f</td><td>7.22</td><td>100</td><td>f</td><td>7.11</td><td>100</td></tr><tr><td>g</td><td>10</td><td>g</td><td>10.31</td><td>100</td><td>g</td><td>10.16</td><td>100</td><td>g</td><td>10.18</td><td>100</td><td>g</td><td>10.44</td><td>100</td><td>g</td><td>10.14</td><td>100</td><td>g</td><td>9.47</td><td>100</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>ac</td><td>0.08</td><td>99</td><td>abdfg</td><td>0.04</td><td>15</td><td> </td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>abcdf</td><td>0.08</td><td>97</td><td>ag</td><td>0.04</td><td>13</td><td> </td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>acdeg</td><td>0.02</td><td>74</td><td>ae</td><td>0.03</td><td>12</td><td> </td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>acdef</td><td>0.03</td><td>66</td><td>abdef</td><td>0.04</td><td>10</td><td> </td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>ae</td><td>0.04</td><td>65</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>abdeg</td><td>0.03</td><td>65</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>ag</td><td>0.04</td><td>64</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>abdfg</td><td>0.04</td><td>64</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>acdfg</td><td>0.02</td><td>62</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>abdef</td><td>0.04</td><td>59</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>af</td><td>0.03</td><td>58</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr></table>
<table><tr><td colspan="2">True Phylo</td><td colspan="3">QuartetS</td><td colspan="3">QuartetA</td><td colspan="3">QuartetM</td><td colspan="3">Quartet-Net</td><td colspan="3">Neighbor-Net</td><td colspan="3">Neighbor-Joining</td></tr><tr><td>Sp</td><td>Wei</td><td>Spli</td><td></td><td>B</td><td></td><td>Wei</td><td>BV</td><td>Spli</td><td></td><td></td><td>Spl</td><td></td><td></td><td></td><td>Wei</td><td>B</td><td>Spli</td><td></td><td>B</td></tr></table>
<table><tr><td>lit</td><td></td><td>t</td><td>Wei</td><td>V</td><td>Split</td><td></td><td></td><td>t</td><td>Wei</td><td>BV</td><td>it</td><td>Wei</td><td>BV</td><td>Split</td><td></td><td>V</td><td>t</td><td>Wei</td><td>V</td></tr><tr><td>ab</td><td>1</td><td>ab</td><td>1.08</td><td>100</td><td>ab</td><td>1.09</td><td>100</td><td>ab</td><td>1.12</td><td>100</td><td>ab</td><td>1.08</td><td>100</td><td>ab</td><td>0.76</td><td>80</td><td>ab</td><td>0.41</td><td>56</td></tr><tr><td>abc</td><td>4</td><td>abc</td><td>4</td><td>100</td><td>abc</td><td>4</td><td>100</td><td>abc</td><td>4</td><td>100</td><td>abc</td><td>4</td><td>100</td><td>abc</td><td>4</td><td>100</td><td>abc</td><td>4</td><td>100</td></tr><tr><td>abd</td><td>1</td><td>abd</td><td>1.03</td><td>100</td><td>abd</td><td>1.03</td><td>100</td><td>abd</td><td>1.03</td><td>100</td><td>abd</td><td>1.02</td><td>100</td><td>abd</td><td>1.32</td><td>50</td><td></td><td></td><td></td></tr><tr><td>abcd</td><td>4</td><td>abcd</td><td>3.99</td><td>100</td><td>abcd</td><td>3.99</td><td>100</td><td>abcd</td><td>3.99</td><td>100</td><td>abcd</td><td>3.99</td><td>100</td><td>abcd</td><td>4.17</td><td>100</td><td>abcd</td><td>3.97</td><td>100</td></tr><tr><td>abce</td><td>1</td><td>abce</td><td>1.01</td><td>100</td><td>abce</td><td>1.02</td><td>100</td><td>abce</td><td>1.01</td><td>100</td><td>abce</td><td>1.01</td><td>100</td><td>abce</td><td>0.86</td><td>46</td><td></td><td></td><td></td></tr><tr><td>abcg</td><td>1</td><td>abcg</td><td>1.03</td><td>100</td><td>abcg</td><td>1.03</td><td>100</td><td>abcg</td><td>1.03</td><td>100</td><td>abcg</td><td>1.02</td><td>100</td><td>abcg</td><td>0.89</td><td>54</td><td></td><td></td><td></td></tr><tr><td>aefg</td><td>1</td><td>aefg</td><td>1.02</td><td>100</td><td>aefg</td><td>1.03</td><td>100</td><td>aefg</td><td>1.02</td><td>100</td><td>aefg</td><td>1.02</td><td>100</td><td>aefg</td><td>1.39</td><td>50</td><td></td><td></td><td></td></tr><tr><td>abcde</td><td>1</td><td>abcde</td><td>1.08</td><td>100</td><td>abcde</td><td>1.09</td><td>100</td><td>abcde</td><td>1.12</td><td>100</td><td>abcde</td><td>1.07</td><td>100</td><td>abcde</td><td>0.76</td><td>67</td><td>abcde</td><td>0.39</td><td>46</td></tr><tr><td>abcdg</td><td>1</td><td>abcdg</td><td>1.07</td><td>100</td><td>abcdg</td><td>1.08</td><td>100</td><td>abcdg</td><td>1.11</td><td>100</td><td>abcdg</td><td>1.07</td><td>100</td><td>abcdg</td><td>0.71</td><td>68</td><td>abcdg</td><td>0.39</td><td>54</td></tr><tr><td>abceg</td><td>2</td><td>abceg</td><td>2.07</td><td>100</td><td>abceg</td><td>2.09</td><td>100</td><td>abceg</td><td>2.12</td><td>100</td><td>abceg</td><td>2.07</td><td>100</td><td>abceg</td><td>2.36</td><td>47</td><td></td><td></td><td></td></tr><tr><td>acefg</td><td>2</td><td>acefg</td><td>2.06</td><td>100</td><td>acefg</td><td>2.07</td><td>100</td><td>acefg</td><td>2.11</td><td>100</td><td>acefg</td><td>2.06</td><td>100</td><td>acefg</td><td>2.23</td><td>8</td><td></td><td></td><td></td></tr><tr><td>adefg</td><td>1</td><td>adefg</td><td>1.08</td><td>100</td><td>adefg</td><td>1.09</td><td>100</td><td>adefg</td><td>1.12</td><td>100</td><td>adefg</td><td>1.07</td><td>100</td><td>adefg</td><td>0.76</td><td>73</td><td>adefg</td><td>0.43</td><td>44</td></tr><tr><td>a</td><td>10</td><td>a</td><td>10.31</td><td>100</td><td>a</td><td>10.15</td><td>100</td><td>a</td><td>10.17</td><td>100</td><td>a</td><td>10.43</td><td>100</td><td>a</td><td>10.07</td><td>100</td><td>a</td><td>9.42</td><td>100</td></tr><tr><td>b</td><td>6</td><td>b</td><td>6.25</td><td>100</td><td>b</td><td>6.11</td><td>100</td><td>b</td><td>6.07</td><td>100</td><td>b</td><td>6.33</td><td>100</td><td>b</td><td>7.62</td><td>100</td><td>b</td><td>7.15</td><td>100</td></tr><tr><td>c</td><td>10</td><td>c</td><td>10.26</td><td>100</td><td>c</td><td>10.11</td><td>100</td><td>c</td><td>10.12</td><td>100</td><td>c</td><td>10.38</td><td>100</td><td>c</td><td>10.05</td><td>100</td><td>c</td><td>9.40</td><td>100</td></tr><tr><td>d</td><td>4</td><td>d</td><td>4.21</td><td>100</td><td>d</td><td>4.06</td><td>100</td><td>d</td><td>4.08</td><td>100</td><td>d</td><td>4.26</td><td>100</td><td>d</td><td>6.02</td><td>100</td><td>d</td><td>6.82</td><td>100</td></tr><tr><td>e</td><td>10</td><td>e</td><td>10.28</td><td>100</td><td>e</td><td>10.14</td><td>100</td><td>e</td><td>10.16</td><td>100</td><td>e</td><td>10.41</td><td>100</td><td>e</td><td>10.12</td><td>100</td><td>e</td><td>9.43</td><td>100</td></tr><tr><td>f</td><td>6</td><td>f</td><td>6.25</td><td>100</td><td>f</td><td>6.11</td><td>100</td><td>f</td><td>6.06</td><td>100</td><td>f</td><td>6.34</td><td>100</td><td>f</td><td>7.22</td><td>100</td><td>f</td><td>7.11</td><td>100</td></tr><tr><td>g</td><td>10</td><td>g</td><td>10.31</td><td>100</td><td>g</td><td>10.16</td><td>100</td><td>g</td><td>10.18</td><td>100</td><td>g</td><td>10.44</td><td>100</td><td>g</td><td>10.14</td><td>100</td><td>g</td><td>9.47</td><td>100</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>ac</td><td>0.08</td><td>99</td><td>abdfg</td><td>0.04</td><td>15</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>abcdf</td><td>0.08</td><td>97</td><td>ag</td><td>0.04</td><td>13</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>acdeg</td><td>0.02</td><td>74</td><td>ae</td><td>0.03</td><td>12</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>acdef</td><td>0.03</td><td>66</td><td>abdef</td><td>0.04</td><td>10</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>ae</td><td>0.04</td><td>65</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>abdeg</td><td>0.03</td><td>65</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>ag</td><td>0.04</td><td>64</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>abdfg</td><td>0.04</td><td>64</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>acdfg</td><td>0.02</td><td>62</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>abdef</td><td>0.04</td><td>59</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>af</td><td>0.03</td><td>58</td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
51b83e119d718535953f95ef3373d8397cb9df191ad4d3346315cc6af48b7808.png
complex
<table><tr><td></td><td colspan="3">6-8 h postoperative &gt;20%</td><td colspan="3">66-72 h postoperative &gt;20%</td></tr><tr><td></td><td>Sevoflurane</td><td>Xenon</td><td><i>P</i>-value</td><td>Sevoflurane</td><td>Xenon</td><td><i>P</i>-value</td></tr><tr><td>DS</td><td>5 (26)</td><td>2 (11)</td><td>0,405</td><td>5 (28)</td><td>3 (21)</td><td>1</td></tr><tr><td>DSST</td><td>4 (21)</td><td>3 (17)</td><td>1</td><td>1 (6)</td><td>0 (0)</td><td>1</td></tr><tr><td>TMT A</td><td>4 (21)</td><td>4 (22)</td><td>1</td><td>1 (6)</td><td>6 (43)</td><td>0,027</td></tr><tr><td>TMT B</td><td>4 (21)</td><td>6 (33)</td><td>0,476</td><td>3 (17)</td><td>0 (0)</td><td>0,238</td></tr><tr><td>Alertness RT</td><td>5 (26)</td><td>4 (22)</td><td>1</td><td>2 (12)</td><td>2 (14)</td><td>1</td></tr><tr><td>Alertness VR</td><td>0 (0)</td><td>2 (11)</td><td>0,23</td><td>1 (6)</td><td>1 (7)</td><td>1</td></tr><tr><td>Divided Attention RT</td><td>2 (11)</td><td>1 (6)</td><td>1</td><td>1 (6)</td><td>2 (14)</td><td>0,576</td></tr><tr><td>Divided Attention VR</td><td>1 (6)</td><td>1 (6)</td><td>1</td><td>2 (12)</td><td>0 (0)</td><td>0,488</td></tr><tr><td>Visual Scanning RT</td><td>7 (37)</td><td>3 (17)</td><td>0,269</td><td>4 (25)</td><td>2 (14)</td><td>0,657</td></tr><tr><td>Visual Scanning VR</td><td>3 16)</td><td>3 (17)</td><td>1</td><td>3 (19)</td><td>2 (14)</td><td>1</td></tr><tr><td>Working Memory RT</td><td>3 (16)</td><td>4 (22)</td><td>0,693</td><td>5 (31)</td><td>3 (21)</td><td>0,689</td></tr><tr><td>Working Memory VR</td><td>5 (26)</td><td>5 (28)</td><td>1</td><td>1 (6)</td><td>0 (0)</td><td>1</td></tr><tr><td>Reaction Change RT</td><td>3 (16)</td><td>1 (6)</td><td>0,608</td><td>0 (0)</td><td>0 (0)</td><td>-</td></tr><tr><td>Reaction Change VR</td><td>0 (0)</td><td>2 (13)</td><td>0,202</td><td>0 (0)</td><td>1 (8)</td><td>0,433</td></tr></table>
<table><tr><td></td><td colspan="3">6-8 h postoperative >20%</td><td colspan="3">66-72 h postoperative >20%</td></tr><tr><td></td><td>Sevoflurane</td><td>Xenon</td><td>P-value</td><td>Sevoflurane</td><td>Xenon</td><td>P-value</td></tr><tr><td>DS</td><td>5 (26)</td><td>2 (11)</td><td>0,405</td><td>5 (28)</td><td>3 (21)</td><td>1</td></tr><tr><td>DSST</td><td>4 (21)</td><td>3 (17)</td><td>1</td><td>1 (6)</td><td>0 (0)</td><td>1</td></tr><tr><td>TMT A</td><td>4 (21)</td><td>4 (22)</td><td>1</td><td>1 (6)</td><td>6 (43)</td><td>0,027</td></tr><tr><td>TMT B</td><td>4 (21)</td><td>6 (33)</td><td>0,476</td><td>3 (17)</td><td>0 (0)</td><td>0,238</td></tr><tr><td>Alertness RT</td><td>5 (26)</td><td>4 (22)</td><td>1</td><td>2 (12)</td><td>2 (14)</td><td>1</td></tr><tr><td>Alertness VR</td><td></td><td>2 (1</td><td>0,23</td><td>1 (6</td><td>1 (7</td><td></td></tr></table>
<table><tr><td></td><td>0 (0)</td><td>1)</td><td></td><td>)</td><td>)</td><td>1</td></tr><tr><td>Divided Attention RT</td><td>2 (11)</td><td>1 (6)</td><td>1</td><td>1 (6)</td><td>2 (14)</td><td>0,576</td></tr><tr><td>Divided Attention VR</td><td>1 (6)</td><td>1 (6)</td><td>1</td><td>2 (12)</td><td>0 (0)</td><td>0,488</td></tr><tr><td>Visual Scanning RT</td><td>7 (37)</td><td>3 (17)</td><td>0,269</td><td>4 (25)</td><td>2 (14)</td><td>0,657</td></tr><tr><td>Visual Scanning VR</td><td>3 16)</td><td>3 (17)</td><td>1</td><td>3 (19)</td><td>2 (14)</td><td>1</td></tr><tr><td>Working Memory RT</td><td>3 (16)</td><td>4 (22)</td><td>0,693</td><td>5 (31)</td><td>3 (21)</td><td>0,689</td></tr><tr><td>Working Memory VR</td><td>5 (26)</td><td>5 (28)</td><td>1</td><td>1 (6)</td><td>0 (0)</td><td>1</td></tr><tr><td>Reaction Change RT</td><td>3 (16)</td><td>1 (6)</td><td>0,608</td><td>0 (0)</td><td>0 (0)</td><td>-</td></tr><tr><td>Reaction Change VR</td><td>0 (0)</td><td>2 (13)</td><td>0,202</td><td>0 (0)</td><td>1 (8)</td><td>0,433</td></tr></table>
a38648f1a71f88d9b16a97dc6b95e5f55921d4c339fa7fca45795f14a4f2a2db.png
simple
<table><tr><td> </td><td>Unadjusted OR</td><td>95% CI</td><td>Adjusted OR</td><td>95% CI</td><td>P-value</td></tr><tr><td>Adherence history:</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>poor at least once vs optimal</td><td>1.34</td><td>(0.81, 2.17)</td><td>1.30</td><td>(0.78, 2.10)</td><td>0.30</td></tr><tr><td>non-response at least once vs optimal</td><td>1.99</td><td>(1.01, 3.63)</td><td>1.98</td><td>(1.00, 3.62)</td><td>0.03</td></tr><tr><td>missing at least once vs optimal</td><td>3.26</td><td>(1.65, 5.96)</td><td>3.60</td><td>(1.80, 6.65)</td><td>&lt;0.001</td></tr><tr><td>Pre-ART WHO disease stage</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>stage 2</td><td>1(ref)</td><td> </td><td>1(ref)</td><td> </td><td>0.8</td></tr><tr><td>stage 3</td><td>1.08</td><td>(0.61, 2.02)</td><td>1.02</td><td>(0.57, 1.91)</td><td> </td></tr><tr><td>stage 4</td><td>1.48</td><td>(0.76, 2.92)</td><td>1.19</td><td>(0.60, 2.41)</td><td> </td></tr><tr><td>Pre-ART CD4 cell count</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>0-49</td><td>1.69</td><td>(0.88, 3.51)</td><td>1.43</td><td>(0.72, 3.07)</td><td> </td></tr><tr><td>50-99</td><td>1.27</td><td>(0.61, 2.77)</td><td>1.18</td><td>(0.55, 2.61)</td><td> </td></tr><tr><td>100-149</td><td>1.07</td><td>(0.49, 2.41)</td><td>1.01</td><td>(0.45, 2.29)</td><td> </td></tr><tr><td>150-199</td><td>1(ref)</td><td> </td><td>1(ref)</td><td> </td><td>0.6</td></tr><tr><td>Pre-ART Body mass index</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>&lt;20</td><td>1.35</td><td>(0.82, 2.18)</td><td>1.31</td><td>(0.79, 2.14)</td><td> </td></tr><tr><td>20-27</td><td>1(ref)</td><td> </td><td>1(ref)</td><td> </td><td>0.5</td></tr><tr><td>&gt;27</td><td>1.37</td><td>(0.59, 2.79)</td><td>1.33</td><td>(0.57,2.77)</td><td> </td></tr><tr><td>Age at ART initiation groups</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>18-35</td><td>1(ref)</td><td> </td><td>1(ref)</td><td> </td><td>0.9</td></tr><tr><td>35-50</td><td>0.84</td><td>(0.53, 1.35)</td><td>0.92</td><td>(0.57, 1.50)</td><td> </td></tr><tr><td>50+</td><td>0.89</td><td>(0.31, 2.09)</td><td>1.03</td><td>(0.35, 2.48)</td><td> </td></tr><tr><td>Sex</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Female vs Male</td><td>1.23</td><td>(0.76, 2.04)</td><td>1.31</td><td>(0.79, 2.22)</td><td>0.3</td></tr><tr><td>Time since ART initiation in years</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>&#8804;2</td><td>1(ref)</td><td> </td><td>1(ref)</td><td> </td><td>0.06</td></tr><tr><td>2-3</td><td>0.37</td><td>(0.17, 0.73)</td><td>0.40</td><td>(0.18, 0.79)</td><td> </td></tr><tr><td>3-4</td><td>0.57</td><td>(0.30, 1.04)</td><td>0.60</td><td>(0.31, 1.10)</td><td> </td></tr><tr><td>4-5</td><td>0.49</td><td>(0.24, 0.93)</td><td>0.47</td><td>(0.23, 0.91)</td><td> </td></tr><tr><td>&gt;5</td><td>0.76</td><td>(0.34, 1.54)</td><td>0.65</td><td>(0.29, 1.34)</td><td> </td></tr></table>
<table><tr><td></td><td>Unadjusted OR</td><td>95% CI</td><td>Adjusted OR</td><td>95% CI</td><td>P-value</td></tr><tr><td>Adherence history:</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>poor at least once vs optimal</td><td>1.34</td><td>(0.81, 2.17)</td><td>1.30</td><td>(0.78, 2.10)</td><td>0.30</td></tr><tr><td>non-response at least once vs optimal</td><td>1.99</td><td>(1.01, 3.63)</td><td>1.98</td><td>(1.00, 3.62)</td><td>0.03</td></tr><tr><td>missing at least once vs optimal</td><td>3.26</td><td>(1.65, 5.96)</td><td>3.60</td><td>(1.80, 6.65)</td><td><0.001</td></tr><tr><td>Pre-ART WHO disease stage</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>stage 2</td><td>1(ref)</td><td></td><td>1(ref)</td><td></td><td>0.8</td></tr><tr><td>stage 3</td><td>1.08</td><td>(0.61, 2.02)</td><td>1.02</td><td>(0.57, 1.91)</td><td></td></tr><tr><td>stage 4</td><td>1.48</td><td>(0.76, 2.92)</td><td>1.19</td><td>(0.60, 2.41)</td><td></td></tr><tr><td>Pre-ART CD4 cell count</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>0-49</td><td>1.69</td><td>(0.88, 3.51)</td><td>1.43</td><td>(0.72, 3.07)</td><td></td></tr><tr><td>50-99</td><td>1.27</td><td>(0.61, 2.77)</td><td>1.18</td><td>(0.55, 2.61)</td><td></td></tr><tr><td>100-149</td><td>1.07</td><td>(0.49, 2.41)</td><td>1.01</td><td>(0.45, 2.29)</td><td></td></tr><tr><td>150-199</td><td>1(ref)</td><td></td><td>1(ref)</td><td></td><td>0.6</td></tr><tr><td>Pre-ART Body mass index</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><20</td><td>1.35</td><td>(0.82, 2.18)</td><td>1.31</td><td>(0.79, 2.14)</td><td></td></tr><tr><td>20-27</td><td>1(ref)</td><td></td><td>1(ref)</td><td></td><td>0.5</td></tr><tr><td>>27</td><td>1.37</td><td>(0.59, 2.79)</td><td>1.33</td><td>(0.57,2.77)</td><td></td></tr></table>
<table><tr><td></td><td>Unadjusted OR</td><td>95% CI</td><td>Adjusted OR</td><td>95% CI</td><td>P-value</td></tr><tr><td>Age at ART initiation groups</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>18-35</td><td>1(ref)</td><td></td><td>1(ref)</td><td></td><td>0.9</td></tr><tr><td>35-50</td><td>0.84</td><td>(0.53, 1.35)</td><td>0.92</td><td>(0.57, 1.50)</td><td></td></tr><tr><td>50+</td><td>0.89</td><td>(0.31, 2.09)</td><td>1.03</td><td>(0.35, 2.48)</td><td></td></tr><tr><td>Sex</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Female vs Male</td><td>1.23</td><td>(0.76, 2.04)</td><td>1.31</td><td>(0.79, 2.22)</td><td>0.3</td></tr><tr><td>Time since ART initiation in years</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>≤2</td><td>1(ref)</td><td></td><td>1(ref)</td><td></td><td>0.06</td></tr><tr><td>2-3</td><td>0.37</td><td>(0.17, 0.73)</td><td>0.40</td><td>(0.18, 0.79)</td><td></td></tr><tr><td>3-4</td><td>0.57</td><td>(0.30, 1.04)</td><td>0.60</td><td>(0.31, 1.10)</td><td></td></tr><tr><td>4-5</td><td>0.49</td><td>(0.24, 0.93)</td><td>0.47</td><td>(0.23, 0.91)</td><td></td></tr><tr><td>>5</td><td>0.76</td><td>(0.34, 1.54)</td><td>0.65</td><td>(0.29, 1.34)</td><td></td></tr></table>
6aeea3d79080b4971978841e42e5640a7bf4ee44c0fb619ae48361fcf346d6c2.png
complex
<table><tr><td rowspan="3"></td><td colspan="2">Full Sample</td><td colspan="2">Sibling Subsample</td><td colspan="2">Non-Sibling Subsample</td></tr><tr><td>(1)</td><td>(2)</td><td>(3)</td><td>(4)</td><td>(5)</td><td>(6)</td></tr><tr><td>Food</td><td>Nutrient-Rich Food Groups</td><td>Food</td><td>Nutrient-Rich Food Groups</td><td>Food</td><td>Nutrient-Rich Food Groups</td></tr><tr><td>LNS</td><td>0.068<sup>*</sup></td><td>0.069<sup>*</sup></td><td>0.070</td><td>0.059</td><td>0.060</td><td>0.068</td></tr><tr><td></td><td>(0.036)</td><td>(0.038)</td><td>(0.058)</td><td>(0.066)</td><td>(0.046)</td><td>(0.047)</td></tr><tr><td>Z-Score of Maternal Height</td><td>&#8722;0.006</td><td>&#8722;0.004</td><td>&#8722;0.026</td><td>&#8722;0.040</td><td>0.016</td><td>0.023</td></tr><tr><td></td><td>(0.019)</td><td>(0.019)</td><td>(0.036)</td><td>(0.039)</td><td>(0.022)</td><td>(0.022)</td></tr><tr><td>LNS<sup>*</sup>Z-Score of Maternal Height</td><td>0.031</td><td>0.035</td><td>0.119</td><td>0.170*</td><td>-0.013</td><td>-0.025</td></tr><tr><td></td><td>(0.039)</td><td>(0.042)</td><td>(0.076)</td><td>(0.089)</td><td>(0.046)</td><td>(0.048)</td></tr><tr><td colspan="7">&#8232;&#8232;</td></tr><tr><td>N</td><td>1089</td><td>1111</td><td>394</td><td>403</td><td>695</td><td>708</td></tr><tr><td>Overall R<sup>2</sup></td><td>0.094</td><td>0.089</td><td>0.165</td><td>0.144</td><td>0.062</td><td>0.065</td></tr></table>
<table><tr><td></td><td colspan="2">Full Sample</td><td colspan="2">Sibling Subsample</td><td colspan="2">Non-Sibling Subsample</td></tr></table>
<table><tr><td rowspan="2"></td><td>(1)</td><td>(2)</td><td>(3)</td><td>(4)</td><td>(5)</td><td>(6)</td></tr><tr><td>Food</td><td>Nutrient-Rich Food Groups</td><td>Food</td><td>Nutrient-Rich Food Groups</td><td>Food</td><td>Nutrient-Rich Food Groups</td></tr><tr><td>LNS</td><td>0.068*</td><td>0.069*</td><td>0.070</td><td>0.059</td><td>0.060</td><td>0.068</td></tr><tr><td></td><td>(0.036)</td><td>(0.038)</td><td>(0.058)</td><td>(0.066)</td><td>(0.046)</td><td>(0.047)</td></tr><tr><td>Z-Score of Maternal Height</td><td>−0.006</td><td>−0.004</td><td>−0.026</td><td>−0.040</td><td>0.016</td><td>0.023</td></tr><tr><td></td><td>(0.019)</td><td>(0.019)</td><td>(0.036)</td><td>(0.039)</td><td>(0.022)</td><td>(0.022)</td></tr><tr><td>LNS*Z-Score of Maternal Height</td><td>0.031</td><td>0.035</td><td>0.119</td><td>0.170*</td><td>-0.013</td><td>-0.025</td></tr><tr><td></td><td>(0.039)</td><td>(0.042)</td><td>(0.076)</td><td>(0.089)</td><td>(0.046)</td><td>(0.048)</td></tr><tr><td colspan="7"></td></tr><tr><td>N</td><td>1089</td><td>1111</td><td>394</td><td>403</td><td>695</td><td>708</td></tr><tr><td>Overall R2</td><td>0.094</td><td>0.089</td><td>0.165</td><td>0.144</td><td>0.062</td><td>0.065</td></tr></table>
1d2f4a8b5c63c79e28bf11d0c430853d512573d6ee8b34ce9633f408065c07f7.png
complex
<table><tr><td></td><td>Coefficient</td><td>Robust Std.Err.</td><td>P &gt; |z|</td><td colspan="2">95% confidence interval</td></tr><tr><td>Constant</td><td>-5.6968 <sup>***</sup></td><td>0.8729</td><td>0.000</td><td>-7.4076</td><td>-3.9859</td></tr><tr><td>Cholera cases</td><td>0.0001 <sup>***</sup></td><td>0.00001</td><td>0.000</td><td>0.0001</td><td>0.0002</td></tr><tr><td>Water cover</td><td>-12.5607 <sup>***</sup></td><td>1.5875</td><td>0.000</td><td>-15.6721</td><td>-9.4492</td></tr><tr><td>Observations</td><td colspan="5"> 15</td></tr><tr><td>Log pseudolikelihood</td><td colspan="5">-84.2818</td></tr></table>
<table><tr><td></td><td>Coefficient</td><td>Robust Std.Err.</td><td>P > |z|</td><td colspan="2">95% confidence interval</td></tr></table>
<table><tr><td>Constant</td><td>-5.6968 ***</td><td>0.8729</td><td>0.000</td><td>-7.4076</td><td>-3.9859</td></tr><tr><td>Cholera cases</td><td>0.0001 ***</td><td>0.00001</td><td>0.000</td><td>0.0001</td><td>0.0002</td></tr><tr><td>Water cover</td><td>-12.5607 ***</td><td>1.5875</td><td>0.000</td><td>-15.6721</td><td>-9.4492</td></tr><tr><td>Observations</td><td colspan="5">15</td></tr><tr><td>Log pseudolikelihood</td><td colspan="5">-84.2818</td></tr></table>
27e65555bdfa7870df500d8c57851160474e86a346310c88e32f00368244f8d2.png
simple
<table><tr><td>Sample ID</td><td>Organ</td><td>Related microorganism</td><td>GenBank accession no.</td><td>Similarity %</td></tr><tr><td>12Ue0622</td><td>Placenta</td><td>Not interpretable</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>12Ue1119</td><td>Placenta</td><td><i>Chlamydia abortus</i></td><td>Z49871</td><td>100</td></tr><tr><td>12Ue1503</td><td>Placenta</td><td>Uncultured <i>Chlamydiales</i> bacteriumclone HE210023biof</td><td>JX083111</td><td>99.3</td></tr><tr><td>12Ue1510</td><td>Placenta</td><td><i>Chlamydia abortus</i></td><td>NR_036834</td><td>100</td></tr><tr><td>13Ue0490</td><td>Placenta</td><td><i>Chlamydia abortus</i></td><td>Z49871</td><td>94.7</td></tr><tr><td>13Ue0499</td><td>Placenta</td><td>Not interpretable</td><td> &#8211;</td><td>&#8211; </td></tr><tr><td>13Ue0815</td><td>Placenta</td><td><i>Chlamydiales</i> bacterium cvE71</td><td>JF706724</td><td>96</td></tr><tr><td>13Ue0857</td><td>Placenta</td><td><i>Chlamydia abortus</i></td><td>Z49871</td><td>100</td></tr><tr><td>13Ue1009</td><td>Placenta</td><td><i>Chlamydia abortus</i></td><td>Z49871</td><td>99.3</td></tr><tr><td>13Ue1293</td><td>Placenta</td><td><i>Chlamydia abortus</i></td><td>Z49871</td><td>100</td></tr><tr><td>13Ue1359</td><td>Placenta</td><td><i>Chlamydia abortus</i></td><td>Z49871</td><td>100</td></tr><tr><td>14A0078</td><td>Placenta</td><td><i>Chlamydia abortus</i></td><td>Z49871</td><td>98.5</td></tr><tr><td>15A0068</td><td>Placenta</td><td><i>Chlamydia abortus</i></td><td>Z49871</td><td>90.8</td></tr><tr><td>15A0076</td><td>Placenta</td><td>Not interpretable</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>15A0078</td><td>Placenta</td><td><i>Chlamydia abortus</i></td><td>Z49871</td><td>99.5</td></tr><tr><td>15A0079</td><td>Placenta</td><td><i>Chlamydia abortus</i></td><td>Z49871</td><td>99.8</td></tr><tr><td>15A0080</td><td>Placenta</td><td><i>Chlamydia abortus</i></td><td>Z49871</td><td>99.5</td></tr><tr><td>15A0082</td><td>Placenta</td><td><i>Chlamydia abortus</i></td><td>Z49871</td><td>96.2</td></tr><tr><td>15A0087</td><td>Placenta</td><td>Uncultured <i>Chlamydiales</i> bacteriumclone P-9</td><td>AF364575</td><td>97</td></tr><tr><td>15A0091</td><td>Placenta</td><td><i>Chlamydia abortus</i></td><td>Z49871</td><td>92</td></tr><tr><td>15A0092</td><td>Placenta</td><td><i>Chlamydia abortus</i></td><td>Z49871</td><td>100</td></tr><tr><td>15A0093</td><td>Placenta</td><td><i>Chlamydia abortus</i></td><td>Z49871</td><td>90.8</td></tr><tr><td>15A0096</td><td>Placenta</td><td><i>Chlamydia abortus</i></td><td>Z49871</td><td>99.5</td></tr><tr><td>15A0096</td><td>Abomasal content</td><td><i>Chlamydia abortus</i></td><td>Z49871</td><td>99.5</td></tr><tr><td>15A0099</td><td>Placenta</td><td>Not interpretable</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>15A0104</td><td>Placenta</td><td><i>Chlamydia abortus</i></td><td>Z49871</td><td>100</td></tr><tr><td>15A0107</td><td>Placenta</td><td>Not interpretable</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>15A0111</td><td>Placenta</td><td><i>Chlamydia abortus</i></td><td>Z49871</td><td>99.5</td></tr><tr><td>15A0113</td><td>Placenta</td><td><i>Chlamydia abortus</i></td><td>Z49871</td><td>100</td></tr><tr><td>15A0114</td><td>Placenta</td><td><i>Chlamydia abortus</i></td><td>Z49871</td><td>99.5</td></tr><tr><td>15A0117</td><td>Placenta</td><td>Not interpretable</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>15A0118</td><td>Placenta</td><td><i>Chlamydia abortus</i></td><td>Z49871</td><td>96.8</td></tr><tr><td>15A0121</td><td>Placenta</td><td><i>Chlamydia abortus</i></td><td>Z49871</td><td>98.1</td></tr><tr><td>15A0122</td><td>Placenta</td><td><i>Chlamydia abortus</i></td><td>Z49871</td><td>97.6</td></tr><tr><td>15A0126</td><td>Abomasal content</td><td>Not interpretable</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>15A0129</td><td>Placenta</td><td>Not interpretable</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>15A0137</td><td>Placenta</td><td>Not interpretable</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>15A0148</td><td>Placenta</td><td>Not interpretable</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>15A0155</td><td>Placenta</td><td><i>Parachlamydia acanthamoebae</i> strain Bn9</td><td>NR_026357</td><td>90.3</td></tr><tr><td>15A0160</td><td>Placenta</td><td>Not interpretable</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>15A0172</td><td>Placenta</td><td>Not interpretable</td><td>&#8211;</td><td>&#8211;</td></tr></table>
<table><tr><td>Sample ID</td><td>Organ</td><td>Related microorganism</td><td>GenBank accession no.</td></tr><tr><td>12Ue0622</td><td>Placenta</td><td>Not interpretable</td><td>–</td></tr><tr><td>12Ue1119</td><td>Placenta</td><td>Chlamydia abortus</td><td>Z49871</td></tr><tr><td>12Ue1503</td><td>Placenta</td><td>Uncultured Chlamydiales bacteriumclone HE210023biof</td><td>JX083111</td></tr><tr><td>12Ue1510</td><td>Placenta</td><td>Chlamydia abortus</td><td>NR_036834</td></tr><tr><td>13Ue0490</td><td>Placenta</td><td>Chlamydia abortus</td><td>Z49871</td></tr><tr><td>13Ue0499</td><td>Placenta</td><td>Not interpretable</td><td>–</td></tr><tr><td>13Ue0815</td><td>Placenta</td><td>Chlamydiales bacterium cvE71</td><td>JF706724</td></tr><tr><td>13Ue0857</td><td>Placenta</td><td>Chlamydia abortus</td><td>Z49871</td></tr><tr><td>13Ue1009</td><td>Placenta</td><td>Chlamydia abortus</td><td>Z49871</td></tr><tr><td>13Ue1293</td><td>Placenta</td><td>Chlamydia abortus</td><td>Z49871</td></tr><tr><td>13Ue1359</td><td>Placenta</td><td>Chlamydia abortus</td><td>Z49871</td></tr><tr><td>14A0078</td><td>Placenta</td><td>Chlamydia abortus</td><td>Z49871</td></tr><tr><td>15A0068</td><td>Placenta</td><td>Chlamydia abortus</td><td>Z49871</td></tr><tr><td>15A0076</td><td>Placenta</td><td>Not interpretable</td><td>–</td></tr><tr><td>15A0078</td><td>Placenta</td><td>Chlamydia abortus</td><td>Z49871</td></tr><tr><td>15A0079</td><td>Placenta</td><td>Chlamydia abortus</td><td>Z49871</td></tr><tr><td>15A0080</td><td>Placenta</td><td>Chlamydia abortus</td><td>Z49871</td></tr><tr><td>15A0082</td><td>Placenta</td><td>Chlamydia abortus</td><td>Z49871</td></tr><tr><td>15A0087</td><td>Placenta</td><td>Uncultured Chlamydiales bacteriumclone P-9</td><td>AF364575</td></tr><tr><td>15A0091</td><td>Placenta</td><td>Chlamydia abortus</td><td>Z49871</td></tr><tr><td>15A0092</td><td>Placenta</td><td>Chlamydia abortus</td><td>Z49871</td></tr><tr><td>15A0093</td><td>Placenta</td><td>Chlamydia abortus</td><td>Z49871</td></tr><tr><td>15A0096</td><td>Placenta</td><td>Chlamydia abortus</td><td>Z49871</td></tr><tr><td>15A0096</td><td>Abomasal content</td><td>Chlamydia abortus</td><td>Z49871</td></tr><tr><td>15A0099</td><td>Placenta</td><td>Not interpretable</td><td>–</td></tr><tr><td>15A0104</td><td>Placenta</td><td>Chlamydia abortus</td><td>Z49871</td></tr><tr><td>15A0107</td><td>Placenta</td><td>Not interpretable</td><td>–</td></tr><tr><td>15A0111</td><td>Placenta</td><td>Chlamydia abortus</td><td>Z49871</td></tr><tr><td>15A0113</td><td>Placenta</td><td>Chlamydia abortus</td><td>Z49871</td></tr><tr><td>15A0114</td><td>Placenta</td><td>Chlamydia abortus</td><td>Z49871</td></tr><tr><td>15A0117</td><td>Placenta</td><td>Not interpretable</td><td>–</td></tr><tr><td>15A0118</td><td>Placenta</td><td>Chlamydia abortus</td><td>Z49871</td></tr><tr><td>15A0121</td><td>Placenta</td><td>Chlamydia abortus</td><td>Z49871</td></tr><tr><td>15A0122</td><td>Placenta</td><td>Chlamydia abortus</td><td>Z49871</td></tr><tr><td>15A0126</td><td>Abomasal content</td><td>Not interpretable</td><td>–</td></tr><tr><td>15A0129</td><td>Placenta</td><td>Not interpretable</td><td>–</td></tr><tr><td>15A0137</td><td>Placenta</td><td>Not interpretable</td><td>–</td></tr><tr><td>15A0148</td><td>Placenta</td><td>Not interpretable</td><td>–</td></tr><tr><td>15A0155</td><td>Placenta</td><td>Parachlamydia acanthamoebae strain Bn9</td><td>NR_026357</td></tr><tr><td>15A0160</td><td>Placenta</td><td>Not interpretable</td><td>–</td></tr><tr><td>15A0172</td><td>Placenta</td><td>Not interpretable</td><td>–</td></tr></table>
<table><tr><td>Similarity %</td></tr><tr><td>–</td></tr><tr><td>100</td></tr><tr><td>99.3</td></tr><tr><td>100</td></tr><tr><td>94.7</td></tr><tr><td>–</td></tr><tr><td>96</td></tr><tr><td>100</td></tr><tr><td>99.3</td></tr><tr><td>100</td></tr><tr><td>100</td></tr><tr><td>98.5</td></tr><tr><td>90.8</td></tr><tr><td>–</td></tr><tr><td>99.5</td></tr><tr><td>99.8</td></tr><tr><td>99.5</td></tr><tr><td>96.2</td></tr><tr><td>97</td></tr><tr><td>92</td></tr><tr><td>100</td></tr><tr><td>90.8</td></tr><tr><td>99.5</td></tr><tr><td>99.5</td></tr><tr><td>–</td></tr><tr><td>100</td></tr><tr><td>–</td></tr><tr><td>99.5</td></tr><tr><td>100</td></tr><tr><td>99.5</td></tr><tr><td>–</td></tr><tr><td>96.8</td></tr><tr><td>98.1</td></tr><tr><td>97.6</td></tr><tr><td>–</td></tr><tr><td>–</td></tr><tr><td>–</td></tr><tr><td>–</td></tr><tr><td>90.3</td></tr><tr><td>–</td></tr><tr><td>–</td></tr></table>
c68f427ce834c3fecc2561d30e3fecb2d6c02dccfc1f7b8d361477dfea71cecc.png
simple
<table><tr><td><i> &#955;</i></td><td>Combined <i>t</i>-test</td><td>Linear regression</td><td>Combined Wilcoxon</td><td>Combined BWS</td></tr><tr><td> 0</td><td>0.056</td><td>0.053</td><td>0.073</td><td>0.669</td></tr><tr><td>0.05</td><td>0.075</td><td>0.057</td><td>0.094</td><td>0.703</td></tr><tr><td>0.1</td><td>0.182</td><td>0.087</td><td>0.200</td><td>0.832</td></tr><tr><td>0.15</td><td>0.402</td><td>0.141</td><td>0.412</td><td>0.939</td></tr><tr><td>0.2</td><td>0.701</td><td>0.212</td><td>0.687</td><td>0.988</td></tr><tr><td>0.25</td><td>0.911</td><td>0.298</td><td>0.893</td><td>0.999</td></tr></table>
<table><tr><td>λ</td><td>Combined t-test</td><td>Linear regression</td><td>Combined Wilcoxon</td><td>Combined BWS</td></tr><tr><td>0</td><td></td><td>0</td><td>0.0</td><td>0</td></tr></table>
<table><tr><td></td><td>0.056</td><td>.053</td><td>73</td><td>.669</td></tr><tr><td>0.05</td><td>0.075</td><td>0.057</td><td>0.094</td><td>0.703</td></tr><tr><td>0.1</td><td>0.182</td><td>0.087</td><td>0.200</td><td>0.832</td></tr><tr><td>0.15</td><td>0.402</td><td>0.141</td><td>0.412</td><td>0.939</td></tr><tr><td>0.2</td><td>0.701</td><td>0.212</td><td>0.687</td><td>0.988</td></tr><tr><td>0.25</td><td>0.911</td><td>0.298</td><td>0.893</td><td>0.999</td></tr></table>
567bc9e705a6a9d30bea08beaf9f567ecc14c4da31d327f6258964ded1440f32.png
complex
<table><tr><td rowspan="2"></td><td colspan="2">Out-of-hours GP services</td><td colspan="2">EDs</td></tr><tr><td>Usual care</td><td>UCC</td><td>Usual care</td><td>UCC</td></tr><tr><td>All employees</td><td>12</td><td>12</td><td>3</td><td>3</td></tr><tr><td>Physicians</td><td>19</td><td>20</td><td>7</td><td>12</td></tr><tr><td>Support staff member</td><td>33</td><td>32</td><td>4</td><td>4</td></tr></table>
<table><tr><td></td><td colspan="2">Out-of-hours GP services</td><td colspan="2">EDs</td></tr></table>
<table><tr><td></td><td>Usual care</td><td>UCC</td><td>Usual care</td><td>UCC</td></tr><tr><td>All employees</td><td>12</td><td>12</td><td>3</td><td>3</td></tr><tr><td>Physicians</td><td>19</td><td>20</td><td>7</td><td>12</td></tr><tr><td>Support staff member</td><td>33</td><td>32</td><td>4</td><td>4</td></tr></table>
c8056f3239ee0349119359ea860624ac375f3f76ba920a9c4f43650cdd36cdd4.png
simple
<table><tr><td>Vision</td><td>Number of patients</td><td>Percent</td></tr><tr><td>6/6&#8211;6/18</td><td>8</td><td>16</td></tr><tr><td>&lt;6/18&#8211;6/60</td><td>12</td><td>24</td></tr><tr><td>&lt;6/60&#8211;3/60</td><td>9</td><td>18</td></tr><tr><td>&lt;3/60&#8211;1/60</td><td>12</td><td>24</td></tr><tr><td>&lt;1/60&#8211;PL</td><td>7</td><td>14</td></tr><tr><td>No PL</td><td>2</td><td>4</td></tr><tr><td>Total</td><td>50</td><td>100</td></tr></table>
<table><tr><td>Vision</td><td>Number of patients</td><td>Percent</td></tr><tr><td>6/6–6/18</td><td>8</td><td>16</td></tr><tr><td><6/18–6/60</td><td>12</td><td>24</td></tr><tr><td><6/60–3/60</td><td>9</td><td>18</td></tr><tr><td><3/60–1/60</td><td>12</td><td>24</td></tr><tr><td><1/60–PL</td><td>7</td><td>14</td></tr><tr><td>No PL</td><td>2</td><td>4</td></tr></table>
<table><tr><td>Vision</td><td>Number of patients</td><td>Percent</td></tr><tr><td>Total</td><td>50</td><td>100</td></tr></table>
54e93a08ed91814e6cb691db4fad133557355d96d69da450b0c089ff18efd5ff.png
complex
<table><tr><td> </td><td>Controls</td><td>Welders</td><td>P value</td></tr><tr><td> </td><td>(n = 21)</td><td>(n = 21)</td><td> </td></tr><tr><td>Mean age (years &#177; SD)</td><td>58.6 &#177; 10.8</td><td>58.5 &#177; 10.7</td><td>ns</td></tr><tr><td>Gender</td><td> </td><td> </td><td> </td></tr><tr><td>Female</td><td>6 (28.6%)</td><td>1 (4.8%)</td><td>0.038</td></tr><tr><td>Male</td><td>15 (71.4%)</td><td>20 (95.2%)</td><td>ns</td></tr><tr><td>Tobacco smoking</td><td> </td><td> </td><td> </td></tr><tr><td>Smoking status</td><td> </td><td> </td><td>ns</td></tr><tr><td>Current smokers</td><td>9 (43.0%)</td><td>6 (28.6%)</td><td> </td></tr><tr><td>Former smokers</td><td>9 (43.0%)</td><td>12 (57.1%)</td><td> </td></tr><tr><td>Never smokers</td><td>3 (14.0%)</td><td>3 (14.3%)</td><td> </td></tr><tr><td>Cumulative consumption (P-Y &#177; SD)</td><td>24.6 &#177; 29.0</td><td>22.2 &#177; 15.2</td><td>ns</td></tr><tr><td>Age at onset (years &#177; SD)</td><td>16.8 &#177; 3.4</td><td>18.3 &#177; 4.2</td><td>ns</td></tr><tr><td>Age at cessation (years &#177; SD)</td><td>51.6 &#177; 14.0</td><td>48.8 &#177; 11.2</td><td>ns</td></tr><tr><td>Duration (years &#177; SD)</td><td>32.6 &#177; 16.7</td><td>33.7 &#177; 10.3</td><td>ns</td></tr><tr><td>Duration since cessation (years &#177; SD)</td><td>5.7 &#177; 9.3</td><td>8.2 &#177; 10.4</td><td>ns</td></tr><tr><td>Welding fumes exposure</td><td> </td><td> </td><td rowspan="6">-</td></tr><tr><td>Positive occupational questionnaire</td><td>0</td><td>21</td></tr><tr><td>Age at onset (years &#177; SD)</td><td>-</td><td>19.9 &#177; 7.6</td></tr><tr><td>Age at cessation (years &#177; SD)</td><td>-</td><td>48.2 &#177; 9.9</td></tr><tr><td>Duration (years &#177; SD)</td><td>-</td><td>27.0 &#177; 9.2</td></tr><tr><td>Duration since cessation (years &#177; SD)</td><td>-</td><td>9.2 &#177; 10.4</td></tr></table>
<table><tr><td></td><td>Controls</td><td>Welders</td><td>P value</td></tr><tr><td></td><td>(n = 21)</td><td>(n = 21)</td><td></td></tr><tr><td>Mean age (years ± SD)</td><td>58.6 ± 10.8</td><td>58.5 ± 10.7</td><td>ns</td></tr><tr><td>Gender</td><td></td><td></td><td></td></tr><tr><td>Female</td><td>6 (28.6%)</td><td>1 (4.8%)</td><td>0.038</td></tr></table>
<table><tr><td>Male</td><td>15 (71.4%)</td><td>20 (95.2%)</td><td>ns</td></tr><tr><td>Tobacco smoking</td><td></td><td></td><td></td></tr><tr><td>Smoking status</td><td></td><td></td><td>ns</td></tr><tr><td>Current smokers</td><td>9 (43.0%)</td><td>6 (28.6%)</td><td></td></tr><tr><td>Former smokers</td><td>9 (43.0%)</td><td>12 (57.1%)</td><td></td></tr><tr><td>Never smokers</td><td>3 (14.0%)</td><td>3 (14.3%)</td><td></td></tr><tr><td>Cumulative consumption (P-Y ± SD)</td><td>24.6 ± 29.0</td><td>22.2 ± 15.2</td><td>ns</td></tr><tr><td>Age at onset (years ± SD)</td><td>16.8 ± 3.4</td><td>18.3 ± 4.2</td><td>ns</td></tr><tr><td>Age at cessation (years ± SD)</td><td>51.6 ± 14.0</td><td>48.8 ± 11.2</td><td>ns</td></tr><tr><td>Duration (years ± SD)</td><td>32.6 ± 16.7</td><td>33.7 ± 10.3</td><td>ns</td></tr><tr><td>Duration since cessation (years ± SD)</td><td>5.7 ± 9.3</td><td>8.2 ± 10.4</td><td>ns</td></tr><tr><td>Welding fumes exposure</td><td></td><td></td><td rowspan="6">-</td></tr><tr><td>Positive occupational questionnaire</td><td>0</td><td>21</td></tr><tr><td>Age at onset (years ± SD)</td><td>-</td><td>19.9 ± 7.6</td></tr><tr><td>Age at cessation (years ± SD)</td><td>-</td><td>48.2 ± 9.9</td></tr><tr><td>Duration (years ± SD)</td><td>-</td><td>27.0 ± 9.2</td></tr><tr><td>Duration since cessation (years ± SD)</td><td>-</td><td>9.2 ± 10.4</td></tr></table>
24fa3c77bea6c781ecac38483745229e8d7398d77128b9de9b39db42bbc4c032.png
simple
<table><tr><td>Age</td><td>Quebec, Geometric Mean (95th Percentile)</td><td>Ontario, Geometric Mean (95th Percentile)</td></tr><tr><td>4</td><td>0.03 (0.13)</td><td>0.06 (0.17)</td></tr><tr><td>8</td><td>0.02 (0.05)</td><td>0.05 (0.12)</td></tr></table>
<table><tr><td>Age</td><td>Quebec, Geometric Mean (95th Percentile)</td><td>Ontario, Geometric Mean (95th Percentile)</td></tr></table>
<table><tr><td>4</td><td>0.03 (0.13)</td><td>0.06 (0.17)</td></tr><tr><td>8</td><td>0.02 (0.05)</td><td>0.05 (0.12)</td></tr></table>
025aabb0e60db401ce9118b0971eb8580bffb95f881f698bd103f165750f0da1.png
complex
<table><tr><td rowspan="2"></td><td colspan="2">SASIn = 123&#8211;124</td><td colspan="2">Non-SASIn = 5514&#8211;5515</td><td colspan="2">Totaln = 5635&#8211;5639</td><td></td></tr><tr><td>Mean</td><td>SD</td><td>Mean</td><td>SD</td><td>Mean</td><td>SD</td><td><i>p </i> value</td></tr><tr><td>Anxiety</td><td>9.6</td><td>5.5</td><td>4.6</td><td>3.9</td><td>4.7</td><td>4.0</td><td>&lt;.001</td></tr><tr><td>Depression</td><td>12.4</td><td>6.2</td><td>5.0</td><td>4.4</td><td>5.2</td><td>4.6</td><td>&lt;.001</td></tr><tr><td>Anger</td><td>9.0</td><td>5.7</td><td>4.0</td><td>4.0</td><td>4.2</td><td>4.1</td><td>&lt;.001</td></tr><tr><td>Post-traumatic stress</td><td>14.0</td><td>6.4</td><td>6.1</td><td>4.9</td><td>6.2</td><td>5.1</td><td>&lt;.001</td></tr><tr><td>Dissociation</td><td>12.9</td><td>6.2</td><td>5.9</td><td>4.8</td><td>6.0</td><td>4.9</td><td>&lt;.001</td></tr><tr><td>Sexual concerns</td><td>4.8</td><td>3.9</td><td>2.2</td><td>2.4</td><td>2.6</td><td>2.5</td><td>&lt;.001</td></tr></table>
<table><tr><td rowspan="2"></td><td colspan="2">SASIn = 123–124</td><td colspan="2">Non-SASIn = 5514–5515</td><td colspan="2">Totaln = 5635–5639</td><td></td></tr><tr><td>Mean</td><td>SD</td><td>Mean</td><td>SD</td><td>Mean</td><td>SD</td><td>p value</td></tr></table>
<table><tr><td>Anxiety</td><td>9.6</td><td>5.5</td><td>4.6</td><td>3.9</td><td>4.7</td><td>4.0</td><td><.001</td></tr><tr><td>Depression</td><td>12.4</td><td>6.2</td><td>5.0</td><td>4.4</td><td>5.2</td><td>4.6</td><td><.001</td></tr><tr><td>Anger</td><td>9.0</td><td>5.7</td><td>4.0</td><td>4.0</td><td>4.2</td><td>4.1</td><td><.001</td></tr><tr><td>Post-traumatic stress</td><td>14.0</td><td>6.4</td><td>6.1</td><td>4.9</td><td>6.2</td><td>5.1</td><td><.001</td></tr><tr><td>Dissociation</td><td>12.9</td><td>6.2</td><td>5.9</td><td>4.8</td><td>6.0</td><td>4.9</td><td><.001</td></tr><tr><td>Sexual concerns</td><td>4.8</td><td>3.9</td><td>2.2</td><td>2.4</td><td>2.6</td><td>2.5</td><td><.001</td></tr></table>
65fd53a61fa6a24a7754fd495236558740b1ad7274dbbfa38db4cf27ce112abd.png
complex
<table><tr><td></td><td>First Contact (Admission)</td><td>Second contact (Discharge)</td><td>Third Contact (Community- based phase)</td><td>Defaulted &amp; Loss to follow-up</td></tr><tr><td colspan="5">Children&#8217;s Sex (%)</td></tr><tr><td> Male</td><td>46</td><td>46.2</td><td>47</td><td>44</td></tr><tr><td> Female</td><td>54</td><td>53.8</td><td>53</td><td>56</td></tr><tr><td colspan="5">Children&#8217;s Age, months (%)</td></tr><tr><td> 6&#8211;11</td><td>38.7</td><td>33.9</td><td>25</td><td>32</td></tr><tr><td> 12&#8211;23</td><td>45.3</td><td>49.2</td><td>55</td><td>46</td></tr><tr><td> 24&#8211;35</td><td>12</td><td>14.4</td><td>14</td><td>16</td></tr><tr><td> 36+</td><td>4</td><td>2.5</td><td>6</td><td>6</td></tr><tr><td colspan="5">Mother&#8217;s religion(%)</td></tr><tr><td> Hindu</td><td>29.3</td><td>30.5</td><td>30</td><td>28</td></tr><tr><td> Muslim</td><td>6</td><td>5.1</td><td>6</td><td>4</td></tr><tr><td> Sarna</td><td>54</td><td>56.8</td><td>55</td><td>60</td></tr><tr><td> Others</td><td>10.7</td><td>7.6</td><td>9</td><td>8</td></tr><tr><td colspan="5">Mother&#8217;s caste(%)</td></tr><tr><td> SC</td><td>9.3</td><td>11</td><td>10</td><td>10</td></tr><tr><td> ST</td><td>68</td><td>70.3</td><td>71</td><td>72</td></tr><tr><td> OBC</td><td>15.3</td><td>14.4</td><td>14</td><td>12</td></tr><tr><td> General</td><td>7.4</td><td>4.2</td><td>5</td><td>6</td></tr><tr><td colspan="5">Mother&#8217;s age (%)</td></tr><tr><td> 18&#8211;25</td><td>46.7</td><td>47.5</td><td>47</td><td>42</td></tr><tr><td> 26&#8211;30</td><td>24</td><td>22.9</td><td>24</td><td>26</td></tr><tr><td> 31+</td><td>29.3</td><td>29.7</td><td>29</td><td>32</td></tr><tr><td colspan="5">Mother&#8217;s education (%)</td></tr><tr><td> No schooling</td><td>67.3</td><td>66.1</td><td>66</td><td>70</td></tr><tr><td> 1&#8211;8</td><td>26.1</td><td>29</td><td>29</td><td>28</td></tr><tr><td> 9+</td><td>6.6</td><td>5.2</td><td>5</td><td>2</td></tr><tr><td>Total children and mothers</td><td>150</td><td>116</td><td>100</td><td>50</td></tr></table>
<table><tr><td></td><td>First Contact (Admission)</td><td>Second contact (Discharge)</td><td>Third Contact (Community- based phase)</td><td>Defaulted & Loss to follow-up</td></tr><tr><td colspan="5">Children’s Sex (%)</td></tr><tr><td>Male</td><td>46</td><td>46.2</td><td>47</td><td>44</td></tr><tr><td>Female</td><td>54</td><td>53.8</td><td>53</td><td>56</td></tr><tr><td colspan="5">Children’s Age, months (%)</td></tr><tr><td>6–11</td><td>38.7</td><td>33.9</td><td>25</td><td>32</td></tr><tr><td>12–23</td><td>45.3</td><td>49.2</td><td>55</td><td>46</td></tr><tr><td>24–35</td><td>12</td><td>14.4</td><td>14</td><td>16</td></tr><tr><td>36+</td><td>4</td><td>2.5</td><td>6</td><td>6</td></tr><tr><td colspan="5">Mother’s religion(%)</td></tr><tr><td>Hindu</td><td>29.3</td><td>30.5</td><td>30</td><td>28</td></tr><tr><td>Muslim</td><td>6</td><td>5.1</td><td>6</td><td>4</td></tr><tr><td>Sarna</td><td>54</td><td>56.8</td><td>55</td><td>60</td></tr><tr><td>Others</td><td>10.7</td><td>7.6</td><td>9</td><td>8</td></tr><tr><td colspan="5">Mother’s caste(%)</td></tr><tr><td>SC</td><td>9.3</td><td>11</td><td>10</td><td>10</td></tr><tr><td>ST</td><td>68</td><td>70.3</td><td>71</td><td>72</td></tr><tr><td>OBC</td><td>15.3</td><td>14.4</td><td>14</td><td>12</td></tr><tr><td>General</td><td>7.4</td><td>4.2</td><td>5</td><td>6</td></tr><tr><td colspan="5">Mother’s age (%)</td></tr><tr><td>18–25</td><td>46.7</td><td>47.5</td><td>47</td><td>42</td></tr><tr><td>26–30</td><td>24</td><td>22.9</td><td>24</td><td>26</td></tr><tr><td>31+</td><td>29.3</td><td>29.7</td><td>29</td><td>32</td></tr><tr><td colspan="5">Mother’s education (%)</td></tr><tr><td>No schooling</td><td>67.3</td><td>66.1</td><td>66</td><td>70</td></tr><tr><td>1–8</td><td>26.1</td><td>29</td><td>29</td><td>28</td></tr><tr><td>9+</td><td>6.6</td><td>5.2</td><td>5</td><td>2</td></tr></table>
<table><tr><td>Total children and mothers</td><td>150</td><td>116</td><td>100</td><td>50</td></tr></table>
45f901a9c6c9c0a4bd2afaee99f0e2d3f4ebb8d4c25641b86077d1790feeef92.png
simple
<table><tr><td>1st author and year</td><td><i>N</i></td><td>ALD</td><td>HBV or HCV</td><td>Cryptogenic</td><td>ALD + HCV</td><td>Miscellaneous</td></tr><tr><td>Krowka 1999</td><td>14</td><td>1</td><td>1</td><td>3</td><td>3</td><td>1 HCC + HCV, 1 sarcoidosis,2 PBC, 1 Budd Chiari, 1 AIH </td></tr><tr><td>Hoeper 2005</td><td>11</td><td>7</td><td>1</td><td>0</td><td>2</td><td>1 biliary atresia</td></tr><tr><td>Reichenberger 2006</td><td>14</td><td>7</td><td>3</td><td> </td><td> </td><td>3 PBC, 1 Budd Chiari</td></tr><tr><td>Sussman 2006</td><td>8</td><td>4</td><td>1</td><td>2</td><td>1</td><td> </td></tr><tr><td>Fix 2007</td><td>35</td><td>7</td><td>9</td><td>3</td><td>10</td><td>1 HIV, 2 HCC, 2 PBC, 1 AIH</td></tr><tr><td>Hoeper 2007 (bosentan)</td><td>18</td><td>11</td><td>3 </td><td>1</td><td>0</td><td>1 PVT, 2 AIH</td></tr><tr><td>Hoeper 2007 (iloprost)</td><td>13</td><td>6</td><td>2 </td><td>0</td><td>0</td><td>1 biliary duct atresia, 4 AIH</td></tr><tr><td>Gough and White 2009</td><td>11</td><td>4</td><td>2</td><td>0</td><td>4</td><td>1 ALD + NASH</td></tr><tr><td>Hemnes 2009</td><td>13</td><td>1</td><td>8</td><td>0</td><td>0</td><td>1 PBC</td></tr><tr><td>Melgosa 2010</td><td>13</td><td>2</td><td>7</td><td>0</td><td>0</td><td>1 hemochromatosis, 2 PBC, 1 portal vein thrombosis</td></tr><tr><td>Halank 2011</td><td>13</td><td>8</td><td>1</td><td>3</td><td>0</td><td>1 PBC</td></tr><tr><td>Hollatz 2012</td><td>11</td><td>5</td><td>1</td><td>0</td><td>3</td><td>1 ALD + NASH + PBC, 1 biliary atresia</td></tr><tr><td>Savale 2013</td><td>34</td><td>20</td><td>4</td><td> </td><td>3</td><td>6 PVT, 1 AIH</td></tr><tr><td>Total</td><td> </td><td>83 (40%)</td><td>43 (20%)</td><td>12 (5%)</td><td>26 (12%)</td><td>41 (20%)</td></tr></table>
<table><tr><td>1st author and year</td><td>N</td><td>ALD</td><td>HBV or HCV</td><td>Cryptogenic</td><td>ALD + HCV</td><td>Miscellaneous</td></tr><tr><td>Krowka 1999</td><td>14</td><td>1</td><td>1</td><td>3</td><td>3</td><td>1 HCC + HCV, 1 sarcoidosis,2 PBC, 1 Budd Chiari, 1 AIH</td></tr><tr><td>Hoeper 2005</td><td>11</td><td>7</td><td>1</td><td>0</td><td>2</td><td>1 biliary atresia</td></tr><tr><td>Reichenberger 2006</td><td>14</td><td>7</td><td>3</td><td></td><td></td><td>3 PBC, 1 Budd Chiari</td></tr><tr><td>Sussman 2006</td><td>8</td><td>4</td><td>1</td><td>2</td><td>1</td><td></td></tr><tr><td>Fix 2007</td><td>35</td><td>7</td><td>9</td><td>3</td><td>10</td><td>1 HIV, 2 HCC, 2 PBC, 1 AIH</td></tr></table>
<table><tr><td>1st author and year</td><td>N</td><td>ALD</td><td>HBV or HCV</td><td>Cryptogenic</td><td>ALD + HCV</td><td>Miscellaneous</td></tr><tr><td>Hoeper 2007 (bosentan)</td><td>18</td><td>11</td><td>3</td><td>1</td><td>0</td><td>1 PVT, 2 AIH</td></tr><tr><td>Hoeper 2007 (iloprost)</td><td>13</td><td>6</td><td>2</td><td>0</td><td>0</td><td>1 biliary duct atresia, 4 AIH</td></tr><tr><td>Gough and White 2009</td><td>11</td><td>4</td><td>2</td><td>0</td><td>4</td><td>1 ALD + NASH</td></tr><tr><td>Hemnes 2009</td><td>13</td><td>1</td><td>8</td><td>0</td><td>0</td><td>1 PBC</td></tr><tr><td>Melgosa 2010</td><td>13</td><td>2</td><td>7</td><td>0</td><td>0</td><td>1 hemochromatosis, 2 PBC, 1 portal vein thrombosis</td></tr><tr><td>Halank 2011</td><td>13</td><td>8</td><td>1</td><td>3</td><td>0</td><td>1 PBC</td></tr><tr><td>Hollatz 2012</td><td>11</td><td>5</td><td>1</td><td>0</td><td>3</td><td>1 ALD + NASH + PBC, 1 biliary atresia</td></tr><tr><td>Savale 2013</td><td>34</td><td>20</td><td>4</td><td></td><td>3</td><td>6 PVT, 1 AIH</td></tr><tr><td>Total</td><td></td><td>83 (40%)</td><td>43 (20%)</td><td>12 (5%)</td><td>26 (12%)</td><td>41 (20%)</td></tr></table>
cff5b7874eef09fe4c39b4ffb7af5fc249a00a6e00b5c02afcc952306580fc50.png
simple
<table><tr><td>Food Item</td><td>Copacabana</td><td>Bertioga</td><td>Itacimirim</td><td>Pa&#770;ntano do Sul</td><td>Vito&#769;ria sland</td><td>TOTAL</td></tr><tr><td>Algae</td><td></td><td>1</td><td></td><td></td><td></td><td>1</td></tr><tr><td>Anything</td><td>3</td><td>3</td><td>3</td><td>7</td><td>1</td><td>17</td></tr><tr><td>Bonito</td><td>1</td><td>4</td><td>1</td><td>1</td><td>1</td><td>8</td></tr><tr><td>Crabs</td><td>1</td><td>2</td><td>1</td><td>2</td><td></td><td>6</td></tr><tr><td>Crustacean</td><td>2</td><td></td><td></td><td></td><td></td><td>2</td></tr><tr><td>Deteriorated fish/meat</td><td>1</td><td>5</td><td></td><td>7</td><td></td><td>13</td></tr><tr><td>Fish</td><td>2</td><td></td><td>15</td><td>8</td><td>2</td><td>27</td></tr><tr><td>Meat</td><td></td><td></td><td>1</td><td></td><td></td><td>1</td></tr><tr><td>Mouse/snake</td><td></td><td></td><td></td><td>1</td><td></td><td>1</td></tr><tr><td>Octopus</td><td></td><td>2</td><td></td><td></td><td>1</td><td>3</td></tr><tr><td>Sardine</td><td>3</td><td>6</td><td>2</td><td>2</td><td>1</td><td>14</td></tr><tr><td>Shrimp</td><td>1</td><td></td><td>2</td><td></td><td></td><td>3</td></tr><tr><td>Small mollusks</td><td>4</td><td>1</td><td></td><td></td><td></td><td>5</td></tr><tr><td>Squid</td><td></td><td>3</td><td></td><td>3</td><td></td><td>6</td></tr><tr><td>Interviews</td><td>10</td><td>11</td><td>15</td><td>11</td><td>2</td><td>49</td></tr></table>
<table><tr><td>Food Item</td><td>Copacabana</td><td>Bertioga</td><td>Itacimirim</td></tr><tr><td>Algae</td><td></td><td>1</td><td></td></tr><tr><td>Anything</td><td>3</td><td>3</td><td>3</td></tr><tr><td>Bonito</td><td>1</td><td>4</td><td>1</td></tr><tr><td>Crabs</td><td>1</td><td>2</td><td>1</td></tr><tr><td>Crustacean</td><td>2</td><td></td><td></td></tr><tr><td>Deteriorated fish/meat</td><td>1</td><td>5</td><td></td></tr><tr><td>Fish</td><td>2</td><td></td><td>15</td></tr><tr><td>Meat</td><td></td><td></td><td>1</td></tr><tr><td>Mouse/snake</td><td></td><td></td><td></td></tr><tr><td>Octopus</td><td></td><td>2</td><td></td></tr><tr><td>Sardine</td><td>3</td><td>6</td><td>2</td></tr><tr><td>Shrimp</td><td>1</td><td></td><td>2</td></tr><tr><td>Small mollusks</td><td>4</td><td>1</td><td></td></tr><tr><td>Squid</td><td></td><td>3</td><td></td></tr><tr><td>Interviews</td><td>10</td><td>11</td><td>15</td></tr></table>
<table><tr><td>Pântano do Sul</td><td>Vitória sland</td><td>TOTAL</td></tr><tr><td></td><td></td><td>1</td></tr><tr><td>7</td><td>1</td><td>17</td></tr><tr><td>1</td><td>1</td><td>8</td></tr><tr><td>2</td><td></td><td>6</td></tr><tr><td></td><td></td><td>2</td></tr><tr><td>7</td><td></td><td>13</td></tr><tr><td>8</td><td>2</td><td>27</td></tr><tr><td></td><td></td><td>1</td></tr><tr><td>1</td><td></td><td>1</td></tr><tr><td></td><td>1</td><td>3</td></tr><tr><td>2</td><td>1</td><td>14</td></tr><tr><td></td><td></td><td>3</td></tr><tr><td></td><td></td><td>5</td></tr><tr><td>3</td><td></td><td>6</td></tr><tr><td>11</td><td>2</td><td>49</td></tr></table>
10ebd28a14efe90a4a5b4704ffbafb5157e7b6229dae3d114f71a620475dc6c6.png
simple
<table><tr><td>Process</td><td>Tool</td><td>Parameters</td><td>Subject database</td></tr><tr><td>Screening of rRNAs</td><td>BLASTALL</td><td>-p blastn &#8211;e 1e-3 &#8211;f T &#8211; b 1 &#8211;v 1 &#8211;M BLOSUM62</td><td></td></tr><tr><td>Identification of tRNAs</td><td>tRNA scan SE</td><td>-b G</td><td></td></tr><tr><td>ORF calling</td><td>MetaGene Annotator</td><td>-m</td><td></td></tr><tr><td>Known protein identification</td><td>BLASTALL</td><td>-p blastp &#8211;e 1e-1 &#8211;F T &#8211; b 50 &#8211;v 50 &#8211;M BLOSUM 62</td><td>UNIREF 100</td></tr><tr><td>Environmental Protein Identification</td><td>BLASTALL</td><td>-p blastp &#8211;e 1e-1 &#8211;F T &#8211;b 50 &#8211;v 50 &#8211;M BLOSUM62</td><td>MGOL</td></tr></table>
<table><tr><td>Process</td></tr><tr><td>Screening of rRNAs</td></tr><tr><td>Identification of tRNAs</td></tr><tr><td>ORF calling</td></tr><tr><td>Known protein identification</td></tr><tr><td>Environmental Protein Identification</td></tr></table>
<table><tr><td>Tool</td><td>Parameters</td><td>Subject database</td></tr><tr><td>BLASTALL</td><td>-p blastn –e 1e-3 –f T – b 1 –v 1 –M BLOSUM62</td><td></td></tr><tr><td>tRNA scan SE</td><td>-b G</td><td></td></tr><tr><td>MetaGene Annotator</td><td>-m</td><td></td></tr><tr><td>BLASTALL</td><td>-p blastp –e 1e-1 –F T – b 50 –v 50 –M BLOSUM 62</td><td>UNIREF 100</td></tr><tr><td>BLASTALL</td><td>-p blastp –e 1e-1 –F T –b 50 –v 50 –M BLOSUM62</td><td>MGOL</td></tr></table>
2f1aa1b4a1665724e91434ea61c72b01dedcb52f033567a3ed4bc07d3a2f49f1.png
complex
<table><tr><td>S/P value</td><td></td><td>Mean</td><td>S.D.</td><td>Minimum</td><td>Maximum</td></tr><tr><td rowspan="2">Group 2</td><td>Positive</td><td>1.46</td><td>0.66</td><td>0.42</td><td>3.01</td></tr><tr><td>Negative</td><td>0.13</td><td>0.13</td><td>0.00</td><td>0.37</td></tr><tr><td>Group 3</td><td></td><td>0.01</td><td>0.02</td><td>0.00</td><td>0.20</td></tr><tr><td>Group 4</td><td></td><td>0.06</td><td>0.07</td><td>0.00</td><td>0.39</td></tr><tr><td rowspan="2">Group 5</td><td>Negative</td><td>0.07</td><td>0.06</td><td>0.00</td><td>0.31</td></tr><tr><td>Positive n = 2</td><td>-</td><td>-</td><td>0.64</td><td>2.22</td></tr></table>
<table><tr><td>S/P value</td><td></td><td>Mean</td></tr><tr><td rowspan="2">Group 2</td><td>Positive</td><td>1.46</td></tr><tr><td>Negative</td><td>0.13</td></tr><tr><td>Group 3</td><td></td><td>0.01</td></tr><tr><td>Group 4</td><td></td><td>0.06</td></tr><tr><td rowspan="2">Group 5</td><td>Negative</td><td>0.07</td></tr><tr><td>Positive n = 2</td><td>-</td></tr></table>
<table><tr><td>S.D.</td><td>Minimum</td><td>Maximum</td></tr><tr><td>0.66</td><td>0.42</td><td>3.01</td></tr><tr><td>0.13</td><td>0.00</td><td>0.37</td></tr><tr><td>0.02</td><td>0.00</td><td>0.20</td></tr><tr><td>0.07</td><td>0.00</td><td>0.39</td></tr><tr><td>0.06</td><td>0.00</td><td>0.31</td></tr><tr><td>-</td><td>0.64</td><td>2.22</td></tr></table>
055e08847443864c2b4147a334a7d97405d8c82c7086faef29f6710213ae7bc0.png
complex
<table><tr><td rowspan="2">Sociodemographic</td><td colspan="2">Total <i>N</i> = 70</td></tr><tr><td><i>N</i></td><td>(%)</td></tr><tr><td colspan="3">Gender of the respondent</td></tr><tr><td> Female</td><td>54</td><td>77</td></tr><tr><td colspan="2">Type of the respondent</td><td></td></tr><tr><td> Compound members</td><td>55</td><td>79</td></tr><tr><td> Compound manager</td><td>15</td><td>21</td></tr><tr><td colspan="3">Age of the respondent</td></tr><tr><td> 19&#8211;35 year</td><td>38</td><td>54</td></tr><tr><td> Above 36 year</td><td>32</td><td>46</td></tr><tr><td colspan="3">Education of the respondent</td></tr><tr><td> No education</td><td>25</td><td>36</td></tr><tr><td> Primary</td><td>21</td><td>30</td></tr><tr><td> Secondary</td><td>17</td><td>24</td></tr><tr><td> Above secondary</td><td>7</td><td>10</td></tr><tr><td colspan="3">Occupation of the respondent</td></tr><tr><td> Housewife</td><td>54</td><td>77</td></tr><tr><td> School teacher</td><td>1</td><td>1</td></tr><tr><td> Business</td><td>12</td><td>17</td></tr><tr><td> Service</td><td>3</td><td>4</td></tr></table>
<table><tr><td rowspan="2">Sociodemographic</td><td colspan="2">Total N = 70</td></tr><tr><td>N</td><td>(%)</td></tr><tr><td colspan="3">Gender of the respondent</td></tr><tr><td>Female</td><td>54</td><td>77</td></tr><tr><td colspan="2">Type of the respondent</td><td></td></tr><tr><td>Compound members</td><td>55</td><td>79</td></tr><tr><td>Compound manager</td><td>15</td><td>21</td></tr><tr><td colspan="3">Age of the respondent</td></tr><tr><td>19–35 year</td><td>38</td><td>54</td></tr><tr><td>Above 36 year</td><td>32</td><td>46</td></tr><tr><td colspan="3">Education of the respondent</td></tr></table>
<table><tr><td>No education</td><td>25</td><td>36</td></tr><tr><td>Primary</td><td>21</td><td>30</td></tr><tr><td>Secondary</td><td>17</td><td>24</td></tr><tr><td>Above secondary</td><td>7</td><td>10</td></tr><tr><td colspan="3">Occupation of the respondent</td></tr><tr><td>Housewife</td><td>54</td><td>77</td></tr><tr><td>School teacher</td><td>1</td><td>1</td></tr><tr><td>Business</td><td>12</td><td>17</td></tr><tr><td>Service</td><td>3</td><td>4</td></tr></table>
8a5481eeaf14d7389db4ac198d92dc1c76931fa707b67b3f4b504d95458814ea.png
complex
<table><tr><td rowspan="2"></td><td colspan="3">Simplex Assay</td><td colspan="3">Multiplex Assay</td></tr><tr><td>CHIKV</td><td>DENV</td><td><i>Leptospira</i></td><td>CHIKV</td><td>DENV</td><td><i>Leptospira</i></td></tr><tr><td>Slope</td><td>&#8722;3.13</td><td>&#8722;3.19</td><td>&#8722;3.25</td><td>&#8722;3.41</td><td>&#8722;3.15</td><td>&#8722;3.37</td></tr><tr><td>Efficiency</td><td>2.09</td><td>2.06</td><td>2.03</td><td>1.96</td><td>2.08</td><td>1.98</td></tr></table>
<table><tr><td></td><td colspan="3">Simplex</td><td colspan="3">Multipl</td></tr></table>
<table><tr><td rowspan="2"></td><td colspan="3"> Assay</td><td colspan="3">ex Assay</td></tr><tr><td>CHIKV</td><td>DENV</td><td>Leptospira</td><td>CHIKV</td><td>DENV</td><td>Leptospira</td></tr><tr><td>Slope</td><td>−3.13</td><td>−3.19</td><td>−3.25</td><td>−3.41</td><td>−3.15</td><td>−3.37</td></tr><tr><td>Efficiency</td><td>2.09</td><td>2.06</td><td>2.03</td><td>1.96</td><td>2.08</td><td>1.98</td></tr></table>
e29f4395d2e1d5f52ef8bf898907f442ce5c86a8309e817bb3779e380624f136.png
simple
<table><tr><td>Databases</td><td>Contents</td></tr><tr><td>National Eye Institute: NEI Bank Project</td><td>Transcriptome profiling for different tissues of the eye for a variety of different species including mouse and human</td></tr><tr><td>Mouse Retina Serial Analysis of Gene Expression (SAGE)</td><td>Gene expression data from the embryonic and postnatal mouse retina.</td></tr><tr><td>Scripps Friedlander Gene Expression</td><td>Expression of retinal transcripts for the mouse retina during eight different postnatal stages.</td></tr><tr><td>Retinal Information Network</td><td>Mapped loci and cloned genes associated with inherited retinal disease.</td></tr><tr><td>Retinal International Website</td><td>Series of databases listing: retinal diseases, mutations affecting the eye, current animal models, and known proteins involved in retinal disease.</td></tr><tr><td>GENSTAT: Retina Project</td><td>Cell specific labeling in the retina using BAC transgenic mice.</td></tr><tr><td>Retina Central</td><td>Integrated platform for gene related information regarding the adult mammalian retina</td></tr></table>
<table><tr><td>Databases</td></tr><tr><td>National Eye Institute: NEI Bank Project</td></tr><tr><td>Mouse Retina Serial Analysis of Gene Expression (SAGE)</td></tr><tr><td>Scripps Friedlander Gene Expression</td></tr><tr><td>Retinal Information Network</td></tr><tr><td>Retinal International Website</td></tr><tr><td>GENSTAT: Retina Project</td></tr><tr><td>Retina Central</td></tr></table>
<table><tr><td>Contents</td></tr><tr><td>Transcriptome profiling for different tissues of the eye for a variety of different species including mouse and human</td></tr><tr><td>Gene expression data from the embryonic and postnatal mouse retina.</td></tr><tr><td>Expression of retinal transcripts for the mouse retina during eight different postnatal stages.</td></tr><tr><td>Mapped loci and cloned genes associated with inherited retinal disease.</td></tr><tr><td>Series of databases listing: retinal diseases, mutations affecting the eye, current animal models, and known proteins involved in retinal disease.</td></tr><tr><td>Cell specific labeling in the retina using BAC transgenic mice.</td></tr><tr><td>Integrated platform for gene related information regarding the adult mammalian retina</td></tr></table>
1d4a105c2284a3723223b9b5519f3d0227a5aee3129609be529ffb374e933c64.png
simple
<table><tr><td>Hormone</td><td>Quantity of studies</td><td>Normal response</td><td>Blunted response</td><td>Exacerbated response</td></tr><tr><td>Cortisol</td><td>26 (65.0%)</td><td>18 (69.2%)</td><td>8 (30.8%)</td><td>-</td></tr><tr><td>Total T</td><td>18 (45.0%)</td><td>14 (77.8%)</td><td>3 (16.7%)</td><td>1 (5.9%)</td></tr><tr><td>GH</td><td>13 (32.5%)</td><td>7 (53.8%)</td><td>5 (38.4%)</td><td>1 (7.8%)</td></tr><tr><td>T/C</td><td>10 (25.0%)</td><td>5 (50.0%)</td><td>4 (40.0%)</td><td>1 (10.0%)</td></tr><tr><td>ACTH</td><td>10 (25.0%)</td><td>6 (60.0%)</td><td>4 (40.0%)</td><td>-</td></tr><tr><td>Plasma catecholamines</td><td>9 (22.5%)</td><td>4 (44.4%)</td><td>4 (44.4%)</td><td>1 (11.1%)</td></tr><tr><td>Insulin</td><td>8 (20.0%)</td><td>6 (75.0%)</td><td>2 (25.0%)</td><td>-</td></tr><tr><td>LH</td><td>8 (20.0%)</td><td>7 (87.5%)</td><td>1 (12.5%)</td><td>-</td></tr><tr><td>Prolactin</td><td>6 (15.0%)</td><td>4 (66.7%)</td><td>2 (33.3%)</td><td>-</td></tr><tr><td>FSH</td><td>6 (15.0%)</td><td>5 (83.3%)</td><td>1 (16.7%)</td><td>-</td></tr><tr><td>IGF-1</td><td>5 (12.5%)</td><td>3 (60.0%)</td><td>1 (20.0%)</td><td>1 (20.0%)</td></tr><tr><td>Aldosterone</td><td>5 (12.5%)</td><td>1 (20.0%)</td><td>2 (40.0%)</td><td>2 (40.0%)</td></tr><tr><td>Free T</td><td>3 (7.5%)</td><td>1 (33.3%)</td><td>1 (33.3%)</td><td>1 (33.3%)</td></tr><tr><td>T4</td><td>2 (5.0%)</td><td>2 (100%)</td><td>-</td><td>-</td></tr><tr><td>T3</td><td>2 (5.0%)</td><td>2 (100%)</td><td>-</td><td>-</td></tr><tr><td>NUC</td><td>2 (5.0%)</td><td>-</td><td>2 (100%)</td><td>-</td></tr><tr><td>Salivary C</td><td>2 (5.0%)</td><td>-</td><td>2 (100%)</td><td>-</td></tr><tr><td>Salivary T</td><td>2 (5.0%)</td><td>1 (50.0%)</td><td>1 (50.0%)</td><td>-</td></tr><tr><td>NUC</td><td>2 (5.0%)</td><td>1 (50.0%)</td><td>1 (50.0%)</td><td>-</td></tr><tr><td>IGFBP-3</td><td>2 (5.0%)</td><td>1 (50.0%)</td><td>1 (50.0%)</td><td>-</td></tr><tr><td>IGF-1/IGFBP-3</td><td>2 (5.0%)</td><td>2 (100%)</td><td>-</td><td>-</td></tr><tr><td>SHBG</td><td>1</td><td>1</td><td>-</td><td>-</td></tr><tr><td>DHEA-S</td><td>1</td><td>1</td><td>-</td><td>-</td></tr><tr><td>Peptide F</td><td>1</td><td>1</td><td>-</td><td>-</td></tr><tr><td>Fertility</td><td>1</td><td>-</td><td>1</td><td>-</td></tr><tr><td>Beta-2 muscle receptors</td><td>1</td><td>-</td><td>1</td><td>-</td></tr></table>
<table><tr><td>Hormone</td><td>Quantity of studies</td><td>Normal response</td><td>Blunted response</td><td>Exacerbated response</td></tr><tr><td>Cortisol</td><td>26 (65.0%)</td><td>18 (69.2%)</td><td>8 (30.8%)</td><td>-</td></tr><tr><td>Total T</td><td>18 (45.0%)</td><td>14 (77.8%)</td><td>3 (16.7%)</td><td>1 (5.9%)</td></tr><tr><td>GH</td><td>13 (32.5%)</td><td>7 (53.8%)</td><td>5 (38.4%)</td><td>1 (7.8%)</td></tr><tr><td>T/C</td><td>10 (25.0%)</td><td>5 (50.0%)</td><td>4 (40.0%)</td><td>1 (10.0%)</td></tr></table>
<table><tr><td>Hormone</td><td>Quantity of studies</td><td>Normal response</td><td>Blunted response</td><td>Exacerbated response</td></tr><tr><td>ACTH</td><td>10 (25.0%)</td><td>6 (60.0%)</td><td>4 (40.0%)</td><td>-</td></tr><tr><td>Plasma catecholamines</td><td>9 (22.5%)</td><td>4 (44.4%)</td><td>4 (44.4%)</td><td>1 (11.1%)</td></tr><tr><td>Insulin</td><td>8 (20.0%)</td><td>6 (75.0%)</td><td>2 (25.0%)</td><td>-</td></tr><tr><td>LH</td><td>8 (20.0%)</td><td>7 (87.5%)</td><td>1 (12.5%)</td><td>-</td></tr><tr><td>Prolactin</td><td>6 (15.0%)</td><td>4 (66.7%)</td><td>2 (33.3%)</td><td>-</td></tr><tr><td>FSH</td><td>6 (15.0%)</td><td>5 (83.3%)</td><td>1 (16.7%)</td><td>-</td></tr><tr><td>IGF-1</td><td>5 (12.5%)</td><td>3 (60.0%)</td><td>1 (20.0%)</td><td>1 (20.0%)</td></tr><tr><td>Aldosterone</td><td>5 (12.5%)</td><td>1 (20.0%)</td><td>2 (40.0%)</td><td>2 (40.0%)</td></tr><tr><td>Free T</td><td>3 (7.5%)</td><td>1 (33.3%)</td><td>1 (33.3%)</td><td>1 (33.3%)</td></tr><tr><td>T4</td><td>2 (5.0%)</td><td>2 (100%)</td><td>-</td><td>-</td></tr><tr><td>T3</td><td>2 (5.0%)</td><td>2 (100%)</td><td>-</td><td>-</td></tr><tr><td>NUC</td><td>2 (5.0%)</td><td>-</td><td>2 (100%)</td><td>-</td></tr><tr><td>Salivary C</td><td>2 (5.0%)</td><td>-</td><td>2 (100%)</td><td>-</td></tr><tr><td>Salivary T</td><td>2 (5.0%)</td><td>1 (50.0%)</td><td>1 (50.0%)</td><td>-</td></tr><tr><td>NUC</td><td>2 (5.0%)</td><td>1 (50.0%)</td><td>1 (50.0%)</td><td>-</td></tr><tr><td>IGFBP-3</td><td>2 (5.0%)</td><td>1 (50.0%)</td><td>1 (50.0%)</td><td>-</td></tr><tr><td>IGF-1/IGFBP-3</td><td>2 (5.0%)</td><td>2 (100%)</td><td>-</td><td>-</td></tr><tr><td>SHBG</td><td>1</td><td>1</td><td>-</td><td>-</td></tr><tr><td>DHEA-S</td><td>1</td><td>1</td><td>-</td><td>-</td></tr><tr><td>Peptide F</td><td>1</td><td>1</td><td>-</td><td>-</td></tr><tr><td>Fertility</td><td>1</td><td>-</td><td>1</td><td>-</td></tr><tr><td>Beta-2 muscle receptors</td><td>1</td><td>-</td><td>1</td><td>-</td></tr></table>
4270fb47b4bfbfbc2209cd3a9a92e74289505857fc7cbdd8373fb9b7c2ad5d3a.png
complex
<table><tr><td>Level</td><td>Discovery phase</td><td>Improvement phase</td></tr><tr><td colspan="3">Heritability</td></tr><tr><td> 0.25</td><td>0.033 (0.012, 0.056)<sup>a</sup></td><td>0.098 (&#8722;0.005, 0.200)<sup>a</sup></td></tr><tr><td> 0.50</td><td>0.045 (0.020, 0.072)<sup>b</sup></td><td>0.130 ( 0.014, 0.232)<sup>b</sup></td></tr><tr><td colspan="3">Genotyping platform</td></tr><tr><td> GBS10x@10K</td><td>0.029 (0.011, 0.049)<sup>a</sup></td><td>0.098 (&#8722;0.014, 0.210)<sup>a</sup></td></tr><tr><td> GBS1x@100K</td><td>0.050 (0.030, 0.072)<sup>b</sup></td><td>0.130 ( 0.031, 0.232)<sup>b</sup></td></tr><tr><td colspan="3">Number of phenotyped seeds per landrace</td></tr><tr><td> 1</td><td>0.035 (0.013, 0.061)<sup>a</sup></td><td>0.109 (&#8722;0.008, 0.219)<sup>a</sup></td></tr><tr><td> 3</td><td>0.040 (0.014, 0.069)<sup>b</sup></td><td>0.116 ( 0.008, 0.223)<sup>b</sup></td></tr><tr><td> 5</td><td>0.042 (0.017, 0.071)<sup>c</sup></td><td>0.117 ( 0.009, 0.224)<sup>b</sup></td></tr><tr><td colspan="3">Number of selected landraces</td></tr><tr><td> 40</td><td>0.042 (0.016, 0.072)<sup>a</sup></td><td>0.115 ( 0.003, 0.220)<sup>a</sup></td></tr><tr><td> 80</td><td>0.036 (0.013, 0.063)<sup>b</sup></td><td>0.113 ( 0.001, 0.226)<sup>a</sup></td></tr><tr><td colspan="3">Number of tested seeds per selected landrace</td></tr><tr><td> 10</td><td>0.038 (0.014, 0.066)<sup>a</sup></td><td>0.113 (&#8722;0.004, 0.228)<sup>a</sup></td></tr><tr><td> 20</td><td>0.040 (0.014, 0.068)<sup>b</sup></td><td>0.114 ( 0.000, 0.218)<sup>a</sup></td></tr><tr><td> 40</td><td>0.041 (0.015, 0.070)<sup>c</sup></td><td>0.114 ( 0.009, 0.222)<sup>a</sup></td></tr><tr><td colspan="3">Number of phenotyped synthetic seeds</td></tr><tr><td> 0</td><td>/</td><td>0.069 (&#8722;0.020, 0.166)<sup>a</sup></td></tr><tr><td> 20</td><td>/</td><td>0.116 ( 0.016, 0.213)<sup>b</sup></td></tr><tr><td> 40</td><td>/</td><td>0.131 ( 0.036, 0.229)<sup>c</sup></td></tr><tr><td> 60</td><td>/</td><td>0.139 ( 0.038, 0.244)<sup>d</sup></td></tr></table>
<table><tr><td>Level</td><td>Discovery phase</td><td>Improvement phase</td></tr><tr><td colspan="3">Heritability</td></tr><tr><td>0.25</td><td>0.033 (0.012, 0.056)a</td><td>0.098 (−0.005, 0.200)a</td></tr><tr><td>0.50</td><td>0.045 (0.020, 0.072)b</td><td>0.130 ( 0.014, 0.232)b</td></tr><tr><td colspan="3">Genotyping platform</td></tr><tr><td>GBS10x@10K</td><td>0.029 (0.011, 0.049)a</td><td>0.098 (−0.014, 0.210)a</td></tr><tr><td>GBS1x@100K</td><td>0.050 (0.030, 0.072)b</td><td>0.130 ( 0.031, 0.232)b</td></tr><tr><td colspan="3">Number of phenotyped seeds per landrace</td></tr><tr><td>1</td><td>0.035 (0.013, 0.061)a</td><td>0.109 (−0.008, 0.219)a</td></tr><tr><td>3</td><td>0.040 (0.014, 0.069)b</td><td>0.116 ( 0.008, 0.223)b</td></tr><tr><td>5</td><td>0.042 (0.017, 0.071)c</td><td>0.117 ( 0.009, 0.224)b</td></tr><tr><td colspan="3">Number of selected landraces</td></tr><tr><td>40</td><td>0.042 (0.016, 0.072)a</td><td>0.115 ( 0.003, 0.220)a</td></tr><tr><td>80</td><td>0.036 (0.013, 0.063)b</td><td>0.113 ( 0.001, 0.226)a</td></tr><tr><td colspan="3">Number of tested seeds per selected landrace</td></tr><tr><td>10</td><td>0.038 (0.014, 0.066)a</td><td>0.113 (−0.004, 0.228)a</td></tr></table>
<table><tr><td>Level</td><td>Discovery phase</td><td>Improvement phase</td></tr><tr><td>20</td><td>0.040 (0.014, 0.068)b</td><td>0.114 ( 0.000, 0.218)a</td></tr><tr><td>40</td><td>0.041 (0.015, 0.070)c</td><td>0.114 ( 0.009, 0.222)a</td></tr><tr><td colspan="3">Number of phenotyped synthetic seeds</td></tr><tr><td>0</td><td>/</td><td>0.069 (−0.020, 0.166)a</td></tr><tr><td>20</td><td>/</td><td>0.116 ( 0.016, 0.213)b</td></tr><tr><td>40</td><td>/</td><td>0.131 ( 0.036, 0.229)c</td></tr><tr><td>60</td><td>/</td><td>0.139 ( 0.038, 0.244)d</td></tr></table>
7c12e21a184befd3bef2f1fcc1a7d9ecd615c08b8eb137ea632a19e2f3419b8c.png
simple
<table><tr><td>Immune cells</td><td>Enriched genes</td><td>References</td></tr><tr><td>All T cells</td><td>Human: <i>CD3G</i>,<i> CD3D</i>,<i> TRA</i>,<i> CD6, CD5, NPDC1, CD28, CAMK4, GFI1, GATA3, SH2D1A, TRB, TNFRSF25, NK4, TACTILE, BCL11B, CD3E, INPP4B, MAL, NPDC1, ITM2A, ITK, LCK, NFATC3, RORA, MGC19764, TCF7, ZAP70, LEF1, SPOCK2, PRKCQ, SATB1, RASGRP1, LRIG1, DPP4, CD3Z, PDE4D, FYN, WWP1, LAT, DUSP16, KIAA0748, CDR2, STAT4, FLT3LG, IL6ST</i></td><td>78&#8211;79</td></tr><tr><td>CD8+T cells</td><td>Human: <i>FCGBP, C1ORF21, PHEMX, KLRG1, ZNF145, ADRB2, DUSP2, IL2RB, CCL5, GZMC, TBX21, CCL4L, GZMH, PRF1, GNLY, CST7, GPR56, KLRC1, S100B, D12S2489E, CD8B1, CD8A</i></td><td>79, 81, 82</td></tr><tr><td>T regulatory cells</td><td>Human: <i>AKAP2, ANXA2, C8FW, CALM2, CDH13, ENTPD1, EPSTI1, F5, GBP2, GBP5, HS3ST3B1, HSPCA, ICA1, LAIR2, LGALS3, LOC51191, MKP-7, NINJ2, P53DINP1, PMAIP1, PTPLA, GPR2, HLA-DMA, HLA-DPA1, HLA-DPB1, HLA-DQB1, HLA-DRA, HLA-DRB4, HLA-DRB5, HPGD, PTT1, SAT, SHMT2, TMOD3, TNFRSF6, VIL2, LRRC32, CHAC1, EGR1, PYCR1, IL13, C3AR1, ZBED2, IL10, GAB3, NR4A1, IL1R2, ULBP1, IL17F, EIF4EBP1, RGS16, BCAT1, VEGFA, GIMAP1, GPR44, GPT2, PSPH, NLN, MS4A3, UCK2, TNIP3, TNFRSF9, IL7R, NR4A3, CSGALNA, CT1, SLC43A1, ZBTB32, SCFD2, HK2, C17ORF96, C1ORF186, LYZ, SFXN4, CYP1B1, SLC7A5, C17ORF58, SLC4A5, CD52, KLRB1, S100A4, POLA1, SLC7A1, ATPBD4, UBXN8, CASP8, FAIM3, IL12RB2, MPP7, ZNF831, BNIP3L, LRP8, UTRN, SOCS3, LY9, EVI2B, SFXN3, TNFRSF4, ING4, BLM, TNFSF11, SLFN5, CCR8, CD244, MYO1F, HOMER1, ATF3, AGPAT4, CTH, JAKMIP1, TFRC, RPL26L1, MICAL1, GPRASP1, TMX4, FYB, ZNF792, WDR4, HUWE1, CD83, TRIB2, LARP1B, SLC38A5, AUH, CTPS, CYTH1, APOL3, CHD6, IL1R1, LPCAT4, CITED2, DUSP4, SSBP2, LAYN, ZFAND2B, PIK3R1, GCNT4, PPP3CA, TIMP1, SIRPG, CCR3, PTP4A3, SERINC5, MAGOHB, GIMAP4, KLHL24, CCNG2, WDR70, MYBL1, CNPY4, TIMM8A, CCDC28A, MNAT1, MS4A2, GZMB, E2F5, HIBCH, C9ORF91, NHP2, CDC25B, VDR, CSF1, GPATCH4, NFKBID, TMCO7, EHBP1, FAM173B, FARS2, FLVCR2, NPM3, PNPO, P2RY8, TMEM63A, MXI1, MRTO4, SESN2, C1ORF38, STK38, SLC6A6, ALG14, LXN, TNFRSF18, ACSS1, UBA7, MTSS1, PSMA6, FAM8A1, RAB31, TNRC6B, SESN1, CEP68, LAPTM5, PLAGL2, LRRC33, EIF2B3, URB2, DDX21, ITGA4, RGS2, RORC, IFNAR2, CSDA, SORL1, LRRC37B, IL10RA, PRKACB, CBWD1, SMAD3, C1ORF96, FCER1A, HSP90AB1, EMG1</i></td><td>83&#8211;87</td></tr><tr><td>B cells</td><td>Human: <i>PSEN2, FZD5, PLEKHF2, SIDT2, MTPN, TUBB6, FLJ21127, SMC6L1, KIAA1026, NUP88, GNA12, RNTRE, GSTZ1, RFX5, XYLT1, GL012, EPB41L2, LOC51760, SCRN1, PTD008, CYB561D2, SCAP2, MMP11, ERDJ5, TTC7A, PMAIP1, GARNL4, TMEPAI, SH3BP5, EDD, UCP4, EVI5L, PIK3C2B, SMAD3, LHFPL2, LOC57228, GM2A, HRK, ZNF207, LOC92497, F5, DMXL1, CLIC4, PRCP, DKFZP434C0328, STRBP, PHF16, JUP, TEAD2, PPP3CA, CNR2, ATP5B, ABCA1, BMF, ZCCHC7, KIAA0274, SLC22A3, SPI1, AMFR, ANXA4, EBF, ITPR1, HIST1H2BK, COPS3, COL14A1, SAV1, APOBEC3B, CCNG2, STAG3, LOC348938, POLD4, TBC1D1, MK2S4, APG4A, DAPP1, TNFRSF18, HERPUD1, POU2F2, ADK, CKIP-1, ACTA2, PARP14, MTSS1, DTX1, DDR1, RRAS2, RNF141, SYPL, SSPN, CORO1C, NFKBIE, CHD7, SP140, WDR34, BTNL9, ATP6V0A1, UROS, HLA-DOA, C22ORF13, IFI27, JMJD2B, WEE1, ODC1, KIAA0746, WDR11, SYNGR2, FOXP1, BLR1, MYO1E, MYBL2, GYLTL1B, SETBP1, KLF1, INPPL1, LOC54103, ZNF154, MHC2TA, CD24, ARHGEF3, BIRC3, TRIM56, HLA-DPB1, UVRAG, CD38, PEA15, FLJ10697, TLR10, ARHGAP10, HLA-DRA, SHMT2, LGALS9, FLJ10853, CEBPB, PRICKLE1, LCP21, CR1, KLHL14, TLR7, C20ORF72, HLA-DQB2, CORO1A, PRKCE</i><i>HECW2, FLJ25604, TRIM26, FBXO41, GCNT1, LRMP, UBE2J1, IGKV3D, PCCA, GLDC, CYSLTR1, BTLA, NET5, HLA-DPA1, BLNK, CD79B, TM4SF8, TFEB, CD11ORF24,ADRBK2, CDKN2A, RIPK2, STX7, NCF4, SRGAP2, SLC2A5, CTSZ, AIM2, TCF4, TPD52, MAP3K8, MOBKL2B, HLA-DOB, IFIT3, MGC24039, BRD4, RALGPS2, SEMA4B, BSG,IGKC, HLA-DRB6, FUBP1, UNC84B, IFNGR2, HSPA5, HLA-DRB5, MARCKS, KYNU, PACAP, RHOBTB2, FLJ12363, TMED8, FGD2, FBXO10, IL4R, CD1C, MGC50844,MRPL49, CTSH, LYN, WASPIP, C3ORF6, EGR1, IGKV15, SPAP1, CHERP, IGHG3, ADAM28, HLA-DMA, HLA-DMB, PALM2-AKAP2, CD86, LAF4, LOC283663, FREB,DKFZP586A0522, UREB1, IGLL1, HLA-DQA2, KIAA1219, PLCG2, MARCH-1, BCNP1, PNOC, CD20, PSCD1, BCL11A, VPS28, SWAP70, SYK, BCL7A, NAP1L, TEM6, BTK,RAB30, FCGR2B, STAT6, BRDG1, LOC201895, ITGB1, CD74, CORO2B, VPREB3, HSPC182, MGC15619, RHOH, IGHA, CYBASC3, KIAA0125, RAM2, CD83, FCRH1, FLII,SNX10, IGHG1, EPHX1, FLJ10979, GTPAP, IGLL3, E2F5, TNFRSF17, BLK, FLJ00332, SNX2, CD200, HLA-DQB1, TRIO, CYBB, PIK3AP1, IRF4, CD22, BACE2, IGJ, PAX5,RGS13, TCL1A, MEF2C, C13ORF18, POU2AF1, HHEX, IRF8, BANK1, OSBPL10, SLC2A1, NCF1, IGL@, IGLC2, SPAP1, IGHG3, HLA-DMA, HLA-DMB, CD79A, HSPA6, IGHD,KIAA0476, SLC7A7, NKG7, CD19, SAMD9, LY86, SPIB, NAPSB, RNASE6, IGHM, LY64, CD72, IRTA2, CD1D, HLA-DQA1, SAS, CTSH, LYN, WASPIP, C3ORF6, EGR1, FREB,DKFZP586A0522</i></td><td>88, 79, 89</td></tr><tr><td>Resting NK cells</td><td>Human: <i>IL18RAP, PRF1, GZMH, TKTL1</i></td><td>90&#8211;92</td></tr><tr><td>Macrophages</td><td><sup>a</sup>Murine: <i>Pecr, Tmem195, Ptplad2, 1810011H11Rik, Fert2, Tlr4, Pon3, Mr1, Arsg, Fcgr1, Camk1, Pld3, Tpp1, Ctsd, Pla2g15, Lamp2, Pla2g4a, MerTK, Tlr7, Cd14, Tbxas1, Fcgr3, Fgd4, Sqrdl, Csf3r, Plod1, Tom1, Myo7a, A930030A15Rik, Sepp1, Glul, Cd164, Tcn2, Dok3, Ctsl, Tspan14</i></td><td>93&#8211;95</td></tr><tr><td>M1 macrophages</td><td><sup>a</sup>Murine: <i>Cd38, Cfb, Slfn4, H2-Q6, Fpr1, Slfn1, Gpr18, Ccrl2, Fpr2, Cxcl10, Mpa2IOasl1, Tlr2, Ms4a4c, LOC100503664, Irak3, Hp, Itgal, Herc6, Cd300lf, Isf20, Pstpip2, Cp, Isg15, Herc6, Probe, 1452408_at, Ifi44, E030037K03, Rik, Saa3, Ifit1, Marco, F11r, Rsad2, Ddx60, Pilr1, Cpd, Gngt2, Mx1, Pyhin1, Epb4.1l3, Slfn8, Arhgap24, Nfkbiz, Gbp6, Stat1, Zpb1, D14Erd668e, Ddx58, Tuba4a, H2-T10, Ebi3, Fam176b, Xaf1, Stat2, Sepx1, Ifit2</i></td><td>96</td></tr><tr><td>M2 macrophages</td><td><sup>a</sup>Murine: <i>Ptgs1, Egr2, Olfm1, Flrt2, P2ry1, Vwf, Amz1, Tmem158, Tiam1, Rhoj, Mmp9, Mrc1, Bcar3, Il6st, Tanc2, Mmp12, Tcfec, Clec71, Matk, Myc, Clec10a, Atp6v0a1, Lmna, Chst7, Atp6v0d2, Emp2, Socs6, Atp6v0a1, Plk2, Ptpla</i></td><td>96</td></tr><tr><td>Classical monocytes</td><td>Human: <i>S100A12, ALOX5AP, PAD14, NRG1, MCEMP1, THBS1, CRISPLD2, F13A1, MOSC1, CYP27A1, CD163, QPCT, ADAM19, ASGR2, RNASE4, ALDH1A1, EDG3, PROK2, CLEC4D, S100A9, OSM, CSPG2, GALS2, ANG, VNN2, EBI2, UTS2, RPPH1, MGST1, IL8, CCR2, SELL, DYSF, MT1F, CD14, RANSE6, CSF3R, STAB1, CYP1B1, ADHFE1, PLA2G7, MMP25, ZNF395, SLC2A3, EGR1, CMTM2, CD9</i></td><td>97, 98</td></tr><tr><td>Intermediate monocytes</td><td>Human:<i> GFRA2, NKG7, PLVAP, PLAC8, MARCKSL1, E2F2, G8P4, CLEC10A, SCD, COTL1, SLC29A1, DDIT4, TGM2, LILRA3, ATF5, GPA33, C1QC, EVA1, MERTK, MGLL, DDEFL1, MARCO, NR1H3, FBP1, ACP2, GBP1, GPBAR1, SASH1, OLFM1, TIMP1, HLA-DOA, CAMK1, POUFUT1, EPB4IL3, H19, ZNF703, SNX5, CLEC10, AK-ALPHA-1, DPB1, DHRS9, MTHFD2, RGL1, PRDM1, FADS1, SLC2A8, CSK, ISOC2, CD300C, FGD2</i></td><td>97, 98</td></tr><tr><td>Nonclassical monocytes</td><td>Human: <i>C1QA, HES4, CDKN1C, C1QB, RHOC, CLEC4F, ADA, TAGLN, TCF7L2, CD798, CTSL, SFTPD, ABI3, SETBP1, FGFRL1, CD798, SPRED1, SNFT, EVL, MTSS1, SH2D1B, CYFIP2, NELF, STS-1, SIGLEC10, CKS1B, PTP4A3, LYPD2, SIDT2, INSIG1, LTB, PAPSS2, ABCC3, CASP5, VOM1, HSPB1, GNGT2, HMOX1, RRAS, RNF122, CDH23, FMNL2, RGS12, SGGB3A1, FER1L3, CALML4, IFITM3, CKB, CEACAM3, IFITM1</i></td><td>97, 98</td></tr><tr><td>Mature DC&#8217;s</td><td>Human: <i>ACCL5, CXCL10, CCR7, IL15, IF127, IF144L, IFIH1, IFIT1, MX1, ISG15, ISG20, IRF7, GBP4, DUSP5, NFKB1A, ATF3, TNFSF10, IL6, IL8, IL7R, CCL4, TNFA1P6, IFIT3, OASL, GBP1, HES4, CYP27B1, RIPK2, TNFRSF9, SOD2, CD38, CD44, CD80, CD83, CD86, INDO MT2A, TRAF1, GADD45B, MT1M, MTIP2, BIRC3, USP18, TUBB2A, CCL8, EBI3, IFITM1, MT1B, MT1E, MT1G, MT1H, GADD45A, CD200, LAMP3, RGS1, SAT1</i></td><td>99, 100</td></tr><tr><td>Monocyte-derived DC&#8217;s</td><td>Human: <i>CD1A, CD1B, CD1C, CD23A, MRC1, CD36, HLA-DQA, HLA-DP light chain, HLA-DG protein 41, RIL, RAP1GAP, CCND2, DUSP5, PPIC, STAC, PRKACB, TRIB2, SHB</i></td><td>99&#8211;101</td></tr><tr><td>Mature neutrophils</td><td>Human: <i>ALPL, IL8RB, FCGR3B, SEMA3C, HM74, SOD2, FCGR3A, IL-8, STHM, IL8RA, FCGR2A, CSF3R, NCF2, AOAH</i></td><td>102, 103</td></tr><tr><td>Immature neutrophils</td><td>Human: <i>AZU1, ELA2, BPI, LCN2, MPO, CTSG, MMP8, DEFA4, DEFA3, CAMP, X-CGD</i></td><td>103&#8211;105</td></tr></table>
<table><tr><td>Immune cells</td><td>Enriched genes</td><td>References</td></tr><tr><td>All T cells</td><td>Human: CD3G, CD3D, TRA, CD6, CD5, NPDC1, CD28, CAMK4, GFI1, GATA3, SH2D1A, TRB, TNFRSF25, NK4, TACTILE, BCL11B, CD3E, INPP4B, MAL, NPDC1, ITM2A, ITK, LCK, NFATC3, RORA, MGC19764, TCF7, ZAP70, LEF1, SPOCK2, PRKCQ, SATB1, RASGRP1, LRIG1, DPP4, CD3Z, PDE4D, FYN, WWP1, LAT, DUSP16, KIAA0748, CDR2, STAT4, FLT3LG, IL6ST</td><td>78–79</td></tr></table>
<table><tr><td>CD8+T cells</td><td>Human: FCGBP, C1ORF21, PHEMX, KLRG1, ZNF145, ADRB2, DUSP2, IL2RB, CCL5, GZMC, TBX21, CCL4L, GZMH, PRF1, GNLY, CST7, GPR56, KLRC1, S100B, D12S2489E, CD8B1, CD8A</td><td>79, 81, 82</td></tr><tr><td>T regulatory cells</td><td>Human: AKAP2, ANXA2, C8FW, CALM2, CDH13, ENTPD1, EPSTI1, F5, GBP2, GBP5, HS3ST3B1, HSPCA, ICA1, LAIR2, LGALS3, LOC51191, MKP-7, NINJ2, P53DINP1, PMAIP1, PTPLA, GPR2, HLA-DMA, HLA-DPA1, HLA-DPB1, HLA-DQB1, HLA-DRA, HLA-DRB4, HLA-DRB5, HPGD, PTT1, SAT, SHMT2, TMOD3, TNFRSF6, VIL2, LRRC32, CHAC1, EGR1, PYCR1, IL13, C3AR1, ZBED2, IL10, GAB3, NR4A1, IL1R2, ULBP1, IL17F, EIF4EBP1, RGS16, BCAT1, VEGFA, GIMAP1, GPR44, GPT2, PSPH, NLN, MS4A3, UCK2, TNIP3, TNFRSF9, IL7R, NR4A3, CSGALNA, CT1, SLC43A1, ZBTB32, SCFD2, HK2, C17ORF96, C1ORF186, LYZ, SFXN4, CYP1B1, SLC7A5, C17ORF58, SLC4A5, CD52, KLRB1, S100A4, POLA1, SLC7A1, ATPBD4, UBXN8, CASP8, FAIM3, IL12RB2, MPP7, ZNF831, BNIP3L, LRP8, UTRN, SOCS3, LY9, EVI2B, SFXN3, TNFRSF4, ING4, BLM, TNFSF11, SLFN5, CCR8, CD244, MYO1F, HOMER1, ATF3, AGPAT4, CTH, JAKMIP1, TFRC, RPL26L1, MICAL1, GPRASP1, TMX4, FYB, ZNF792, WDR4, HUWE1, CD83, TRIB2, LARP1B, SLC38A5, AUH, CTPS, CYTH1, APOL3, CHD6, IL1R1, LPCAT4, CITED2, DUSP4, SSBP2, LAYN, ZFAND2B, PIK3R1, GCNT4, PPP3CA, TIMP1, SIRPG, CCR3, PTP4A3, SERINC5, MAGOHB, GIMAP4, KLHL24, CCNG2, WDR70, MYBL1, CNPY4, TIMM8A, CCDC28A, MNAT1, MS4A2, GZMB, E2F5, HIBCH, C9ORF91, NHP2, CDC25B, VDR, CSF1, GPATCH4, NFKBID, TMCO7, EHBP1, FAM173B, FARS2, FLVCR2, NPM3, PNPO, P2RY8, TMEM63A, MXI1, MRTO4, SESN2, C1ORF38, STK38, SLC6A6, ALG14, LXN, TNFRSF18, ACSS1, UBA7, MTSS1, PSMA6, FAM8A1, RAB31, TNRC6B, SESN1, CEP68, LAPTM5, PLAGL2, LRRC33, EIF2B3, URB2, DDX21, ITGA4, RGS2, RORC, IFNAR2, CSDA, SORL1, LRRC37B, IL10RA, PRKACB, CBWD1, SMAD3, C1ORF96, FCER1A, HSP90AB1, EMG1</td><td>83–87</td></tr><tr><td>B cells</td><td>Human: PSEN2, FZD5, PLEKHF2, SIDT2, MTPN, TUBB6, FLJ21127, SMC6L1, KIAA1026, NUP88, GNA12, RNTRE, GSTZ1, RFX5, XYLT1, GL012, EPB41L2, LOC51760, SCRN1, PTD008, CYB561D2, SCAP2, MMP11, ERDJ5, TTC7A, PMAIP1, GARNL4, TMEPAI, SH3BP5, EDD, UCP4, EVI5L, PIK3C2B, SMAD3, LHFPL2, LOC57228, GM2A, HRK, ZNF207, LOC92497, F5, DMXL1, CLIC4, PRCP, DKFZP434C0328, STRBP, PHF16, JUP, TEAD2, PPP3CA, CNR2, ATP5B, ABCA1, BMF, ZCCHC7, KIAA0274, SLC22A3, SPI1, AMFR, ANXA4, EBF, ITPR1, HIST1H2BK, COPS3, COL14A1, SAV1, APOBEC3B, CCNG2, STAG3, LOC348938, POLD4, TBC1D1, MK2S4, APG4A, DAPP1, TNFRSF18, HERPUD1, POU2F2, ADK, CKIP-1, ACTA2, PARP14, MTSS1, DTX1, DDR1, RRAS2, RNF141, SYPL, SSPN, CORO1C, NFKBIE, CHD7, SP140, WDR34, BTNL9, ATP6V0A1, UROS, HLA-DOA, C22ORF13, IFI27, JMJD2B, WEE1, ODC1, KIAA0746, WDR11, SYNGR2, FOXP1, BLR1, MYO1E, MYBL2, GYLTL1B, SETBP1, KLF1, INPPL1, LOC54103, ZNF154, MHC2TA, CD24, ARHGEF3, BIRC3, TRIM56, HLA-DPB1, UVRAG, CD38, PEA15, FLJ10697, TLR10, ARHGAP10, HLA-DRA, SHMT2, LGALS9, FLJ10853, CEBPB, PRICKLE1, LCP21, CR1, KLHL14, TLR7, C20ORF72, HLA-DQB2, CORO1A, PRKCEHECW2, FLJ25604, TRIM26, FBXO41, GCNT1, LRMP, UBE2J1, IGKV3D, PCCA, GLDC, CYSLTR1, BTLA, NET5, HLA-DPA1, BLNK, CD79B, TM4SF8, TFEB, CD11ORF24,ADRBK2, CDKN2A, RIPK2, STX7, NCF4, SRGAP2, SLC2A5, CTSZ, AIM2, TCF4, TPD52, MAP3K8, MOBKL2B, HLA-DOB, IFIT3, MGC24039, BRD4, RALGPS2, SEMA4B, BSG,IGKC, HLA-DRB6, FUBP1, UNC84B, IFNGR2, HSPA5, HLA-DRB5, MARCKS, KYNU, PACAP, RHOBTB2, FLJ12363, TMED8, FGD2, FBXO10, IL4R, CD1C, MGC50844,MRPL49, CTSH, LYN, WASPIP, C3ORF6, EGR1, IGKV15, SPAP1, CHERP, IGHG3, ADAM28, HLA-DMA, HLA-DMB, PALM2-AKAP2, CD86, LAF4, LOC283663, FREB,DKFZP586A0522, UREB1, IGLL1, HLA-DQA2, KIAA1219, PLCG2, MARCH-1, BCNP1, PNOC, CD20, PSCD1, BCL11A, VPS28, SWAP70, SYK, BCL7A, NAP1L, TEM6, BTK,RAB30, FCGR2B, STAT6, BRDG1, LOC201895, ITGB1, CD74, CORO2B, VPREB3, HSPC182, MGC15619, RHOH, IGHA, CYBASC3, KIAA0125, RAM2, CD83, FCRH1, FLII,SNX10, IGHG1, EPHX1, FLJ10979, GTPAP, IGLL3, E2F5, TNFRSF17, BLK, FLJ00332, SNX2, CD200, HLA-DQB1, TRIO, CYBB, PIK3AP1, IRF4, CD22, BACE2, IGJ, PAX5,RGS13, TCL1A, MEF2C, C13ORF18, POU2AF1, HHEX, IRF8, BANK1, OSBPL10, SLC2A1, NCF1, IGL@, IGLC2, SPAP1, IGHG3, HLA-DMA, HLA-DMB, CD79A, HSPA6, IGHD,KIAA0476, SLC7A7, NKG7, CD19, SAMD9, LY86, SPIB, NAPSB, RNASE6, IGHM, LY64, CD72, IRTA2, CD1D, HLA-DQA1, SAS, CTSH, LYN, WASPIP, C3ORF6, EGR1, FREB,DKFZP586A0522</td><td>88, 79, 89</td></tr><tr><td>Resting NK cells</td><td>Human: IL18RAP, PRF1, GZMH, TKTL1</td><td>90–92</td></tr><tr><td>Macrophages</td><td>aMurine: Pecr, Tmem195, Ptplad2, 1810011H11Rik, Fert2, Tlr4, Pon3, Mr1, Arsg, Fcgr1, Camk1, Pld3, Tpp1, Ctsd, Pla2g15, Lamp2, Pla2g4a, MerTK, Tlr7, Cd14, Tbxas1, Fcgr3, Fgd4, Sqrdl, Csf3r, Plod1, Tom1, Myo7a, A930030A15Rik, Sepp1, Glul, Cd164, Tcn2, Dok3, Ctsl, Tspan14</td><td>93–95</td></tr><tr><td>M1 macrophages</td><td>aMurine: Cd38, Cfb, Slfn4, H2-Q6, Fpr1, Slfn1, Gpr18, Ccrl2, Fpr2, Cxcl10, Mpa2IOasl1, Tlr2, Ms4a4c, LOC100503664, Irak3, Hp, Itgal, Herc6, Cd300lf, Isf20, Pstpip2, Cp, Isg15, Herc6, Probe, 1452408_at, Ifi44, E030037K03, Rik, Saa3, Ifit1, Marco, F11r, Rsad2, Ddx60, Pilr1, Cpd, Gngt2, Mx1, Pyhin1, Epb4.1l3, Slfn8, Arhgap24, Nfkbiz, Gbp6, Stat1, Zpb1, D14Erd668e, Ddx58, Tuba4a, H2-T10, Ebi3, Fam176b, Xaf1, Stat2, Sepx1, Ifit2</td><td>96</td></tr><tr><td>M2 macrophages</td><td>aMurine: Ptgs1, Egr2, Olfm1, Flrt2, P2ry1, Vwf, Amz1, Tmem158, Tiam1, Rhoj, Mmp9, Mrc1, Bcar3, Il6st, Tanc2, Mmp12, Tcfec, Clec71, Matk, Myc, Clec10a, Atp6v0a1, Lmna, Chst7, Atp6v0d2, Emp2, Socs6, Atp6v0a1, Plk2, Ptpla</td><td>96</td></tr><tr><td>Classical monocytes</td><td>Human: S100A12, ALOX5AP, PAD14, NRG1, MCEMP1, THBS1, CRISPLD2, F13A1, MOSC1, CYP27A1, CD163, QPCT, ADAM19, ASGR2, RNASE4, ALDH1A1, EDG3, PROK2, CLEC4D, S100A9, OSM, CSPG2, GALS2, ANG, VNN2, EBI2, UTS2, RPPH1, MGST1, IL8, CCR2, SELL, DYSF, MT1F, CD14, RANSE6, CSF3R, STAB1, CYP1B1, ADHFE1, PLA2G7, MMP25, ZNF395, SLC2A3, EGR1, CMTM2, CD9</td><td>97, 98</td></tr><tr><td>Intermediate monocytes</td><td>Human: GFRA2, NKG7, PLVAP, PLAC8, MARCKSL1, E2F2, G8P4, CLEC10A, SCD, COTL1, SLC29A1, DDIT4, TGM2, LILRA3, ATF5, GPA33, C1QC, EVA1, MERTK, MGLL, DDEFL1, MARCO, NR1H3, FBP1, ACP2, GBP1, GPBAR1, SASH1, OLFM1, TIMP1, HLA-DOA, CAMK1, POUFUT1, EPB4IL3, H19, ZNF703, SNX5, CLEC10, AK-ALPHA-1, DPB1, DHRS9, MTHFD2, RGL1, PRDM1, FADS1, SLC2A8, CSK, ISOC2, CD300C, FGD2</td><td>97, 98</td></tr><tr><td>Nonclassical monocytes</td><td>Human: C1QA, HES4, CDKN1C, C1QB, RHOC, CLEC4F, ADA, TAGLN, TCF7L2, CD798, CTSL, SFTPD, ABI3, SETBP1, FGFRL1, CD798, SPRED1, SNFT, EVL, MTSS1, SH2D1B, CYFIP2, NELF, STS-1, SIGLEC10, CKS1B, PTP4A3, LYPD2, SIDT2, INSIG1, LTB, PAPSS2, ABCC3, CASP5, VOM1, HSPB1, GNGT2, HMOX1, RRAS, RNF122, CDH23, FMNL2, RGS12, SGGB3A1, FER1L3, CALML4, IFITM3, CKB, CEACAM3, IFITM1</td><td>97, 98</td></tr><tr><td>Mature DC’s</td><td>Human: ACCL5, CXCL10, CCR7, IL15, IF127, IF144L, IFIH1, IFIT1, MX1, ISG15, ISG20, IRF7, GBP4, DUSP5, NFKB1A, ATF3, TNFSF10, IL6, IL8, IL7R, CCL4, TNFA1P6, IFIT3, OASL, GBP1, HES4, CYP27B1, RIPK2, TNFRSF9, SOD2, CD38, CD44, CD80, CD83, CD86, INDO MT2A, TRAF1, GADD45B, MT1M, MTIP2, BIRC3, USP18, TUBB2A, CCL8, EBI3, IFITM1, MT1B, MT1E, MT1G, MT1H, GADD45A, CD200, LAMP3, RGS1, SAT1</td><td>99, 100</td></tr><tr><td>Monocyte-derived DC’s</td><td>Human: CD1A, CD1B, CD1C, CD23A, MRC1, CD36, HLA-DQA, HLA-DP light chain, HLA-DG protein 41, RIL, RAP1GAP, CCND2, DUSP5, PPIC, STAC, PRKACB, TRIB2, SHB</td><td>99–101</td></tr><tr><td>Mature neutrophils</td><td>Human: ALPL, IL8RB, FCGR3B, SEMA3C, HM74, SOD2, FCGR3A, IL-8, STHM, IL8RA, FCGR2A, CSF3R, NCF2, AOAH</td><td>102, 103</td></tr><tr><td>Immature neutrophils</td><td>Human: AZU1, ELA2, BPI, LCN2, MPO, CTSG, MMP8, DEFA4, DEFA3, CAMP, X-CGD</td><td>103–105</td></tr></table>
9c522c7c0a4ac26701ee6f32b62ce7d680ebc5101a78522f22a9d908469f0a57.png
simple
<table><tr><td>Gene</td><td>Primer name</td><td>Primer sequence</td></tr><tr><td>C8J_0133</td><td>C8J0133-F</td><td>TATTGCTGGGCATAGGAAAGG</td></tr><tr><td></td><td>C8J0133-R</td><td>TCTAGCAGCTTCTCTTGGAGTA</td></tr><tr><td>C8J_0398</td><td>C8J0398-F</td><td>GCAACATCTACCGTGATGCTAA</td></tr><tr><td></td><td>C8J0398-R</td><td>ACATATCTACAATCCACCAAATCCA</td></tr><tr><td>C8J_0648</td><td>C8J0648-F</td><td>GTATCAGCAGACATAAGACAAGG</td></tr><tr><td></td><td>C8J0648-R</td><td>TGCTTTCTTCTAGGTACTCTTTATC</td></tr><tr><td>C8J_1333</td><td>C8J1333-F</td><td>TGAGCTTGCACAAGATGATACC</td></tr><tr><td></td><td>C8J1333-R</td><td>GCACCAGAATACAAACCCTTCT</td></tr><tr><td>C8J_1342</td><td>C8J1342-F</td><td>GTTGATTTAGTGGCAGTTGGTG</td></tr><tr><td></td><td>C8J1342-R</td><td>CTCTTTCTACTGCTCCTTGAATACT</td></tr><tr><td>C8J_1423</td><td>C8J1423-F</td><td>AAATTTATGCGCGTGCTTT</td></tr><tr><td></td><td>C8J1423-R</td><td>AACTATGCCACCAAGCAAA</td></tr><tr><td>C8J_1619</td><td>C8J1619-F</td><td>CCAAAGTGGATAGTATTGCAAGAATTAG</td></tr><tr><td></td><td>C8J1619-R</td><td>GACGACTTAAAGAACTTGAAACTGG</td></tr><tr><td>frdA</td><td>qfrdA-F</td><td>GTGTGCCTTGGACTAGAGTTAC</td></tr><tr><td></td><td>qfrdA-R</td><td>CTGCGATATAGCAAGTTCTCCA</td></tr><tr><td>ccpA-2</td><td>qccpA-2-F</td><td>GTGGTATCATTTCTTGTAATACCTGTC</td></tr><tr><td></td><td>qccpA-2-R</td><td>TGATGAGGATTTGCTGTCCAT</td></tr><tr><td>racR</td><td>qracR-F</td><td>ACGGATACAGCGTTTCAAGAG</td></tr><tr><td></td><td>qracR-R</td><td>ACTCTTAAGCGACCGATGATAAC</td></tr><tr><td>flhB</td><td>qflhB-F</td><td>GGAAGGAGATCCTCAGGTTAAAG</td></tr><tr><td></td><td>qflhB-R</td><td>GCATAATGCGTTGGGTTTGT</td></tr><tr><td>kpsM</td><td>qkpsM-F</td><td>TGTGGAACCTTTAAGAACTTTGC</td></tr><tr><td></td><td>qkpsM-R</td><td>AAGCAAAGGACGAGGAGTTAG</td></tr><tr><td>cmeB</td><td>qcmeB-F</td><td>GCCATAGGGATCGTTGTAGATG</td></tr><tr><td></td><td>qcmeB-R</td><td>CTATCCAAGCGATGCAAGAAGT</td></tr><tr><td>16S rRNA</td><td>16S-qF</td><td>AGAGATGCATTAGTGCCTTCGGGA</td></tr><tr><td></td><td>16S-qR</td><td>ACTAAGGATAAGGGTTGCGCTCGT</td></tr></table>
<table><tr><td>Gene</td><td>Primer name</td><td>Primer sequence</td></tr><tr><td>C8J_0133</td><td>C8J0133-F</td><td>TATTGCTGGGCATAGGAAAGG</td></tr><tr><td></td><td>C8J0133-R</td><td>TCTAGCAGCTTCTCTTGGAGTA</td></tr><tr><td>C8J_0398</td><td>C8J0398-F</td><td>GCAACATCTACCGTGATGCTAA</td></tr><tr><td></td><td>C8J0398-R</td><td>ACATATCTACAATCCACCAAATCCA</td></tr><tr><td>C8J_0648</td><td>C8J0648-F</td><td>GTATCAGCAGACATAAGACAAGG</td></tr><tr><td></td><td>C8J0648-R</td><td>TGCTTTCTTCTAGGTACTCTTTATC</td></tr><tr><td>C8J_1333</td><td>C8J1333-F</td><td>TGAGCTTGCACAAGATGATACC</td></tr><tr><td></td><td>C8J1333-R</td><td>GCACCAGAATACAAACCCTTCT</td></tr><tr><td>C8J_1342</td><td>C8J1342-F</td><td>GTTGATTTAGTGGCAGTTGGTG</td></tr><tr><td></td><td>C8J1342-R</td><td>CTCTTTCTACTGCTCCTTGAATACT</td></tr><tr><td>C8J_1423</td><td>C8J1423-F</td><td>AAATTTATGCGCGTGCTTT</td></tr><tr><td></td><td>C8J1423-R</td><td>AACTATGCCACCAAGCAAA</td></tr><tr><td>C8J_1619</td><td>C8J1619-F</td><td>CCAAAGTGGATAGTATTGCAAGAATTAG</td></tr><tr><td></td><td>C8J1619-R</td><td>GACGACTTAAAGAACTTGAAACTGG</td></tr><tr><td>frdA</td><td>qfrdA-F</td><td>GTGTGCCTTGGACTAGAGTTAC</td></tr><tr><td></td><td>qfrdA-R</td><td>CTGCGATATAGCAAGTTCTCCA</td></tr><tr><td>ccpA-2</td><td>qccpA-2-F</td><td>GTGGTATCATTTCTTGTAATACCTGTC</td></tr><tr><td></td><td>qccpA-2-R</td><td>TGATGAGGATTTGCTGTCCAT</td></tr><tr><td>ra</td><td>qracR</td><td>ACGG</td></tr></table>
<table><tr><td>cR</td><td>-F</td><td>ATACAGCGTTTCAAGAG</td></tr><tr><td></td><td>qracR-R</td><td>ACTCTTAAGCGACCGATGATAAC</td></tr><tr><td>flhB</td><td>qflhB-F</td><td>GGAAGGAGATCCTCAGGTTAAAG</td></tr><tr><td></td><td>qflhB-R</td><td>GCATAATGCGTTGGGTTTGT</td></tr><tr><td>kpsM</td><td>qkpsM-F</td><td>TGTGGAACCTTTAAGAACTTTGC</td></tr><tr><td></td><td>qkpsM-R</td><td>AAGCAAAGGACGAGGAGTTAG</td></tr><tr><td>cmeB</td><td>qcmeB-F</td><td>GCCATAGGGATCGTTGTAGATG</td></tr><tr><td></td><td>qcmeB-R</td><td>CTATCCAAGCGATGCAAGAAGT</td></tr><tr><td>16S rRNA</td><td>16S-qF</td><td>AGAGATGCATTAGTGCCTTCGGGA</td></tr><tr><td></td><td>16S-qR</td><td>ACTAAGGATAAGGGTTGCGCTCGT</td></tr></table>
ca381ad4bebf939655740aee1558412b0a0e1c49e2e3e668c77b044173b198ab.png
complex
<table><tr><td>City(project)</td><td colspan="2">Activities described in final report</td></tr><tr><td>Birmingham(Walking Revolution)</td><td colspan="2">Led walks to the park for key stage 2 pupils at one city primary schoolPledge cards for individualsThemed walksCommunity Street AuditsSmall grants fundWalking ChampionsSocial media workStrategic work to share learning</td></tr><tr><td>Cambridge(Walk Local)</td><td colspan="2">Promotion of Walk4Life and WfH campaigns (various media), maps and community walks. 7 walks with 108 participantsWalk to work week activities with 17 employersHealth walks in 3 medical centres. 27 participantsBeat the Street piloted in 4 primary schools. 890 participants (3 week intervention)Weekly buggy walks / wild play with young parents and children under 5 years of age. 230 attendances</td></tr><tr><td>Leeds and Bradford(Best foot forward)</td><td colspan="2">Themed walksCommunity Street AuditsSmall grants fundTendering delivery to local community organisationsSocial media workStrategic work to share learning3 million steps social reward scheme involved388 people who walked over 15 Million steps in Spring 2015.</td></tr><tr><td>Manchester(Get Active)</td><td>Active Oldham Outdoors Project:26 Level 1 health walks with 143 participants14 new volunteer walk leadersCapital funding from Public health to improve walking infrastructure in 9 parksActive Trafford Greenspace Project:20 led walks with 278 participants23 new volunteer walk leaders3 GP Surgeries piloting &#8216;walk prescribing&#8217; or other methods of promoting walking to patients.3 Workplace Walk led walks events held5 new Workplace Walks mapped and promotedBridgewater Canal Walks Project:22 recreational themed walks with 74 participantsSelf-led walking trailPartnership working with a community Leisure TrustFour week Walking FestivalEast Manchester Moving:23 led walks with 163 participants10 led cycle rides with 96 participants8 volunteer action days24 volunteers trained as volunteer walk leaders</td><td>Salford Ranger team project:1 new self-guided walking route11 additional recreational walks with 107 participants12 volunteers trained as walk leaders12 led cycle rides with 108 participantsStockport Walkaday Walks Project:13 additional walks with 217 participants4 new volunteer walk leadersTameside Active Outdoors Project:4 new health walks with 30 participants18 new volunteer walk leaders1 new patient from new exercise referral programme5 new self-guided walking routes in production &#8211; Proposed launch in 2016The Green Corridor Project:9 led health walks with 91 new participants.5 volunteers trained as walk leaders</td></tr><tr><td>Norwich(Walk to)</td><td colspan="2">Group walking champions led walks including 1 km group walk for people with a learning disabilityPledge cards for individualsCommunity Street Audit (1)Small grants fundBeat the Streets project for school children: 1890 participatedSocial media workStrategic work to share learningHealth walks: 185 walks, 12 volunteers and 154 new participantsBeat the Street: 1890 participatedTravel plans: numbers not reported</td></tr></table>
<table><tr><td>City(project)</td><td colspan="2">Activities described in final report</td></tr><tr><td>Birmingham(Walking Revolution)</td><td colspan="2">Led walks to the park for key stage 2 pupils at one city primary schoolPledge cards for individualsThemed walksCommunity Street AuditsSmall grants fundWalking ChampionsSocial media workStrategic work to share learning</td></tr><tr><td>Cambridge(Walk Local)</td><td colspan="2">Promotion of Walk4Life and WfH campaigns (various media), maps and community walks. 7 walks with 108 participantsWalk to work week activities with 17 employersHealth walks in 3 medical centres. 27 participantsBeat the Street piloted in 4 primary schools. 890 participants (3 week intervention)Weekly buggy walks / wild play with young parents and children under 5 years of age. 230 attendances</td></tr><tr><td>Leeds and Bradford(Best foot forward)</td><td colspan="2">Themed walksCommunity Street AuditsSmall grants fundTendering delivery to local community organisationsSocial media workStrategic work to share learning3 million steps social reward scheme involved388 people who walked over 15 Million steps in Spring 2015.</td></tr></table>
<table><tr><td>Manchester(Get Active)</td><td>Active Oldham Outdoors Project:26 Level 1 health walks with 143 participants14 new volunteer walk leadersCapital funding from Public health to improve walking infrastructure in 9 parksActive Trafford Greenspace Project:20 led walks with 278 participants23 new volunteer walk leaders3 GP Surgeries piloting ‘walk prescribing’ or other methods of promoting walking to patients.3 Workplace Walk led walks events held5 new Workplace Walks mapped and promotedBridgewater Canal Walks Project:22 recreational themed walks with 74 participantsSelf-led walking trailPartnership working with a community Leisure TrustFour week Walking FestivalEast Manchester Moving:23 led walks with 163 participants10 led cycle rides with 96 participants8 volunteer action days24 volunteers trained as volunteer walk leaders</td><td>Salford Ranger team project:1 new self-guided walking route11 additional recreational walks with 107 participants12 volunteers trained as walk leaders12 led cycle rides with 108 participantsStockport Walkaday Walks Project:13 additional walks with 217 participants4 new volunteer walk leadersTameside Active Outdoors Project:4 new health walks with 30 participants18 new volunteer walk leaders1 new patient from new exercise referral programme5 new self-guided walking routes in production – Proposed launch in 2016The Green Corridor Project:9 led health walks with 91 new participants.5 volunteers trained as walk leaders</td></tr><tr><td>Norwich(Walk to)</td><td colspan="2">Group walking champions led walks including 1 km group walk for people with a learning disabilityPledge cards for individualsCommunity Street Audit (1)Small grants fundBeat the Streets project for school children: 1890 participatedSocial media workStrategic work to share learningHealth walks: 185 walks, 12 volunteers and 154 new participantsBeat the Street: 1890 participatedTravel plans: numbers not reported</td></tr></table>
e7c3607dd9cf677ba15745a1cef614353f7cc77e8cfec79af22eecd050e8fe0f.png
simple
<table><tr><td>Risk factor</td><td>OR Esteghamati et al.</td><td>OR Harati et al. (18)</td><td>Adjusted OR - Harati et al. (18)</td><td>OR - Valdez et al. (21)</td><td>Adjusted OR - Valdez (21)</td></tr><tr><td>IFG</td><td>-</td><td>8.3 (4.2&#8211;16.5)</td><td>7.4 (3.6&#8211;15.0)</td><td>11.5 (5.6&#8211;23.6)</td><td>8.4 (3.1&#8211;23)</td></tr><tr><td>IGT</td><td>-</td><td>7.1 (5.1&#8211;9.8)</td><td>5.9 (4.2&#8211;8.4)</td><td>6.7 (3.4&#8211;13.3)</td><td>4.7 (1.9&#8211;11.7)</td></tr><tr><td>IFG + IGT</td><td>-</td><td>42.2 (25.8&#8211;75.7)</td><td>42.2 (23.8&#8211;74.9)</td><td>45.6 (15.8&#8211;131.4)</td><td>45.6 (15.8&#8211;131.4)</td></tr><tr><td>General Obesity</td><td>2.04(2.48-1.66)</td><td>4.0 (2.7&#8211;5.8)</td><td>2.3 (1.5&#8211;3.6)</td><td>6.1 (2&#8211;18.8)</td><td>-</td></tr><tr><td>Central Obesity</td><td>1.97(1.61-2.33)</td><td>1.4 (1.3&#8211;1.5)</td><td>1.9 (1.4&#8211;2.6)</td><td>-</td><td>-</td></tr><tr><td>Hypercholesterolemia</td><td>1.99(1.61-2.45)</td><td>-</td><td>-</td><td>1.6 (0.8&#8211;3)</td><td>-</td></tr><tr><td>Hypertriglyceridemia</td><td>2.75(2.14-3.53)</td><td>2.0 (1.5&#8211;2.6) $</td><td>1.4 (1.1&#8211;1.9)</td><td>4.8 (2.2&#8211;10.4)</td><td>-</td></tr><tr><td>Low HDL</td><td>1.19(0.97-1.46)</td><td>1.4 (1.0&#8211;1.9)</td><td>-</td><td>2.9 (1.5&#8211;5.6)</td><td>-</td></tr><tr><td>Hypertension</td><td>-</td><td>1.9 (1.4&#8211;2.6)</td><td>-</td><td>4 (2.1&#8211;7.9)</td><td>-</td></tr><tr><td>Physical Inactivity</td><td>1.5(1.24-1.82)</td><td>-</td><td>-</td><td>2.7 (1.4&#8211;5.1)</td><td> </td></tr></table>
<table><tr><td>Risk factor</td><td>OR Esteghamati et al.</td><td>OR Harati et al. (18)</td><td>Adjusted OR - Harati et al. (18)</td><td>OR - Valdez et al. (21)</td><td>Adjusted OR - Valdez (21)</td></tr><tr><td>IFG</td><td>-</td><td>8.3 (4.2–16.5)</td><td>7.4 (3.6–15.0)</td><td>11.5 (5.6–23.6)</td><td>8.4 (3.1–23)</td></tr><tr><td>IGT</td><td>-</td><td>7.1 (5.1–9.8)</td><td>5.9 (4.2–8.4)</td><td>6.7 (3.4–13.3)</td><td>4.7 (1.9–11.7)</td></tr><tr><td>IFG + IGT</td><td>-</td><td>42.2 (25.8–75.7)</td><td>42.2 (23.8–74.9)</td><td>45.6 (15.8–131.4)</td><td>45.6 (15.8–131.4)</td></tr><tr><td>General Obesity</td><td>2.04(2.48-1.66)</td><td>4.0 (2.7–5.8)</td><td>2.3 (1.5–3.6)</td><td>6.1 (2–18.8)</td><td>-</td></tr><tr><td>Central Obesity</td><td>1.97(1.61-2.33)</td><td>1.4 (1.3–1.5)</td><td>1.9 (1.4–2.6)</td><td>-</td><td>-</td></tr><tr><td>Hypercholesterolemia</td><td>1.99(1.61-2.45)</td><td>-</td><td>-</td><td>1.6 (0.8–3)</td><td>-</td></tr><tr><td>Hypertriglyceridemia</td><td>2.75(2.14-3.53)</td><td>2.0 (1.5–2.6) $</td><td>1.4 (1.1–1.9)</td><td>4.8 (2.2–10.4)</td><td>-</td></tr><tr><td></td><td>1.19(0.97-1.46</td><td>1.4 (1.0–1</td><td></td><td>2.9 </td><td>-</td></tr></table>
<table><tr><td>Low HDL</td><td>)</td><td>.9)</td><td>-</td><td>(1.5–5.6)</td><td></td></tr><tr><td>Hypertension</td><td>-</td><td>1.9 (1.4–2.6)</td><td>-</td><td>4 (2.1–7.9)</td><td>-</td></tr><tr><td>Physical Inactivity</td><td>1.5(1.24-1.82)</td><td>-</td><td>-</td><td>2.7 (1.4–5.1)</td><td></td></tr></table>
decb7dc722a1e654e8bd21a33cb496b0a44c9796c8015e7568a0f3b32cadf8aa.png
simple
<table><tr><td>Bacteria</td><td>Oral n/N (%)</td><td>Vaginal n/N (%)</td><td>P value</td></tr><tr><td><i>Gardnerella vaginalis</i></td><td>24/30 (80%)</td><td>16/22 (73%)</td><td>.43</td></tr><tr><td><i>Megasphaera </i>spp.</td><td>12/22 (55%)</td><td>5/15 (33%)</td><td>.38</td></tr><tr><td><i>Leptotrichia/Sneathia</i></td><td>6/18 (33%)</td><td>5/11 (45%)</td><td>.76</td></tr><tr><td><i>Atopobium vaginae</i></td><td>11/21 (52%)</td><td>9/17 (53%)</td><td>.85</td></tr><tr><td>BVAB1</td><td>0/11 (0%)</td><td>1/5 (20%)</td><td>.29</td></tr><tr><td>BVAB2</td><td>3/18 (17%)</td><td>1/9 (11%)</td><td>.30</td></tr><tr><td>BVAB3</td><td>1/6 (17%)</td><td>1/3 (33%)</td><td>.66</td></tr></table>
<table><tr><td>Bacteria</td><td>Oral n/N (%)</td><td>Vaginal n/N (%)</td><td>P value</td></tr></table>
<table><tr><td>Gardnerella vaginalis</td><td>24/30 (80%)</td><td>16/22 (73%)</td><td>.43</td></tr><tr><td>Megasphaera spp.</td><td>12/22 (55%)</td><td>5/15 (33%)</td><td>.38</td></tr><tr><td>Leptotrichia/Sneathia</td><td>6/18 (33%)</td><td>5/11 (45%)</td><td>.76</td></tr><tr><td>Atopobium vaginae</td><td>11/21 (52%)</td><td>9/17 (53%)</td><td>.85</td></tr><tr><td>BVAB1</td><td>0/11 (0%)</td><td>1/5 (20%)</td><td>.29</td></tr><tr><td>BVAB2</td><td>3/18 (17%)</td><td>1/9 (11%)</td><td>.30</td></tr><tr><td>BVAB3</td><td>1/6 (17%)</td><td>1/3 (33%)</td><td>.66</td></tr></table>
c89880ea71b2ffb236037c7d0e2b3064c906189f3b874b68d3d30d71c394dfc8.png
complex
<table><tr><td> </td><td>Reference</td><td>Nr studies included</td><td>Nr subjects included</td><td>Pooled effect size (95% CI)</td></tr><tr><td colspan="5">Metabolic dysregulation</td></tr><tr><td>Metabolic syndrome</td><td>Pan <i>et al</i>. 2012<sup>1</sup>[22]</td><td>29</td><td>155,333</td><td>OR = 1.42 (1.28 to 1.57)</td></tr><tr><td>Abdominal obesity</td><td>Xu <i>et al</i>. 2011<sup>1</sup>[57]</td><td>15</td><td>34,832</td><td>OR = 1.38 (1.22 to 1.57)</td></tr><tr><td colspan="5">Immuno-inflammatory dysregulation</td></tr><tr><td>C-Reactive Protein</td><td>Howren <i>et al</i>. 2009<sup>1</sup>[58]</td><td>49</td><td>51,234</td><td>d = 0.15 (0.10 to 0.21)</td></tr><tr><td>Interleukin-6</td><td> </td><td>61</td><td>24,837</td><td>d = 0.25 (0.18 to 0.31)</td></tr><tr><td>Interleukin-1&#946;</td><td> </td><td>14</td><td>756</td><td>d = 0.35 (0.03 to 0.67)</td></tr><tr><td>Interleukin-1RA</td><td> </td><td>9</td><td>1,214</td><td>d = 0.25 (0.04 to 0.46)</td></tr><tr><td>Interleukin-6</td><td>Dowlati <i>et al</i>. 2010<sup>2</sup>[59]</td><td>16</td><td>892</td><td>MD = 1.8 pg/mL (1.2 to 2.3)</td></tr><tr><td>TNF-&#945;</td><td> </td><td>13</td><td>788</td><td>MD = 4.0 pg/mL (2.2 to 5.7)</td></tr><tr><td>Interleukin-1&#946;</td><td> </td><td>9</td><td>533</td><td>MD = -1.6 pg/mL (-3.6 to 0.4)</td></tr><tr><td>Soluble Interleukin-2R</td><td>Liu <i>et al</i>. 2012<sup>2</sup>[60]</td><td>8</td><td>596</td><td>MD = 0.56 pg/mL (0.28 to 0.84)</td></tr><tr><td>Interleukin-6</td><td> </td><td>18</td><td>923</td><td>MD = 0.68 pg/mL (0.44 to 0.92)</td></tr><tr><td>TNF-&#945;</td><td> </td><td>15</td><td>995</td><td>MD = 0.55 pg/mL (0.13 to 0.99)</td></tr><tr><td>Interleukin-1&#946;</td><td> </td><td>10</td><td>580</td><td>MD = -0.53 pg/mL (-1.36 to 0.31)</td></tr><tr><td colspan="5">Autonomic dysregulation</td></tr><tr><td>Heart rate variability</td><td>Rottenberg, 2007<sup>2</sup>[61]</td><td>13</td><td>686</td><td>d = 0.33 (0.18 to 0.49)</td></tr><tr><td>Heart rate variability</td><td>Kemp <i>et al</i>. 2010<sup>2</sup>[62]</td><td>14</td><td>726</td><td>Hedges&#8217; g = -0.21 (-0.40 to -0.02)<sup>4</sup></td></tr><tr><td colspan="5">HPA-axis dysregulation</td></tr><tr><td>Higher cortisol <sup>3</sup></td><td>Stetler and Miller 2011<sup>1</sup>[63]</td><td>354</td><td>18,374</td><td>d = 0.60 (0.54 to 0.66)</td></tr><tr><td>Higher ACTH</td><td> </td><td>96</td><td>3,812</td><td>d = 0.28 (0.16 to 0.41)</td></tr><tr><td>Higher CRH</td><td> </td><td>16</td><td>888</td><td>d = -0.53 (-1.71 to 0.65)</td></tr><tr><td>Saliva morning cortisol</td><td>Knorr <i>et al</i>. 2010<sup>1</sup>[64]</td><td>20</td><td>2,318</td><td>MD = 2.6 nmol/l (1.0 to 4.2)</td></tr><tr><td>Saliva evening cortisol</td><td> </td><td>10</td><td>1,617</td><td>MD = 0.3 nmol/l (0.03 to 0.5)</td></tr></table>
<table><tr><td></td><td>Reference</td><td>Nr studies included</td><td>Nr subjects included</td><td>Pooled effect size (95% CI)</td></tr><tr><td colspan="5">Metabolic dysregulation</td></tr><tr><td>Metabolic syndrome</td><td>Pan et al. 20121[22]</td><td>29</td><td>155,333</td><td>OR = 1.42 (1.28 to 1.57)</td></tr><tr><td>Abdominal obesity</td><td>Xu et al. 20111[57]</td><td>15</td><td>34,832</td><td>OR = 1.38 (1.22 to 1.57)</td></tr><tr><td colspan="5">Immuno-inflammatory dysregulation</td></tr><tr><td>C-Reactive Protein</td><td>Howren et al. 20091[58]</td><td>49</td><td>51,234</td><td>d = 0.15 (0.10 to 0.21)</td></tr><tr><td>Interleukin-6</td><td></td><td>61</td><td>24,837</td><td>d = 0.25 (0.18 to 0.31)</td></tr><tr><td>Interleukin-1β</td><td></td><td>14</td><td>756</td><td>d = 0.35 (0.03 to 0.67)</td></tr><tr><td>Interleukin-1RA</td><td></td><td>9</td><td>1,214</td><td>d = 0.25 (0.04 to 0.46)</td></tr><tr><td>Interleukin-6</td><td>Dowlati et al. 20102[59]</td><td>16</td><td>892</td><td>MD = 1.8 pg/mL (1.2 to 2.3)</td></tr><tr><td>TNF-α</td><td></td><td>13</td><td>788</td><td>MD = 4.0 pg/mL (2.2 to 5.7)</td></tr><tr><td>Interleukin-1β</td><td></td><td>9</td><td>533</td><td>MD = -1.6 pg/mL (-3.6 to 0.4)</td></tr><tr><td>Soluble Interleukin-2R</td><td>Liu et al. 20122[60]</td><td>8</td><td>596</td><td>MD = 0.56 pg/mL (0.28 to 0.84)</td></tr><tr><td>Interleukin-6</td><td></td><td>18</td><td>923</td><td>MD = 0.68 pg/mL (0.44 to 0.92)</td></tr><tr><td>TNF-α</td><td></td><td>15</td><td>995</td><td>MD = 0.55 pg/mL (0.13 to 0.99)</td></tr><tr><td>Interleukin-1β</td><td></td><td>10</td><td>580</td><td>MD = -0.53 pg/mL (-1.36 to 0.31)</td></tr><tr><td colspan="5">Autonomic dysregulation</td></tr><tr><td>Heart rate variability</td><td>Rottenberg, 20072[61]</td><td>13</td><td>686</td><td>d = 0.33 (0.18 to 0.49)</td></tr><tr><td>Heart rate variability</td><td>Kemp et al. 20102[62]</td><td>14</td><td>726</td><td>Hedges’ g = -0.21 (-0.40 to -0.02)4</td></tr><tr><td colspan="5">HPA-axis dysregulation</td></tr><tr><td>Higher cortisol 3</td><td>Stetler and Miller 20111[63]</td><td>354</td><td>18,374</td><td>d = 0.60 (0.54 to 0.66)</td></tr><tr><td>Higher ACTH</td><td></td><td>96</td><td>3,812</td><td>d = 0.28 (0.16 to 0.41)</td></tr><tr><td>Higher CRH</td><td></td><td>16</td><td>888</td><td>d = -0.53 (-1.71 to 0.65)</td></tr><tr><td>Saliva morning cortisol</td><td>Knorr et al. 20101[64]</td><td>20</td><td>2,318</td><td>MD = 2.6 nmol/l (1.0 to 4.2)</td></tr></table>
<table><tr><td></td><td>Reference</td><td>Nr studies included</td><td>Nr subjects included</td><td>Pooled effect size (95% CI)</td></tr><tr><td>Saliva evening cortisol</td><td></td><td>10</td><td>1,617</td><td>MD = 0.3 nmol/l (0.03 to 0.5)</td></tr></table>
8faa79a4284bec4a5554ee7fb626d0807de98e2095f95f055208c1066d832ce7.png
simple
<table><tr><td>Gene</td><td><i>BMPR1A</i></td><td><i>SMAD4</i></td><td><i>PTEN</i></td><td><i>STK11</i></td></tr><tr><td>Name</td><td>Bone morphogenetic protein receptor, type Ia</td><td>Mothers against decapentaplegic, drosophila, homolog of, 4</td><td>Phosphatase and tensin homologue</td><td>Serine/threonine protein kinase 11</td></tr><tr><td>Function of the protein</td><td>receptor</td><td>signalling protein</td><td>phosphatase</td><td>kinase</td></tr><tr><td>MIM</td><td>*601299</td><td>*600993</td><td>*601728</td><td>*602216</td></tr><tr><td>Chromosome</td><td>10q22.3</td><td>18q21</td><td>10q23.31</td><td>19q13.3</td></tr><tr><td>Size</td><td>168.5 kbp</td><td>38.5 kbp</td><td>108 kbp</td><td>23 kbp</td></tr><tr><td>Exons</td><td>13</td><td>11</td><td>9</td><td>10</td></tr><tr><td>Amino acids</td><td>532</td><td>552</td><td>403</td><td>433</td></tr><tr><td>Transcript (bp)</td><td>3613</td><td>8365</td><td><i>9007</i></td><td>3276</td></tr><tr><td>Mass of protein</td><td>60 kDa</td><td>60 kDa</td><td>47 <i>kDa</i></td><td>48.6 kDa</td></tr></table>
<table><tr><td>Gene</td><td>BMPR1A</td><td>SMAD4</td><td>PTEN</td></tr><tr><td>Name</td><td>Bone morphogenetic protein receptor, type Ia</td><td>Mothers against decapentaplegic, drosophila, homolog of, 4</td><td>Phosphatase and tensin homologue</td></tr><tr><td>Function of the protein</td><td>receptor</td><td>signalling protein</td><td>phosphatase</td></tr><tr><td>MIM</td><td>*601299</td><td>*600993</td><td>*601728</td></tr><tr><td>Chromosome</td><td>10q22.3</td><td>18q21</td><td>10q23.31</td></tr><tr><td>Size</td><td>168.5 kbp</td><td>38.5 kbp</td><td>108 kbp</td></tr><tr><td>Exons</td><td>13</td><td>11</td><td>9</td></tr><tr><td>Amino acids</td><td>532</td><td>552</td><td>403</td></tr><tr><td>Transcript (bp)</td><td>3613</td><td>8365</td><td>9007</td></tr><tr><td>Mass of protein</td><td>60 kDa</td><td>60 kDa</td><td>47 kDa</td></tr></table>
<table><tr><td>STK11</td></tr><tr><td>Serine/threonine protein kinase 11</td></tr><tr><td>kinase</td></tr><tr><td>*602216</td></tr><tr><td>19q13.3</td></tr><tr><td>23 kbp</td></tr><tr><td>10</td></tr><tr><td>433</td></tr><tr><td>3276</td></tr><tr><td>48.6 kDa</td></tr></table>
4e150559ec55602c2c118d51077b0312e77cde5ed296d3fff3fba48f7d931d0c.png
complex
<table><tr><td></td><td>All</td><td>&#8804; 40 years</td><td>&gt; 40 years</td></tr><tr><td>Variables</td><td>(n = 641)</td><td>(n = 150)</td><td>(n = 491)</td></tr><tr><td>Age, years (SD)</td><td>49 (13.0)</td><td>31 (7.2)</td><td>55 (8.6)</td></tr><tr><td>Female, n (%)</td><td>280 (44)</td><td>50 (33)</td><td>230 (47)</td></tr><tr><td>BMI (SD)</td><td>27 (4.4)</td><td>26 (4.2)</td><td>28 (4.5)</td></tr><tr><td colspan="4">Symptom onset, n (%)</td></tr><tr><td> Developed slowly over time</td><td>208 (32)</td><td>29 (19)</td><td>179 (36)</td></tr><tr><td> Developed as a result of</td><td></td><td></td><td></td></tr><tr><td>less severe incident</td><td>260 (41)</td><td>51 (34)</td><td>209 (43)</td></tr><tr><td>severe incident</td><td>173 (27)</td><td>70 (47)</td><td>103 (21)</td></tr><tr><td colspan="4">Duration of symptoms, n (%)</td></tr><tr><td> 0&#8211;3 months</td><td>129 (20)</td><td>41 (27)</td><td>88 (18)</td></tr><tr><td> 4&#8211;6 months</td><td>181 (28)</td><td>24 (16)</td><td>157 (32)</td></tr><tr><td> 7&#8211;12 months</td><td>135 (21)</td><td>31 (21)</td><td>104 (21)</td></tr><tr><td> 13&#8211;24 months</td><td>94 (15)</td><td>20 (13)</td><td>74 (15)</td></tr><tr><td>Longer than 24 months</td><td>102 (16)</td><td>34 (23)</td><td>68 (14)</td></tr><tr><td colspan="4">KOOS subscale scores, mean (SD)</td></tr><tr><td> Pain</td><td>54.9 (18)</td><td>58.9 (20)</td><td>53.6 (18)</td></tr><tr><td> Symptoms</td><td>60.0 (19)</td><td>60.6 (19)</td><td>59.8 (18)</td></tr><tr><td> ADL</td><td>63.7 (19)</td><td>69.8 (20)</td><td>61.8 (19)</td></tr><tr><td> Sport/Rec</td><td>26.3 (22)</td><td>31.1 (23)</td><td>24.9 (21)</td></tr><tr><td> QOL</td><td>41.6 (15)</td><td>40.2 (16)</td><td>42.0 (15)</td></tr><tr><td colspan="4">Type of surgery, no. (%)</td></tr><tr><td> Resection</td><td>600 (94)</td><td>118 (79)</td><td>482 (98.)</td></tr><tr><td> Repair</td><td>33 (5.1)</td><td>24 (16)</td><td>9 (1.8)</td></tr><tr><td> Both</td><td>8 (1.2)</td><td>8 (5.3)</td><td>0 (0.0)</td></tr></table>
<table><tr><td></td><td>All</td><td>≤ 40 years</td><td>> 40 years</td></tr><tr><td>Variables</td><td>(n = 641)</td><td>(n = 150)</td><td>(n = 491)</td></tr><tr><td>Age, years (SD)</td><td>49 (13.0)</td><td>31 (7.2)</td><td>55 (8.6)</td></tr><tr><td>Female, n (%)</td><td>280 (44)</td><td>50 (33)</td><td>230 (47)</td></tr><tr><td>BMI (SD)</td><td>27 (4.4)</td><td>26 (4.2)</td><td>28 (4.5)</td></tr><tr><td colspan="4">Symptom onset, n (%)</td></tr><tr><td>Developed slowly over time</td><td>208 (32)</td><td>29 (19)</td><td>179 (36)</td></tr><tr><td>Developed as a result of</td><td></td><td></td><td></td></tr><tr><td>less severe incident</td><td>260 (41)</td><td>51 (34)</td><td>209 (43)</td></tr><tr><td>severe incident</td><td>173 (27)</td><td>70 (47)</td><td>103 (21)</td></tr><tr><td colspan="4">Duration of symptoms, n (%)</td></tr><tr><td>0–3 months</td><td>129 (20)</td><td>41 (27)</td><td>88 (18)</td></tr><tr><td>4–6 months</td><td>181 (28)</td><td>24 (16)</td><td>157 (32)</td></tr><tr><td>7–12 months</td><td>135 (21)</td><td>31 (21)</td><td>104 (21)</td></tr><tr><td>13–24 months</td><td>94 (15)</td><td>20 (13)</td><td>74 (15)</td></tr><tr><td>Longer than 24 months</td><td>102 (16)</td><td>34 (23)</td><td>68 (14)</td></tr><tr><td colspan="4">KOOS subscale scores, mean (SD)</td></tr><tr><td>Pain</td><td>54.9 (18)</td><td>58.9 (20)</td><td>53.6 (18)</td></tr><tr><td>Symptoms</td><td>60.0 (19)</td><td>60.6 (19)</td><td>59.8 (18)</td></tr><tr><td>ADL</td><td>63.7 (19)</td><td>69.8 (20)</td><td>61.8 (19)</td></tr><tr><td>Sport/Rec</td><td>26.3 (22)</td><td>31.1 (23)</td><td>24.9 (21)</td></tr><tr><td>QOL</td><td>41.6 (15)</td><td>40.2 (16)</td><td>42.0 (15)</td></tr><tr><td colspan="4">Type of surgery, no. (%)</td></tr><tr><td>Resection</td><td>600 (94)</td><td>118 (79)</td><td>482 (98.)</td></tr><tr><td>Repair</td><td>33 (5.1)</td><td>24 (16)</td><td>9 (1.8)</td></tr></table>
<table><tr><td></td><td>All</td><td>≤ 40 years</td><td>> 40 years</td></tr><tr><td>Both</td><td>8 (1.2)</td><td>8 (5.3)</td><td>0 (0.0)</td></tr></table>
d1122eb26ac40823aed090089ec51b0c609bcc79c21eba25273a09364d08bfea.png
simple
<table><tr><td>Variable</td><td>Cases (n=110)</td><td>Controls (n=110)</td></tr><tr><td>Average age at blood collection, years (SD)</td><td>44.2 (7.3)</td><td>44.2 (7.2)</td></tr><tr><td>Average age at cancer diagnosis, years (SD)</td><td>55.9 (8.6)</td><td>n/a</td></tr><tr><td>Average time from blood collection to diagnosis, years (SD)</td><td>12.6 (5.1)</td><td>n/a</td></tr><tr><td>Date of blood collection, median, calendar years (range)</td><td>1990 (1986-1991)</td><td>1990 (1986-1991)</td></tr><tr><td>Date of birth, median, calendar years (range)</td><td>1948 (1923-1955)</td><td>1948 (1923-1955)</td></tr><tr><td>Male sex, number (%)</td><td>82 (74.5%)</td><td>82 (74.5%)</td></tr><tr><td>Average sample storage time in freezer, years (SD)</td><td>24.7 (1.5)</td><td>24.7 (1.5)</td></tr><tr><td>Blood collection to glioblastoma diagnosis, number/time period</td><td></td><td></td></tr><tr><td> 0&#8211;5 years</td><td>8</td><td>n/a</td></tr><tr><td> 5&#8211;10 years</td><td>26</td><td>n/a</td></tr><tr><td> 10&#8211;15 years</td><td>35</td><td>n/a</td></tr><tr><td> 15&#8211;20 years</td><td>37</td><td>n/a</td></tr><tr><td> &gt;20 years</td><td>4</td><td>n/a</td></tr></table>
<table><tr><td>Variable</td><td>Cases (n=110)</td><td>Controls (n=110)</td></tr><tr><td>Average age at blood collection, years (SD)</td><td>44.2 (7.3)</td><td>44.2 (7.2)</td></tr><tr><td>Average age at cancer diagnosis, years (SD)</td><td>55.9 (8.6)</td><td>n/a</td></tr><tr><td>Average time from blood collection to diagnosis, years (SD)</td><td>12.6 (5.1)</td><td>n/a</td></tr><tr><td>Date of blood collection, median, calendar years (range)</td><td>1990 (1986-1991)</td><td>1990 (1986-1991)</td></tr><tr><td>Date of birth, median, calendar years (range)</td><td>1948 (1923-1955)</td><td>1948 (1923-1955)</td></tr><tr><td>Male sex, number (%)</td><td>82 (74.5%)</td><td>82 (74.5%)</td></tr><tr><td>Average sample storage time in freezer, years (SD)</td><td>24.7 (1.5)</td><td>24.7 (1.5)</td></tr><tr><td>Blood collection to glioblastoma diagnosis, number/time period</td><td></td><td></td></tr><tr><td>0–5 years</td><td>8</td><td>n/a</td></tr><tr><td>5–10 years</td><td>26</td><td>n/a</td></tr><tr><td>10–15 years</td><td>35</td><td>n/a</td></tr><tr><td>15–20 years</td><td>37</td><td>n/a</td></tr><tr><td>>20 </td><td></td><td>n</td></tr></table>
<table><tr><td>Variable</td><td>Cases (n=110)</td><td>Controls (n=110)</td></tr><tr><td>years</td><td>4</td><td>/a</td></tr></table>
15fc35bcec9ed85e9a8ebe710532da29f73f04a15e007a29f6d515fc3238fce5.png
simple
<table><tr><td>Subject area</td><td>Frequency</td><td>% <i>N</i> = 8619 <sup>a</sup></td></tr><tr><td>Medicine</td><td>5406</td><td>62.7</td></tr><tr><td>Immunology and Microbiology</td><td>3075</td><td>35.7</td></tr><tr><td>Biochemistry, Genetics and Molecular Biology</td><td>1681</td><td>19.5</td></tr><tr><td>Pharmacology, Toxicology and Pharmaceutics</td><td>533</td><td>6.2</td></tr><tr><td>Agricultural and Biological Sciences</td><td>407</td><td>4.7</td></tr><tr><td>Veterinary</td><td>283</td><td>3.3</td></tr><tr><td>Multidisciplinary</td><td>234</td><td>2.7</td></tr><tr><td>Social Sciences</td><td>179</td><td>2.1</td></tr><tr><td>Chemistry</td><td>170</td><td>2.0</td></tr><tr><td>Environmental Science</td><td>133</td><td>1.5</td></tr><tr><td>Nursing</td><td>123</td><td>1.4</td></tr></table>
<table><tr><td>Subject area</td><td>Frequency</td></tr><tr><td>Medicine</td><td>5406</td></tr><tr><td>Immunology and Microbiology</td><td>3075</td></tr><tr><td>Biochemistry, Genetics and Molecular Biology</td><td>1681</td></tr><tr><td>Pharmacology, Toxicology and Pharmaceutics</td><td>533</td></tr><tr><td>Agricultural and Biological Sciences</td><td>407</td></tr><tr><td>Veterinary</td><td>283</td></tr><tr><td>Multidisciplinary</td><td>234</td></tr><tr><td>Social Sciences</td><td>179</td></tr><tr><td>Chemistry</td><td>170</td></tr><tr><td>Environmental Science</td><td>133</td></tr><tr><td>Nursing</td><td>123</td></tr></table>
<table><tr><td>% N = 8619 a</td></tr><tr><td>62.7</td></tr><tr><td>35.7</td></tr><tr><td>19.5</td></tr><tr><td>6.2</td></tr><tr><td>4.7</td></tr><tr><td>3.3</td></tr><tr><td>2.7</td></tr><tr><td>2.1</td></tr><tr><td>2.0</td></tr><tr><td>1.5</td></tr><tr><td>1.4</td></tr></table>
37483c529b97b7f034bfe1475e9c37367f3e9083832dda51d18f97608dbd7f1a.png
complex
<table><tr><td colspan="2"></td><td></td><td>Participants</td><td colspan="4">Non-participants or not included in analysis</td></tr><tr><td colspan="2">Baseline characteristics</td><td>Missing values</td><td>Followed-up <i>n</i> = 2166 (49.4%)</td><td>Not followed-up Alive/Unknown/DM status missing <i>n</i> = 1814 (41.3%)</td><td><i>p</i>-value*</td><td>Deceased <i>n</i> = 408 (9.3%)</td><td><i>p</i>-value**</td></tr><tr><td colspan="2">Age in years, mean (SD)</td><td>0</td><td>62.7 (9.4)</td><td>62.6 (10.4)</td><td>0.84</td><td>71.6 (12.8)</td><td>&lt;0.001</td></tr><tr><td colspan="2">Systolic BP in mmHg, mean (SD)</td><td>12</td><td>139.5 (23.5)</td><td>140.8 (24.8)</td><td>0.16</td><td>147.4 (30.3)</td><td>&lt;0.001</td></tr><tr><td colspan="2">Diastolic BP in mmHg , mean (SD)</td><td>12</td><td>82.6 (13.0)</td><td>83.3 (13.6)</td><td>0.19</td><td>82.7 (16.5)</td><td>0.94</td></tr><tr><td colspan="2">Random Blood Glucose, mean (SD)</td><td>92</td><td>5.1 (2.3)</td><td>5.3 (2.3)</td><td>0.12</td><td>5.7 (3.7)</td><td>&lt;0.001</td></tr><tr><td rowspan="2">Sex, % (n)</td><td>Female</td><td rowspan="2">0</td><td>1025 (47.3%)</td><td>841 (46.4%)</td><td rowspan="2">0.59</td><td>236 (57.8%)</td><td rowspan="2">&lt;0.001</td></tr><tr><td>Male</td><td>1141 (52.7%)</td><td>973 (53.6%)</td><td>172 (42.2%)</td></tr><tr><td rowspan="4">BMI, % (n)</td><td>Underweight (&lt;18.5 kg/m<sup>2</sup>)</td><td rowspan="4">42</td><td>267 (12.4%)</td><td>250 (14.0%)</td><td rowspan="4">0.52</td><td>99 (25.0%)</td><td rowspan="4">&lt;0.001</td></tr><tr><td>Normal (18.5&#8211;24.99 kg/m<sup>2</sup>)</td><td>1091 (50.5%)</td><td>882 (49.2%)</td><td>199 (50.3%)</td></tr><tr><td>Overweight (25&#8211;29.99 kg/m<sup>2</sup>)</td><td>506 (23.4%)</td><td>419 (23.4%)</td><td>66 (16.7%)</td></tr><tr><td>Obese (30 + kg/m<sup>2</sup>)</td><td>295 (13.7%)</td><td>240 (13.4%)</td><td>32 (8.1%)</td></tr><tr><td rowspan="2">Vision status impaired (&lt;6/12 better eye), % (n)</td><td>Normal</td><td rowspan="2">17</td><td>1985 (91.7%)</td><td>1635 (90.8%)</td><td rowspan="2">0.36</td><td>306 (75.4%)</td><td rowspan="2">&lt;0.001</td></tr><tr><td>Impaired</td><td>180 (8.3%)</td><td>165 (9.2%)</td><td>100 (24.6%)</td></tr><tr><td rowspan="3">Tribe, % (n)</td><td>Kikuyu</td><td rowspan="3">0</td><td>1393 (64.3%)</td><td>1079 (59.5%)</td><td rowspan="3">&lt;0.001</td><td>283 (69.4%)</td><td rowspan="3">0.09</td></tr><tr><td>Kalenjin</td><td>540 (24.9%)</td><td>380 (20.9%)</td><td>92 (22.5%)</td></tr><tr><td>Other</td><td>233 (10.8%)</td><td>355 (19.6%)</td><td>33 (8.1%)</td></tr><tr><td rowspan="4">Education, % (n)</td><td>None</td><td rowspan="4">1</td><td>193 (8.9%)</td><td>204 (11.3%)</td><td rowspan="4">0.03</td><td>26 (6.4%)</td><td rowspan="4">&lt;0.001</td></tr><tr><td>Primary</td><td>687 (31.7%)</td><td>588 (32.4%)</td><td>179 (43.9%)</td></tr><tr><td>Secondary</td><td>1069 (49.4%)</td><td>806 (44.5%)</td><td>174 (42.6%)</td></tr><tr><td>Higher</td><td>217 (10.0%)</td><td>215 (11.9%)</td><td>29 (7.1%)</td></tr><tr><td rowspan="2">Residence, % (n)</td><td>Rural</td><td rowspan="2">0</td><td>1636 (75.5%)</td><td>1014 (55.9%)</td><td rowspan="2">&lt;0.001</td><td>302 (74.0%)</td><td rowspan="2">0.59</td></tr><tr><td>Urban</td><td>530 (24.5%)</td><td>800 (44.1%)</td><td>106 (26.0%)</td></tr><tr><td rowspan="4">SES Quartile, % (n)</td><td>Lower</td><td rowspan="4">22</td><td>514 (23.8%)</td><td>442 (24.5%)</td><td rowspan="4">0.01</td><td>136 (33.3%)</td><td rowspan="4">0.003</td></tr><tr><td>Middle lower</td><td>591 (27.4%)</td><td>404 (22.4%)</td><td>96 (23.5%)</td></tr><tr><td>Middle upper</td><td>557 (25.8%)</td><td>438 (24.3%)</td><td>97 (23.8%)</td></tr><tr><td>Upper</td><td>495 (22.9%)</td><td>517 (28.7%)</td><td>79 (19.4%)</td></tr><tr><td rowspan="3">Smokers, % (n)</td><td>Never</td><td rowspan="3">0</td><td>1503 (69.4%)</td><td>1322 (72.9%)</td><td rowspan="3">0.007</td><td>255 (62.5%)</td><td rowspan="3">0.02</td></tr><tr><td>Former</td><td>163 (7.5%)</td><td>145 (8.0%)</td><td>33 (8.1%)</td></tr><tr><td>Current</td><td>500 (23.1%)</td><td>347 (19.1%)</td><td>120 (29.4%)</td></tr><tr><td rowspan="3">Alcohol, % (n)</td><td>Never</td><td rowspan="3">5</td><td>882 (40.8%)</td><td>704 (38.9%)</td><td rowspan="3">0.10</td><td>117 (28.7%)</td><td rowspan="3">&lt;0.001</td></tr><tr><td>Former</td><td>942 (43.6%)</td><td>772 (42.6%)</td><td>221 (54.2%)</td></tr><tr><td>Current</td><td>339 (15.7%)</td><td>336 (18.5%)</td><td>70 (17.2%)</td></tr></table>
<table><tr><td colspan="2"></td><td></td><td>Participants</td><td colspan="4">Non-participants or not included in analysis</td></tr><tr><td colspan="2">Baseline characteristics</td><td>Missing values</td><td>Followed-up n = 2166 (49.4%)</td><td>Not followed-up Alive/Unknown/DM status missing n = 1814 (41.3%)</td><td>p-value*</td><td>Deceased n = 408 (9.3%)</td><td>p-value**</td></tr><tr><td colspan="2">Age in years, mean (SD)</td><td>0</td><td>62.7 (9.4)</td><td>62.6 (10.4)</td><td>0.84</td><td>71.6 (12.8)</td><td><0.001</td></tr><tr><td colspan="2">Systolic BP in mmHg, mean (SD)</td><td>12</td><td>139.5 (23.5)</td><td>140.8 (24.8)</td><td>0.16</td><td>147.4 (30.3)</td><td><0.001</td></tr><tr><td colspan="2">Diastolic BP in mmHg , mean (SD)</td><td>12</td><td>82.6 (13.0)</td><td>83.3 (13.6)</td><td>0.19</td><td>82.7 (16.5)</td><td>0.94</td></tr><tr><td colspan="2">Random Blood Glucose, mean (SD)</td><td>92</td><td>5.1 (2.3)</td><td>5.3 (2.3)</td><td>0.12</td><td>5.7 (3.7)</td><td><0.001</td></tr><tr><td rowspan="2">Sex, % (n)</td><td>Female</td><td rowspan="2">0</td><td>1025 (47.3%)</td><td>841 (46.4%)</td><td rowspan="2">0.59</td><td>236 (57.8%)</td><td rowspan="2"><0.001</td></tr><tr><td>Male</td><td>1141 (52.7%)</td><td>973 (53.6%)</td><td>172 (42.2%)</td></tr><tr><td rowspan="3">BMI, % (n)</td><td>Underweight (<18.5 kg/m2)</td><td rowspan="3">42</td><td>267 (12.4%)</td><td>250 (14.0%)</td><td rowspan="3">0.52</td><td>99 (25.0%)</td><td rowspan="3"><0.001</td></tr><tr><td>Normal (18.5–24.99 kg/m2)</td><td>1091 (50.5%)</td><td>882 (49.2%)</td><td>199 (50.3%)</td></tr><tr><td>Overweight (25–29.99 kg/m2)</td><td>506 (23.4%)</td><td>419 (23.4%)</td><td>66 (16.7%)</td></tr></table>
<table><tr><td>BMI, % (n)</td><td>Obese (30 + kg/m2)</td><td>42</td><td>295 (13.7%)</td><td>240 (13.4%)</td><td>0.52</td><td>32 (8.1%)</td><td><0.001</td></tr><tr><td rowspan="2">Vision status impaired (<6/12 better eye), % (n)</td><td>Normal</td><td rowspan="2">17</td><td>1985 (91.7%)</td><td>1635 (90.8%)</td><td rowspan="2">0.36</td><td>306 (75.4%)</td><td rowspan="2"><0.001</td></tr><tr><td>Impaired</td><td>180 (8.3%)</td><td>165 (9.2%)</td><td>100 (24.6%)</td></tr><tr><td rowspan="3">Tribe, % (n)</td><td>Kikuyu</td><td rowspan="3">0</td><td>1393 (64.3%)</td><td>1079 (59.5%)</td><td rowspan="3"><0.001</td><td>283 (69.4%)</td><td rowspan="3">0.09</td></tr><tr><td>Kalenjin</td><td>540 (24.9%)</td><td>380 (20.9%)</td><td>92 (22.5%)</td></tr><tr><td>Other</td><td>233 (10.8%)</td><td>355 (19.6%)</td><td>33 (8.1%)</td></tr><tr><td rowspan="4">Education, % (n)</td><td>None</td><td rowspan="4">1</td><td>193 (8.9%)</td><td>204 (11.3%)</td><td rowspan="4">0.03</td><td>26 (6.4%)</td><td rowspan="4"><0.001</td></tr><tr><td>Primary</td><td>687 (31.7%)</td><td>588 (32.4%)</td><td>179 (43.9%)</td></tr><tr><td>Secondary</td><td>1069 (49.4%)</td><td>806 (44.5%)</td><td>174 (42.6%)</td></tr><tr><td>Higher</td><td>217 (10.0%)</td><td>215 (11.9%)</td><td>29 (7.1%)</td></tr><tr><td rowspan="2">Residence, % (n)</td><td>Rural</td><td rowspan="2">0</td><td>1636 (75.5%)</td><td>1014 (55.9%)</td><td rowspan="2"><0.001</td><td>302 (74.0%)</td><td rowspan="2">0.59</td></tr><tr><td>Urban</td><td>530 (24.5%)</td><td>800 (44.1%)</td><td>106 (26.0%)</td></tr><tr><td rowspan="4">SES Quartile, % (n)</td><td>Lower</td><td rowspan="4">22</td><td>514 (23.8%)</td><td>442 (24.5%)</td><td rowspan="4">0.01</td><td>136 (33.3%)</td><td rowspan="4">0.003</td></tr><tr><td>Middle lower</td><td>591 (27.4%)</td><td>404 (22.4%)</td><td>96 (23.5%)</td></tr><tr><td>Middle upper</td><td>557 (25.8%)</td><td>438 (24.3%)</td><td>97 (23.8%)</td></tr><tr><td>Upper</td><td>495 (22.9%)</td><td>517 (28.7%)</td><td>79 (19.4%)</td></tr><tr><td rowspan="3">Smokers, % (n)</td><td>Never</td><td rowspan="3">0</td><td>1503 (69.4%)</td><td>1322 (72.9%)</td><td rowspan="3">0.007</td><td>255 (62.5%)</td><td rowspan="3">0.02</td></tr><tr><td>Former</td><td>163 (7.5%)</td><td>145 (8.0%)</td><td>33 (8.1%)</td></tr><tr><td>Current</td><td>500 (23.1%)</td><td>347 (19.1%)</td><td>120 (29.4%)</td></tr><tr><td rowspan="3">Alcohol, % (n)</td><td>Never</td><td rowspan="3">5</td><td>882 (40.8%)</td><td>704 (38.9%)</td><td rowspan="3">0.10</td><td>117 (28.7%)</td><td rowspan="3"><0.001</td></tr><tr><td>Former</td><td>942 (43.6%)</td><td>772 (42.6%)</td><td>221 (54.2%)</td></tr><tr><td>Current</td><td>339 (15.7%)</td><td>336 (18.5%)</td><td>70 (17.2%)</td></tr></table>
55826b927db90367cf22811662eed435973a21a86c2adb75cb7652daadda2a32.png
complex
<table><tr><td colspan="5">Variability of U6 and miR-99b as reference assays</td></tr><tr><td></td><td colspan="2">hsa-miR-99b</td><td colspan="2">U6</td></tr><tr><td></td><td><i>P</i>-value</td><td>C of V</td><td><i>P</i>-value</td><td>C of V</td></tr><tr><td>Nucleus accumbens</td><td>0.69</td><td>0.40</td><td>0.024*</td><td>0.71</td></tr><tr><td>EDL</td><td>0.64</td><td>0.22</td><td>0.13</td><td>0.86</td></tr><tr><td>Soleus</td><td>0.23</td><td>0.23</td><td>0.09</td><td>0.21</td></tr></table>
<table><tr><td colspan="5">Variability of U6 and miR-99b as reference assays</td></tr><tr><td></td><td colspan="2">hsa-miR-99b</td><td colspan="2">U6</td></tr></table>
<table><tr><td></td><td>P-value</td><td>C of V</td><td>P-value</td><td>C of V</td></tr><tr><td>Nucleus accumbens</td><td>0.69</td><td>0.40</td><td>0.024*</td><td>0.71</td></tr><tr><td>EDL</td><td>0.64</td><td>0.22</td><td>0.13</td><td>0.86</td></tr><tr><td>Soleus</td><td>0.23</td><td>0.23</td><td>0.09</td><td>0.21</td></tr></table>
0572ac6e55f255e5e63acd0590601c11dcba67afb819a3d7240e3eb5a4a44fd9.png
complex
<table><tr><td></td><td></td><td colspan="4">3 months</td></tr><tr><td></td><td></td><td>&#916;DAS28</td><td>&#916;DAS28-CRP</td><td>&#916;SDAI</td><td>&#916;CDAI</td></tr><tr><td rowspan="2">&#916;SUV (12 joints)</td><td>r</td><td>0.615*</td><td>0.696*</td><td>0.652*</td><td>0.662*</td></tr><tr><td>p</td><td>0.009</td><td>0.002</td><td>0.005</td><td>0.004</td></tr><tr><td>&#916;SUV (8 joints)</td><td>r</td><td>0.61*</td><td>0.723*</td><td>0.637*</td><td>0.64*</td></tr><tr><td></td><td>p</td><td>0.009</td><td>0.001</td><td>0.006</td><td>0.006</td></tr><tr><td></td><td></td><td colspan="4">6 months</td></tr><tr><td></td><td></td><td>&#916;DAS28</td><td>&#916;DAS28-CRP</td><td>&#916;SDAI</td><td>&#916;CDAI</td></tr><tr><td rowspan="2">&#916;SUV (12 joints)</td><td>r</td><td>0.775*</td><td>0.828*</td><td>0.686*</td><td>0.711*</td></tr><tr><td>p</td><td>&lt;0.001</td><td>&lt;0.001</td><td>0.002</td><td>0.001</td></tr><tr><td>&#916;SUV (8 joints)</td><td>r</td><td>0.749*</td><td>0.775*</td><td>0.623*</td><td>0.686*</td></tr><tr><td></td><td>p</td><td>0.001</td><td>&lt;0.001</td><td>0.008</td><td>0.002</td></tr></table>
<table><tr><td></td><td></td><td colspan="3">3 months</td></tr><tr><td></td><td></td><td>ΔDAS28</td><td>ΔDAS28-CRP</td><td>ΔSDAI</td></tr><tr><td rowspan="2">ΔSUV (12 joints)</td><td>r</td><td>0.615*</td><td>0.696*</td><td>0.652*</td></tr><tr><td>p</td><td>0.009</td><td>0.002</td><td>0.005</td></tr><tr><td>ΔSUV (8 joints)</td><td>r</td><td>0.61*</td><td>0.723*</td><td>0.637*</td></tr><tr><td></td><td>p</td><td>0.009</td><td>0.001</td><td>0.006</td></tr><tr><td></td><td></td><td colspan="3">6 months</td></tr><tr><td></td><td></td><td>ΔDAS28</td><td>ΔDAS28-CRP</td><td>ΔSDAI</td></tr><tr><td rowspan="2">ΔSUV (12 joints)</td><td>r</td><td>0.775*</td><td>0.828*</td><td>0.686*</td></tr><tr><td>p</td><td><0.001</td><td><0.001</td><td>0.002</td></tr><tr><td>ΔSUV (8 joints)</td><td>r</td><td>0.749*</td><td>0.775*</td><td>0.623*</td></tr><tr><td></td><td>p</td><td>0.001</td><td><0.001</td><td>0.008</td></tr></table>
<table><tr><td>3 months</td></tr><tr><td>ΔCDAI</td></tr><tr><td>0.662*</td></tr><tr><td>0.004</td></tr><tr><td>0.64*</td></tr><tr><td>0.006</td></tr><tr><td>6 months</td></tr><tr><td>ΔCDAI</td></tr><tr><td>0.711*</td></tr><tr><td>0.001</td></tr><tr><td>0.686*</td></tr><tr><td>0.002</td></tr></table>
8214abd90183d358ae7f8b7f9969c3e9664c388cc32973d900d56035f9b1bd34.png
simple
<table><tr><td> Variables</td><td>Low CHO</td><td>Low fat</td><td><i>P</i>*</td></tr><tr><td>Males/females</td><td>25/24</td><td>25/26</td><td></td></tr><tr><td>Energy (Cal)</td><td>1114 &#177; 22.5</td><td>1138 &#177; 26.0</td><td>N.S.</td></tr><tr><td>Carbohydrate (%)</td><td>45 &#177; 0.6</td><td>57 &#177; 0.9</td><td>&lt;0.001</td></tr><tr><td>Total fat (%)</td><td>35 &#177; 0.8</td><td>28 &#177; 0.9</td><td>&lt;0.001</td></tr><tr><td>Saturated fat (%)</td><td>10 &#177; 0.5</td><td>9 &#177; 0.4</td><td>&lt;0.02</td></tr><tr><td>Protein (%)</td><td>20 &#177; 0.5</td><td>15 &#177; 0.6</td><td>N.S</td></tr><tr><td>Cholesterol (g)</td><td>163 &#177; 13.1</td><td>103 &#177; 9.1</td><td>&lt;0.001</td></tr><tr><td>Fiber (g)</td><td>14 &#177; 0.6</td><td>16 &#177; 0.8</td><td>&lt;0.02</td></tr></table>
<table><tr><td>Variables</td></tr><tr><td>Males/females</td></tr><tr><td>Energy (Cal)</td></tr><tr><td>Carbohydrate (%)</td></tr><tr><td>Total fat (%)</td></tr><tr><td>Saturated fat (%)</td></tr><tr><td>Protein (%)</td></tr><tr><td>Cholesterol (g)</td></tr><tr><td>Fiber (g)</td></tr></table>
<table><tr><td>Low CHO</td><td>Low fat</td><td>P*</td></tr><tr><td>25/24</td><td>25/26</td><td></td></tr><tr><td>1114 ± 22.5</td><td>1138 ± 26.0</td><td>N.S.</td></tr><tr><td>45 ± 0.6</td><td>57 ± 0.9</td><td><0.001</td></tr><tr><td>35 ± 0.8</td><td>28 ± 0.9</td><td><0.001</td></tr><tr><td>10 ± 0.5</td><td>9 ± 0.4</td><td><0.02</td></tr><tr><td>20 ± 0.5</td><td>15 ± 0.6</td><td>N.S</td></tr><tr><td>163 ± 13.1</td><td>103 ± 9.1</td><td><0.001</td></tr><tr><td>14 ± 0.6</td><td>16 ± 0.8</td><td><0.02</td></tr></table>
2fc85296a500155a94e39e9b82a35fa52ce27637d19a6c10a676368939b86089.png
simple
<table><tr><td>Test</td><td>Observed</td><td>Predicted</td><td>Difference</td></tr><tr><td>1</td><td>4,084.05</td><td>3,996.40</td><td>87.64</td></tr><tr><td>2</td><td>4,108.22</td><td>4,040.57</td><td>67.65</td></tr><tr><td>3</td><td>4,140.16</td><td>4,101.24</td><td>38.92</td></tr><tr><td>4</td><td>4,023.51</td><td>4,019.85</td><td>3.66</td></tr><tr><td>5</td><td>4,113.16</td><td>4,047.87</td><td>65.29</td></tr><tr><td>6</td><td>3,950.07</td><td>4,050.91</td><td>&#8722;100.84</td></tr><tr><td>7</td><td>4,058.73</td><td>4,085.59</td><td>&#8722;26.85</td></tr><tr><td>8</td><td>4,054.97</td><td>4,062.27</td><td>&#8722;7.30</td></tr><tr><td>9</td><td>4,046.38</td><td>4,007.67</td><td>38.71</td></tr><tr><td>10</td><td>3,997.07</td><td>3,989.82</td><td>7.25</td></tr><tr><td>11</td><td>4,044.88</td><td>3,969.98</td><td>74.89</td></tr><tr><td>12</td><td>4,062.20</td><td>4,042.23</td><td>19.97</td></tr><tr><td>13</td><td>4,062.67</td><td>3,994.71</td><td>67.95</td></tr><tr><td>14</td><td>4,009.57</td><td>3,974.33</td><td>35.23</td></tr><tr><td>15</td><td>3,957.41</td><td>3,962.92</td><td>&#8722;5.51</td></tr><tr><td>16</td><td>4,036.46</td><td>4,036.31</td><td>0.15</td></tr><tr><td>17</td><td>3,983.54</td><td>3,970.58</td><td>12.96</td></tr><tr><td>18</td><td>4,011.42</td><td>3,993.93</td><td>17.49</td></tr><tr><td>19</td><td>3,932.03</td><td>3,951.91</td><td>&#8722;19.88</td></tr><tr><td>20</td><td>3,980.49</td><td>4,035.48</td><td>&#8722;54.99</td></tr><tr><td>21</td><td>4,065.07</td><td>4,054.47</td><td>61.22</td></tr><tr><td>22</td><td>4,024.33</td><td>4043.60</td><td>&#8722;19.28</td></tr><tr><td>23</td><td>4,025.92</td><td>4,020.54</td><td>5.38</td></tr><tr><td>24</td><td>4,020.02</td><td>4,024.04</td><td>&#8722;4.02</td></tr><tr><td>25</td><td>4,016.88</td><td>4,005.85</td><td>11.03</td></tr><tr><td>26</td><td>4,051.08</td><td>3,996.01</td><td>55.06</td></tr><tr><td>27</td><td>4,058.55</td><td>3,987.99</td><td>70.57</td></tr><tr><td>28</td><td>4,051.18</td><td>4,018.28</td><td>32.90</td></tr><tr><td>29</td><td>4,088.96</td><td>4,036.06</td><td>52.90</td></tr><tr><td>30</td><td>4,087.01</td><td>4,028.30</td><td>58.71</td></tr><tr><td>31</td><td>4,121.96</td><td>4,017.35</td><td>104.61</td></tr><tr><td>32</td><td>4,084.62</td><td>4,055.96</td><td>28.66</td></tr><tr><td>33</td><td>4,002.90</td><td>4,050.52</td><td>&#8722;47.62</td></tr><tr><td>34</td><td>3,979.24</td><td>4,014.76</td><td>&#8722;35.52</td></tr><tr><td>35</td><td>4,003.71</td><td>4,022.21</td><td>&#8722;18.50</td></tr><tr><td>36</td><td>4,066.90</td><td>4,022.56</td><td>44.34</td></tr><tr><td>37</td><td>3,934.52</td><td>4,003.62</td><td>&#8722;69.10</td></tr><tr><td>38</td><td>4,041.55</td><td>4,038.95</td><td>2.59</td></tr><tr><td>39</td><td>4,029.50</td><td>4,062.03</td><td>&#8722;32.54</td></tr><tr><td>40</td><td>3,991.01</td><td>4,031.85</td><td>&#8722;40.84</td></tr><tr><td>SD<sup>*</sup></td><td>49.74</td><td>32.93</td><td> </td></tr><tr><td>RSD<sup>&#8251;*</sup></td><td> </td><td> </td><td>46.75</td></tr><tr><td><i>P</i>-value</td><td> </td><td> </td><td>0.16</td></tr></table>
<table><tr><td>Test</td><td>Observed</td><td>Predicted</td><td>Difference</td></tr><tr><td>1</td><td>4,084.05</td><td>3,996.40</td><td>87.64</td></tr><tr><td>2</td><td>4,108.22</td><td>4,040.57</td><td>67.65</td></tr><tr><td>3</td><td>4,140.16</td><td>4,101.24</td><td>38.92</td></tr><tr><td>4</td><td>4,023.51</td><td>4,019.85</td><td>3.66</td></tr><tr><td>5</td><td>4,113.16</td><td>4,047.87</td><td>65.29</td></tr><tr><td>6</td><td>3,950.07</td><td>4,050.91</td><td>−100.84</td></tr><tr><td>7</td><td>4,058.73</td><td>4,085.59</td><td>−26.85</td></tr><tr><td>8</td><td>4,054.97</td><td>4,062.27</td><td>−7.30</td></tr><tr><td>9</td><td>4,046.38</td><td>4,007.67</td><td>38.71</td></tr><tr><td>10</td><td>3,997.07</td><td>3,989.82</td><td>7.25</td></tr><tr><td>11</td><td>4,044.88</td><td>3,969.98</td><td>74.89</td></tr><tr><td>12</td><td>4,062.20</td><td>4,042.23</td><td>19.97</td></tr><tr><td>13</td><td>4,062.67</td><td>3,994.71</td><td>67.95</td></tr><tr><td>14</td><td>4,009.57</td><td>3,974.33</td><td>35.23</td></tr><tr><td>15</td><td>3,957.41</td><td>3,962.92</td><td>−5.51</td></tr><tr><td>16</td><td>4,036.46</td><td>4,036.31</td><td>0.15</td></tr><tr><td>17</td><td>3,983.54</td><td>3,970.58</td><td>12.96</td></tr><tr><td>18</td><td>4,011.42</td><td>3,993.93</td><td>17.49</td></tr><tr><td>19</td><td>3,932.03</td><td>3,951.91</td><td>−19.88</td></tr><tr><td>20</td><td>3,980.49</td><td>4,035.48</td><td>−54.99</td></tr><tr><td>21</td><td>4,065.07</td><td>4,054.47</td><td>61.22</td></tr><tr><td>22</td><td>4,024.33</td><td>4043.60</td><td>−19.28</td></tr><tr><td>23</td><td>4,025.92</td><td>4,020.54</td><td>5.38</td></tr><tr><td>24</td><td>4,020.02</td><td>4,024.04</td><td>−4.02</td></tr><tr><td>25</td><td>4,016.88</td><td>4,005.85</td><td>11.03</td></tr><tr><td>26</td><td>4,051.08</td><td>3,996.01</td><td>55.06</td></tr><tr><td>27</td><td>4,058.55</td><td>3,987.99</td><td>70.57</td></tr><tr><td>28</td><td>4,051.18</td><td>4,018.28</td><td>32.90</td></tr><tr><td>29</td><td>4,088.96</td><td>4,036.06</td><td>52.90</td></tr><tr><td>30</td><td>4,087.01</td><td>4,028.30</td><td>58.71</td></tr></table>
<table><tr><td>31</td><td>4,121.96</td><td>4,017.35</td><td>104.61</td></tr><tr><td>32</td><td>4,084.62</td><td>4,055.96</td><td>28.66</td></tr><tr><td>33</td><td>4,002.90</td><td>4,050.52</td><td>−47.62</td></tr><tr><td>34</td><td>3,979.24</td><td>4,014.76</td><td>−35.52</td></tr><tr><td>35</td><td>4,003.71</td><td>4,022.21</td><td>−18.50</td></tr><tr><td>36</td><td>4,066.90</td><td>4,022.56</td><td>44.34</td></tr><tr><td>37</td><td>3,934.52</td><td>4,003.62</td><td>−69.10</td></tr><tr><td>38</td><td>4,041.55</td><td>4,038.95</td><td>2.59</td></tr><tr><td>39</td><td>4,029.50</td><td>4,062.03</td><td>−32.54</td></tr><tr><td>40</td><td>3,991.01</td><td>4,031.85</td><td>−40.84</td></tr><tr><td>SD*</td><td>49.74</td><td>32.93</td><td></td></tr><tr><td>RSD※*</td><td></td><td></td><td>46.75</td></tr><tr><td>P-value</td><td></td><td></td><td>0.16</td></tr></table>
176835b70f1fd204cee1dfcc278ddd562dfa5ac8f30adf6e2458f6fe378f5a1a.png
simple
<table><tr><td>Name</td><td>Species</td><td>Activity against</td><td>Cytotoxic activity</td><td>Anticancer activity</td><td>Reference</td></tr><tr><td>Sesquin </td><td><i>Vigna sesquipedalis </i></td><td>MCF-7 and M1</td><td>Not tested</td><td>Yes</td><td>[44]</td></tr><tr><td>Limenin</td><td><i>Phaseolus limensis </i></td><td>L1210 and M1</td><td>Not tested</td><td>Yes</td><td>[41]</td></tr><tr><td>Lunatusin</td><td><i>Phaseolus lunatus </i></td><td>MCF-7rabbit reticulocyte</td><td>Yes</td><td>Yes</td><td>[45]</td></tr><tr><td>Purple pole defensin</td><td><i>Phaseolus vulgaris</i> cv. &#8220;Extra-long Purple Pole bean&#8221;</td><td>HepG2, MCF7, HT-29, and SiHa</td><td>No</td><td>Yes</td><td>[46]</td></tr><tr><td>Coccinin</td><td><i>Phaseolus coccineus</i> cv. &#8220;Major&#8221;</td><td>HL60 and L1210</td><td>No</td><td>Yes</td><td>[47]</td></tr><tr><td>Phaseococcin</td><td><i>Phaseolus coccineus </i></td><td>L1210 and HL60</td><td>No</td><td>Yes</td><td>[48]</td></tr><tr><td><i>&#947;</i>-Thionin</td><td><i>Capsicum chinense </i></td><td>HeLa</td><td>No</td><td>Yes</td><td>[49]</td></tr><tr><td>NaD1</td><td><i>Nicotiana alata </i></td><td>U937</td><td>Not tested</td><td>Yes</td><td>[67]</td></tr><tr><td>Mitogenic defensin</td><td><i>Phaseolus vulgaris </i></td><td>MCF-7, murine splenocytes</td><td>Yes</td><td>Yes</td><td>[68]</td></tr><tr><td>Vulgarinin</td><td><i>Phaseolus vulgaris </i></td><td>MCF-7, L1210, and M1</td><td>Not tested</td><td>Yes</td><td>[69]</td></tr><tr><td>Cloud bean defensin</td><td><i>Phaseolus vulgaris</i> cv. cloud bean</td><td>L1210 and MBL2</td><td>Not tested</td><td>Yes</td><td>[70]</td></tr><tr><td>Nepalese</td><td><i>Phaseolus angularis </i></td><td>L1210, MBL2</td><td>Not tested</td><td>Yes</td><td>[71]</td></tr><tr><td>Gymnin</td><td><i>Gymnocladus chinensis</i> Baill</td><td>M1, HepG2, and L1210</td><td>Not tested</td><td>Yes</td><td>[72]</td></tr></table>
<table><tr><td>Name</td><td>Species</td><td>Activity against</td><td>Cytotoxic activity</td><td>Anticancer activity</td><td>Reference</td></tr><tr><td>Sesquin</td><td>Vigna sesquipedalis</td><td>MCF-7 and M1</td><td>Not tested</td><td>Yes</td><td>[44]</td></tr><tr><td>Limenin</td><td>Phaseolus limensis</td><td>L1210 and M1</td><td>Not tested</td><td>Yes</td><td>[41]</td></tr><tr><td>Lunatusin</td><td>Phaseolus lunatus</td><td>MCF-7rabbit reticulocyte</td><td>Yes</td><td>Yes</td><td>[45]</td></tr><tr><td>Purple pole defensin</td><td>Phaseolus vulgaris cv. “Extra-long Purple Pole bean”</td><td>HepG2, MCF7, HT-29, and SiHa</td><td>No</td><td>Yes</td><td>[46]</td></tr><tr><td>Coccinin</td><td>Phaseolus coccineus cv. “Major”</td><td>HL60 and L1210</td><td>No</td><td>Yes</td><td>[47]</td></tr><tr><td>Phaseococcin</td><td>Phaseolus coccineus</td><td>L1210 and HL60</td><td>No</td><td>Yes</td><td>[48]</td></tr><tr><td>γ-Thionin</td><td>Capsicum chinense</td><td>HeLa</td><td>No</td><td>Yes</td><td>[49]</td></tr></table>
<table><tr><td>NaD1</td><td>Nicotiana alata</td><td>U937</td><td>Not tested</td><td>Yes</td><td>[67]</td></tr><tr><td>Mitogenic defensin</td><td>Phaseolus vulgaris</td><td>MCF-7, murine splenocytes</td><td>Yes</td><td>Yes</td><td>[68]</td></tr><tr><td>Vulgarinin</td><td>Phaseolus vulgaris</td><td>MCF-7, L1210, and M1</td><td>Not tested</td><td>Yes</td><td>[69]</td></tr><tr><td>Cloud bean defensin</td><td>Phaseolus vulgaris cv. cloud bean</td><td>L1210 and MBL2</td><td>Not tested</td><td>Yes</td><td>[70]</td></tr><tr><td>Nepalese</td><td>Phaseolus angularis</td><td>L1210, MBL2</td><td>Not tested</td><td>Yes</td><td>[71]</td></tr><tr><td>Gymnin</td><td>Gymnocladus chinensis Baill</td><td>M1, HepG2, and L1210</td><td>Not tested</td><td>Yes</td><td>[72]</td></tr></table>
cf894541f316ca76bab1f5a3f3b61ef0e9c52bf43fb8a7c3c372441aee6ad891.png
simple
<table><tr><td> </td><td>Odds ratio</td><td>95% CI</td><td>p-value</td></tr><tr><td>Aortic valve replacement</td><td>4.36</td><td>2.68&#8211;7.07</td><td>&lt; 0.001</td></tr><tr><td>Chronic heart failure</td><td>1.81</td><td>1.10&#8211;2.99</td><td>&lt; 0.001</td></tr><tr><td>EuroSCORE (per point)</td><td>1.10</td><td>1.03&#8211;1.17</td><td>&lt; 0.001</td></tr><tr><td>Age (per year)</td><td>1.05</td><td>1.03&#8211;1.07</td><td>&lt; 0.001</td></tr></table>
<table><tr><td></td><td>Odds ratio</td><td>95% CI</td></tr><tr><td>Aortic valve replacement</td><td>4.36</td><td>2.68–7.07</td></tr><tr><td>Chronic heart failure</td><td>1.81</td><td>1.10–2.99</td></tr><tr><td>EuroSCORE (per point)</td><td>1.10</td><td>1.03–1.17</td></tr><tr><td>Age (per year)</td><td>1.05</td><td>1.03–1.07</td></tr></table>
<table><tr><td>p-value</td></tr><tr><td>< 0.001</td></tr><tr><td>< 0.001</td></tr><tr><td>< 0.001</td></tr><tr><td>< 0.001</td></tr></table>
543f014935d9ae254a0a5f4f43807b048bed335519f31ada5a19890139223e63.png
simple
<table><tr><td>Pulse feature</td><td>Frequency</td><td>Proportion of the total (%)</td></tr><tr><td><i>Rate</i></td><td></td><td></td></tr><tr><td>Normal</td><td>33</td><td>76.7</td></tr><tr><td>Slow</td><td>1</td><td>2.3</td></tr><tr><td>Fast</td><td>6</td><td>14.0</td></tr><tr><td>Uneven</td><td>2</td><td>4.6</td></tr><tr><td><i>Left pulse</i></td><td></td><td></td></tr><tr><td>Slippery</td><td>15</td><td>34.9</td></tr><tr><td>Thin</td><td>15</td><td>34.9</td></tr><tr><td>Soft/weak</td><td>23</td><td>53.5</td></tr><tr><td>Wiry</td><td>22</td><td>51.2</td></tr><tr><td><i>Right pulse</i></td><td></td><td></td></tr><tr><td>Slippery</td><td>18</td><td>41.9</td></tr><tr><td>Thin</td><td>19</td><td>44.2</td></tr><tr><td>Soft/Weak</td><td>25</td><td>58.1</td></tr><tr><td>Wiry</td><td>15</td><td>34.9</td></tr></table>
<table><tr><td>Pulse feature</td></tr><tr><td>Rate</td></tr><tr><td>Normal</td></tr><tr><td>Slow</td></tr><tr><td>Fast</td></tr><tr><td>Uneven</td></tr><tr><td>Left pulse</td></tr><tr><td>Slippery</td></tr><tr><td>Thin</td></tr><tr><td>Soft/weak</td></tr><tr><td>Wiry</td></tr><tr><td>Right pulse</td></tr><tr><td>Slippery</td></tr><tr><td>Thin</td></tr><tr><td>Soft/Weak</td></tr><tr><td>Wiry</td></tr></table>
<table><tr><td>Frequency</td><td>Proportion of the total (%)</td></tr><tr><td></td><td></td></tr><tr><td>33</td><td>76.7</td></tr><tr><td>1</td><td>2.3</td></tr><tr><td>6</td><td>14.0</td></tr><tr><td>2</td><td>4.6</td></tr><tr><td></td><td></td></tr><tr><td>15</td><td>34.9</td></tr><tr><td>15</td><td>34.9</td></tr><tr><td>23</td><td>53.5</td></tr><tr><td>22</td><td>51.2</td></tr><tr><td></td><td></td></tr><tr><td>18</td><td>41.9</td></tr><tr><td>19</td><td>44.2</td></tr><tr><td>25</td><td>58.1</td></tr><tr><td>15</td><td>34.9</td></tr></table>
2c2d03ac79459b8ca233bb1303fd7b9bf7176e3828bba13b49867ec55754039b.png
simple
<table><tr><td>Groups</td><td>Mean &#177; SD</td><td>Median</td><td>Minimum</td><td>Maximum</td></tr><tr><td>C</td><td>71.34 &#177; 26.74</td><td>88.12</td><td>36.91</td><td>99.07</td></tr><tr><td>P-Ch 0</td><td>116.73 &#177; 62.94</td><td>97.37</td><td>59.17</td><td>302.61</td></tr><tr><td>P-Ch A</td><td>126.67 &#177; 32.79</td><td>122.19</td><td>79.46</td><td>177.40</td></tr><tr><td>P-Ch B</td><td>180.51 &#177; 68.74</td><td>171.58</td><td>47.69</td><td>343.53</td></tr><tr><td>P-Ch C</td><td>231.26 &#177; 80.51</td><td>228.85</td><td>108.28</td><td>398.34</td></tr></table>
<table><tr><td>Groups</td><td>Mean ± SD</td></tr><tr><td>C</td><td>71.34 ± 26.74</td></tr><tr><td>P-Ch 0</td><td>116.73 ± 62.94</td></tr><tr><td>P-Ch A</td><td>126.67 ± 32.79</td></tr><tr><td>P-Ch B</td><td>180.51 ± 68.74</td></tr><tr><td>P-Ch C</td><td>231.26 ± 80.51</td></tr></table>
<table><tr><td>Median</td><td>Minimum</td><td>Maximum</td></tr><tr><td>88.12</td><td>36.91</td><td>99.07</td></tr><tr><td>97.37</td><td>59.17</td><td>302.61</td></tr><tr><td>122.19</td><td>79.46</td><td>177.40</td></tr><tr><td>171.58</td><td>47.69</td><td>343.53</td></tr><tr><td>228.85</td><td>108.28</td><td>398.34</td></tr></table>
2d81bc3cb2e8bffea558c279034af02e74a8bb11892cda81f4633ead80351406.png
simple
<table><tr><td>Station Name</td><td>CLS</td><td>MIP</td><td>ALN</td><td>CIS</td><td>CIRS</td><td>CUC</td><td>STA</td></tr><tr><td>Ejin Banner</td><td>0.86&#8211;0.93</td><td>0.18&#8211;0.25</td><td>0.22&#8211;0.28</td><td>0.44&#8211;0.56</td><td>0.18&#8211;0.26</td><td>0.10&#8211;0.15</td><td>0.30&#8211;0.39</td></tr><tr><td>Mazongshan</td><td>0.80&#8211;0.90</td><td>0.16&#8211;0.29</td><td>0.20&#8211;0.27</td><td>0.47&#8211;0.54</td><td>0.19&#8211;0.26</td><td>0.12&#8211;0.14</td><td>0.32&#8211;0.36</td></tr><tr><td>Yumenzhen</td><td>0.83&#8211;0.96</td><td>0.18&#8211;0.27</td><td>0.24&#8211;0.29</td><td>0.48&#8211;0.55</td><td>0.17&#8211;0.27</td><td>0.09&#8211;0.14</td><td>0.30&#8211;0.41</td></tr><tr><td>Dingxin</td><td>0.79&#8211;0.98</td><td>0.18&#8211;0.26</td><td>0.21&#8211;0.28</td><td>0.50&#8211;0.54</td><td>0.22&#8211;0.27</td><td>0.08&#8211;0.15</td><td>0.32&#8211;0.38</td></tr><tr><td>Jinta</td><td>0.81&#8211;0.94</td><td>0.20&#8211;0.24</td><td>0.25&#8211;0.26</td><td>0.46&#8211;0.57</td><td>0.18&#8211;0.27</td><td>0.10&#8211;0.15</td><td>0.33&#8211;0.37</td></tr><tr><td>Jiuquan</td><td>0.80&#8211;0.94</td><td>0.17&#8211;0.28</td><td>0.22&#8211;0.27</td><td>0.46&#8211;0.55</td><td>0.23&#8211;0.25</td><td>0.09&#8211;0.16</td><td>0.31&#8211;0.36</td></tr><tr><td>Gaotai</td><td>0.85&#8211;0.95</td><td>0.18&#8211;0.27</td><td>0.20&#8211;0.29</td><td>0.49&#8211;0.53</td><td>0.22&#8211;0.28</td><td>0.10&#8211;0.14</td><td>0.30&#8211;0.37</td></tr><tr><td>Alxa Right Banner</td><td>0.82&#8211;0.93</td><td>0.18&#8211;0.27</td><td>0.23&#8211;0.26</td><td>0.48&#8211;0.58</td><td>0.18&#8211;0.27</td><td>0.11&#8211;0.15</td><td>0.32&#8211;0.36</td></tr><tr><td>Tuole</td><td>0.80&#8211;0.96</td><td>0.20&#8211;0.25</td><td>0.21&#8211;0.26</td><td>0.45&#8211;0.55</td><td>0.23&#8211;0.26</td><td>0.10&#8211;0.15</td><td>0.34&#8211;0.37</td></tr><tr><td>Yeniugou</td><td>0.80&#8211;0.93</td><td>0.18&#8211;0.27</td><td>0.23&#8211;0.28</td><td>0.47&#8211;0.56</td><td>0.19&#8211;0.25</td><td>0.12&#8211;0.14</td><td>0.30&#8211;0.38</td></tr><tr><td>Zhangye</td><td>0.87&#8211;0.92</td><td>0.15&#8211;0.22</td><td>0.22&#8211;0.32</td><td>0.48&#8211;0.58</td><td>0.21&#8211;0.25</td><td>0.09&#8211;0.15</td><td>0.33&#8211;0.36</td></tr><tr><td>Qilian</td><td>0.78&#8211;0.92</td><td>0.20&#8211;0.25</td><td>0.19&#8211;0.29</td><td>0.49&#8211;0.52</td><td>0.18&#8211;0.27</td><td>0.11&#8211;0.14</td><td>0.31&#8211;0.38</td></tr><tr><td>Shandan</td><td>0.83&#8211;0.96</td><td>0.18&#8211;0.28</td><td>0.22&#8211;0.28</td><td>0.47&#8211;0.53</td><td>0.22&#8211;0.25</td><td>0.10&#8211;0.16</td><td>0.32&#8211;0.37</td></tr><tr><td>Yongchang</td><td>0.81&#8211;0.95</td><td>0.18&#8211;0.27</td><td>0.20&#8211;0.30</td><td>0.48&#8211;0.53</td><td>0.20&#8211;0.25</td><td>0.12&#8211;0.15</td><td>0.34&#8211;0.36</td></tr><tr><td>Range</td><td>0.78&#8211;0.98</td><td>0.15&#8211;0.29</td><td>0.19&#8211;0.32</td><td>0.45&#8211;0.58</td><td>0.17&#8211;0.28</td><td>0.08&#8211;0.16</td><td>0.30&#8211;0.41</td></tr></table>
<table><tr><td>Station Name</td><td>CLS</td><td>MIP</td><td>ALN</td><td>CIS</td><td>CIRS</td><td>CUC</td><td>STA</td></tr><tr><td>Ejin Banner</td><td>0.86–0.93</td><td>0.18–0.25</td><td>0.22–0.28</td><td>0.44–0.56</td><td>0.18–0.26</td><td>0.10–0.15</td><td>0.30–0.39</td></tr><tr><td>Mazongshan</td><td>0.80–0.90</td><td>0.16–0.29</td><td>0.20–0.27</td><td>0.47–0.54</td><td>0.19–0.26</td><td>0.12–0.14</td><td>0.32–0.36</td></tr><tr><td>Yumenzhen</td><td>0.83–0.96</td><td>0.18–0.27</td><td>0.24–0.29</td><td>0.48–0.55</td><td>0.17–0.27</td><td>0.09–0.14</td><td>0.30–0.41</td></tr><tr><td>Dingxin</td><td>0.79–0.98</td><td>0.18–0.26</td><td>0.21–0.28</td><td>0.50–0.54</td><td>0.22–0.27</td><td>0.08–0.15</td><td>0.32–0.38</td></tr><tr><td>Jinta</td><td>0.81–0.94</td><td>0.20–0.24</td><td>0.25–0.26</td><td>0.46–0.57</td><td>0.18–0.27</td><td>0.10–0.15</td><td>0.33–0.37</td></tr><tr><td>Jiuquan</td><td>0.80–0.94</td><td>0.17–0.28</td><td>0.22–0.27</td><td>0.46–0.55</td><td>0.23–0.25</td><td>0.09–0.16</td><td>0.31–0.36</td></tr><tr><td>Gaotai</td><td>0.85–0.95</td><td>0.18–0.27</td><td>0.20–0.29</td><td>0.49–0.53</td><td>0.22–0.28</td><td>0.10–0.14</td><td>0.30–0.37</td></tr><tr><td>Alxa Right Banner</td><td>0.82–0.93</td><td>0.18–0.27</td><td>0.23–0.26</td><td>0.48–0.58</td><td>0.18–0.27</td><td>0.11–0.15</td><td>0.32–0.36</td></tr></table>
<table><tr><td>Station Name</td><td>CLS</td><td>MIP</td><td>ALN</td><td>CIS</td><td>CIRS</td><td>CUC</td><td>STA</td></tr><tr><td>Tuole</td><td>0.80–0.96</td><td>0.20–0.25</td><td>0.21–0.26</td><td>0.45–0.55</td><td>0.23–0.26</td><td>0.10–0.15</td><td>0.34–0.37</td></tr><tr><td>Yeniugou</td><td>0.80–0.93</td><td>0.18–0.27</td><td>0.23–0.28</td><td>0.47–0.56</td><td>0.19–0.25</td><td>0.12–0.14</td><td>0.30–0.38</td></tr><tr><td>Zhangye</td><td>0.87–0.92</td><td>0.15–0.22</td><td>0.22–0.32</td><td>0.48–0.58</td><td>0.21–0.25</td><td>0.09–0.15</td><td>0.33–0.36</td></tr><tr><td>Qilian</td><td>0.78–0.92</td><td>0.20–0.25</td><td>0.19–0.29</td><td>0.49–0.52</td><td>0.18–0.27</td><td>0.11–0.14</td><td>0.31–0.38</td></tr><tr><td>Shandan</td><td>0.83–0.96</td><td>0.18–0.28</td><td>0.22–0.28</td><td>0.47–0.53</td><td>0.22–0.25</td><td>0.10–0.16</td><td>0.32–0.37</td></tr><tr><td>Yongchang</td><td>0.81–0.95</td><td>0.18–0.27</td><td>0.20–0.30</td><td>0.48–0.53</td><td>0.20–0.25</td><td>0.12–0.15</td><td>0.34–0.36</td></tr><tr><td>Range</td><td>0.78–0.98</td><td>0.15–0.29</td><td>0.19–0.32</td><td>0.45–0.58</td><td>0.17–0.28</td><td>0.08–0.16</td><td>0.30–0.41</td></tr></table>
80637b28f900a88be95c55be57f09f279ab728d5a817a8819b8633bb9ab04295.png
complex
<table><tr><td>Sequence</td><td>QP</td><td>Level 0</td><td>Level 1</td><td>Level 2</td><td>Level 3</td></tr><tr><td>FourPeople</td><td>22</td><td>49.48</td><td>24.79</td><td>22.13</td><td>3.60</td></tr><tr><td></td><td>27</td><td>66.59</td><td>16.50</td><td>15.19</td><td>1.71</td></tr><tr><td></td><td>32</td><td>74.69</td><td>11.88</td><td>12.46</td><td>0.98</td></tr><tr><td></td><td>37</td><td>79.57</td><td>8.78</td><td>11.15</td><td>0.50</td></tr><tr><td>Johnny</td><td>22</td><td>51.30</td><td>26.48</td><td>19.91</td><td>2.31</td></tr><tr><td></td><td>27</td><td>68.30</td><td>17.63</td><td>13.26</td><td>0.81</td></tr><tr><td></td><td>32</td><td>76.74</td><td>11.87</td><td>10.95</td><td>0.44</td></tr><tr><td></td><td>37</td><td>82.57</td><td>7.58</td><td>9.59</td><td>0.25</td></tr><tr><td>Vidyo1</td><td>22</td><td>48.94</td><td>26.55</td><td>21.07</td><td>3.44</td></tr><tr><td></td><td>27</td><td>65.94</td><td>18.27</td><td>14.51</td><td>1.27</td></tr><tr><td></td><td>32</td><td>74.66</td><td>13.12</td><td>11.66</td><td>0.55</td></tr><tr><td></td><td>37</td><td>80.34</td><td>9.35</td><td>10.07</td><td>0.24</td></tr><tr><td colspan="2">Average</td><td>68.26</td><td>16.07</td><td>14.33</td><td>1.34</td></tr></table>
<table><tr><td>Sequence</td><td>QP</td><td>Level 0</td><td>Level 1</td><td>Level 2</td><td>Level 3</td></tr><tr><td>FourPeople</td><td>22</td><td>49.48</td><td>24.79</td><td>22.13</td><td>3.60</td></tr><tr><td></td><td>27</td><td>66.59</td><td>16.50</td><td>15.19</td><td>1.71</td></tr><tr><td></td><td>32</td><td>74.69</td><td>11.88</td><td>12.46</td><td>0.98</td></tr><tr><td></td><td>37</td><td>79.57</td><td>8.78</td><td>11.15</td><td>0.50</td></tr><tr><td>Johnny</td><td>22</td><td>51.30</td><td>26.48</td><td>19.91</td><td>2.31</td></tr><tr><td></td><td>27</td><td>68.30</td><td>17.63</td><td>13.26</td><td>0.81</td></tr><tr><td></td><td></td><td></td><td>11.87</td><td>1</td><td>0.</td></tr></table>
<table><tr><td></td><td>32</td><td>76.74</td><td></td><td>0.95</td><td>44</td></tr><tr><td></td><td>37</td><td>82.57</td><td>7.58</td><td>9.59</td><td>0.25</td></tr><tr><td>Vidyo1</td><td>22</td><td>48.94</td><td>26.55</td><td>21.07</td><td>3.44</td></tr><tr><td></td><td>27</td><td>65.94</td><td>18.27</td><td>14.51</td><td>1.27</td></tr><tr><td></td><td>32</td><td>74.66</td><td>13.12</td><td>11.66</td><td>0.55</td></tr><tr><td></td><td>37</td><td>80.34</td><td>9.35</td><td>10.07</td><td>0.24</td></tr><tr><td colspan="2">Average</td><td>68.26</td><td>16.07</td><td>14.33</td><td>1.34</td></tr></table>
03fd798dea665c061662228cd79daac546ce7c052f0c0ca1bcba3ca30cdd56d3.png
complex
<table><tr><td rowspan="2"> </td><td rowspan="2">Cases (number, %)</td><td colspan="2">NLR (number)</td><td rowspan="2"><i>P </i>value</td><td colspan="2">PLR (number)</td><td rowspan="2"><i>P </i>value</td></tr><tr><td>&lt;3.5</td><td>&#8805;3.5</td><td>&lt;150</td><td>&#8805;150</td></tr><tr><td>Gender</td><td> </td><td> </td><td> </td><td rowspan="3">0.143</td><td> </td><td> </td><td rowspan="3">0.473</td></tr><tr><td>Female</td><td>72 (14.9)</td><td>51</td><td>21</td><td>42</td><td>30</td></tr><tr><td>Male</td><td>411 (85.1)</td><td>254</td><td>157</td><td>221</td><td>190</td></tr><tr><td>Age (years)</td><td> </td><td> </td><td> </td><td rowspan="3">0.305</td><td> </td><td> </td><td rowspan="3">0.804</td></tr><tr><td>&#8804;60</td><td>273 (56.5)</td><td>167</td><td>106</td><td>150</td><td>123</td></tr><tr><td>&gt;60</td><td>210 (43.5)</td><td>138</td><td>72</td><td>113</td><td>97</td></tr><tr><td>Tumor length</td><td> </td><td> </td><td> </td><td rowspan="3">&lt;0.001</td><td> </td><td> </td><td rowspan="3">&lt;0.001</td></tr><tr><td>&#8804;3</td><td>138 (28.6)</td><td>117</td><td>21</td><td>95</td><td>43</td></tr><tr><td>&gt;3</td><td>345 (71.4)</td><td>188</td><td>157</td><td>168</td><td>177</td></tr><tr><td>Tumor location</td><td> </td><td> </td><td> </td><td rowspan="4">0.101</td><td> </td><td> </td><td rowspan="4">0.561</td></tr><tr><td>Upper</td><td>27 (5.6)</td><td>12</td><td>15</td><td>15</td><td>12</td></tr><tr><td>Middle</td><td>247 (51.1)</td><td>156</td><td>91</td><td>140</td><td>107</td></tr><tr><td>Lower</td><td>209 (43.3)</td><td>137</td><td>72</td><td>108</td><td>101</td></tr><tr><td>Vessel involvement</td><td> </td><td> </td><td> </td><td rowspan="3">0.121</td><td> </td><td> </td><td rowspan="3">0.729</td></tr><tr><td>Negative</td><td>407 (84.3)</td><td>263</td><td>144</td><td>223</td><td>184</td></tr><tr><td>Positive</td><td>76 (15.7)</td><td>42</td><td>34</td><td>40</td><td>36</td></tr><tr><td>Perineural invasion</td><td> </td><td> </td><td> </td><td rowspan="3">0.862</td><td> </td><td> </td><td rowspan="3">0.882</td></tr><tr><td>Negative</td><td>390 (80.7)</td><td>247</td><td>143</td><td>213</td><td>177</td></tr><tr><td>Positive</td><td>93 (19.3)</td><td>58</td><td>35</td><td>50</td><td>43</td></tr><tr><td>Differentiation</td><td> </td><td> </td><td> </td><td rowspan="4">0.021</td><td> </td><td> </td><td rowspan="4">0.038</td></tr><tr><td>Well</td><td>71 (14.7)</td><td>42</td><td>29</td><td>38</td><td>33</td></tr><tr><td>Moderate</td><td>323 (66.9)</td><td>217</td><td>106</td><td>187</td><td>136</td></tr><tr><td>Poor</td><td>89 (18.4)</td><td>46</td><td>43</td><td>38</td><td>51</td></tr><tr><td>Depth of invasion</td><td> </td><td> </td><td> </td><td rowspan="5">&lt;0.001</td><td> </td><td> </td><td rowspan="5">0.003</td></tr><tr><td>T1</td><td>87 (18.0)</td><td>81</td><td>6</td><td>63</td><td>24</td></tr><tr><td>T2</td><td>80 (16.6)</td><td>54</td><td>26</td><td>41</td><td>39</td></tr><tr><td>T3</td><td>265 (54.9)</td><td>154</td><td>111</td><td>134</td><td>131</td></tr><tr><td>T4</td><td>51 (10.5)</td><td>16</td><td>35</td><td>25</td><td>26</td></tr><tr><td>Nodal metastasis</td><td> </td><td> </td><td> </td><td rowspan="3">&lt;0.001</td><td> </td><td> </td><td rowspan="3">&lt;0.001</td></tr><tr><td>Negative</td><td>274 (56.7)</td><td>199</td><td>75</td><td>169</td><td>105</td></tr><tr><td>Positive</td><td>209 (43.3)</td><td>106</td><td>103</td><td>94</td><td>115</td></tr></table>
<table><tr><td rowspan="2"></td><td rowspan="2">Cases (number, %)</td></tr><tr></tr><tr><td>Gender</td><td></td></tr><tr><td>Female</td><td>72 (14.9)</td></tr><tr><td>Male</td><td>411 (85.1)</td></tr><tr><td>Age (years)</td><td></td></tr><tr><td>≤60</td><td>273 (56.5)</td></tr><tr><td>>60</td><td>210 (43.5)</td></tr><tr><td>Tumor length</td><td></td></tr><tr><td>≤3</td><td>138 (28.6)</td></tr><tr><td>>3</td><td>345 (71.4)</td></tr><tr><td>Tumor location</td><td></td></tr><tr><td>Upper</td><td>27 (5.6)</td></tr><tr><td>Middle</td><td>247 (51.1)</td></tr><tr><td>Lower</td><td>209 (43.3)</td></tr><tr><td>Vessel involvement</td><td></td></tr><tr><td>Negative</td><td>407 (84.3)</td></tr><tr><td>Positive</td><td>76 (15.7)</td></tr><tr><td>Perineural invasion</td><td></td></tr><tr><td>Negative</td><td>390 (80.7)</td></tr><tr><td>Positive</td><td>93 (19.3)</td></tr><tr><td>Differentiation</td><td></td></tr><tr><td>Well</td><td>71 (14.7)</td></tr><tr><td>Moderate</td><td>323 (66.9)</td></tr><tr><td>Poor</td><td>89 (18.4)</td></tr><tr><td>Depth of invasion</td><td></td></tr><tr><td>T1</td><td>87 (18.0)</td></tr><tr><td>T2</td><td>80 (16.6)</td></tr><tr><td>T3</td><td>265 (54.9)</td></tr><tr><td>T4</td><td>51 (10.5)</td></tr><tr><td>Nodal metastasis</td><td></td></tr><tr><td>Negative</td><td>274 (56.7)</td></tr><tr><td>Positive</td><td>209 (43.3)</td></tr></table>
<table><tr><td colspan="2">NLR (number)</td><td rowspan="2">P value</td><td colspan="2">PLR (number)</td><td rowspan="2">P value</td></tr><tr><td><3.5</td><td>≥3.5</td><td><150</td><td>≥150</td></tr><tr><td></td><td></td><td rowspan="3">0.143</td><td></td><td></td><td rowspan="3">0.473</td></tr><tr><td>51</td><td>21</td><td>42</td><td>30</td></tr><tr><td>254</td><td>157</td><td>221</td><td>190</td></tr><tr><td></td><td></td><td rowspan="3">0.305</td><td></td><td></td><td rowspan="3">0.804</td></tr><tr><td>167</td><td>106</td><td>150</td><td>123</td></tr><tr><td>138</td><td>72</td><td>113</td><td>97</td></tr><tr><td></td><td></td><td rowspan="3"><0.001</td><td></td><td></td><td rowspan="3"><0.001</td></tr><tr><td>117</td><td>21</td><td>95</td><td>43</td></tr><tr><td>188</td><td>157</td><td>168</td><td>177</td></tr><tr><td></td><td></td><td rowspan="4">0.101</td><td></td><td></td><td rowspan="4">0.561</td></tr><tr><td>12</td><td>15</td><td>15</td><td>12</td></tr><tr><td>156</td><td>91</td><td>140</td><td>107</td></tr><tr><td>137</td><td>72</td><td>108</td><td>101</td></tr><tr><td></td><td></td><td rowspan="3">0.121</td><td></td><td></td><td rowspan="3">0.729</td></tr><tr><td>263</td><td>144</td><td>223</td><td>184</td></tr><tr><td>42</td><td>34</td><td>40</td><td>36</td></tr><tr><td></td><td></td><td rowspan="3">0.862</td><td></td><td></td><td rowspan="3">0.882</td></tr><tr><td>247</td><td>143</td><td>213</td><td>177</td></tr><tr><td>58</td><td>35</td><td>50</td><td>43</td></tr><tr><td></td><td></td><td rowspan="4">0.021</td><td></td><td></td><td rowspan="4">0.038</td></tr><tr><td>42</td><td>29</td><td>38</td><td>33</td></tr><tr><td>217</td><td>106</td><td>187</td><td>136</td></tr><tr><td>46</td><td>43</td><td>38</td><td>51</td></tr><tr><td></td><td></td><td rowspan="5"><0.001</td><td></td><td></td><td rowspan="5">0.003</td></tr><tr><td>81</td><td>6</td><td>63</td><td>24</td></tr><tr><td>54</td><td>26</td><td>41</td><td>39</td></tr><tr><td>154</td><td>111</td><td>134</td><td>131</td></tr><tr><td>16</td><td>35</td><td>25</td><td>26</td></tr><tr><td></td><td></td><td rowspan="3"><0.001</td><td></td><td></td><td rowspan="3"><0.001</td></tr><tr><td>199</td><td>75</td><td>169</td><td>105</td></tr><tr><td>106</td><td>103</td><td>94</td><td>115</td></tr></table>
cacc306f9478978ef4fa4112f8063e6bd62b69836db04a11c3b0a976d48db071.png
simple
<table><tr><td></td><td>Case 1</td><td>Case 2</td><td>Case 3</td><td>Case 4</td><td>Case 5</td><td>Case 6</td><td>Case 7</td><td>Our patient</td></tr><tr><td>T4 &#956;g/dL</td><td>1</td><td>0.9</td><td>0.23</td><td>0.43</td><td>1.8</td><td>1</td><td>&lt; 1</td><td>1.8</td></tr><tr><td>TSH &#956;U/mL</td><td>?</td><td>0.34</td><td>1.9</td><td>1.4</td><td>0.39</td><td>2.9</td><td>1.49</td><td>3.9</td></tr><tr><td>FSH IU/L</td><td>0.3</td><td>1.6</td><td>1</td><td>0.58</td><td>2.9</td><td>1.07</td><td>7.43</td><td>3.6</td></tr><tr><td>LH IU/L</td><td>0.8</td><td>1.1</td><td>1.6</td><td>0.18</td><td>0.74</td><td>1.07</td><td>0.75</td><td>0.6</td></tr><tr><td>PRL &#956;g/L</td><td>-</td><td>-</td><td>-</td><td>-</td><td>2.8</td><td>1</td><td>1.9</td><td>2.8</td></tr><tr><td>Cortisol &#956;g/dL</td><td>4</td><td>-</td><td>0.7</td><td>&lt; 1</td><td>5.8</td><td>&lt; 1</td><td>6.6</td><td>20</td></tr><tr><td>GH &#956;g/L</td><td>0.3</td><td>0.08</td><td>-</td><td>&lt; 0.05</td><td>&lt; 0.25</td><td>&lt; 0.25</td><td>0.24</td><td>-</td></tr><tr><td>ACTH ng/mL</td><td>-</td><td>&lt; 1</td><td>12</td><td>&lt; 10</td><td>-</td><td>-</td><td>-</td><td>-</td></tr></table>
<table><tr><td></td><td>Case 1</td><td>Case 2</td><td>Case 3</td><td>Case 4</td><td>Case 5</td><td>Case 6</td><td>Case 7</td><td>Our patient</td></tr></table>
<table><tr><td>T4 μg/dL</td><td>1</td><td>0.9</td><td>0.23</td><td>0.43</td><td>1.8</td><td>1</td><td>< 1</td><td>1.8</td></tr><tr><td>TSH μU/mL</td><td>?</td><td>0.34</td><td>1.9</td><td>1.4</td><td>0.39</td><td>2.9</td><td>1.49</td><td>3.9</td></tr><tr><td>FSH IU/L</td><td>0.3</td><td>1.6</td><td>1</td><td>0.58</td><td>2.9</td><td>1.07</td><td>7.43</td><td>3.6</td></tr><tr><td>LH IU/L</td><td>0.8</td><td>1.1</td><td>1.6</td><td>0.18</td><td>0.74</td><td>1.07</td><td>0.75</td><td>0.6</td></tr><tr><td>PRL μg/L</td><td>-</td><td>-</td><td>-</td><td>-</td><td>2.8</td><td>1</td><td>1.9</td><td>2.8</td></tr><tr><td>Cortisol μg/dL</td><td>4</td><td>-</td><td>0.7</td><td>< 1</td><td>5.8</td><td>< 1</td><td>6.6</td><td>20</td></tr><tr><td>GH μg/L</td><td>0.3</td><td>0.08</td><td>-</td><td>< 0.05</td><td>< 0.25</td><td>< 0.25</td><td>0.24</td><td>-</td></tr><tr><td>ACTH ng/mL</td><td>-</td><td>< 1</td><td>12</td><td>< 10</td><td>-</td><td>-</td><td>-</td><td>-</td></tr></table>
854bd9271015845e1b004a9d8cdd48bb406bd6fc2e2528c93b5dc8da04688741.png
simple
<table><tr><td>Clinical / laboratory characteristic</td><td>Number of patients (of <i>n</i> = 99)</td></tr><tr><td>Altered level of consciousness</td><td>99</td></tr><tr><td>Fever</td><td>93</td></tr><tr><td>Headache</td><td>54</td></tr><tr><td>Seizures</td><td>58</td></tr><tr><td>Prodromal symptoms</td><td>77</td></tr><tr><td>Focal neurological signs</td><td>44</td></tr><tr><td> Cerebellar signs</td><td>12</td></tr><tr><td> Extrapyramidal signs</td><td>6</td></tr><tr><td>Neuropsychiatric symptoms</td><td>21</td></tr><tr><td>Cerebrospinal fluid</td><td></td></tr><tr><td> Protein &gt;40 mg/dl</td><td>22</td></tr><tr><td> CSF:plasma glucose ratio &lt; 30%</td><td>39</td></tr><tr><td> Pleocytosis</td><td>26</td></tr><tr><td> Gram stain positivity</td><td>0</td></tr><tr><td> Bacterial culture positivity</td><td>0</td></tr></table>
<table><tr><td>Clini</td><td>Number of patien</td></tr></table>
<table><tr><td>cal / laboratory characteristic</td><td>ts (of n = 99)</td></tr><tr><td>Altered level of consciousness</td><td>99</td></tr><tr><td>Fever</td><td>93</td></tr><tr><td>Headache</td><td>54</td></tr><tr><td>Seizures</td><td>58</td></tr><tr><td>Prodromal symptoms</td><td>77</td></tr><tr><td>Focal neurological signs</td><td>44</td></tr><tr><td>Cerebellar signs</td><td>12</td></tr><tr><td>Extrapyramidal signs</td><td>6</td></tr><tr><td>Neuropsychiatric symptoms</td><td>21</td></tr><tr><td>Cerebrospinal fluid</td><td></td></tr><tr><td>Protein >40 mg/dl</td><td>22</td></tr><tr><td>CSF:plasma glucose ratio < 30%</td><td>39</td></tr><tr><td>Pleocytosis</td><td>26</td></tr><tr><td>Gram stain positivity</td><td>0</td></tr><tr><td>Bacterial culture positivity</td><td>0</td></tr></table>
955dc66c6b8b5d89ed5a9279988df72c45438b87293704a288b1c0b3936a507a.png
complex
<table><tr><td></td><td>S100&#946; &#8805;0.13 &#956;g/L<i>n =</i> 10 (8.47%)</td><td>S100&#946; &lt;0.13 &#956;g/L<i>n =</i> 108 (91.53%)</td><td><i>p</i> value</td></tr><tr><td colspan="4">Age</td></tr><tr><td> &#8805;55</td><td>3 (30%)</td><td>64 (59.26%)</td><td rowspan="2">0.099</td></tr><tr><td>&lt; 55</td><td>7 (70%)</td><td>44 (40.74%)</td></tr><tr><td colspan="4">PR</td></tr><tr><td>+ ve</td><td>8 (80%)</td><td>87 (80.56%)</td><td rowspan="2">1.00</td></tr><tr><td> &#8211;ve</td><td>2 (20%)</td><td>21 (19.44%)</td></tr><tr><td colspan="4">HER2</td></tr><tr><td>+ ve</td><td>3 (30%)</td><td>52 (51.49%)</td><td rowspan="2">0.097</td></tr><tr><td> &#8211;ve</td><td>7 (70%)</td><td>49 (48.51%)</td></tr><tr><td colspan="4">Node</td></tr><tr><td>+ ve</td><td>2 (22.22%)</td><td>43 (47.25%)</td><td rowspan="2">0.162</td></tr><tr><td> &#8211;ve</td><td>7 (77.78%)</td><td>48 (52.75%)</td></tr><tr><td colspan="4">Grade</td></tr><tr><td> &#8805;3</td><td>4 (40%)</td><td>26 (24.07%)</td><td rowspan="2">0.273</td></tr><tr><td> &lt;3</td><td>6 (60%)</td><td>82 (75.93%)</td></tr><tr><td colspan="4">Size</td></tr><tr><td> &#8805;20 mm</td><td>7 (100%)</td><td>81 (96.43%)</td><td rowspan="2">1.00</td></tr><tr><td>&lt; 20 mm</td><td>&#8211;</td><td>3 (3.57%)</td></tr><tr><td colspan="4">Recurrence</td></tr><tr><td>+ ve</td><td>5 (50%)</td><td>17 (15.74%)</td><td rowspan="2">0.019(<i>r</i> = +0.245)</td></tr><tr><td> &#8211;ve</td><td>5 (50%)</td><td>91 (84.26%)</td></tr></table>
<table><tr><td></td><td>S100β ≥0.13 μg/Ln = 10 (8.47%)</td><td>S100β <0.13 μg/Ln = 108 (91.53%)</td><td>p value</td></tr><tr><td colspan="4">Age</td></tr><tr><td>≥55</td><td>3 (30%)</td><td>64 (59.26%)</td><td>0.099</td></tr></table>
<table><tr><td>< 55</td><td>7 (70%)</td><td>44 (40.74%)</td><td>0.099</td></tr><tr><td colspan="4">PR</td></tr><tr><td>+ ve</td><td>8 (80%)</td><td>87 (80.56%)</td><td rowspan="2">1.00</td></tr><tr><td>–ve</td><td>2 (20%)</td><td>21 (19.44%)</td></tr><tr><td colspan="4">HER2</td></tr><tr><td>+ ve</td><td>3 (30%)</td><td>52 (51.49%)</td><td rowspan="2">0.097</td></tr><tr><td>–ve</td><td>7 (70%)</td><td>49 (48.51%)</td></tr><tr><td colspan="4">Node</td></tr><tr><td>+ ve</td><td>2 (22.22%)</td><td>43 (47.25%)</td><td rowspan="2">0.162</td></tr><tr><td>–ve</td><td>7 (77.78%)</td><td>48 (52.75%)</td></tr><tr><td colspan="4">Grade</td></tr><tr><td>≥3</td><td>4 (40%)</td><td>26 (24.07%)</td><td rowspan="2">0.273</td></tr><tr><td><3</td><td>6 (60%)</td><td>82 (75.93%)</td></tr><tr><td colspan="4">Size</td></tr><tr><td>≥20 mm</td><td>7 (100%)</td><td>81 (96.43%)</td><td rowspan="2">1.00</td></tr><tr><td>< 20 mm</td><td>–</td><td>3 (3.57%)</td></tr><tr><td colspan="4">Recurrence</td></tr><tr><td>+ ve</td><td>5 (50%)</td><td>17 (15.74%)</td><td rowspan="2">0.019(r = +0.245)</td></tr><tr><td>–ve</td><td>5 (50%)</td><td>91 (84.26%)</td></tr></table>
a57d6981e0c170e080929d4beeb904afa3413000d66c477283fa7c5203d05922.png
simple
<table><tr><td>Implementation unit</td><td>No. of pools</td><td>Average pool size</td><td>No. of <i>An. gambiae</i> processed</td><td>No. of <i>An. gambiae</i> collected</td><td>% of <i>An. gambiae</i> processed</td><td>Positive</td><td>95% CI</td></tr><tr><td>Cinkasse</td><td>166</td><td>15.9</td><td>2646</td><td>2782</td><td>95.1</td><td>0</td><td>0&#8211;0.073</td></tr><tr><td>Kpendjal</td><td>172</td><td>14.5</td><td>2495</td><td>2807</td><td>88.9</td><td>0</td><td>0&#8211;0.077</td></tr><tr><td>Tone</td><td>291</td><td>13.9</td><td>4050</td><td>5283</td><td>76.7</td><td>0</td><td>0&#8211;0.047</td></tr><tr><td>Total</td><td>629</td><td>14.6</td><td>9191</td><td>10,872</td><td>84.5</td><td>0</td><td>0&#8211;0.021</td></tr></table>
<table><tr><td>Implementation uni</td><td>No. of pools</td><td></td><td>No. of An. </td><td>No. o</td><td></td><td>Po</td><td></td></tr></table>
<table><tr><td>t</td><td></td><td>Average pool size</td><td>gambiae processed</td><td>f An. gambiae collected</td><td>% of An. gambiae processed</td><td>sitive</td><td>95% CI</td></tr><tr><td>Cinkasse</td><td>166</td><td>15.9</td><td>2646</td><td>2782</td><td>95.1</td><td>0</td><td>0–0.073</td></tr><tr><td>Kpendjal</td><td>172</td><td>14.5</td><td>2495</td><td>2807</td><td>88.9</td><td>0</td><td>0–0.077</td></tr><tr><td>Tone</td><td>291</td><td>13.9</td><td>4050</td><td>5283</td><td>76.7</td><td>0</td><td>0–0.047</td></tr><tr><td>Total</td><td>629</td><td>14.6</td><td>9191</td><td>10,872</td><td>84.5</td><td>0</td><td>0–0.021</td></tr></table>
7abd856d1851472bd83dcb51f67a77d14ce2d5fa2550b1ea3b5da1ca2ad36301.png
simple
<table><tr><td></td><td>Subjects (n = 35)</td></tr><tr><td>Age (yrs)</td><td>22.6 &#177; 3.5</td></tr><tr><td>Height (cm)</td><td>177.1 &#177; 7.1</td></tr><tr><td>Weight (kg)</td><td>77.0 &#177; 11.0</td></tr></table>
<table><tr><td></td><td>Subjects (n = 35)</td></tr></table>
<table><tr><td>Age (yrs)</td><td>22.6 ± 3.5</td></tr><tr><td>Height (cm)</td><td>177.1 ± 7.1</td></tr><tr><td>Weight (kg)</td><td>77.0 ± 11.0</td></tr></table>
765c7aa9461ac807c458bd19eaf55ac79eac0ca1834ced6aeab477f28f0723d7.png
simple
<table><tr><td> </td><td>Time period</td><td>Findings</td></tr><tr><td>1</td><td>Any time-point</td><td>Brain death.</td></tr><tr><td>2</td><td>&lt;24 h from ROSC</td><td>Early myoclonus status<sup>#</sup> and bilateral absence of N20 peak on SSEP after rewarming.</td></tr><tr><td>3</td><td>72 h after rewarming</td><td>GCS-M 1&#8211;2 and bilateral absence of N20 peak on SSEP performed 48&#8211;72 hours after rewarming, or later.</td></tr><tr><td>4</td><td>72 h after rewarming</td><td>A treatment refractory status epilepticus* and GCS-M 1&#8211;2.</td></tr></table>
<table><tr><td></td><td>Time period</td></tr><tr><td>1</td><td>Any time-point</td></tr><tr><td>2</td><td><24 h from ROSC</td></tr><tr><td>3</td><td>72 h after rewarming</td></tr><tr><td>4</td><td>72 h after rewarming</td></tr></table>
<table><tr><td>Findings</td></tr><tr><td>Brain death.</td></tr><tr><td>Early myoclonus status# and bilateral absence of N20 peak on SSEP after rewarming.</td></tr><tr><td>GCS-M 1–2 and bilateral absence of N20 peak on SSEP performed 48–72 hours after rewarming, or later.</td></tr><tr><td>A treatment refractory status epilepticus* and GCS-M 1–2.</td></tr></table>
f730ebc4d0eb8103cacdcf74ff9e0e26374cb833132fecff76e2e40ee0b56852.png
simple
<table><tr><td></td><td>Response rate</td><td><i>p</i> value</td><td>Local control rate</td><td><i>p</i> value</td><td>Disease-free survival</td><td><i>p</i> value</td><td>Overall survival</td><td><i>p</i> value</td></tr><tr><td>Algorithm</td><td></td><td>0.008</td><td></td><td>0.879</td><td></td><td>0.408</td><td></td><td>0.311</td></tr><tr><td> RAT group</td><td>77.3%</td><td></td><td>94.1%</td><td></td><td>43.8%</td><td></td><td>38.9%</td><td></td></tr><tr><td> MC group</td><td>100.0%</td><td></td><td>90.9%</td><td></td><td>21.5%</td><td></td><td>67.1%</td><td></td></tr><tr><td>Tumor origin</td><td></td><td>0.309</td><td></td><td>0.367</td><td></td><td>&lt;0.001</td><td></td><td>0.088</td></tr><tr><td> Lung cancer</td><td>93.8%</td><td></td><td>88.5%</td><td></td><td>38.2%</td><td></td><td>62.2%</td><td></td></tr><tr><td> Metastasis</td><td>80.0%</td><td></td><td>100.0%</td><td></td><td>10.0%</td><td></td><td>50.0%</td><td></td></tr><tr><td>RT dose</td><td></td><td>0.571</td><td></td><td>0.132</td><td></td><td></td><td></td><td></td></tr><tr><td> 48&#8211;50 Gy</td><td>100.0%</td><td></td><td>83.3%</td><td></td><td>n/a</td><td></td><td>n/a</td><td></td></tr><tr><td> 60 Gy</td><td>87.2%</td><td></td><td>94.1%</td><td></td><td>n/a</td><td></td><td>n/a</td><td></td></tr><tr><td>Tumor size</td><td></td><td>0.143</td><td></td><td>0.629</td><td></td><td></td><td></td><td></td></tr><tr><td> &#8804;3 cm</td><td>83.3%</td><td></td><td>95.7%</td><td></td><td>n/a</td><td></td><td>n/a</td><td></td></tr><tr><td> &gt;3 cm</td><td>100.0%</td><td></td><td>83.3%</td><td></td><td>n/a</td><td></td><td>n/a</td><td></td></tr></table>
<table><tr><td></td><td>Response rate</td><td>p value</td><td>Local control rate</td><td>p value</td><td>Disease-free survival</td><td>p value</td><td>Overall survival</td><td>p value</td></tr><tr><td>Algorithm</td><td></td><td>0.008</td><td></td><td>0.879</td><td></td><td>0.408</td><td></td><td>0.311</td></tr><tr><td>RAT group</td><td>77.3%</td><td></td><td>94.1%</td><td></td><td>43.8%</td><td></td><td>38.9%</td><td></td></tr><tr><td>MC group</td><td>100.0%</td><td></td><td>90.9%</td><td></td><td>21.5%</td><td></td><td>67.1%</td><td></td></tr></table>
<table><tr><td></td><td>Response rate</td><td>p value</td><td>Local control rate</td><td>p value</td><td>Disease-free survival</td><td>p value</td><td>Overall survival</td><td>p value</td></tr><tr><td>Tumor origin</td><td></td><td>0.309</td><td></td><td>0.367</td><td></td><td><0.001</td><td></td><td>0.088</td></tr><tr><td>Lung cancer</td><td>93.8%</td><td></td><td>88.5%</td><td></td><td>38.2%</td><td></td><td>62.2%</td><td></td></tr><tr><td>Metastasis</td><td>80.0%</td><td></td><td>100.0%</td><td></td><td>10.0%</td><td></td><td>50.0%</td><td></td></tr><tr><td>RT dose</td><td></td><td>0.571</td><td></td><td>0.132</td><td></td><td></td><td></td><td></td></tr><tr><td>48–50 Gy</td><td>100.0%</td><td></td><td>83.3%</td><td></td><td>n/a</td><td></td><td>n/a</td><td></td></tr><tr><td>60 Gy</td><td>87.2%</td><td></td><td>94.1%</td><td></td><td>n/a</td><td></td><td>n/a</td><td></td></tr><tr><td>Tumor size</td><td></td><td>0.143</td><td></td><td>0.629</td><td></td><td></td><td></td><td></td></tr><tr><td>≤3 cm</td><td>83.3%</td><td></td><td>95.7%</td><td></td><td>n/a</td><td></td><td>n/a</td><td></td></tr><tr><td>>3 cm</td><td>100.0%</td><td></td><td>83.3%</td><td></td><td>n/a</td><td></td><td>n/a</td><td></td></tr></table>
5548990a54ff7160113bcf52b683ad78c1cd60080fc70cb7bacaaab561c7f022.png
simple
<table><tr><td>Percentage of biobanks which get specimens from...</td><td>n</td><td>%</td></tr><tr><td>Direct from individuals donating them</td><td>343</td><td>75</td></tr><tr><td>Residual specimens acquired from clinical care in hospitals, clinical laboratories, or pathology departments</td><td>261</td><td>57</td></tr><tr><td>Research</td><td>60</td><td>13</td></tr><tr><td>Residual specimens from public health departments or programs</td><td>19</td><td>4</td></tr><tr><td>Vendors</td><td>8</td><td>2</td></tr><tr><td>Organ/body donation organization</td><td>7</td><td>2</td></tr><tr><td>Other repositories</td><td>7</td><td>2</td></tr><tr><td>Other</td><td>6</td><td>1</td></tr><tr><td>Orphaned collections</td><td>4</td><td>1</td></tr></table>
<table><tr><td>Percentage of biobanks which get specimens from...</td><td>n</td><td>%</td></tr><tr><td>Direct from individuals donating them</td><td>343</td><td>75</td></tr><tr><td>Residual specimens acquired from clinical care in hospitals, clinical laboratories, or pathology departments</td><td>261</td><td>57</td></tr><tr><td>Research</td><td>60</td><td>13</td></tr><tr><td>Residual specimens from public health departments or programs</td><td>19</td><td>4</td></tr></table>
<table><tr><td>Percentage of biobanks which get specimens from...</td><td>n</td><td>%</td></tr><tr><td>Vendors</td><td>8</td><td>2</td></tr><tr><td>Organ/body donation organization</td><td>7</td><td>2</td></tr><tr><td>Other repositories</td><td>7</td><td>2</td></tr><tr><td>Other</td><td>6</td><td>1</td></tr><tr><td>Orphaned collections</td><td>4</td><td>1</td></tr></table>
12b84f63f0a9c1cb4bd7019c2c2887d8e29a688c36d2afcab40e426dd106f6dc.png
simple
<table><tr><td>Strategy</td><td>Intervention</td><td>Comments</td></tr><tr><td>Formulary restriction</td><td>Only certain agents available for use</td><td>Effective, minimal effort to maintain, usurps prescriber autonomy, &#8216;squeezing the balloon&#8217;</td></tr><tr><td>Pre-authorization</td><td>Certain agents available if specific criteria are met</td><td>Effective, allows education, requires designated call person, creates tension between prescriber and stewardship program, clinician may circumvent the system</td></tr><tr><td>Audit and feedback</td><td>Review of ordered antimicrobials or culture results</td><td>Customizable, educational, maintains prescriber autonomy, recommendations specific to clinical situation, optional, time intensive, requires reviewer with broad knowledge</td></tr><tr><td>Guidelines/clinical pathways</td><td>Development of institution specific recommendations for management of specific disease states</td><td>Ability to standardize practice and meet quality measures; customized to institutional needs, resources and formulary, compliance usually not mandatory; perception of &#8216;cookbook medicine&#8217;</td></tr><tr><td>Education</td><td>Education to clinicians regarding appropriate antimicrobial use</td><td>Alters behavioral patterns, improves compliance with guidelines, decreased misuse, poor efficacy of passive education, diminishing effect over time, rotation of personal means repeated education needed</td></tr><tr><td>Biomarkers</td><td>Use of laboratory information (procalcitonin, etc.) to assist in therapy decisions</td><td>Objective marker, well validated in certain situations, must be used with overall patient evaluation, false positive and negative results can occur, clinicians must be able to interpret to use correctly</td></tr><tr><td>Antibiotic cycling</td><td>Scheduled removal and substitution of antimicrobial or class</td><td>May decrease resistance rates, compliance difficult due to patient allergies, national guidelines, and adverse events</td></tr><tr><td>Combination therapy</td><td>Use of two or more agents to prevent resistance and improve clinical outcomes</td><td>Evidence for improvement in clinical outcomes is variable, minimal data to support decrease in resistance, increased risk of allergy and toxicity, increased cost</td></tr><tr><td>Streamlining/de-escalation</td><td>Narrowing of broad spectrum therapy when no pathogen isolated or targeting of pathogen isolated</td><td>Decreases antimicrobial use and costs, allows narrowest effective therapy if culture data available, possible under-treatment if no culture data acquired, treatment of colonizers</td></tr><tr><td>Dose optimization</td><td>Use of pharmacokinetic-pharmacodynamic (PK-PD) parameters to optimize dosing</td><td>Improves likelihood of achieving PK-PD targets, may allow use of agents against resistant pathogens, may decrease selection of resistant strains, some data improves clinical outcomes, requires expertise and time, may be limited by microbiologic data available (MIC), limited data on clinical outcomes</td></tr><tr><td>Computerized decision support</td><td>Use of information technology to assist clinicians in antimicrobial decision making</td><td>Can be integrated into EHR, integrates local data for customized recommendations, requires significant technology and personnel input to set up, alert fatigue, requires constant updating</td></tr><tr><td>IV to oral conversion</td><td>Agents with excellent oral bioavailability are switched from IV to oral</td><td>Decreases cost and need for IV access, may decrease length of stay, only certain agents have excellent oral bioavailability</td></tr></table>
<table><tr><td>Strategy</td><td>Intervention</td><td>Comments</td></tr><tr><td>Formulary restriction</td><td>Only certain agents available for use</td><td>Effective, minimal effort to maintain, usurps prescriber autonomy, ‘squeezing the balloon’</td></tr><tr><td>Pre-authorization</td><td>Certain agents available if specific criteria are met</td><td>Effective, allows education, requires designated call person, creates tension between prescriber and stewardship program, clinician may circumvent the system</td></tr><tr><td>Audit and feedback</td><td>Review of ordered antimicrobials or culture results</td><td>Customizable, educational, maintains prescriber autonomy, recommendations specific to clinical situation, optional, time intensive, requires reviewer with broad knowledge</td></tr><tr><td>Guidelines/clinical pathways</td><td>Development of institution specific recommendations for management of specific disease states</td><td>Ability to standardize practice and meet quality measures; customized to institutional needs, resources and formulary, compliance usually not mandatory; perception of ‘cookbook medicine’</td></tr><tr><td>Education</td><td>Education to clinicians regarding appropriate antimicrobial use</td><td>Alters behavioral patterns, improves compliance with guidelines, decreased misuse, poor efficacy of passive education, diminishing effect over time, rotation of personal means repeated education needed</td></tr><tr><td>Biomarkers</td><td>Use of laboratory information (procalcitonin, etc.) to assist in therapy decisions</td><td>Objective marker, well validated in certain situations, must be used with overall patient evaluation, false positive and negative results can occur, clinicians must be able to interpret to use correctly</td></tr><tr><td>Antibiotic cycling</td><td>Scheduled removal and substitution of antimicrobial or class</td><td>May decrease resistance rates, compliance difficult due to patient allergies, national guidelines, and adverse events</td></tr><tr><td>Comb</td><td>Use of two or more agents to prevent resistance and improve clinical out</td><td>Evidence for improvement in clinical outcomes is variable, minimal data to support decrease in resist</td></tr></table>
<table><tr><td>Strategy</td><td>Intervention</td><td>Comments</td></tr><tr><td>ination therapy</td><td>comes</td><td>ance, increased risk of allergy and toxicity, increased cost</td></tr><tr><td>Streamlining/de-escalation</td><td>Narrowing of broad spectrum therapy when no pathogen isolated or targeting of pathogen isolated</td><td>Decreases antimicrobial use and costs, allows narrowest effective therapy if culture data available, possible under-treatment if no culture data acquired, treatment of colonizers</td></tr><tr><td>Dose optimization</td><td>Use of pharmacokinetic-pharmacodynamic (PK-PD) parameters to optimize dosing</td><td>Improves likelihood of achieving PK-PD targets, may allow use of agents against resistant pathogens, may decrease selection of resistant strains, some data improves clinical outcomes, requires expertise and time, may be limited by microbiologic data available (MIC), limited data on clinical outcomes</td></tr><tr><td>Computerized decision support</td><td>Use of information technology to assist clinicians in antimicrobial decision making</td><td>Can be integrated into EHR, integrates local data for customized recommendations, requires significant technology and personnel input to set up, alert fatigue, requires constant updating</td></tr><tr><td>IV to oral conversion</td><td>Agents with excellent oral bioavailability are switched from IV to oral</td><td>Decreases cost and need for IV access, may decrease length of stay, only certain agents have excellent oral bioavailability</td></tr></table>
f35a091db826699e6a50b151d4c11750bcf3ff13cc8b222b7638c662e828011b.png
complex
<table><tr><td> </td><td rowspan="2">Total (overall)</td><td colspan="2">Mediastinal radiotherapy</td><td rowspan="2"><i>p</i> value<sup>&#8224;</sup></td></tr><tr><td> </td><td>Yes (<i>n</i> = 52)</td><td>No (<i>n</i> = 82)</td></tr><tr><td>Fractional shortening, %</td><td>33.3 (30.4, 36.1)</td><td>33.3 (30.6, 36.0)</td><td>33.1 (29.9, 36.1)</td><td>0.948</td></tr><tr><td>Fractional shortening &lt; 27%</td><td>7 (5.2)</td><td>5 (9.6)</td><td>2 (2.4)</td><td>NA</td></tr><tr><td>Ejection fraction, %</td><td>61.1 (58.0, 63.6)</td><td>60.7 (57.6, 63.4)</td><td>61.2 (58.1, 64.0)</td><td>0.457</td></tr><tr><td>Ejection fraction &lt; 55%</td><td>8 (6.0)</td><td>5 (9.6)</td><td>3 (3.7)</td><td>NA</td></tr><tr><td>GLS, %</td><td>18.0 (17.0, 20.0)</td><td>18.0 (16.0, 19.5)</td><td>19.0 (17.0, 20.0)</td><td>0.040</td></tr><tr><td>GLS &#8804; 16%</td><td>31 (23.1)</td><td>19 (36.5)</td><td>12 (14.6)</td><td>0.036</td></tr><tr><td>GLS (APLAX), %</td><td>18.0 (16.0, 20.0)</td><td>17.0 (15.0, 19.0)</td><td>19.0 (17.0, 21.0)</td><td>0.023</td></tr><tr><td>GLS (A4C), %</td><td>18.0 (16.0, 20.0)</td><td>17.0 (15.0, 19.0)</td><td>18.0 (17.0, 20.0)</td><td>0.010</td></tr><tr><td>GLS (A2C), %</td><td>19.0 (17.0, 21.0)</td><td>19.0 (16.5, 20.0)</td><td>19.0 (17.0, 21.0)</td><td>0.279</td></tr><tr><td>GLS rate, 1/s</td><td>1.1 (1.0, 1.2)</td><td>1.1 (1.0, 1.2)</td><td>1.1 (1.0, 1.2)</td><td>0.995</td></tr><tr><td>GRS, %<sup><i>&#8727;&#8727;</i></sup></td><td>42.1 (31.1, 53.7)</td><td>42.1 (26.5, 55.2)</td><td>42.0 (31.9, 51.4)</td><td>0.843</td></tr><tr><td>GRS rate, 1/s<sup><i>&#8727;&#8727;</i></sup></td><td>2.2 (1.9, 2.7)</td><td>2.3 (1.9, 2.9)</td><td>2.2 (1.9, 2.7)</td><td>0.086</td></tr><tr><td>GCS, %<sup><i>&#8727;&#8727;</i></sup></td><td>17.3 (15.2, 19.7)</td><td>16.1 (14.5, 19.7)</td><td>17.6 (16.0, 19.7)</td><td>0.086</td></tr><tr><td>GCS rate, 1/s<sup><i>&#8727;&#8727;</i></sup></td><td>1.5 (1.3, 1.8)</td><td>1.5 (1.3, 1.9)</td><td>1.4 (1.3, 1.8)</td><td>0.058</td></tr><tr><td>LV mass/BSA, g/m<sup>2</sup></td><td>64.3 (55.9, 72.1)</td><td>63.1 (56.9, 69.2)</td><td>65.4 (55.6, 74.3)</td><td>0.099</td></tr><tr><td>Mitral <i>E</i>/<i>A</i> ratio</td><td>1.5 (1.2, 1.8)</td><td>1.3 (1.0, 1.6)</td><td>1.6 (1.3, 1.9)</td><td>0.005</td></tr><tr><td>Septal <i>e</i>&#8242;, cm/s</td><td>10.4 (8.8, 12.3)</td><td>9.3 (8.3, 11.2)</td><td>11.6 (9.8, 12.6)</td><td>0.003</td></tr></table>
<table><tr><td></td><td rowspan="2">Total (overall)</td><td>Mediastinal radiotherapy</td></tr><tr><td></td><td>Yes (n = 52)</td></tr><tr><td>Fractional shortening, %</td><td>33.3 (30.4, 36.1)</td><td>33.3 (30.6, 36.0)</td></tr><tr><td>Fractional shortening < 27%</td><td>7 (5.2)</td><td>5 (9.6)</td></tr><tr><td>Ejection fraction, %</td><td>61.1 (58.0, 63.6)</td><td>60.7 (57.6, 63.4)</td></tr><tr><td>Ejection fraction < 55%</td><td>8 (6.0)</td><td>5 (9.6)</td></tr><tr><td>GLS, %</td><td>18.0 (17.0, 20.0)</td><td>18.0 (16.0, 19.5)</td></tr><tr><td>GLS ≤ 16%</td><td>31 (23.1)</td><td>19 (36.5)</td></tr><tr><td>GLS (APLAX), %</td><td>18.0 (16.0, 20.0)</td><td>17.0 (15.0, 19.0)</td></tr><tr><td>GLS (A4C), %</td><td>18.0 (16.0, 20.0)</td><td>17.0 (15.0, 19.0)</td></tr><tr><td>GLS (A2C), %</td><td>19.0 (17.0, 21.0)</td><td>19.0 (16.5, 20.0)</td></tr><tr><td>GLS rate, 1/s</td><td>1.1 (1.0, 1.2)</td><td>1.1 (1.0, 1.2)</td></tr><tr><td>GRS, %∗∗</td><td>42.1 (31.1, 53.7)</td><td>42.1 (26.5, 55.2)</td></tr><tr><td>GRS rate, 1/s∗∗</td><td>2.2 (1.9, 2.7)</td><td>2.3 (1.9, 2.9)</td></tr><tr><td>GCS, %∗∗</td><td>17.3 (15.2, 19.7)</td><td>16.1 (14.5, 19.7)</td></tr><tr><td>GCS rate, 1/s∗∗</td><td>1.5 (1.3, 1.8)</td><td>1.5 (1.3, 1.9)</td></tr><tr><td>LV mass/BSA, g/m2</td><td>64.3 (55.9, 72.1)</td><td>63.1 (56.9, 69.2)</td></tr><tr><td>Mitral E/A ratio</td><td>1.5 (1.2, 1.8)</td><td>1.3 (1.0, 1.6)</td></tr><tr><td>Septal e′, cm/s</td><td>10.4 (8.8, 12.3)</td><td>9.3 (8.3, 11.2)</td></tr></table>
<table><tr><td>Mediastinal radiotherapy</td><td rowspan="2">p value†</td></tr><tr><td>No (n = 82)</td></tr><tr><td>33.1 (29.9, 36.1)</td><td>0.948</td></tr><tr><td>2 (2.4)</td><td>NA</td></tr><tr><td>61.2 (58.1, 64.0)</td><td>0.457</td></tr><tr><td>3 (3.7)</td><td>NA</td></tr><tr><td>19.0 (17.0, 20.0)</td><td>0.040</td></tr><tr><td>12 (14.6)</td><td>0.036</td></tr><tr><td>19.0 (17.0, 21.0)</td><td>0.023</td></tr><tr><td>18.0 (17.0, 20.0)</td><td>0.010</td></tr><tr><td>19.0 (17.0, 21.0)</td><td>0.279</td></tr><tr><td>1.1 (1.0, 1.2)</td><td>0.995</td></tr><tr><td>42.0 (31.9, 51.4)</td><td>0.843</td></tr><tr><td>2.2 (1.9, 2.7)</td><td>0.086</td></tr><tr><td>17.6 (16.0, 19.7)</td><td>0.086</td></tr><tr><td>1.4 (1.3, 1.8)</td><td>0.058</td></tr><tr><td>65.4 (55.6, 74.3)</td><td>0.099</td></tr><tr><td>1.6 (1.3, 1.9)</td><td>0.005</td></tr><tr><td>11.6 (9.8, 12.6)</td><td>0.003</td></tr></table>
04ad564a3a8a7961e19fa16784af275bd789bdb8ecdec718eb2397f525b4219c.png
complex
<table><tr><td rowspan="2">Days post CD instillation</td><td colspan="2">Reactors</td></tr><tr><td>PC (GC mL<sup>&#8722;1</sup>)</td><td>TDC (GC mL<sup>&#8722;1</sup>)</td></tr><tr><td>0.25</td><td>7.4</td><td>7.3</td></tr><tr><td>1</td><td>5.7</td><td>6.2</td></tr><tr><td>2</td><td>4.4</td><td>5.1</td></tr><tr><td>3</td><td>ND</td><td>ND</td></tr><tr><td>4</td><td>ND</td><td>ND</td></tr><tr><td>5</td><td>ND</td><td>ND</td></tr><tr><td>6</td><td>ND</td><td>ND</td></tr><tr><td>7</td><td>ND</td><td>ND</td></tr><tr><td>8</td><td>ND</td><td>ND</td></tr><tr><td>9</td><td>ND</td><td>6.0</td></tr><tr><td>10</td><td>ND</td><td>6.0</td></tr><tr><td>11</td><td>ND</td><td>6.4</td></tr><tr><td>12</td><td>ND</td><td>6.9</td></tr><tr><td>13</td><td>ND</td><td>7.1</td></tr><tr><td>14</td><td>ND</td><td>7.5</td></tr><tr><td>15</td><td>ND</td><td>7.8</td></tr><tr><td>16</td><td>ND</td><td>7.8</td></tr></table>
<table><tr><td rowspan="2">Days post CD instillation</td><td colspan="2">Reactors</td></tr><tr><td>PC (GC mL−1)</td><td>TDC (GC mL−1)</td></tr><tr><td>0.25</td><td>7.4</td><td>7.3</td></tr></table>
<table><tr><td>1</td><td>5.7</td><td>6.2</td></tr><tr><td>2</td><td>4.4</td><td>5.1</td></tr><tr><td>3</td><td>ND</td><td>ND</td></tr><tr><td>4</td><td>ND</td><td>ND</td></tr><tr><td>5</td><td>ND</td><td>ND</td></tr><tr><td>6</td><td>ND</td><td>ND</td></tr><tr><td>7</td><td>ND</td><td>ND</td></tr><tr><td>8</td><td>ND</td><td>ND</td></tr><tr><td>9</td><td>ND</td><td>6.0</td></tr><tr><td>10</td><td>ND</td><td>6.0</td></tr><tr><td>11</td><td>ND</td><td>6.4</td></tr><tr><td>12</td><td>ND</td><td>6.9</td></tr><tr><td>13</td><td>ND</td><td>7.1</td></tr><tr><td>14</td><td>ND</td><td>7.5</td></tr><tr><td>15</td><td>ND</td><td>7.8</td></tr><tr><td>16</td><td>ND</td><td>7.8</td></tr></table>
306a4d919d966ac66128a73273352d8321f92eb36fab23c2e4ef5099beb9f80e.png
simple
<table><tr><td>Variable</td><td>Pre-study</td><td>Post-study</td><td>Treatment interaction p-value</td></tr><tr><td>Saliva IgA concentration (&#956;g <sup>. </sup>mL<sup>-1</sup>)</td><td></td><td></td><td>0.461</td></tr><tr><td> Low</td><td>333 &#177; 181</td><td>314 &#177; 152</td><td></td></tr><tr><td> Medium</td><td>292 &#177; 143</td><td>302 &#177; 151</td><td></td></tr><tr><td> High</td><td>315 &#177; 159</td><td>289 &#177; 158</td><td></td></tr><tr><td>Saliva protein IgA concentration (&#956;g <sup>. </sup>mg<sup>-1</sup>)</td><td></td><td></td><td>0.675</td></tr><tr><td> Low</td><td>471 &#177; 162</td><td>484 &#177; 156</td><td></td></tr><tr><td> Medium</td><td>444 &#177; 170</td><td>419 &#177; 155</td><td></td></tr><tr><td> High</td><td>535 &#177; 224</td><td>499 &#177; 187</td><td></td></tr><tr><td>Saliva IgA secretion rate (&#956;g <sup>. </sup>min<sup>-1</sup>)</td><td></td><td></td><td>0.476</td></tr><tr><td> Low</td><td>173 &#177; 135</td><td>220 &#177; 163</td><td></td></tr><tr><td> Medium</td><td>185 &#177; 118</td><td>233 &#177; 129</td><td></td></tr><tr><td> High</td><td>207 &#177; 118</td><td>212 &#177; 74</td><td></td></tr></table>
<table><tr><td>Variable</td><td>Pre-study</td><td>Post-study</td><td>Treatment interaction p-value</td></tr><tr><td>Saliva IgA concentration (μg . mL-1)</td><td></td><td></td><td>0.461</td></tr><tr><td>Low</td><td>333 ± 181</td><td>314 ± 152</td><td></td></tr><tr><td>Medium</td><td>292 ± 143</td><td>302 ± 151</td><td></td></tr><tr><td>High</td><td>315 ± 159</td><td>289 ± 158</td><td></td></tr><tr><td>Saliva protein IgA concentration (μg . mg-1)</td><td></td><td></td><td>0.675</td></tr><tr><td>Low</td><td>471 ± 162</td><td>484 ± 156</td><td></td></tr></table>
<table><tr><td>Medium</td><td>444 ± 170</td><td>419 ± 155</td><td></td></tr><tr><td>High</td><td>535 ± 224</td><td>499 ± 187</td><td></td></tr><tr><td>Saliva IgA secretion rate (μg . min-1)</td><td></td><td></td><td>0.476</td></tr><tr><td>Low</td><td>173 ± 135</td><td>220 ± 163</td><td></td></tr><tr><td>Medium</td><td>185 ± 118</td><td>233 ± 129</td><td></td></tr><tr><td>High</td><td>207 ± 118</td><td>212 ± 74</td><td></td></tr></table>
d11797de34222626e13b6073b735c281199da49a11b4e53384c522cac2ed5118.png
complex
<table><tr><td colspan="2">Variable</td><td colspan="3">Univariate analysis</td><td colspan="3">Multivariate analysis</td></tr><tr><td></td><td></td><td>OR</td><td>95% CI</td><td>p-value</td><td>Adjusted OR</td><td>95% CI</td><td>p-value</td></tr><tr><td colspan="2">Age, per 10 years older</td><td>2.93</td><td>1.24-6.91</td><td>0.014</td><td>3.07</td><td>1.22-7.74</td><td>0.017</td></tr><tr><td colspan="2">Female</td><td>0.96</td><td>0.20-4.52</td><td>0.073</td><td>2.22</td><td>0.33-14.7</td><td>0.409</td></tr><tr><td colspan="2">Body mass index, per 5 kg/m<sup>2 </sup>increase</td><td>1.71</td><td>0.62-4.69</td><td>0.300</td><td></td><td></td><td></td></tr><tr><td colspan="2">Non-white ethnicity</td><td>0.22</td><td>0.04-1.55</td><td>0.092</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Risk</td><td>Men who have sex with men</td><td>1*</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td></td><td>Heterosexual</td><td>0.25</td><td>0.15-1.14</td><td>0.134</td><td>-</td><td>-</td><td>-</td></tr><tr><td></td><td>Intravenous drug use</td><td>0.67</td><td>0.13-3.45</td><td>0.629</td><td>-</td><td>-</td><td>-</td></tr><tr><td colspan="2">Prior AIDS-defining condition</td><td>3.35</td><td>0.87-13.0</td><td>0.080</td><td>3.02</td><td>0.56-16.2</td><td>0.198</td></tr><tr><td colspan="2">Antiretroviral treatment</td><td>1.24</td><td>0.31-4.96</td><td>0.764</td><td>0.71</td><td>0.13-4.01</td><td>0.699</td></tr><tr><td colspan="2">CD4 cell count, per 50 cells/&#956;L increase</td><td>0.86</td><td>0.70-1.04</td><td>0.123</td><td>-</td><td>-</td><td>-</td></tr><tr><td colspan="2">CD4 cell count &#8805;200 versus &lt; 200 cells/&#956;L</td><td>0.41</td><td>0.11-1.46</td><td>0.168</td><td>0.46</td><td>0.10-2.05</td><td>0.306</td></tr><tr><td colspan="2">CD8 cell count, per 50 cells/&#956;L increase</td><td>1.01</td><td>0.96-1.05</td><td>0.740</td><td>-</td><td>-</td><td>-</td></tr><tr><td colspan="2">Extrapulmonary versus pulmonary TB</td><td>1.22</td><td>0.34-4.32</td><td>0.759</td><td>-</td><td>-</td><td>-</td></tr></table>
<table><tr><td colspan="2">Variable</td><td colspan="3">Univariate analysis</td><td colspan="3">Multivariate analysis</td></tr><tr><td></td><td></td><td>OR</td><td>95% CI</td><td>p-value</td><td>Adjusted OR</td><td>95% CI</td><td>p-value</td></tr></table>
<table><tr><td colspan="2">Age, per 10 years older</td><td>2.93</td><td>1.24-6.91</td><td>0.014</td><td>3.07</td><td>1.22-7.74</td><td>0.017</td></tr><tr><td colspan="2">Female</td><td>0.96</td><td>0.20-4.52</td><td>0.073</td><td>2.22</td><td>0.33-14.7</td><td>0.409</td></tr><tr><td colspan="2">Body mass index, per 5 kg/m2 increase</td><td>1.71</td><td>0.62-4.69</td><td>0.300</td><td></td><td></td><td></td></tr><tr><td colspan="2">Non-white ethnicity</td><td>0.22</td><td>0.04-1.55</td><td>0.092</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Risk</td><td>Men who have sex with men</td><td>1*</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td></td><td>Heterosexual</td><td>0.25</td><td>0.15-1.14</td><td>0.134</td><td>-</td><td>-</td><td>-</td></tr><tr><td></td><td>Intravenous drug use</td><td>0.67</td><td>0.13-3.45</td><td>0.629</td><td>-</td><td>-</td><td>-</td></tr><tr><td colspan="2">Prior AIDS-defining condition</td><td>3.35</td><td>0.87-13.0</td><td>0.080</td><td>3.02</td><td>0.56-16.2</td><td>0.198</td></tr><tr><td colspan="2">Antiretroviral treatment</td><td>1.24</td><td>0.31-4.96</td><td>0.764</td><td>0.71</td><td>0.13-4.01</td><td>0.699</td></tr><tr><td colspan="2">CD4 cell count, per 50 cells/μL increase</td><td>0.86</td><td>0.70-1.04</td><td>0.123</td><td>-</td><td>-</td><td>-</td></tr><tr><td colspan="2">CD4 cell count ≥200 versus < 200 cells/μL</td><td>0.41</td><td>0.11-1.46</td><td>0.168</td><td>0.46</td><td>0.10-2.05</td><td>0.306</td></tr><tr><td colspan="2">CD8 cell count, per 50 cells/μL increase</td><td>1.01</td><td>0.96-1.05</td><td>0.740</td><td>-</td><td>-</td><td>-</td></tr><tr><td colspan="2">Extrapulmonary versus pulmonary TB</td><td>1.22</td><td>0.34-4.32</td><td>0.759</td><td>-</td><td>-</td><td>-</td></tr></table>
3907abfe91ac5fa73a5914f947f83f1e4c7ce718112fa945f64218713e6f61b2.png
complex
<table><tr><td></td><td></td><td></td><td colspan="2">Gene set = <i>G</i></td><td colspan="3">Centroid set = <i>C</i></td></tr><tr><td>Data set</td><td><i>S</i></td><td><i>D</i></td><td><i>j</i></td><td>Description</td><td><i>c</i><sub><i>j0</i></sub></td><td><i>c</i><sub><i>j1</i></sub></td><td><i>v</i><sub><i>jP</i></sub></td></tr><tr><td>Colon cancer</td><td>Swirl</td><td>1</td><td>1772</td><td>myosin heavy chain</td><td>44</td><td>125</td><td>61</td></tr><tr><td></td><td></td><td></td><td>249</td><td>desmin</td><td>1958</td><td>467</td><td>793</td></tr><tr><td></td><td></td><td></td><td>1582</td><td>p cadherin</td><td>53</td><td>174</td><td>83</td></tr><tr><td></td><td></td><td></td><td>1423</td><td>myosin reg light chain 2</td><td>763</td><td>196</td><td>213</td></tr><tr><td></td><td></td><td></td><td>745</td><td>ORF, xq terminal portion</td><td>188</td><td>226</td><td>179</td></tr><tr><td>Leukemia 1</td><td>Swirl</td><td>1</td><td>3532</td><td>glutathione S-transferase</td><td>37</td><td>1460</td><td>569</td></tr><tr><td>Medulloblastoma</td><td>Swirl</td><td>1</td><td>977</td><td>zinc finger protein HZfq</td><td>38</td><td>-102</td><td>87</td></tr><tr><td>Prostate cancer</td><td>Swirl</td><td>1</td><td>8850</td><td>cDNA DKFZp564A072</td><td>24</td><td>215</td><td>110</td></tr><tr><td>Leukemia 2</td><td>Swirl</td><td>1</td><td>8828</td><td>HLA class II alpha</td><td>785</td><td>41345</td><td>7280</td></tr></table>
<table><tr><td></td><td></td><td></td><td colspan="2">Gene set = G</td><td colspan="3">Centroid set = C</td></tr><tr><td>Data set</td><td>S</td><td>D</td><td>j</td><td>Description</td><td>cj0</td><td>cj1</td><td>vjP</td></tr><tr><td>Colon cancer</td><td>Swirl</td><td>1</td><td>1772</td><td>myosin heavy chain</td><td>44</td><td>125</td><td>61</td></tr><tr><td></td><td></td><td></td><td>249</td><td>desmin</td><td>1958</td><td>467</td><td>793</td></tr><tr><td></td><td></td><td></td><td>1582</td><td>p cadherin</td><td>53</td><td>174</td><td>83</td></tr><tr><td></td><td></td><td></td><td>1423</td><td>myosin reg light chain 2</td><td>763</td><td>196</td><td>213</td></tr></table>
<table><tr><td></td><td></td><td></td><td colspan="2">Gene set = G</td><td colspan="3">Centroid set = C</td></tr><tr><td>Data set</td><td>S</td><td>D</td><td>j</td><td>Description</td><td>cj0</td><td>cj1</td><td>vjP</td></tr><tr><td></td><td></td><td></td><td>745</td><td>ORF, xq terminal portion</td><td>188</td><td>226</td><td>179</td></tr><tr><td>Leukemia 1</td><td>Swirl</td><td>1</td><td>3532</td><td>glutathione S-transferase</td><td>37</td><td>1460</td><td>569</td></tr><tr><td>Medulloblastoma</td><td>Swirl</td><td>1</td><td>977</td><td>zinc finger protein HZfq</td><td>38</td><td>-102</td><td>87</td></tr><tr><td>Prostate cancer</td><td>Swirl</td><td>1</td><td>8850</td><td>cDNA DKFZp564A072</td><td>24</td><td>215</td><td>110</td></tr><tr><td>Leukemia 2</td><td>Swirl</td><td>1</td><td>8828</td><td>HLA class II alpha</td><td>785</td><td>41345</td><td>7280</td></tr></table>
f0a4eb571ea692af623b3aeb4a6896dc73d8537e46611ae2cac1306396f9dd6c.png
complex
<table><tr><td> </td><td colspan="2">Genotypes</td><td><i>p</i>value</td></tr><tr><td>(n=1394,100%)</td><td>AA(n=1223)</td><td>AG+GG(n=171)</td><td> </td></tr><tr><td>Age(years)</td><td>59.9 &#177; 10.1</td><td>59.5 &#177; 10.8</td><td>0.62</td></tr><tr><td>Gender,female(%)</td><td>40.6</td><td>37.4</td><td>0.42</td></tr><tr><td>Race/color(%)</td><td> </td><td> </td><td> </td></tr><tr><td>White</td><td>65.0</td><td>74.9</td><td> </td></tr><tr><td>Intermediate</td><td>29.8</td><td>23.4</td><td>0.02</td></tr><tr><td>Black</td><td>5.2</td><td>1.8</td><td> </td></tr><tr><td>Hypertension(%)</td><td>70.0</td><td>68.4</td><td>0.68</td></tr><tr><td>Diabetes(%)</td><td>31.2</td><td>27.5</td><td>0.33</td></tr><tr><td>Hyperlipidemia(%)</td><td>57.2</td><td>71.3</td><td>0.002</td></tr><tr><td>Statin use(%)</td><td>28.0</td><td>30.5</td><td>0.61</td></tr><tr><td>Smokers(%)</td><td>35.6</td><td>38.0</td><td>0.44</td></tr><tr><td>Body mass index(Kg/m<sup>2</sup>)</td><td>27.7 &#177; 4.8</td><td>27.6 &#177; 4.9</td><td>0.99</td></tr><tr><td>Total cholesterol(mg/dL)</td><td>228 &#177; 49</td><td>237 &#177; 46</td><td>0.05</td></tr><tr><td>LDL-C(mg/dL)</td><td>147 &#177; 44</td><td>155 &#177; 39</td><td>0.11</td></tr><tr><td>HDL-C(mg/dL)</td><td>42 &#177; 12</td><td>42 &#177; 10</td><td>0.82</td></tr><tr><td>Triglycerides(mg/dL)</td><td>183 &#177; 130</td><td>179 &#177; 108</td><td>0.75</td></tr><tr><td>Systolic blood pressure(mmHg)</td><td>149 &#177; 34</td><td>152 &#177; 39</td><td>0.61</td></tr><tr><td>Diastolic blood pressure(mmHg)</td><td>82 &#177; 15</td><td>84 &#177; 15</td><td>0.29</td></tr><tr><td>Ejection fraction(%)</td><td>60.6 &#177; 14.4</td><td>56.8 &#177; 17.7</td><td>0.07</td></tr><tr><td>Coronary lesions(%)</td><td>79.6</td><td>88.9</td><td>0.004</td></tr><tr><td>Extension score</td><td>2.1 &#177; 1.6</td><td>2.6 &#177; 1.7</td><td>&lt;0.001</td></tr><tr><td>Severity score</td><td>1.5 &#177; 1.2</td><td>1.9 &#177; 1.3</td><td>&lt;0.001</td></tr><tr><td>Gensini score</td><td>19.7 &#177; 28.2</td><td>25.7 &#177; 32.0</td><td>0.05</td></tr></table>
<table><tr><td></td><td colspan="2">Genotypes</td><td>pvalue</td></tr><tr><td>(n=1394,100%)</td><td>AA(n=1223)</td><td>AG+GG(n=171)</td><td></td></tr><tr><td>Age(years)</td><td>59.9 ± 10.1</td><td>59.5 ± 10.8</td><td>0.62</td></tr><tr><td>Gender,female(%)</td><td>40.6</td><td>37.4</td><td>0.42</td></tr><tr><td>Race/color(%)</td><td></td><td></td><td></td></tr><tr><td>White</td><td>65.0</td><td>74.9</td><td></td></tr><tr><td>Intermediate</td><td>29.8</td><td>23.4</td><td>0.02</td></tr><tr><td>Black</td><td>5.2</td><td>1.8</td><td></td></tr><tr><td>Hypertension(%)</td><td>70.0</td><td>68.4</td><td>0.68</td></tr></table>
<table><tr><td></td><td colspan="2">Genotypes</td><td>pvalue</td></tr><tr><td>(n=1394,100%)</td><td>AA(n=1223)</td><td>AG+GG(n=171)</td><td></td></tr><tr><td>Diabetes(%)</td><td>31.2</td><td>27.5</td><td>0.33</td></tr><tr><td>Hyperlipidemia(%)</td><td>57.2</td><td>71.3</td><td>0.002</td></tr><tr><td>Statin use(%)</td><td>28.0</td><td>30.5</td><td>0.61</td></tr><tr><td>Smokers(%)</td><td>35.6</td><td>38.0</td><td>0.44</td></tr><tr><td>Body mass index(Kg/m2)</td><td>27.7 ± 4.8</td><td>27.6 ± 4.9</td><td>0.99</td></tr><tr><td>Total cholesterol(mg/dL)</td><td>228 ± 49</td><td>237 ± 46</td><td>0.05</td></tr><tr><td>LDL-C(mg/dL)</td><td>147 ± 44</td><td>155 ± 39</td><td>0.11</td></tr><tr><td>HDL-C(mg/dL)</td><td>42 ± 12</td><td>42 ± 10</td><td>0.82</td></tr><tr><td>Triglycerides(mg/dL)</td><td>183 ± 130</td><td>179 ± 108</td><td>0.75</td></tr><tr><td>Systolic blood pressure(mmHg)</td><td>149 ± 34</td><td>152 ± 39</td><td>0.61</td></tr><tr><td>Diastolic blood pressure(mmHg)</td><td>82 ± 15</td><td>84 ± 15</td><td>0.29</td></tr><tr><td>Ejection fraction(%)</td><td>60.6 ± 14.4</td><td>56.8 ± 17.7</td><td>0.07</td></tr><tr><td>Coronary lesions(%)</td><td>79.6</td><td>88.9</td><td>0.004</td></tr><tr><td>Extension score</td><td>2.1 ± 1.6</td><td>2.6 ± 1.7</td><td><0.001</td></tr><tr><td>Severity score</td><td>1.5 ± 1.2</td><td>1.9 ± 1.3</td><td><0.001</td></tr><tr><td>Gensini score</td><td>19.7 ± 28.2</td><td>25.7 ± 32.0</td><td>0.05</td></tr></table>
d279aa5ffa2b2e761b34544e5f211e74019e93ac1c4a06ffe0bb2aab8879a91c.png
complex
<table><tr><td rowspan="2">Codes</td><td rowspan="2">Oil (%)</td><td>Surfactant and cosurfactant (3 : 1)</td><td rowspan="2">Water (%)</td><td>Permeation flux</td></tr><tr><td>(Tween 80 and isopropyl alcohol, %)</td><td>(<i>&#956;</i>g/cm<sup>2</sup>/hour)<sup>b</sup></td></tr><tr><td></td><td>Oleic acid</td><td></td><td></td><td></td></tr><tr><td>F-1</td><td>25</td><td>60</td><td>15</td><td>0.090 &#177; 0.001</td></tr><tr><td>F-2</td><td>20</td><td>65</td><td>15</td><td>0.146 &#177; 0.001</td></tr><tr><td>F-3</td><td>15</td><td>75</td><td>10</td><td>0.186 &#177; 0.002</td></tr><tr><td>F-4</td><td>10</td><td>82</td><td>8</td><td>0.199 &#177; 0.002</td></tr><tr><td></td><td>Isopropyl myristate</td><td></td><td></td><td></td></tr><tr><td>F-5</td><td>25</td><td>60</td><td>15</td><td>0.229 &#177; 0.002</td></tr><tr><td>F-6</td><td>20</td><td>65</td><td>15</td><td>0.233 &#177; 0.002</td></tr><tr><td>F-7</td><td>15</td><td>75</td><td>10</td><td>0.257 &#177; 0.003</td></tr><tr><td>F-8</td><td>10</td><td>82</td><td>8</td><td>0.284 &#177; 0.003</td></tr></table>
<table><tr><td>C</td><td></td><td></td><td>Wate</td><td>Perme</td></tr></table>
<table><tr><td rowspan="2">odes</td><td rowspan="2">Oil (%)</td><td>Surfactant and cosurfactant (3 : 1)</td><td rowspan="2">r (%)</td><td>ation flux</td></tr><tr><td>(Tween 80 and isopropyl alcohol, %)</td><td>(μg/cm2/hour)b</td></tr><tr><td></td><td>Oleic acid</td><td></td><td></td><td></td></tr><tr><td>F-1</td><td>25</td><td>60</td><td>15</td><td>0.090 ± 0.001</td></tr><tr><td>F-2</td><td>20</td><td>65</td><td>15</td><td>0.146 ± 0.001</td></tr><tr><td>F-3</td><td>15</td><td>75</td><td>10</td><td>0.186 ± 0.002</td></tr><tr><td>F-4</td><td>10</td><td>82</td><td>8</td><td>0.199 ± 0.002</td></tr><tr><td></td><td>Isopropyl myristate</td><td></td><td></td><td></td></tr><tr><td>F-5</td><td>25</td><td>60</td><td>15</td><td>0.229 ± 0.002</td></tr><tr><td>F-6</td><td>20</td><td>65</td><td>15</td><td>0.233 ± 0.002</td></tr><tr><td>F-7</td><td>15</td><td>75</td><td>10</td><td>0.257 ± 0.003</td></tr><tr><td>F-8</td><td>10</td><td>82</td><td>8</td><td>0.284 ± 0.003</td></tr></table>
ca35fd26ec0bfdac998424c742f10b914f0c9c34ff5c4c32db13a8f1dce0c9dc.png
complex
<table><tr><td colspan="2"><i>n</i> = 30</td><td>30/15</td><td>Valsalva</td><td>E/I</td><td>VLF</td><td>LF</td><td>HF</td><td>Total espectrum</td></tr><tr><td rowspan="2">Age</td><td>r</td><td>0.155</td><td>&#8722;0.245</td><td>&#8722;0.190</td><td>&#8722;0.029</td><td>&#8722;0.128</td><td>&#8722;0.275</td><td>&#8722;0.181</td></tr><tr><td>p</td><td>0.412</td><td>0.191</td><td>0.313</td><td>0.876</td><td>0.499</td><td>0.142</td><td>0.337</td></tr><tr><td rowspan="2">BMI</td><td>r</td><td>0.034</td><td>&#8722;0.182</td><td>&#8722;0.447</td><td>&#8722;0.201</td><td>&#8722;0.315</td><td>&#8722;0.436</td><td>&#8722;0.405</td></tr><tr><td>p</td><td>0.860</td><td>0.335</td><td><i>0.013</i></td><td>0.287</td><td>0.090</td><td><i>0.016</i></td><td><i>0.026</i></td></tr><tr><td rowspan="2">Fasting glycemia</td><td>r</td><td>&#8722;0.204</td><td>&#8722;0.184</td><td>&#8722;0.253</td><td>&#8722;0.488</td><td>&#8722;0.313</td><td>&#8722;0.259</td><td>&#8722;0.311</td></tr><tr><td>p</td><td>0.280</td><td>0.330</td><td>0.178</td><td><i>0.006</i></td><td>0.093</td><td>0.167</td><td>0.095</td></tr><tr><td rowspan="2">A1c</td><td>r</td><td>&#8722;0.400</td><td>&#8722;0.190</td><td>&#8722;0.310</td><td>&#8722;0.460</td><td>&#8722;0.525</td><td>&#8722;0.326</td><td>&#8722;0.434</td></tr><tr><td>p</td><td><i>0.029</i></td><td>0.315</td><td>0.096</td><td><i>0.010</i></td><td><i>0.003</i></td><td>0.079</td><td><i>0.017</i></td></tr><tr><td rowspan="2">Basal Insulin</td><td>r</td><td>&#8722;0.432</td><td>&#8722;0.358</td><td>&#8722;0.610</td><td>&#8722;0.501</td><td>&#8722;0.590</td><td>&#8722;0.645</td><td>&#8722;0.583</td></tr><tr><td>p</td><td><i>0.017</i></td><td>0.052</td><td><i>0.000</i></td><td><i>0.005</i></td><td><i>0.001</i></td><td><i>0.000</i></td><td><i>0.001</i></td></tr><tr><td rowspan="2">HOMA-IR</td><td>r</td><td>&#8722;0.439</td><td>&#8722;0.362</td><td>&#8722;0.591</td><td>&#8722;0.543</td><td>&#8722;0.561</td><td>&#8722;0.598</td><td>&#8722;0.555</td></tr><tr><td>p</td><td><i>0.015</i></td><td><i>0.049</i></td><td><i>0.001</i></td><td><i>0.002</i></td><td><i>0.001</i></td><td><i>0.000</i></td><td><i>0.001</i></td></tr><tr><td rowspan="2">Leptin</td><td>r</td><td>0.537</td><td>0.312</td><td>0.291</td><td>0.338</td><td>0.339</td><td>0.379</td><td>0.364</td></tr><tr><td>p</td><td><i>0.002</i></td><td>0.094</td><td>0.119</td><td>0.067</td><td>0.067</td><td><i>0.039</i></td><td><i>0.048</i></td></tr><tr><td rowspan="2">ACR</td><td>r</td><td>&#8722;0.514</td><td>&#8722;0.200</td><td>&#8722;0.356</td><td>&#8722;0.627</td><td>&#8722;0.374</td><td>&#8722;0.276</td><td>&#8722;0.477</td></tr><tr><td>p</td><td><i>0.004</i></td><td>0.289</td><td>0.053</td><td><i>0.000</i></td><td><i>0.042</i></td><td>0.140</td><td><i>0.008</i></td></tr><tr><td rowspan="2">Total cholesterol</td><td>r</td><td>&#8722;0.259</td><td>&#8722;0.021</td><td>&#8722;0.262</td><td>&#8722;0.103</td><td>&#8722;0.193</td><td>&#8722;0.145</td><td>&#8722;0.156</td></tr><tr><td>p</td><td>0.167</td><td>0.913</td><td>0.161</td><td>0.589</td><td>0.306</td><td>0.444</td><td>0.411</td></tr><tr><td rowspan="2">HDL-c</td><td>r</td><td>0.366</td><td>0.248</td><td>0.301</td><td>0.313</td><td>0.198</td><td>0.199</td><td>0.221</td></tr><tr><td>p</td><td><i>0.046</i></td><td>0.186</td><td>0.106</td><td>0.092</td><td>0.294</td><td>0.292</td><td>0.240</td></tr><tr><td rowspan="2">LDL-c</td><td>r</td><td>&#8722;0.259</td><td>0.058</td><td>&#8722;0.214</td><td>&#8722;0.027</td><td>&#8722;0.079</td><td>&#8722;0.123</td><td>&#8722;0.077</td></tr><tr><td>p</td><td>0.184</td><td>0.769</td><td>0.275</td><td>0.892</td><td>0.688</td><td>0.532</td><td>0.698</td></tr><tr><td rowspan="2">Triglycerides</td><td>r</td><td>&#8722;0.632</td><td>&#8722;0.261</td><td>&#8722;0.674</td><td>&#8722;0.470</td><td>&#8722;0.548</td><td>&#8722;0.420</td><td>&#8722;0.539</td></tr><tr><td>p</td><td><i>0.000</i></td><td>0.163</td><td><i>0.000</i></td><td><i>0.009</i></td><td><i>0.002</i></td><td><i>0.021</i></td><td><i>0.002</i></td></tr></table>
<table><tr><td colspan="2">n = 30</td><td>30/15</td><td>Valsalva</td><td>E/I</td><td>VLF</td><td>LF</td><td>HF</td><td>Total espectrum</td></tr><tr><td rowspan="2">Age</td><td>r</td><td>0.155</td><td>−0.245</td><td>−0.190</td><td>−0.029</td><td>−0.128</td><td>−0.275</td><td>−0.181</td></tr><tr><td>p</td><td>0.412</td><td>0.191</td><td>0.313</td><td>0.876</td><td>0.499</td><td>0.142</td><td>0.337</td></tr><tr><td rowspan="2">BMI</td><td>r</td><td>0.034</td><td>−0.182</td><td>−0.447</td><td>−0.201</td><td>−0.315</td><td>−0.436</td><td>−0.405</td></tr><tr><td>p</td><td>0.860</td><td>0.335</td><td>0.013</td><td>0.287</td><td>0.090</td><td>0.016</td><td>0.026</td></tr><tr><td rowspan="2">Fasting glycemia</td><td>r</td><td>−0.204</td><td>−0.184</td><td>−0.253</td><td>−0.488</td><td>−0.313</td><td>−0.259</td><td>−0.311</td></tr><tr><td>p</td><td>0.280</td><td>0.330</td><td>0.178</td><td>0.006</td><td>0.093</td><td>0.167</td><td>0.095</td></tr><tr><td rowspan="2">A1c</td><td>r</td><td>−0.400</td><td>−0.190</td><td>−0.310</td><td>−0.460</td><td>−0.525</td><td>−0.326</td><td>−0.434</td></tr><tr><td>p</td><td>0.029</td><td>0.315</td><td>0.096</td><td>0.010</td><td>0.003</td><td>0.079</td><td>0.017</td></tr><tr><td rowspan="2">Basal Insulin</td><td>r</td><td>−0.432</td><td>−0.358</td><td>−0.610</td><td>−0.501</td><td>−0.590</td><td>−0.645</td><td>−0.583</td></tr><tr><td>p</td><td>0.017</td><td>0.052</td><td>0.000</td><td>0.005</td><td>0.001</td><td>0.000</td><td>0.001</td></tr><tr><td rowspan="2"></td><td>r</td><td>−0.439</td><td>−0.362</td><td>−0.591</td><td>−0.543</td><td>−0.561</td><td>−0.598</td><td>−0.555</td></tr><tr><td>p</td><td>0.01</td><td>0.</td><td>0.0</td><td>0.0</td><td>0</td><td>0.</td><td>0.00</td></tr></table>
<table><tr><td colspan="2">n = 30</td><td>30/15</td><td>Valsalva</td><td>E/I</td><td>VLF</td><td>LF</td><td>HF</td><td>Total espectrum</td></tr><tr><td>HOMA-IR</td><td></td><td>5</td><td>049</td><td>01</td><td>02</td><td>.001</td><td>000</td><td>1</td></tr><tr><td rowspan="2">Leptin</td><td>r</td><td>0.537</td><td>0.312</td><td>0.291</td><td>0.338</td><td>0.339</td><td>0.379</td><td>0.364</td></tr><tr><td>p</td><td>0.002</td><td>0.094</td><td>0.119</td><td>0.067</td><td>0.067</td><td>0.039</td><td>0.048</td></tr><tr><td rowspan="2">ACR</td><td>r</td><td>−0.514</td><td>−0.200</td><td>−0.356</td><td>−0.627</td><td>−0.374</td><td>−0.276</td><td>−0.477</td></tr><tr><td>p</td><td>0.004</td><td>0.289</td><td>0.053</td><td>0.000</td><td>0.042</td><td>0.140</td><td>0.008</td></tr><tr><td rowspan="2">Total cholesterol</td><td>r</td><td>−0.259</td><td>−0.021</td><td>−0.262</td><td>−0.103</td><td>−0.193</td><td>−0.145</td><td>−0.156</td></tr><tr><td>p</td><td>0.167</td><td>0.913</td><td>0.161</td><td>0.589</td><td>0.306</td><td>0.444</td><td>0.411</td></tr><tr><td rowspan="2">HDL-c</td><td>r</td><td>0.366</td><td>0.248</td><td>0.301</td><td>0.313</td><td>0.198</td><td>0.199</td><td>0.221</td></tr><tr><td>p</td><td>0.046</td><td>0.186</td><td>0.106</td><td>0.092</td><td>0.294</td><td>0.292</td><td>0.240</td></tr><tr><td rowspan="2">LDL-c</td><td>r</td><td>−0.259</td><td>0.058</td><td>−0.214</td><td>−0.027</td><td>−0.079</td><td>−0.123</td><td>−0.077</td></tr><tr><td>p</td><td>0.184</td><td>0.769</td><td>0.275</td><td>0.892</td><td>0.688</td><td>0.532</td><td>0.698</td></tr><tr><td rowspan="2">Triglycerides</td><td>r</td><td>−0.632</td><td>−0.261</td><td>−0.674</td><td>−0.470</td><td>−0.548</td><td>−0.420</td><td>−0.539</td></tr><tr><td>p</td><td>0.000</td><td>0.163</td><td>0.000</td><td>0.009</td><td>0.002</td><td>0.021</td><td>0.002</td></tr></table>
f07700d7455421c93cb10c8003706608892cf96cbd2dcbfafafd3da1d29e1cc7.png
simple
<table><tr><td>Features analysed</td><td><i>P. aeruginosa</i> pangenome</td></tr><tr><td>Genomes</td><td>181</td></tr><tr><td>Total genes</td><td>1,117,803</td></tr><tr><td>Average genome size</td><td>6175 genes</td></tr><tr><td>Pangenome size (non-redundant genes)</td><td>16,820</td></tr><tr><td>Core genome</td><td>2503 genes</td></tr><tr><td>Accessory genome</td><td>9108 genes</td></tr><tr><td>Unique genes</td><td>5209</td></tr><tr><td>Average unique genes/strain</td><td>16</td></tr><tr><td>Gene families under positive selection</td><td>233</td></tr></table>
<table><tr><td>Features analysed</td></tr><tr><td>Genomes</td></tr><tr><td>Total genes</td></tr><tr><td>Average genome size</td></tr><tr><td>Pangenome size (non-redundant genes)</td></tr><tr><td>Core genome</td></tr><tr><td>Accessory genome</td></tr><tr><td>Unique genes</td></tr><tr><td>Average unique genes/strain</td></tr><tr><td>Gene families under positive selection</td></tr></table>
<table><tr><td>P. aeruginosa pangenome</td></tr><tr><td>181</td></tr><tr><td>1,117,803</td></tr><tr><td>6175 genes</td></tr><tr><td>16,820</td></tr><tr><td>2503 genes</td></tr><tr><td>9108 genes</td></tr><tr><td>5209</td></tr><tr><td>16</td></tr><tr><td>233</td></tr></table>
571f009b855efaa36d01012a1f0308a1bfe5c40397c3c55daed21138231cd50a.png
complex
<table><tr><td> </td><td colspan="3">Whole sample</td><td colspan="3">18- 30 years old sample</td></tr><tr><td>Support</td><td>PCOS (%)</td><td>Control (%)</td><td><i>&#935;</i><sup><i>2 </i></sup><i>(p)</i></td><td>PCOS (%)</td><td>Control (%)</td><td><i>&#935;</i><sup><i>2 </i></sup><i>(pcp</i></td></tr><tr><td>Husband/partner<sup><i>a</i></sup></td><td>116 (76)</td><td>37 (58)</td><td>2.42 (0.120)</td><td>52 (74)</td><td>14 (42)</td><td>8.83 (0.003)</td></tr><tr><td>Friends</td><td>93 (61)</td><td>30 (47)</td><td>1.82 (0.178)</td><td>46 (66)</td><td>22 (67)</td><td>0.01 (0.931)</td></tr><tr><td>Parents</td><td>86 (56)</td><td>24 (38)</td><td>3.45 (0.063)</td><td>49 (70)</td><td>21 (64)</td><td>0.27 (0.604)</td></tr><tr><td>Other family*</td><td>77 (50)</td><td>19 (30)</td><td>5.00 (0.025)</td><td>42 (60)</td><td>14 (42)</td><td>3.18 (0.075)</td></tr><tr><td>Children*<sup><i>a</i></sup></td><td>65 (42)</td><td>16 (25)</td><td>4.31 (0.038)</td><td>15 (21)</td><td>2 (6)</td><td>8.33 (0.004)</td></tr><tr><td>Health care profs</td><td>42 (27)</td><td>14 (22)</td><td>0.51 (0.475)</td><td>22 (31)</td><td>8 (24)</td><td>0.89 (0.345)</td></tr><tr><td>Co-workers</td><td>40 (26)</td><td>13 (20)</td><td>0.78 (0.376)</td><td>24 (34)</td><td>9 (27)</td><td>0.80 (0.370)</td></tr><tr><td>Physical activity instructors</td><td>40 (26)</td><td>14 (22)</td><td>0.33 (0.564)</td><td>25 (36)</td><td>10 (30)</td><td>0.55 (0.460)</td></tr><tr><td>Myself</td><td>9 (6)</td><td>4 (6)</td><td>0.00 (1.00)</td><td>5 (7)</td><td>4 (12)</td><td>1.32 (0.251)</td></tr><tr><td>Other</td><td>4 (3)</td><td>0 (0)</td><td>-</td><td>2 (3)</td><td>0 (0)</td><td>-</td></tr><tr><td>Exercise friends/team</td><td>2 (1)</td><td>2 (3)</td><td>-</td><td>2 (3)</td><td>0 (0)</td><td>-</td></tr><tr><td>No one</td><td>1 (1)</td><td>1 (2)</td><td>-</td><td>0 (0)</td><td>1 (3)</td><td>-</td></tr><tr><td>Pets</td><td>1 (1)</td><td>1 (2)</td><td>-</td><td>1 (1)</td><td>0 (0)</td><td>-</td></tr></table>
<table><tr><td></td><td colspan="3">Whole sample</td><td colspan="3">18- 30 years old sample</td></tr><tr><td>Support</td><td>PCOS (%)</td><td>Control (%)</td><td>Χ2 (p)</td><td>PCOS (%)</td><td>Control (%)</td><td>Χ2 (pcp</td></tr></table>
<table><tr><td>Husband/partnera</td><td>116 (76)</td><td>37 (58)</td><td>2.42 (0.120)</td><td>52 (74)</td><td>14 (42)</td><td>8.83 (0.003)</td></tr><tr><td>Friends</td><td>93 (61)</td><td>30 (47)</td><td>1.82 (0.178)</td><td>46 (66)</td><td>22 (67)</td><td>0.01 (0.931)</td></tr><tr><td>Parents</td><td>86 (56)</td><td>24 (38)</td><td>3.45 (0.063)</td><td>49 (70)</td><td>21 (64)</td><td>0.27 (0.604)</td></tr><tr><td>Other family*</td><td>77 (50)</td><td>19 (30)</td><td>5.00 (0.025)</td><td>42 (60)</td><td>14 (42)</td><td>3.18 (0.075)</td></tr><tr><td>Children*a</td><td>65 (42)</td><td>16 (25)</td><td>4.31 (0.038)</td><td>15 (21)</td><td>2 (6)</td><td>8.33 (0.004)</td></tr><tr><td>Health care profs</td><td>42 (27)</td><td>14 (22)</td><td>0.51 (0.475)</td><td>22 (31)</td><td>8 (24)</td><td>0.89 (0.345)</td></tr><tr><td>Co-workers</td><td>40 (26)</td><td>13 (20)</td><td>0.78 (0.376)</td><td>24 (34)</td><td>9 (27)</td><td>0.80 (0.370)</td></tr><tr><td>Physical activity instructors</td><td>40 (26)</td><td>14 (22)</td><td>0.33 (0.564)</td><td>25 (36)</td><td>10 (30)</td><td>0.55 (0.460)</td></tr><tr><td>Myself</td><td>9 (6)</td><td>4 (6)</td><td>0.00 (1.00)</td><td>5 (7)</td><td>4 (12)</td><td>1.32 (0.251)</td></tr><tr><td>Other</td><td>4 (3)</td><td>0 (0)</td><td>-</td><td>2 (3)</td><td>0 (0)</td><td>-</td></tr><tr><td>Exercise friends/team</td><td>2 (1)</td><td>2 (3)</td><td>-</td><td>2 (3)</td><td>0 (0)</td><td>-</td></tr><tr><td>No one</td><td>1 (1)</td><td>1 (2)</td><td>-</td><td>0 (0)</td><td>1 (3)</td><td>-</td></tr><tr><td>Pets</td><td>1 (1)</td><td>1 (2)</td><td>-</td><td>1 (1)</td><td>0 (0)</td><td>-</td></tr></table>
64d02a57172af1c126ffe47fca5db459778b1aff2ab5936f6e55dcc1a9593fbe.png
complex
<table><tr><td> </td><td colspan="4">15th postoperative day</td><td colspan="4">30th postoperative day</td></tr><tr><td> </td><td>Treatment group</td><td>Control group</td><td><i>F</i> value</td><td><i>P</i> value</td><td>Treatment group</td><td>Control group</td><td><i>F</i> value</td><td><i>P</i> value</td></tr><tr><td>First voiding desire (mL)</td><td>190.22 &#177; 12.77186.92&#8211;193.52</td><td>198.52 &#177; 16.33194.30&#8211;202.74</td><td>3.722</td><td>0.002</td><td>184.88 &#177; 10.98182.05&#8211;187.72</td><td>191.25 &#177; 14.44187.52&#8211;194.98</td><td>2.136</td><td>0.008</td></tr><tr><td>MCC (mL)</td><td>370.92 &#177; 13.06367.54&#8211;374.29</td><td>362.57 &#177; 13.46359.09&#8211;366.04</td><td>0.01</td><td>0.001</td><td>384.97 &#177; 15.73380.90&#8211;389.03</td><td>372.92 &#177; 14.46369.18&#8211;376.65</td><td>0.534</td><td>&lt;0.001</td></tr><tr><td>Maximal flow rate (mL/sec)</td><td>8.07 &#177; 1.757.62&#8211;8.52</td><td>6.42 &#177; 2.405.80&#8211;7.04</td><td>6.573</td><td>&lt;0.001</td><td>13.52 &#177; 2.4112.89&#8211;14.14</td><td>10.70 &#177; 3.139.89&#8211;11.51</td><td>6.38</td><td>&lt;0.001</td></tr><tr><td>PVR (mL)</td><td>92.52 &#177; 10.3789.84&#8211;95.20</td><td>100.53 &#177; 17.2896.07&#8211;105.00</td><td>7.058</td><td>0.003</td><td>86.05 &#177; 10.1683.42&#8211;88.68</td><td>94.85 &#177; 11.8291.80&#8211;97.90</td><td>0.054</td><td>&lt;0.001</td></tr><tr><td>BC (mL/cmH<sub>2</sub>O)</td><td>22.27 &#177; 2.8121.54&#8211;22.99</td><td>20.03 &#177; 4.0119.00&#8211;21.07</td><td>5.237</td><td>0.001</td><td>28.22 &#177; 5.5926.77&#8211;29.66</td><td>24.32 &#177; 4.7723.08&#8211;25.55</td><td>0.046</td><td>&lt;0.001</td></tr></table>
<table><tr><td></td><td colspan="4">15th postoperative day</td><td colspan="4">30th postoperative day</td></tr><tr><td></td><td>Treatment group</td><td>Control group</td><td>F value</td><td>P value</td><td>Treatment group</td><td>Control group</td><td>F value</td><td>P value</td></tr><tr><td>First voiding desire (mL)</td><td>190.22 ± 12.77186.92–193.52</td><td>198.52 ± 16.33194.30–202.74</td><td>3.722</td><td>0.002</td><td>184.88 ± 10.98182.05–187.72</td><td>191.25 ± 14.44187.52–194.98</td><td>2.136</td><td>0.008</td></tr><tr><td>MCC </td><td>370.92 ±</td><td>362.57 ± 13</td><td></td><td>0.</td><td>384.97 ± 15.733</td><td>372.92 ± 14.46369.18–376.65</td><td>0.53</td><td><0.0</td></tr></table>
<table><tr><td>(mL)</td><td> 13.06367.54–374.29</td><td>.46359.09–366.04</td><td>0.01</td><td>001</td><td>80.90–389.03</td><td></td><td>4</td><td>01</td></tr><tr><td>Maximal flow rate (mL/sec)</td><td>8.07 ± 1.757.62–8.52</td><td>6.42 ± 2.405.80–7.04</td><td>6.573</td><td><0.001</td><td>13.52 ± 2.4112.89–14.14</td><td>10.70 ± 3.139.89–11.51</td><td>6.38</td><td><0.001</td></tr><tr><td>PVR (mL)</td><td>92.52 ± 10.3789.84–95.20</td><td>100.53 ± 17.2896.07–105.00</td><td>7.058</td><td>0.003</td><td>86.05 ± 10.1683.42–88.68</td><td>94.85 ± 11.8291.80–97.90</td><td>0.054</td><td><0.001</td></tr><tr><td>BC (mL/cmH2O)</td><td>22.27 ± 2.8121.54–22.99</td><td>20.03 ± 4.0119.00–21.07</td><td>5.237</td><td>0.001</td><td>28.22 ± 5.5926.77–29.66</td><td>24.32 ± 4.7723.08–25.55</td><td>0.046</td><td><0.001</td></tr></table>
db74738775d8273112504063d1ce6ff9647672edd24174262d12164d6f1362a6.png
complex
<table><tr><td rowspan="2">Parameters</td><td rowspan="2">Group</td><td colspan="2">Before</td><td colspan="2">After</td><td>Before versus after</td><td>Group comparison</td></tr><tr><td>Median</td><td>25&#8211;75 percentile</td><td>Median</td><td>25&#8211;75 percentile</td><td><i>p</i> value<sup><i>&#8727;</i></sup></td><td><i>p</i> value<sup><i>&#8727;&#8727;</i></sup></td></tr><tr><td rowspan="2">Stool Hp antigen</td><td><i>L. gasseri</i> group</td><td>1.45</td><td>0.38&#8211;2.38</td><td>1.17</td><td>0.48&#8211;2.13</td><td>0.588</td><td rowspan="2">0.958</td></tr><tr><td>Placebo group</td><td>1.22</td><td>0.38&#8211;2.83</td><td>1.24</td><td>0.44&#8211;2.50</td><td>0.584</td></tr><tr><td rowspan="2">UBT</td><td><i>L. gasseri</i> group</td><td>19.4</td><td>10.4&#8211;35.0</td><td>21.9</td><td>11.1&#8211;31.2</td><td>0.395</td><td rowspan="2">0.516</td></tr><tr><td>Placebo group</td><td>19.6</td><td>10.3&#8211;36.7</td><td>19.9</td><td>10.3&#8211;32.8</td><td>0.958</td></tr><tr><td rowspan="2">PGI/PGII</td><td><i>L. gasseri</i> group</td><td>2.6</td><td>2.1&#8211;3.5</td><td>2.7</td><td>2.1&#8211;3.6</td><td>0.537</td><td rowspan="2">0.414</td></tr><tr><td>Placebo group</td><td>2.7</td><td>2.0&#8211;3.9</td><td>2.7</td><td>2.1&#8211;3.7</td><td>0.604</td></tr><tr><td rowspan="2">PGI</td><td><i>L. gasseri</i> group</td><td>61.0</td><td>45.2&#8211;76.5</td><td>63.3</td><td>48.5&#8211;79.6</td><td>0.006</td><td rowspan="2">0.497</td></tr><tr><td>Placebo group</td><td>59.2</td><td>42.0&#8211;74.5</td><td>62.3</td><td>43.9&#8211;77.0</td><td>0.018</td></tr><tr><td rowspan="2">PGII</td><td><i>L. gasseri</i> group</td><td>21.4</td><td>16.4&#8211;32.5</td><td>22.5</td><td>16.1&#8211;35.1</td><td>0.012</td><td rowspan="2">0.725</td></tr><tr><td>Placebo group</td><td>20.6</td><td>16.9&#8211;27.5</td><td>24.3</td><td>16.4&#8211;29.8</td><td>0.003</td></tr></table>
<table><tr><td rowspan="2">Parameters</td><td rowspan="2">Group</td><td colspan="2">Before</td><td colspan="2">After</td><td>Before versus after</td><td>Group comparison</td></tr><tr><td>Median</td><td>25–75 percentile</td><td>Median</td><td>25–75 percentile</td><td>p value∗</td><td>p value∗∗</td></tr><tr><td rowspan="2">Stool Hp antigen</td><td>L. gasseri group</td><td>1.45</td><td>0.38–2.38</td><td>1.17</td><td>0.48–2.13</td><td>0.588</td><td rowspan="2">0.958</td></tr><tr><td>Placebo group</td><td>1.22</td><td>0.38–2.83</td><td>1.24</td><td>0.44–2.50</td><td>0.584</td></tr><tr><td rowspan="2">UBT</td><td>L. gasseri group</td><td>19.4</td><td>10.4–35.0</td><td>21.9</td><td>11.1–31.2</td><td>0.395</td><td rowspan="2">0.5</td></tr><tr><td>Place</td><td>1</td><td>10.3–36.</td><td>1</td><td>10.</td><td></td></tr></table>
<table><tr><td></td><td>bo group</td><td>9.6</td><td>7</td><td>9.9</td><td>3–32.8</td><td>0.958</td><td>16</td></tr><tr><td rowspan="2">PGI/PGII</td><td>L. gasseri group</td><td>2.6</td><td>2.1–3.5</td><td>2.7</td><td>2.1–3.6</td><td>0.537</td><td rowspan="2">0.414</td></tr><tr><td>Placebo group</td><td>2.7</td><td>2.0–3.9</td><td>2.7</td><td>2.1–3.7</td><td>0.604</td></tr><tr><td rowspan="2">PGI</td><td>L. gasseri group</td><td>61.0</td><td>45.2–76.5</td><td>63.3</td><td>48.5–79.6</td><td>0.006</td><td rowspan="2">0.497</td></tr><tr><td>Placebo group</td><td>59.2</td><td>42.0–74.5</td><td>62.3</td><td>43.9–77.0</td><td>0.018</td></tr><tr><td rowspan="2">PGII</td><td>L. gasseri group</td><td>21.4</td><td>16.4–32.5</td><td>22.5</td><td>16.1–35.1</td><td>0.012</td><td rowspan="2">0.725</td></tr><tr><td>Placebo group</td><td>20.6</td><td>16.9–27.5</td><td>24.3</td><td>16.4–29.8</td><td>0.003</td></tr></table>
1a2164c7782bf20b16c3e60d42188f373ceb396ff2c7a9273c8c6897f3ce9653.png
simple
<table><tr><td>Class</td><td>Drug name</td><td>n<sub>11</sub></td><td>n<sub>1+</sub></td><td>ROR (95%CI)</td><td>IC (95%CI)</td></tr><tr><td>GLP-1-RAs</td><td>(ALL)</td><td>36</td><td>429</td><td>5.61* (3.95&#8211;7.96)</td><td>2.17* (1.66&#8211;2.67)</td></tr><tr><td></td><td>dulaglutide</td><td>1</td><td>20</td><td>3.08 (0.41&#8211;23.04)</td><td>0.56 (&#8722;1.57&#8211;2.70)</td></tr><tr><td></td><td>exenatide</td><td>19</td><td>122</td><td>11.08* (6.75&#8211;18.18)</td><td>2.70* (2.00&#8211;3.41)</td></tr><tr><td></td><td>liraglutide</td><td>15</td><td>278</td><td>3.39* (2.00&#8211;5.74)</td><td>1.49* (0.74&#8211;2.24)</td></tr><tr><td></td><td>lixisenatide</td><td>1</td><td>12</td><td>5.32 (0.69&#8211;41.28)</td><td>0.71 (&#8722; 1.48&#8211;2.91)</td></tr><tr><td>DPP-4-Is</td><td>(ALL)</td><td>31</td><td>3276</td><td>0.54 (0.37&#8211;0.77)</td><td>-0.81 (&#8722; 1.34 &#8211; &#8722;0.29)</td></tr><tr><td></td><td>alogliptin</td><td>1</td><td>345</td><td>0.17 (0.02&#8211;1.20)</td><td>&#8722; 1.77 (&#8722;3.82&#8211;0.28)</td></tr><tr><td></td><td>anagliptin</td><td>0</td><td>72</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td></td><td>linagliptin</td><td>4</td><td>332</td><td>0.71 (0.26&#8211;1.91)</td><td>&#8722;0.40 (&#8722;1.71&#8211;0.90)</td></tr><tr><td></td><td>omarigliptin</td><td>0</td><td>2</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td></td><td>saxagliptin</td><td>0</td><td>70</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td></td><td>sitagliptin</td><td>16</td><td>1181</td><td>0.80 (0.48&#8211;1.31)</td><td>&#8722;0.30 (&#8722;1.01&#8211;0.41)</td></tr><tr><td></td><td>teneligliptin</td><td>0</td><td>98</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td></td><td>trelagliptin</td><td>1</td><td>19</td><td>3.25 (0.43&#8211;24.39)</td><td>0.58 (&#8722;1.56&#8211;2.72)</td></tr><tr><td></td><td>vildagliptin</td><td>9</td><td>1189</td><td>0.44 (0.23&#8211;0.85)</td><td>&#8722;1.07 (&#8722;2.00 &#8211; &#8722;0.15)</td></tr></table>
<table><tr><td>Class</td><td>Drug name</td><td>n11</td><td>n1+</td><td>ROR (95%CI)</td><td>IC (95%CI)</td></tr><tr><td>GLP-1-RAs</td><td>(ALL)</td><td>36</td><td>429</td><td>5.61* (3.95–7.96)</td><td>2.17* (1.66–2.67)</td></tr><tr><td></td><td>dulaglutide</td><td>1</td><td>20</td><td>3.08 (0.41–23.04)</td><td>0.56 (−1.57–2.70)</td></tr><tr><td></td><td>exenatide</td><td>19</td><td>122</td><td>11.08* (6.75–18.18)</td><td>2.70* (2.00–3.41)</td></tr><tr><td></td><td>liraglutide</td><td>15</td><td>278</td><td>3.39* (2.00–5.74)</td><td>1.49* (0.74–2.24)</td></tr><tr><td></td><td>lixisenatide</td><td>1</td><td>12</td><td>5.32 (0.69–41.28)</td><td>0.71 (− 1.48–2.91)</td></tr><tr><td>DPP-4-Is</td><td>(ALL)</td><td>31</td><td>3276</td><td>0.54 (0.37–0.77)</td><td>-0.81 (− 1.34 – −0.29)</td></tr><tr><td></td><td>alogliptin</td><td>1</td><td>345</td><td>0.17 (0.02–1.20)</td><td>− 1.77 (−3.82–0.28)</td></tr><tr><td></td><td>anagliptin</td><td>0</td><td>72</td><td>–</td><td>–</td></tr><tr><td></td><td>linagliptin</td><td>4</td><td>332</td><td>0.71 (0.26–1.91)</td><td>−0.40 (−1.71–0.90)</td></tr><tr><td></td><td>omarigliptin</td><td>0</td><td>2</td><td>–</td><td>–</td></tr><tr><td></td><td>saxagli</td><td>0</td><td></td><td></td><td>–</td></tr></table>
<table><tr><td>Class</td><td>Drug name</td><td>n11</td><td>n1+</td><td>ROR (95%CI)</td><td>IC (95%CI)</td></tr><tr><td></td><td>ptin</td><td></td><td>70</td><td>–</td><td></td></tr><tr><td></td><td>sitagliptin</td><td>16</td><td>1181</td><td>0.80 (0.48–1.31)</td><td>−0.30 (−1.01–0.41)</td></tr><tr><td></td><td>teneligliptin</td><td>0</td><td>98</td><td>–</td><td>–</td></tr><tr><td></td><td>trelagliptin</td><td>1</td><td>19</td><td>3.25 (0.43–24.39)</td><td>0.58 (−1.56–2.72)</td></tr><tr><td></td><td>vildagliptin</td><td>9</td><td>1189</td><td>0.44 (0.23–0.85)</td><td>−1.07 (−2.00 – −0.15)</td></tr></table>
b91e4c8f0c3a1dfb3d2bb61556e270532ccafd8045cd2c3dce19fa284683543f.png
complex
<table><tr><td></td><td>N (%)</td></tr><tr><td>Median age at diagnosis (range)</td><td>63 (20&#8211;92)</td></tr><tr><td colspan="2">Histological subtype</td></tr><tr><td> High-grade serous</td><td>90 (92.7)</td></tr><tr><td> High-grade endometrioid</td><td>5 (5.2)</td></tr><tr><td> Clear cell</td><td>2 (2.1)</td></tr><tr><td colspan="2">FIGO stage at diagnosis</td></tr><tr><td> I</td><td>7 (7.2)</td></tr><tr><td> II</td><td>4 (4.1)</td></tr><tr><td> III</td><td>73 (75.3)</td></tr><tr><td> IV</td><td>13 (13.4)</td></tr><tr><td colspan="2">ER-status</td></tr><tr><td> Positive</td><td>50 (51.5)</td></tr><tr><td> Negative</td><td>1 (1)</td></tr><tr><td> Unknown</td><td>46 (47.4)</td></tr><tr><td colspan="2">PR-status</td></tr><tr><td> Positive</td><td>20 (20.1)</td></tr><tr><td> Negative</td><td>11 (11.3)</td></tr><tr><td> Unknown</td><td>66 (68)</td></tr><tr><td colspan="2">Primary Surgery status</td></tr><tr><td> Complete debulking</td><td>37 (38.1)</td></tr><tr><td> Suboptimal debulking (&gt;1 cm residual disease)</td><td>44 (45.3)</td></tr><tr><td> No surgery</td><td>16 (16.5)</td></tr><tr><td colspan="2">Platinum-sensitivity</td></tr><tr><td> Platinum-sensitive</td><td>39 (40)</td></tr><tr><td> Platinum-resistant</td><td>58 (60)</td></tr><tr><td colspan="2">Number of lines of prior chemotherapy</td></tr><tr><td> 1</td><td>18 (18.6)</td></tr><tr><td> 2</td><td>15 (15.5)</td></tr><tr><td> 3</td><td>21 (21.6)</td></tr><tr><td> 4</td><td>17 (17.5)</td></tr><tr><td> 5</td><td>10 (10.3)</td></tr><tr><td> &#8805; 6</td><td>16 (16.5)</td></tr></table>
<table><tr><td></td><td>N (%)</td></tr></table>
<table><tr><td>Median age at diagnosis (range)</td><td>63 (20–92)</td></tr><tr><td colspan="2">Histological subtype</td></tr><tr><td>High-grade serous</td><td>90 (92.7)</td></tr><tr><td>High-grade endometrioid</td><td>5 (5.2)</td></tr><tr><td>Clear cell</td><td>2 (2.1)</td></tr><tr><td colspan="2">FIGO stage at diagnosis</td></tr><tr><td>I</td><td>7 (7.2)</td></tr><tr><td>II</td><td>4 (4.1)</td></tr><tr><td>III</td><td>73 (75.3)</td></tr><tr><td>IV</td><td>13 (13.4)</td></tr><tr><td colspan="2">ER-status</td></tr><tr><td>Positive</td><td>50 (51.5)</td></tr><tr><td>Negative</td><td>1 (1)</td></tr><tr><td>Unknown</td><td>46 (47.4)</td></tr><tr><td colspan="2">PR-status</td></tr><tr><td>Positive</td><td>20 (20.1)</td></tr><tr><td>Negative</td><td>11 (11.3)</td></tr><tr><td>Unknown</td><td>66 (68)</td></tr><tr><td colspan="2">Primary Surgery status</td></tr><tr><td>Complete debulking</td><td>37 (38.1)</td></tr><tr><td>Suboptimal debulking (>1 cm residual disease)</td><td>44 (45.3)</td></tr><tr><td>No surgery</td><td>16 (16.5)</td></tr><tr><td colspan="2">Platinum-sensitivity</td></tr><tr><td>Platinum-sensitive</td><td>39 (40)</td></tr><tr><td>Platinum-resistant</td><td>58 (60)</td></tr><tr><td colspan="2">Number of lines of prior chemotherapy</td></tr><tr><td>1</td><td>18 (18.6)</td></tr><tr><td>2</td><td>15 (15.5)</td></tr><tr><td>3</td><td>21 (21.6)</td></tr><tr><td>4</td><td>17 (17.5)</td></tr><tr><td>5</td><td>10 (10.3)</td></tr><tr><td>≥ 6</td><td>16 (16.5)</td></tr></table>
b5d74664f1e4086977ffcd2c67a48f2c2682462abf2f6bf9c983949738e0d249.png
complex
<table><tr><td rowspan="2">Variable</td><td colspan="4">Breakpoint-Specific PCR</td><td rowspan="2">Concordance, %</td></tr><tr><td>CN1</td><td>CN2+</td><td>Fail</td><td>Total</td></tr><tr><td colspan="6">Sequence read depth: Thailand</td></tr><tr><td> CN1</td><td>57 (22<sup>a</sup>)</td><td>13 (13)</td><td>1</td><td>71</td><td>...</td></tr><tr><td> CN2+</td><td>0</td><td>17 (7)</td><td>0</td><td>17</td><td>...</td></tr><tr><td> Total</td><td>57</td><td>30</td><td>1</td><td>88</td><td>85</td></tr><tr><td colspan="6">qPCR: Thailand</td></tr><tr><td> CN1</td><td>33 (11<sup>b</sup>)</td><td>3 (2)</td><td>1</td><td>37</td><td>...</td></tr><tr><td> CN2+</td><td>1 (0)</td><td>9 (4)</td><td>1</td><td>11</td><td>...</td></tr><tr><td> Total</td><td>34</td><td>12</td><td>2</td><td>48</td><td>91</td></tr><tr><td colspan="6">qPCR: Indonesia</td></tr><tr><td> CN1</td><td>25</td><td>0</td><td>2</td><td>27</td><td>...</td></tr><tr><td> CN2+</td><td>0</td><td>0</td><td>0</td><td>0</td><td>...</td></tr><tr><td> Total</td><td>25</td><td>0</td><td>2</td><td>27</td><td>100</td></tr></table>
<table><tr><td rowspan="2">Variable</td><td colspan="4">Breakpoint-Specific PCR</td><td rowspan="2">Concordance, %</td></tr><tr><td>CN1</td><td>CN2+</td><td>Fail</td><td>Total</td></tr><tr><td colspan="6">Sequence read depth: Thailand</td></tr><tr><td>CN1</td><td>57 (22a)</td><td>13 (13)</td><td>1</td><td>71</td><td>...</td></tr><tr><td>CN2+</td><td>0</td><td>17 (7)</td><td>0</td><td>17</td><td>...</td></tr><tr><td>Total</td><td>57</td><td>30</td><td>1</td><td>88</td><td>85</td></tr><tr><td colspan="6">qPCR: Thailand</td></tr><tr><td>CN1</td><td>33 (11b)</td><td>3 (2)</td><td>1</td><td>37</td><td>...</td></tr><tr><td>CN2+</td><td>1 (0)</td><td>9 (4)</td><td>1</td><td>11</td><td>...</td></tr><tr><td>Total</td><td>34</td><td>12</td><td>2</td><td>48</td><td>91</td></tr><tr><td colspan="6">qPCR: Indonesia</td></tr><tr><td>CN1</td><td>25</td><td>0</td><td>2</td><td>27</td><td>...</td></tr><tr><td>CN2+</td><td>0</td><td>0</td><td>0</td><td>0</td><td>...</td></tr></table>
<table><tr><td rowspan="2">Variable</td><td colspan="4">Breakpoint-Specific PCR</td><td rowspan="2">Concordance, %</td></tr><tr><td>CN1</td><td>CN2+</td><td>Fail</td><td>Total</td></tr><tr><td>Total</td><td>25</td><td>0</td><td>2</td><td>27</td><td>100</td></tr></table>
707b4c8822554c1bccb0ff9e8fc1fafb697d199201ee640d775093329f5cc14e.png
simple
<table><tr><td>Gene</td><td>Mesor</td><td>Amplitude</td><td>Acrophase ZT (h)</td></tr><tr><td><i>C57 ND</i></td><td> </td><td> </td><td> </td></tr><tr><td>Bmal1</td><td>0.61 &#177; 0.04</td><td>0.44 &#177; 0.05</td><td>23.58 &#177; 0.09</td></tr><tr><td>Cry1</td><td>0.93 &#177; 0.01</td><td>0.51 &#177; 0.04</td><td>19.22 &#177; 0.12</td></tr><tr><td>Per2</td><td>1.39 &#177; 0.08</td><td>0.64 &#177; 0.08</td><td>10.77 &#177; 0.08</td></tr><tr><td>Rev-erb <i>&#945;</i></td><td>2.23 &#177; 0.14</td><td>2.08 &#177; 0.19</td><td>7.75 &#177; 0.01</td></tr><tr><td>PPAR <i>&#945;</i></td><td>7.34 &#177; 0.16</td><td>6.83 &#177; 0.29</td><td>12.1 &#177; 0.03</td></tr><tr><td>PPAR <i>&#947;</i></td><td>1.25 &#177; 0.05</td><td>0.68 &#177; 0.05</td><td>15.55 &#177; 0.03</td></tr><tr><td>ROR <i>&#945;</i></td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>RXR X</td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>Sirt1</td><td>7.24 &#177; 0.24</td><td>7.18 &#177; 0.28</td><td>6.33 &#177; 0.01</td></tr><tr><td><i>ApoE-KO</i></td><td> </td><td> </td><td> </td></tr><tr><td>Bmal1</td><td>0.30 &#177; 0.03<sup><i>&#8727;&#8727;</i></sup></td><td>0.13 &#177; 0.03<sup><i>&#8727;&#8727;</i></sup></td><td>23.27 &#177; 0.15</td></tr><tr><td>Cry1</td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>Per2</td><td>0.66 &#177; 0.01<sup><i>&#8727;&#8727;</i></sup></td><td>0.57 &#177; 0.09</td><td>13.41 &#177; 0.06<sup><i>&#8727;&#8727;</i></sup></td></tr><tr><td>Rev-erb <i>&#945;</i></td><td>2.99 &#177; 0.08<sup><i>&#8727;&#8727;</i></sup></td><td>2.58 &#177; 0.22<sup><i>&#8727;</i></sup></td><td>10.96 &#177; 0.02<sup><i>&#8727;&#8727;</i></sup></td></tr><tr><td>PPAR <i>&#945;</i></td><td>11.27 &#177; 0.20<sup><i>&#8727;&#8727;</i></sup></td><td>7.71 &#177; 0.10<sup><i>&#8727;&#8727;</i></sup></td><td>12.68 &#177; 0.01</td></tr><tr><td>PPAR <i>&#947;</i></td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>ROR <i>&#945;</i></td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>RXR <i>&#945;</i></td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>Sirt1</td><td>15.27 &#177; 0.73<sup><i>&#8727;&#8727;</i></sup></td><td>9.60 &#177; 0.97<sup><i>&#8727;&#8727;</i></sup></td><td>6.10 &#177; 0.02</td></tr><tr><td><i>ApoE-KO LD/DL</i></td><td> </td><td> </td><td> </td></tr><tr><td>Bmal1</td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>Cry1</td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>Per2</td><td>0.42 &#177; 0.05<sup><i>&#8727;&#8727;</i>##</sup></td><td>0.18 &#177; 0.03<sup><i>&#8727;&#8727;</i>##</sup></td><td>10.28 &#177; 0.09<sup>##</sup></td></tr><tr><td>Rev-erb <i>&#945;</i></td><td>2.16 &#177; 0.18<sup><i>&#8727;</i>##</sup></td><td>2.01 &#177; 0.36<sup>#</sup></td><td>11.12 &#177; 0.03<sup><i>&#8727;&#8727;</i></sup></td></tr><tr><td>PPAR <i>&#945;</i></td><td>13.81 &#177; 0.33<sup><i>&#8727;&#8727;</i>##</sup></td><td>6.70 &#177; 0.05</td><td>12.03 &#177; 0.02</td></tr><tr><td>PPAR <i>&#947;</i></td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>ROR <i>&#945;</i></td><td>2.01 &#177; 0.04</td><td>0.84 &#177; 0.05</td><td>4.79 &#177; 0.02</td></tr><tr><td>RXR <i>&#945;</i></td><td>1.52 &#177; 0.04</td><td>0.44 &#177; 0.02</td><td>2.29 &#177; 0.07</td></tr><tr><td>Sirt1</td><td>13.12 &#177; 0.10<sup><i>&#8727;&#8727;</i>#</sup></td><td>7.47 &#177; 0.18</td><td>5.84 &#177; 0.01</td></tr></table>
<table><tr><td>Gene</td><td>Mesor</td><td>Amplitude</td><td>Acrophase ZT (h)</td></tr><tr><td>C57 ND</td><td></td><td></td><td></td></tr><tr><td>Bmal1</td><td>0.61 ± 0.04</td><td>0.44 ± 0.05</td><td>23.58 ± 0.09</td></tr><tr><td>Cry1</td><td>0.93 ± 0.01</td><td>0.51 ± 0.04</td><td>19.22 ± 0.12</td></tr><tr><td>Per2</td><td>1.39 ± 0.08</td><td>0.64 ± 0.08</td><td>10.77 ± 0.08</td></tr><tr><td>Rev-erb α</td><td>2.23 ± 0.14</td><td>2.08 ± 0.19</td><td>7.75 ± 0.01</td></tr><tr><td>PPAR α</td><td>7.34 ± 0.16</td><td>6.83 ± 0.29</td><td>12.1 ± 0.03</td></tr></table>
<table><tr><td>Gene</td><td>Mesor</td><td>Amplitude</td><td>Acrophase ZT (h)</td></tr><tr><td>PPAR γ</td><td>1.25 ± 0.05</td><td>0.68 ± 0.05</td><td>15.55 ± 0.03</td></tr><tr><td>ROR α</td><td>—</td><td>—</td><td>—</td></tr><tr><td>RXR X</td><td>—</td><td>—</td><td>—</td></tr><tr><td>Sirt1</td><td>7.24 ± 0.24</td><td>7.18 ± 0.28</td><td>6.33 ± 0.01</td></tr><tr><td>ApoE-KO</td><td></td><td></td><td></td></tr><tr><td>Bmal1</td><td>0.30 ± 0.03∗∗</td><td>0.13 ± 0.03∗∗</td><td>23.27 ± 0.15</td></tr><tr><td>Cry1</td><td>—</td><td>—</td><td>—</td></tr><tr><td>Per2</td><td>0.66 ± 0.01∗∗</td><td>0.57 ± 0.09</td><td>13.41 ± 0.06∗∗</td></tr><tr><td>Rev-erb α</td><td>2.99 ± 0.08∗∗</td><td>2.58 ± 0.22∗</td><td>10.96 ± 0.02∗∗</td></tr><tr><td>PPAR α</td><td>11.27 ± 0.20∗∗</td><td>7.71 ± 0.10∗∗</td><td>12.68 ± 0.01</td></tr><tr><td>PPAR γ</td><td>—</td><td>—</td><td>—</td></tr><tr><td>ROR α</td><td>—</td><td>—</td><td>—</td></tr><tr><td>RXR α</td><td>—</td><td>—</td><td>—</td></tr><tr><td>Sirt1</td><td>15.27 ± 0.73∗∗</td><td>9.60 ± 0.97∗∗</td><td>6.10 ± 0.02</td></tr><tr><td>ApoE-KO LD/DL</td><td></td><td></td><td></td></tr><tr><td>Bmal1</td><td>—</td><td>—</td><td>—</td></tr><tr><td>Cry1</td><td>—</td><td>—</td><td>—</td></tr><tr><td>Per2</td><td>0.42 ± 0.05∗∗##</td><td>0.18 ± 0.03∗∗##</td><td>10.28 ± 0.09##</td></tr><tr><td>Rev-erb α</td><td>2.16 ± 0.18∗##</td><td>2.01 ± 0.36#</td><td>11.12 ± 0.03∗∗</td></tr><tr><td>PPAR α</td><td>13.81 ± 0.33∗∗##</td><td>6.70 ± 0.05</td><td>12.03 ± 0.02</td></tr><tr><td>PPAR γ</td><td>—</td><td>—</td><td>—</td></tr><tr><td>ROR α</td><td>2.01 ± 0.04</td><td>0.84 ± 0.05</td><td>4.79 ± 0.02</td></tr><tr><td>RXR α</td><td>1.52 ± 0.04</td><td>0.44 ± 0.02</td><td>2.29 ± 0.07</td></tr><tr><td>Sirt1</td><td>13.12 ± 0.10∗∗#</td><td>7.47 ± 0.18</td><td>5.84 ± 0.01</td></tr></table>
044025c96918bb55a5bcfe269922b32fc729bd013529f94f20cfd2bfa32c8d43.png
complex
<table><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="4">Yield (%)</td><td></td><td></td></tr><tr><td>Entry</td><td>Catalyst</td><td>Additive (equiv.)</td><td>Solvent</td><td>Temp.(K)</td><td>O<sub>2</sub> (MPa)</td><td>Time (h)</td><td>FDCA</td><td>DFF</td><td>HFCA</td><td>FFCA</td><td>Comments</td><td>Reference</td></tr><tr><td>1</td><td>Ru(OH)<sub><i>x</i></sub>/CeO<sub>2</sub></td><td>&#8212;</td><td>Water</td><td>413</td><td>0.25</td><td>6</td><td>38</td><td>12</td><td>50</td><td>&#8212;</td><td>Reuse (3 times)</td><td>[173]</td></tr><tr><td>2<sup>b</sup></td><td>Ru(OH)<sub><i>x</i></sub>/MgAl<sub>2</sub>O<sub>4</sub></td><td>&#8212;</td><td>Water</td><td>413</td><td>0.5</td><td>18</td><td>56</td><td>4</td><td>30</td><td>&#8212;</td><td>Reuse (4 times), leaching (Mg: 0.9%, Ru: 0.02%)</td><td>[174]</td></tr><tr><td>3<sup>c</sup></td><td>Ru(OH)<sub><i>x</i></sub>/La<sub>2</sub>O<sub>3</sub></td><td>&#8212;</td><td>[EMIm] [OAc]</td><td>373</td><td>3</td><td>5</td><td>48</td><td>&#8212;</td><td>12</td><td>&#8212;</td><td>Leaching (9.9%)</td><td>[175]</td></tr><tr><td>4</td><td>Au/CeO<sub>2</sub></td><td>NaOH (4)</td><td>Water</td><td>338</td><td>Flow (1)</td><td>8</td><td>&gt;99</td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td><td>Au/CeO<sub>2</sub>: reuse (3 times), leaching (no)</td><td>[176]</td></tr><tr><td></td><td>Au/TiO<sub>2</sub></td><td>NaOH (4)</td><td>Water</td><td>338</td><td>Flow (1)</td><td>8</td><td>&gt;99</td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td><td></td><td>[176]</td></tr><tr><td>5</td><td>Pt/C</td><td>NaOH (2)</td><td>Water</td><td>295</td><td>0.68</td><td>6</td><td>79</td><td>&#8212;</td><td>21</td><td>&#8212;</td><td>Pt/C: reuse (3 times),</td><td>[177]</td></tr><tr><td></td><td>Pd/C</td><td>NaOH (2)</td><td>Water</td><td>295</td><td>0.68</td><td>6</td><td>71</td><td>&#8212;</td><td>29</td><td>&#8212;</td><td>Au/C: leaching (no)</td><td>[177]</td></tr><tr><td></td><td>Au/C</td><td>NaOH (2)</td><td>Water</td><td>295</td><td>0.68</td><td>6</td><td>8</td><td>&#8212;</td><td>92</td><td>&#8212;</td><td></td><td>[177]</td></tr><tr><td>6</td><td>Au/hydrotalcite</td><td>&#8212;</td><td>Water</td><td>368</td><td>Flow (0.1)</td><td>7</td><td>&gt;99</td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td><td>Reuse (3 times), leaching (no)</td><td>[178]</td></tr><tr><td>7<sup>d</sup></td><td>Au/TiO<sub>2</sub></td><td>HTFA (18&#8211;21)</td><td>AcOH</td><td>403</td><td>1</td><td>3</td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td><td>78</td><td>&#8212;</td><td>[179]</td></tr><tr><td>8</td><td>Au/HY zeolite</td><td>NaOH (4)</td><td>Water</td><td>333</td><td>0.3</td><td>6</td><td>&gt;99</td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td><td>Reuse (4 times)</td><td>[180]</td></tr><tr><td>9</td><td>Ru/C</td><td>&#8212;</td><td>Water</td><td>383</td><td>2</td><td>&#8212;</td><td>&#8212;</td><td>29</td><td>&#8212;</td><td>&lt;1</td><td>Reuse (5 times, decrease in activity), leaching (no)</td><td>[181]</td></tr><tr><td>10<sup>e</sup></td><td>Ag/OMS-2</td><td>&#8212;</td><td>IPA</td><td>438</td><td>1.5 (air)</td><td>6</td><td>&#8212;</td><td>99</td><td>&#8212;</td><td>&#8212;</td><td>Reuse (6 times)</td><td>[182]</td></tr><tr><td>11</td><td>Au&#8211;Cu/TiO<sub>2</sub></td><td>NaOH (4)</td><td>Water</td><td>368</td><td>1</td><td>4.5</td><td>95</td><td>&#8212;</td><td>5</td><td>&#8212;</td><td>Reuse (5 times), leaching (&#8804;2% after 5th reuse)</td><td>[183]</td></tr><tr><td>12</td><td>Pt&#8211;Bi/C</td><td>NaHCO<sub>3</sub> (4)</td><td>Water</td><td>373</td><td>4 (air)</td><td>6</td><td>98</td><td>&#8212;</td><td>1</td><td>&#8212;</td><td>Reuse (5 times), leaching (&lt;0.5%)</td><td>[184]</td></tr><tr><td>13<sup>f</sup></td><td>Au<sub>8</sub>Pd<sub>2</sub>/AC</td><td>NaOH (2)</td><td>Water</td><td>333</td><td>0.3</td><td>2</td><td>99</td><td>&#8212;</td><td>1</td><td>&#8212;</td><td>Reuse (5 times), leaching (no)</td><td>[185]</td></tr><tr><td>14</td><td>Au&#8211;Pd/CNT</td><td>&#8212;</td><td>Water</td><td>373</td><td>0.5</td><td>12</td><td>94</td><td>&#8212;</td><td>&#8212;</td><td>2</td><td>Reuse (6 times)</td><td>[186]</td></tr></table>
<table><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Entry</td><td>Catalyst</td><td>Additive (equiv.)</td><td>Solvent</td><td>Temp.(K)</td><td>O2 (MPa)</td></tr><tr><td>1</td><td>Ru(OH)x/CeO2</td><td>—</td><td>Water</td><td>413</td><td>0.25</td></tr><tr><td>2b</td><td>Ru(OH)x/MgAl2O4</td><td>—</td><td>Water</td><td>413</td><td>0.5</td></tr><tr><td>3c</td><td>Ru(OH)x/La2O3</td><td>—</td><td>[EMIm] [OAc]</td><td>373</td><td>3</td></tr><tr><td>4</td><td>Au/CeO2</td><td>NaOH (4)</td><td>Water</td><td>338</td><td>Flow (1)</td></tr><tr><td></td><td>Au/TiO2</td><td>NaOH (4)</td><td>Water</td><td>338</td><td>Flow (1)</td></tr><tr><td>5</td><td>Pt/C</td><td>NaOH (2)</td><td>Water</td><td>295</td><td>0.68</td></tr><tr><td></td><td>Pd/C</td><td>NaOH (2)</td><td>Water</td><td>295</td><td>0.68</td></tr><tr><td></td><td>Au/C</td><td>NaOH (2)</td><td>Water</td><td>295</td><td>0.68</td></tr><tr><td>6</td><td>Au/hydrotalcite</td><td>—</td><td>Water</td><td>368</td><td>Flow (0.1)</td></tr><tr><td>7d</td><td>Au/TiO2</td><td>HTFA (18–21)</td><td>AcOH</td><td>403</td><td>1</td></tr><tr><td>8</td><td>Au/HY zeolite</td><td>NaOH (4)</td><td>Water</td><td>333</td><td>0.3</td></tr><tr><td>9</td><td>Ru/C</td><td>—</td><td>Water</td><td>383</td><td>2</td></tr><tr><td>10e</td><td>Ag/OMS-2</td><td>—</td><td>IPA</td><td>438</td><td>1.5 (air)</td></tr><tr><td>11</td><td>Au–Cu/TiO2</td><td>NaOH (4)</td><td>Water</td><td>368</td><td>1</td></tr><tr><td>12</td><td>Pt–Bi/C</td><td>NaHCO3 (4)</td><td>Water</td><td>373</td><td>4 (air)</td></tr><tr><td>13f</td><td>Au8Pd2/AC</td><td>NaOH (2)</td><td>Water</td><td>333</td><td>0.3</td></tr><tr><td>14</td><td>Au–Pd/CNT</td><td>—</td><td>Water</td><td>373</td><td>0.5</td></tr></table>
<table><tr><td></td><td colspan="4">Yield (%)</td><td></td><td></td></tr><tr><td>Time (h)</td><td>FDCA</td><td>DFF</td><td>HFCA</td><td>FFCA</td><td>Comments</td><td>Reference</td></tr><tr><td>6</td><td>38</td><td>12</td><td>50</td><td>—</td><td>Reuse (3 times)</td><td>[173]</td></tr><tr><td>18</td><td>56</td><td>4</td><td>30</td><td>—</td><td>Reuse (4 times), leaching (Mg: 0.9%, Ru: 0.02%)</td><td>[174]</td></tr><tr><td>5</td><td>48</td><td>—</td><td>12</td><td>—</td><td>Leaching (9.9%)</td><td>[175]</td></tr><tr><td>8</td><td>>99</td><td>—</td><td>—</td><td>—</td><td>Au/CeO2: reuse (3 times), leaching (no)</td><td>[176]</td></tr><tr><td>8</td><td>>99</td><td>—</td><td>—</td><td>—</td><td></td><td>[176]</td></tr><tr><td>6</td><td>79</td><td>—</td><td>21</td><td>—</td><td>Pt/C: reuse (3 times),</td><td>[177]</td></tr><tr><td>6</td><td>71</td><td>—</td><td>29</td><td>—</td><td>Au/C: leaching (no)</td><td>[177]</td></tr><tr><td>6</td><td>8</td><td>—</td><td>92</td><td>—</td><td></td><td>[177]</td></tr><tr><td>7</td><td>>99</td><td>—</td><td>—</td><td>—</td><td>Reuse (3 times), leaching (no)</td><td>[178]</td></tr><tr><td>3</td><td>—</td><td>—</td><td>—</td><td>78</td><td>—</td><td>[179]</td></tr><tr><td>6</td><td>>99</td><td>—</td><td>—</td><td>—</td><td>Reuse (4 times)</td><td>[180]</td></tr><tr><td>—</td><td>—</td><td>29</td><td>—</td><td><1</td><td>Reuse (5 times, decrease in activity), leaching (no)</td><td>[181]</td></tr><tr><td>6</td><td>—</td><td>99</td><td>—</td><td>—</td><td>Reuse (6 times)</td><td>[182]</td></tr><tr><td>4.5</td><td>95</td><td>—</td><td>5</td><td>—</td><td>Reuse (5 times), leaching (≤2% after 5th reuse)</td><td>[183]</td></tr><tr><td>6</td><td>98</td><td>—</td><td>1</td><td>—</td><td>Reuse (5 times), leaching (<0.5%)</td><td>[184]</td></tr><tr><td>2</td><td>99</td><td>—</td><td>1</td><td>—</td><td>Reuse (5 times), leaching (no)</td><td>[185]</td></tr><tr><td>12</td><td>94</td><td>—</td><td>—</td><td>2</td><td>Reuse (6 times)</td><td>[186]</td></tr></table>
c31b954164d14e34c1192c91691a4b81b27266645e4155e240976c3fabd4e89b.png
simple
<table><tr><td>Antimicrobial</td><td>MIC (&#956;g/ml)</td></tr><tr><td>Nisin A</td><td>12.5</td></tr><tr><td>Nisin V</td><td>6.25</td></tr><tr><td>M21A</td><td>6.25</td></tr><tr><td>Citric Acid</td><td>2340</td></tr><tr><td>99% cinnamaldehyde</td><td>625</td></tr><tr><td>Lactoferrin</td><td>&gt;2500</td></tr><tr><td>Sodium acetate</td><td>250,000</td></tr><tr><td>Sodium benzoate</td><td>25,000</td></tr><tr><td>Carvacrol</td><td>310</td></tr><tr><td>Potassium sorbate</td><td>37,500</td></tr><tr><td>Nisaplin<sup>&#174;</sup></td><td>393</td></tr></table>
<table><tr><td>Antimicrobial</td><td>MIC (μg/ml)</td></tr><tr><td>Nisin A</td><td>12.5</td></tr><tr><td>Nisin V</td><td>6.25</td></tr><tr><td>M21A</td><td>6.25</td></tr><tr><td>Citric Acid</td><td>2340</td></tr><tr><td>99% cinnamaldehyde</td><td>625</td></tr><tr><td>Lactoferrin</td><td>>2500</td></tr><tr><td>Sodium acetate</td><td>250,000</td></tr><tr><td>Sodium benzoate</td><td>25,000</td></tr></table>
<table><tr><td>Carvacrol</td><td>310</td></tr><tr><td>Potassium sorbate</td><td>37,500</td></tr><tr><td>Nisaplin®</td><td>393</td></tr></table>
41be5641fdde440f8bf71d396a874ee07f9166a345a65fd0879c4b94cafa6535.png
complex
<table><tr><td rowspan="2">Variable</td><td colspan="2">Presence of hypertension</td><td rowspan="2"><i>P</i>-value*</td></tr><tr><td>Yes (<i>n</i> = 398)</td><td>No (<i>n</i> = 460) </td></tr><tr><td>Age (yrs)</td><td>61.2 (9.3)</td><td>58.6 (10.2)</td><td>&lt;0.0001</td></tr><tr><td>Height (m)</td><td>1.56 (0.08)</td><td>1.56 (0.07)</td><td>0.779</td></tr><tr><td>Weight (kg)</td><td>57.6 (13.5)</td><td>55.9 (12.9)</td><td>0.06</td></tr><tr><td>Body mass index (Kg/m<sup>2</sup>)</td><td>23.6 (5.3)</td><td>22.8 (4.6)</td><td>0.019</td></tr><tr><td>Waist circumference (cm)</td><td>85.9 (12.6)</td><td>83.5 (12.7)</td><td>0.006</td></tr><tr><td>Waist to Hip ratio</td><td>0.88 (0.07)</td><td>0.87 (0.06)</td><td>0.011</td></tr><tr><td>Systolic blood pressure (mmHg)</td><td>158.4 (19.7)</td><td>118.6 (12.8)</td><td>&lt;0.0001</td></tr><tr><td>Diastolic blood pressure (mmHg)</td><td>91.4 (14.1)</td><td>70.9 (9.3)</td><td>&lt;0.0001</td></tr><tr><td>Fasting blood glucose (mmol/L)</td><td>4.6 (1.5)</td><td>4.6 (1.8)</td><td>0.989</td></tr><tr><td>Total cholesterol (mmol/L)<sup>&#8224;</sup></td><td>4.6 (0.8)</td><td>4.6 (0.9)</td><td>0.972</td></tr></table>
<table><tr><td rowspan="2">Variable</td><td colspan="2">Presence of hypertension</td><td rowspan="2">P-value*</td></tr><tr><td>Yes (n = 398)</td><td>No (n = 460)</td></tr><tr><td>Age (yrs)</td><td>61.2 (9.3)</td><td>58.6 (10.2)</td><td><0.0001</td></tr><tr><td>Height (m)</td><td>1.56 (0.08)</td><td>1.56 (0.07)</td><td>0.779</td></tr><tr><td>Weight (kg)</td><td>57.6 (13.5)</td><td>55.9 (12.9)</td><td>0.06</td></tr><tr><td>Body mass index (Kg/m2)</td><td>23.6 (5.3)</td><td>22.8 (4.6)</td><td>0.019</td></tr><tr><td>Waist circumference (cm)</td><td>85.9 (12.6)</td><td>83.5 (12.7)</td><td>0.006</td></tr><tr><td>Waist to Hip ratio</td><td>0.88 (0.07)</td><td>0.87 (0.06)</td><td>0.011</td></tr><tr><td>Systolic blood pressure (mmHg)</td><td>158.4 (19.7)</td><td>118.6 (12.8)</td><td><0.0001</td></tr><tr><td>Diastolic blood pressure (mmHg)</td><td>91.4 (14.1)</td><td>70.9 (9.3)</td><td><0.0001</td></tr><tr><td>Fasting blood glucose (mmol/L)</td><td>4.6 (1.5)</td><td>4.6 (1.8)</td><td>0.989</td></tr></table>
<table><tr><td rowspan="2">Variable</td><td colspan="2">Presence of hypertension</td><td rowspan="2">P-value*</td></tr><tr><td>Yes (n = 398)</td><td>No (n = 460)</td></tr><tr><td>Total cholesterol (mmol/L)†</td><td>4.6 (0.8)</td><td>4.6 (0.9)</td><td>0.972</td></tr></table>
b14d3b834fb8dcae50fb145fa1325346e4358c6772c6edef4082f8886a115a01.png
simple
<table><tr><td>Current density</td><td>44 mA g<sup>&#8722;1</sup> (mAh g<sup>&#8722;1</sup>)</td><td>110 mA g<sup>&#8722;1</sup> (mAh g<sup>&#8722;1</sup>)</td><td>220 mA g<sup>&#8722;1</sup> (mAh g<sup>&#8722;1</sup>)</td><td>660 mA g<sup>&#8722;1</sup> (mAh g<sup>&#8722;1</sup>)</td><td>1320 mA g<sup>&#8722;1</sup> (mAh g<sup>&#8722;1</sup>)</td><td>Retention rate (%)</td></tr><tr><td>Pristine</td><td>229</td><td>194</td><td>170</td><td>134</td><td>101</td><td>44.1</td></tr><tr><td>Composite 0.5</td><td>260</td><td>228</td><td>203</td><td>164</td><td>123</td><td>47.3</td></tr><tr><td>Composite 2.0</td><td>287</td><td>253</td><td>225</td><td>179</td><td>151</td><td>52.6</td></tr><tr><td>Composite 5.0</td><td>276</td><td>243</td><td>215</td><td>174</td><td>145</td><td>52.5</td></tr></table>
<table><tr><td>Current density</td><td>44 mA g−1 (mAh g−1)</td><td>110 mA g−1 (mAh g−1)</td><td>220 mA g−1 (mAh g−1)</td><td>660 mA g−1 (mAh g−1)</td><td>1320 mA g−1 (mAh g−1)</td><td>Retention rate (%)</td></tr></table>
<table><tr><td>Pristine</td><td>229</td><td>194</td><td>170</td><td>134</td><td>101</td><td>44.1</td></tr><tr><td>Composite 0.5</td><td>260</td><td>228</td><td>203</td><td>164</td><td>123</td><td>47.3</td></tr><tr><td>Composite 2.0</td><td>287</td><td>253</td><td>225</td><td>179</td><td>151</td><td>52.6</td></tr><tr><td>Composite 5.0</td><td>276</td><td>243</td><td>215</td><td>174</td><td>145</td><td>52.5</td></tr></table>